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FOREWORD 
This Ph.D. thesis was carried out in parallel to an European project funded by the 4
th
 
framework programme of the European Commission (DG XII, Standards, Measurement 
and Testing). This project, named SMT CT98-2277 was funded, for the Swiss part, by the 
Federal Office of Education and Science (Bern, Switzerland). This pioneering study was 
carried out by four laboratories and three advisors during the period 1999 – 2002 (see list 
of participants in Annex 0). The ultimate aim of the project, i.e. development of a 
harmonised method for the profiling of amphetamine, was completely achieved. The 
resulting method has not only shown to produce interchangeable data but also to be 
superior in terms of speed and user-friendliness compared to the previous methods. 
Moreover, statistical data handling methods were compared and the final recommended 
method optimised in the course of the study proved to be more thorough than any 
previously published study in the discipline. 
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A. General introduction 
 
 
A.1 Brief history of amphetamine 
 
Amphetamine is believed to be first synthesised by a German chemist named L. Edeleano in the end of the 19
th
 
century [Edeleano, 1887]. After that, it has been largely forgotten for about 40 years.  
In 1930, amphetamine was discovered to increase blood pressure and in 1932, amphetamine was first marketed 
as Benzedrine
®
 by the chemical company Smith, Kline and French and was sold as an inhaler to treat congestion.  
In 1935, the stimulant effect of amphetamine is first recognized and physicians successfully use it to treat 
narcolepsy [Lukas, 1985]. 
In 1937, the American Medical Association approve the sale of amphetamine in tablet form. It is sold by 
prescription for use in the treatment of narcolepsy and ADHD (attention deficit hyperactivity disorder). 
Amphetamine also found an important military application during World War II and the Korean War (1950-
1953). Indeed, it was largely distributed to soldiers in order to improve performance. 
It is only in 1970 that amphetamine is listed in the Schedule II of the US Drug Abuse Regulation and Control 
Act of 1970. In effect, this renders the possession of amphetamine illegal without a prescription. 
 
Then, in the seventies, criminal networks got themselves organised in order to produce and distribute 
amphetamine and the first clandestine laboratories appeared in the United States and Europe. Frank [Frank, 
1983] reported almost 70 illicit production sites in the United States for the period 1978-1981 whereas Sinnema 
[Sinnema and Verweij, 1981] reported 23 of them in the Netherlands for more or less the same time period. 
 
Nowadays and according to the United Nations World Drug Report [UNODC, 2004], it seems that the number of 
detected amphetamine clandestine laboratories has increased in recent years after falling in the 1990’s. The 
production is mainly concentrated in Europe and the Netherlands, Poland and Belgium are the most frequently 
mentioned source countries although some others have also reported the dismantling of amphetamine clandestine 
laboratories (Russian Federation, Germany, Bulgaria, the Baltic countries, UK and France). 
Moreover, in 2002, more than 80 % of all BMK seizures (the main precursor to amphetamine, also known as 
P2P or 1-phenyl-2-propanone) were made in Europe. 
 
Also, in relation to trafficking, 90 % of all seizures were made in Europe and within Europe, more than 90 % in 
Western Europe (period 2001-2002). Over the last few years, the world’s largest amphetamine seizures have 
been made in the UK followed by Belgium, the Netherlands, Germany and Sweden. Most amphetamine seized in 
the EU is produced in the member states. The drugs are subsequently distributed across the EU. According to 
Europol [Europol, 2001], quantities of up to 30 kg are smuggled to the Nordic member states by car whereas the 
larger amounts of 100 kg or more are transported in lorries.  
 
As for consumption, it seems that amphetamine is mainly a « northern » problem. Indeed, it is still the number 
one illicit drug in Sweden and Finland and high levels of abuse have been reported by the UK and Denmark 
[UNODC, 2004]. No data is available for Norway but it seems that they have a similar situation compared to 
their neighbour Sweden. 
Regarding the new EU member countries, the highest levels are found in Poland and Estonia. High figures are 
also reported for the Czech Republic but this concerns mainly methamphetamine which is a specific problem in 
this country. 
 
Finally, with regards to Switzerland, it is quite difficult to obtain reliable statistics as amphetamine is often 
confounded with other illicit synthetic drugs such as methamphetamine and MDMA. Moreover, there seems to 
be no distinction between amphetamine in tablet and powder form. Still, according to federal statistics [OFP, 
1999], the number of cases involving amphetamine has increased steadily from 4 in 1986 to almost 400 in 1999. 
However, there is no indication that amphetamine is a serious issue in Switzerland and there is also no indication 
of possible home production. 
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A.2 Concepts of organic profiling [UNODC, 2000] 
 
Amphetamine is not a plant-based drug and is considered to be purely synthetic. It is manufactured in illicit 
clandestine laboratories and as a consequence of the crude laboratory conditions under which it is produced, the 
final product is rarely pure. Indeed, depending on the synthetic process it will contain a number of by-products 
which are generated during the synthesis. Moreover, traces of the starting material and even impurities of the 
starting material may still be present in the final product. 
The presence of by-products and their relative concentrations will depend on many factors such as : 
 
- the synthetic method 
- the starting material and its eventual impurities 
- the proportions of the chemicals involved in the synthetic method 
- general reaction conditions (temperature, pressure, time) 
- extraction and purification processes (including cristallisation and washing) 
 
Detailed chemical analysis will enable the detection of all these by-products as well as the measurement of their 
relative concentrations. By such an approach, a characteristic chemical signature can be assigned to every 
sample. The information generated can then be used to determine if two or more samples are connected. All 
relationships between samples may then provide information as to the extent of supply and distribution networks 
at a local, national or international level. 
It may also help in determining common batch
*
 memberships. In the case of amphetamine, it would not 
determine a geographical origin but a common source such as a batch coming from one illicit laboratory. 
Finally, the chemical signature or « profile » may help in determining the method of production and eventually 
which specific chemicals have been employed. For amphetamine, the production methods are well known and, 
in the majority of cases, the determination of the synthetic method is quite straightforward. However, this is not 
the case for other synthetic drugs such as, for example, MDMA. 
Profiling is generally used only for intelligence purposes and not as evidence. In the case of amphetamine, it is 
used in support of law enforcement investigations to : 
 
- confirm or negate a connection between two or more samples. 
- provide general intelligence information in relation to the distribution network (at a local, national or 
international level). 
- find links between samples that would not have been suspected by other means. 
- monitor the methods used in drug manufacture and identify eventual new trends. 
 
When taking about profiling, one should also bear in mind the concept of batch variation. Indeed, when 
amphetamine is manufactured, separate and discrete batches of powder may be synthesised at any one time. 
Because the production conditions may never be reproduced exactly each time, variations will occur in the 
profile, i.e. different batches from the same clandestine operator or « laboratory » will generate different 
chemical signatures (so called inter-batch variation). In addition, depending on the size of the batch and because 
illicit products are usually non-homogeneous, differences may also be seen across a single batch (so-called intra-
variation). In general, it is safe to assume that the inter-batch variation will always be bigger than the intra-batch 
variation. However, it is important to gather as much as possible information on such variations (when possible) 
in order to carry out proper interpretation of results. Indeed, without any indication of the range of these 
variations, it is quite difficult to determine by how much samples must differ before they can be assumed to be 
coming from different batches or sources. 
 
Finally, the strength of evidence of a link between samples is determined by the closeness of their respective 
profiles but also by the frequency of the particular pattern of the profile. If it can be demonstrated that the pattern 
of a particular profile is of an unusual type, then the evidential value of the link is increased. Thus, the need of 
building a reference population of profiles (in a appropriate database for example) in order to improve the 
interpretation of links between samples. 
In profiling, other characteristics can also be important in interpreting links between samples. These are : i) 
cutting agents, ii) visual and physical characteristics (especially for drugs in tablet form) and iii) packaging. 
However, these characteristics were not addressed in this project as it focused only on the organic profiling of 
amphetamine. 
 
 
 
* A batch is considered here as an amount of powder coming from one cristallisation process. 
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A.3 The Project 
 
Development of a harmonised method for the profiling of amphetamine has been a multi-task project which 
began on February 1
st
, 1999 and ended on October 30
th
, 2002, after a 9 months extension period. The ultimate 
aim of the project was to develop a harmonised, collaboratively tested method for the profiling of illicit 
amphetamine so that meaningful analytical data, for use in the control of amphetamine, may be distributed on a 
pan-European basis [Ballany et al., 2001]. 
Capillary gas chromatography (GC) has been commonly applied to chemical profiling of amphetamine which is 
mainly due to its user-friendliness and to its high separation power. The existing profiling methods [Jonson et al., 
1993, King et al., 1994, Kärkkäinen et al., 1994, Krawczyk et al., 2001] are however developed only for 
amphetamine synthesized through the so-called Leuckart method. In real life, at least three principle routes 
employed for the synthesis of amphetamine can be identified, namely (i) the nitrostyrene route, (ii) the reductive 
amination of benzyl methyl ketone and (iii) the Leuckart synthesis. Regardless that GC has its limitations such as 
decomposition of thermo-labile compounds, typically found in the amine family, it still can be considered 
superior to other separation techniques e.g. in terms of high separation power, stable retention times and user-
friendliness. It was therefore chosen for this study.  
 
The development of the profiling method was broken down into a seven distinct phases taking into consideration 
all three types of amphetamine: 
 
1. Synthesis of documented standards for use throughout the project; 
2. Study of the stability of the impurities in solution; 
3. Optimisation of GC and detector systems; 
4. Optimisation of extraction protocols; 
5. Determination of variability of results; 
6. Investigation of numerical classification schemes for amphetamine; 
7. Report preparation and completion. 
 
Moreover, each task was subdivided into subtasks which have been discussed in more detail under each task. 
The technical work was performed in four partner laboratories whereas the work programmes were devised 
together with all partners of the project (four active + three advisers). However, the following description 
outlines in more detail the work performed by the author of this thesis (further referred to as partner 4 in the 
text) : 
 
Task 1 : 
 
21 target compounds were synthesised by the four partners. Partner 4 performed the syntheses of five target 
compounds (n° 17 to 21, see table 1). GC-MS and FTIR data was collected by partner 4 for these five 
compounds. Dr Frank Dunand and Dr Amira Abou-Hamdan from the Institute of Mineral and Analytical 
Chemistry (ICMA, University of Lausanne) are greatly acknowledged for the acquisition of the NMR data. 
Partners 1 and 2 are likewise acknowledged for the acquisition of the UV data. 
Syntheses and analytical data of compounds 1 to 16 were performed and acquired by partners 1, 2 and 3. 
The remaining information found in this task was solely the work of partner 4. 
 
Task 2 : 
 
Linearity of GC-FID responses for compounds 17 to 21 was determined by partner 4. The stability of these 
compounds in various solvents was also determined by partner 4. In addition, a batch of amphetamine sulfate 
was synthesised (via the Leuckart route) and analysed by partner 4 in order to study the stability of present target 
compounds. The aim was to determine if the detected target compounds were more stable when present in the 
amphetamine matrix (and then extracted) as opposed to the synthesised standards directly dissolved in the 
solvent. 
Results for compounds 1 to 16 were obtained from partners 1, 2 and 3.  
 
Task 3 : 
 
For the study of the injection technique (task 3.2), again a Leuckart amphetamine batch was synthesised and 
analysed by partner 4. The amphetamine extracts were analysed using split and splitless injections with inlet 
temperatures of 220, 240, 260 and 280°C. The same extracts were sent to partner 2 for analysis and comparison 
with cool on column injection (reference sample introduction method). 
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In task 3.3 (choice of column and temperature programme), the amphetamine extracts were analysed by partner 
4 with six different temperature programmes (2, 4, 6, 8, 10 and 12°C per minute) and on three different 
analytical columns (Ultra 1, Ultra 2 and HP 50+). Separation power, resolution and inertness values were then 
calculated for all conditions. The same work was done by the other partners using their own synthesised 
amphetamine. In addition, partner 2 briefly studied four supplementary analytical columns. 
In task 3.4 (selection of detection technique), a modified Grob sample (test sample consisting of a mixture of 
alkanes, esters, amines and phenolic compounds) was prepared by partner 4. Repeatability, reproducibility, 
sensitivity and linearity for all compounds in the test sample were determined for both GC-FID and GC-MS. The 
same work was carried out in the laboratories of partners 2 and 3. NPD (Nitrogen-Phosphorous Detector) was 
further evaluated by partner 3. 
Finally, the liner study described in task 3.6 was solely the work of partner 4. 
 
Task 4 : 
 
Six amphetamine batches were synthesised by partner 4 and then mixed together to obtain 57 grams of 
amphetamine sulfate. This amount was necessary to perform all studies throughout the task. Various 
combinations of buffer types (with different pH), buffer concentrations, buffer volumes, solvents and solvent 
volumes were tested and studied on the synthesised amphetamine. Results were evaluated according to recovery, 
sensitivity and repeatability of target compounds. Each partner performed the same experiments on their own 
synthesised amphetamine. However, partner 4 synthesised an extra batch of nitrostyrene amphetamine in order 
to get more results about nitrostyrene target compounds. 
Matrix effects were also studied by cutting the synthesised amphetamine with various amounts of caffeine. 
Again, each partner performed the same analyses on their own synthesised amphetamine. This latter remark is 
also valid for the final subtask (optimisation of solid phase extraction). However, preliminary experiments were 
performed by partner 2. This lead to the choice of two SPE columns. Each partner evaluated the recovery and 
repeatability of these two columns and also compared both SPE columns with the optimised liquid-liquid 
extraction method.  
 
Task 5 : 
 
Task 5 was entirely devised by partner 4. All data was collected, treated and reported by partner 4. In addition, 
partner 4 synthesised three new batches of Leuckart amphetamine and two new batches of nitrostyrene 
amphetamine for this task. 
 
Task 6 : 
 
One batch of BMK (precursor) and three new batches of amphetamine were synthesised by partner 4. In 
addition, six batches of Leuckart amphetamine were synthesised according to the same recipe under controlled 
conditions. Partner 3 carried out the same syntheses in order to get some insight into the variability between 
amphetamine synthesised by two operators following the same recipe. 
More than 100 illicit samples were also collected thanks to the collaboration of a few police forces (Zurich 
Canton, Geneva, Neuchatel, Valais, Jura) and special thanks are directed towards Dr Michael Bovens of the 
scientific section of the Zurich city police for providing the great majority of the samples. 
In total (partners 2, 3 and 4), 768 samples were analysed and their results available for data interpretation. These 
results were shared between the three partners. 
Although the various decisions regarding the work programmes and the way forward were the result of group 
discussions (choice of pre-treatment methods and their evaluation, choice of distance metrics and their 
evaluation, reduction of target compounds, use of principal component analysis, etc.), task 6 presented in this 
thesis was rewritten by partner 4 in order to present the results in a different way. Most of the data was also re-
evaluated by partner 4 (for example, evaluation of false positives and false negatives). 
 
Chapter 7 : 
 
This task was not part of the project and belongs only to this thesis. 
 
Chapters 8 and 9 : 
 
Were solely the work of the author of this thesis. 
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1. Task 1 – Synthesis and Identification of Amphetamine 
and Potentially Route Specific Impurities 
 
1.1 Introduction 
 
The task started by synthesising amphetamine through each of the three synthetic routes (Leuckart, reductive 
amination and nitrostyrene). The produced amphetamines were then analysed to identify typical synthesis 
impurities. This data was used parallel to the information found in the literature. The final group of target 
compounds consisted therefore of compounds synthesised in the four active laboratories and, additionally, of 
compounds that were identified or tentatively identified in the home-made amphetamine batches.  
21 amphetamine impurities were successfully synthesised, and their identity confirmed by various spectroscopic 
techniques. 
 
1.2 Phenyl-2-propanone syntheses 
 
In this chapter, some details will be given regarding the various syntheses of phenyl-2-propanone. This precursor 
to amphetamine (and methamphetamine), also known as P2P, phenylacetone, BMK or benzylmethylketone is a 
controlled substance according to the United Nations Convention against illicit traffic in narcotic drugs and 
psychotropic substances (1988). For sake of simplicity, this substance will be named BMK throughout this text. 
However, this commercial substance, although controlled, can easily be synthesised from uncontrolled 
precursors. The aim of this chapter is to emphasise the availablity of synthetic methods and ease of synthesis of 
this vital precursor which is widely used in the manufacture of amphetamine and also methamphetamine. 
 
Numerous published methods are available to synthesise BMK. However, the diagram in the next page illustrates 
the main routes found in the literature (see figure 1). In summary, BMK can be synthesised from : 
 
 
- Phenylacetic acid 
- Alpha-acetylbenzylcyanide (also known as alpha-acetylphenylacetonitrile or 2-phenylacetoacetonitrile) 
- Benzene 
- Allylbenzene 
- Benzyl cyanide (phenylacetonitrile) 
- Benzyl chloride 
- Benzaldehyde 
- 2-Phenylpropanal (2-phenylpropionaldehyde, hydratropaldehyde) 
- Ephedrine, pseudoephedrine, norpseudoephedrine (phenylpropanolamine) or norephedrine 
- Phenyl-2-nitropropene (also known as trans-beta-methyl-beta-nitrostyrene) 
- Bromobenzene 
- Alpha-methylstyrene (2-phenylpropene, isopropenylbenzene) 
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Diagram of various methods for synthesis of BMK 
 
 
Figure 1 : various precursors and routes in the synthesis of BMK 
 
A : From phenylacetic acid : Sodium acetate and acetic anhydride : [Magidson and Garkusha, 1941] 
         [Forbes and Kirkbride, 1992] 
         [Hurd and Thomas, 1936] 
    Acetic anhydride and pyridine :  [King and McMillan, 1951] 
    Lead acetate :    [Tsutsumi, 1953] 
         [Allen et al., 1992] 
 
B1 : From benzyl cyanide : trimethylaluminium :   [Lau et al., 1997] 
 
B2 : Benzyl cyanide to alpha-acetylbenzylcyanide : 
 
Sodium ethoxide in ethyl acetate  [Julian et al., 1943b] 
 
B3 : From alpha-acetylbenzylcyanide :  Sulfuric acid  [Julian and Oliver., 1943a] 
      Phosphoric acid  [Bobranski and Drabik, 1942] 
 
C : From benzene : 2-nitropropene and titanium chloride  [Lee and Oh, 1988] 
   2-nitropropene and triflic acid   [Okabe et al., 1989] 
   chloroacetone and AlCl3 :    [Mason and Terry, 1940] 
   acetone and Mn (III) acetate :   [Kurz et al. 1984] 
OH
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D : From bromobenzene : potassium acetylacetonate / CuI in DMF : [Sugai et al., 1982] 
    Heck arylation :    [Kosugi et al., 1984] 
 
E : From alpha-methylstyrene : Thallium nitrate :   [McKillop et al., 1970] 
 
F1 : From benzyl chloride : Electrolysis with acetic anhydride :  [Chaussard and Moingeon, 1986] 
    Acetonitrile    [Bombard et al., 1980] 
         [Jones et al., 1972] 
 
F2 : Benzyl chloride to benzylmagnesium chloride :   [Newman and Booth, 1945] 
 
F3 : From benzylmagnesium chloride : Acetic anhydride :  [Newman and Booth, 1945] 
 
G : From 2-phenylpropanal :  HgCl2 or sulfuric acid .  [Danilow and Danilowa, 1927] 
     Bromine / H2SO4 :  [Inoi and Okamoto, 1969] 
 
H : From allylbenzene :  H2O2 / formic acid  [Fujisawa et al. 1958] 
         [Dal Cason et al., 1984] 
     Pd acetate / benzoquinone  [Miller and Wayner, 1990] 
 
I . From ephedrine or pseudoephedrine (R = CH3). Norephedrine or norpseudoephedrine (R = H) 
 
    Sulfuric acid and zinc chloride :  [Brauch, 1982] 
         [Blanke and Brauch, 1983] 
 
J1 . From benzaldehyde :  Phosphonium ylide  [Coulson, 1964] 
     Via glycidic ester   [Elks and Hey, 1943] 
 
J2 : Benzaldehyde to phenyl-2-nitropropene : nitroethane :  [Shulgin, 1991] 
         [Gairaud and Lappin, 1953] 
 
J3 : From phenyl-2-nitropropene : Sodium borohydride :  [Ballini and Bosica, 1994] 
     Iron and HCl :   [Shulgin, 1991] 
         [Hass et al., 1950] 
     Chromium (II) chloride :  [Varma et al. 1985] 
     Tin chloride and Mg :  [Das et al., 1996] 
     Nickel chloride and Al :  [Bezbarua et al. 1999] 
     LiAlH4 :    [Gilsdorf and Nord, 1952] 
 
J4 : Phenyl-2-nitropropene to phenyl-2-nitropropane : LiAlH4 :  [Gilsdorf and Nord, 1952] 
 
J5 : From phenyl-2-nitropropane : NaOH / H2SO4 :   [Gilsdorf and Nord, 1952] 
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Note : 
 
In Switzerland, according to the O Prec-Swissmedic (Ordonnance de l’institut suisse des produits thérapeutiques 
sur les précurseurs et autres produits chimiques utilisés pour la fabrication de stupéfiants et de substances 
psychotropes, Nov 8, 1996 ; updated in November 2001), only BMK, phenylacetic acid, ephedrine, 
norephedrine, phenylpropanolamine (norpseudoephedrine) and pseudoephedrine are controlled substances (as in 
the 1988 United Nations Convention against illicit traffic in narcotic drugs and psychotropic substances). 
All the other potential precursors (alpha-acetylbenzylcyanide, benzene, bromobenzene, allylbenzene, benzyl 
cyanide, benzyl chloride, benzaldehyde, 2-phenylpropanal, phenyl-2-nitropropene and alpha-methylstyrene) are 
commercially available and not under international control. However, in Switzerland, allylbenzene, 
benzaldehyde, benzyl chloride and benzyl cyanide are on the Alert List of the Chemical Industry [OFSP, 1997]. 
This means that any purchase of these chemicals is recorded and the report to authorities is on a voluntary basis. 
In other words, if the vendor suspects the chemical will be used for illicit drug manufacture, he is encouraged to 
report it to the authorities but this is not compulsary. 
 
The synthetic routes to BMK described above vary in terms of cost, simplicity and skill. However, it is important 
to mention that route C (benzene, chloroacetone and aluminium chloride) was used in one of the biggest 
amphetamine clandestine laboratory found in Europe which was dismantled in 2000 [Bakouri and van Rijn, 
2001]. 
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1.3 The Leuckart route 
 
This route is named after R. Leuckart who first published his method of aminating ketones into amines in 1885 
[Leuckart, 1885]. The two-step reaction is the following : 
 
 
Figure 2 : the Leuckart route 
 
Originally, Leuckart and subsequently Wallach [Wallach, 1891] used formamide or ammonium formate and 
heated the reaction mixture in sealed tubes at 210-240°C. Later one, Ingersoll and others showed that refluxing 
the mixture was an excellent alternative and that the use of formamide gave better yields [Ingersoll et al., 1936, 
Crossley and Moore, 1944, Moore, 1949]. 
In this reaction, BMK is refluxed with formamide at temperatures between 150 and 170°C. Formic acid is added 
to improve the yield of the intermediate N-formylamphetamine. 
For the hydrolysis step, sulfuric acid or hydrochloric acid are generally used. Boiling times can vary a lot. 
Generally, 3 to 6 hours refluxing is the rule for the first step while 1 to 3 hours are typically performed for the 
hydrolysis step. 
 
1.4 The reductive amination route 
 
This synthesis is a more straightforward reaction and is performed in one step. The precursor is the same as for 
the Leuckart route (BMK). Ammonia or ammonium acetate are used as the amine reactants and sodium 
borohydride (NaBH4) or sodium cyanoborohydride (NaBH3CN) [Borch et al., 1971, Braun et al., 1980, Schulgin, 
1991] are used as the reducing agents : 
 
 
BMK        Amphetamine 
 
Figure 3 : the reductive amination route 
 
There are various alternatives to reduce ketones to primary or secondary amines and most of them have been 
reviewed by Allen and Cantrell [Allen and Cantrell, 1989]. It is interesting to note that, although much easier 
(the reaction can be carried out at room temperature) and much cleaner (higher purity) than the Leuckart method, 
it has not been found to be a popular method for the manufacture of amphetamine. On the other hand, this 
synthetic route is widely used for the production of MDMA (MethyleneDioxyMethylAmphetamine, the active 
ingredient of ecstasy). 
O NH
O
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2
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One explanation could be the lack of publications with regard to primary amines. Indeed, the main applications 
of this synthetic route have been described for secondary amines rather than primary amines such as 
amphetamine or MDA (MethyleneDioxyAmphetamine). 
 
 
1.5 The nitrostyrene route 
 
In this case, it’s also a reductive amination but the precursor is phenyl-2-nitropropene. This compound can be 
purchased (Aldrich Chemicals) or synthesised from benzaldehyde [Schulgin, 1991, Noggle et al., 1994]. 
Reduction of phenyl-2-nitropropene to amphetamine can be carried out with various reducing agents such as 
Red-Al [Butterick and Unrau, 1974], sodium borohydride with BH3-THF [Mourad et al, 1984] or lithium 
aluminium hydride (LiAlH4) [Noggle et al., 1994, Kabalka and Varma, 1990] 
 
 
Figure 4 : the nitrostyrene route 
 
 
1.6 Miscellaneous 
 
Of course, many other synthetic routes can be found in the open literature. Amphetamine is a rather simple 
molecule and there are various ways to synthesise it. Again, Allen and Cantrell [Allen and Cantrell, 1989] have 
reviewed most of them as well as Dal Cason where various synthetic routes were described for the manufacture 
of MDA, the methylenedioxy derivative of amphetamine [Dal Cason, 1990]. However, it was considered useful 
to illustrate three others : 
 
The Ritter reaction : 
 
 
Figure 5 : the Ritter route 
 
Allylbenzene is simply mixed with acetonitrile and sulfuric acid in an ice-bath. The intermediate N-
acetylamphetamine will be formed. Then, it is hydrolysed with hydrochloric acid to produce amphetamine 
[Ritter and Kalish, 1948, Noggle et al., 1995]. It is important to mention that this reaction will not work if safrole 
is used instead of allylbenzene to produce MDA (safrole being the corresponding methylenedioxy derivative of 
allylbenzene) [Ritter and Murphy, 1952, Noggle et al., 1995, Robak, 1995]. 
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Direct and one-pot reaction from benzyl cyanide [Rinehart et al., 1987] 
 
 
 
Figure 6 : synthesis of amphetamine from benzyl cyanide 
 
 
 
This new method has the advantage of being performed at room temperature and is a one-step synthesis. Methyl 
iodide and magnesium turnings are added to dry tetrahydrofuran to form a solution of methylmagnesium iodide. 
This was added to a cooled solution of benzylcyanide in tetrahydrofuran. The reaction mixture is then stirred at 
room temperature and cooled in an ice-bath. The solution is then diluted with methanol and sodium borohydride 
added. The reaction mixture is further stirred at room temperature. In theory, this very easy synthesis should give 
80 % yield. 
This uncommon route is one illustration of the various possibilities to synthesise amphetamine from uncontrolled 
and very cheap chemicals. Indeed, the example here uses benzyl cyanide (also known as phenylacetonitrile) 
which costs approximately 12 Euro per litre. 
 
Synthesis from norephedrine or norpseudoephedrine (phenylpropanolamine). 
 
Figure 7 : synthesis pathways from norephedrine or norpseudoephedrine to amphetamine 
 
This route is derived from several popular methods used to synthetise methamphetamine [Remberg and Stead, 
1999] where ephedrine (or pseudoephedrine) is the starting material instead of norephedrine or 
norpseudoephedrine. Boswell has decribed three different ways to synthetise amphetamine from norephedrine or 
norpseudoephedrine [Boswell et al., 2002]. Norephedrine is reacted 22 hours with hydriodic acid and red 
phosphorous to yield amphetamine in a relatively low yield of 38 % (route 1). This route is very well known in 
methamphetamine synthesis [Skinner, 1990] and can be adapted as well for amphetamine by substituting the 
starting material. The second method consists of reacting norephedrine with thionyl chloride to form the 
chlorinated intermediate (route 2). The latter was then submitted to catalytic hydrogenation (palladium on 
carbon) to obtain amphetamine as an oil with a yield of 72 % (route 3). This method is also used in 
methamphetamine synthesis [Allen, 1987] and again can be adapted to amphetamine. 
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In the third method, norephedrine is reacted with acetic acid and acetic anhydride to form O-acetylnorephedrine 
(route 4). The latter is then submitted to catalytic hydrogenation (10 % palladium on carbon) or catalytic transfer 
hydrogenation (10 % palladium on carbon and ammonium formate) to give amphetamine in, respectively, 65 % 
and 89 % yield (route 5). 
It should be noted that the use of 1S, 2S-(+)-norpseudoephedrine or 1R, 2S-(-)-norephedrine will produce the 
optical isomer d-amphetamine [Noggle et al., 1987]. If d,l-norephedrine is used as the starting material, then the 
racemic amphetamine will be obtained. The latter will also be obtained with the aforementioned synthesis 
methods (Leuckart, reductive amination, nitrostyrene, Ritter). 
 
1.7 Experimental 
 
First, the synthesised amphetamines were analysed by gas chromatography – mass spectrometry (GC-MS) to 
identify the synthesis products, intermediates and by-products. It is self-evident that amphetamine synthesis 
produces numerous products that cannot all be identified. Indeed, a typical amphetamine profile can contain 
more than 200 peaks (see figure 8 below). Therefore, identification and separate synthesis of all these 
compounds is impossible. For these reasons and because of the short time available for this task, only a limited 
number of compounds (21) were chosen for further investigations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 : typical amphetamine profile of a synthesised sample (Leuckart route) 
 
 
Syntheses of the chosen impurities, i.e. target compounds were carried out. The synthesis methods used are 
described in Annex 1. Table 1 (see next page) lists the compounds produced by each Partner. The reader is 
noted that abbreviated names of the target compounds have been used in the later parts of this text.  
 
GC-MS was used to identify and determine the purity of the synthesised impurities. The latter was estimated on 
the basis of the total ion chromatogram (TIC), which was recognised as non-ideal technique but sufficient for the 
intended use. The GC-MS method was based in part, but not wholly, on published methods and the method was 
reached by empirical experimentation by the group. It was not considered as the final optimised method, but 
well-suited for the identification and purity analysis of the synthesis products. The GC-MS method (Method 1) 
has been described in detail in Annex 2. 
 
Deeper structural information on the synthesised products was obtained using FTIR, UV and NMR 
spectroscopy. Infra-red spectra (450 to 4000 cm
-1
) were obtained using KBr, i.e. each of the compounds as thin 
films on KBr, or mixed with KBr. Alternatively, IR spectra was recorded using the Attenuated Total Reflection 
Fourier Transform Infra Red Spectroscopy (ATR-FTIR) directly from the synthesised product or using the 
Diffuse Reflectance Infrared Fourier Transform Spectroscopy (DRIFTS), between 600 to 4000 cm
-1
. 
 
In respect of NMR data, 
1
H NMR data were obtained at 250 MHz (400 MHz Partner 4) with the sample 
dissolved in CDCl3. 
13
C NMR data were obtained at 90 MHz (62.9 MHz Partner 3) with the sample again 
dissolved in CDCl3.  
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Ultraviolet spectra were obtained for the compounds as synthesised in (i) methanol, (ii) 0.1M sodium hydroxide 
in methanol and (iii) 0.1M sulphuric acid in methanol.  
 
All the chemical structures and spectroscopic data can be found in Annex 3 and the various instruments used in 
this task have been summarised in Table 2. 
 
Table 1 Compounds synthesised by each Partner during the course of Task 1.  
 
Number 
 
Trivial name 
 
Abbreviation 
Molecular 
formula 
 
MW 
Responsible 
Partner 
1 Nitrostyrene    C9H9NO2 163.17 1 
2 Benzyl methyl ketoxime  ketoxime  C10H14NO 164.22 1 
3 N-(β-phenylisopropyl)benzaldiimine  benzaldimine  C17H21N 239.36 1,2 
4 2-methyl-3-phenylaziridine   aziridine  C9H11N 133.19 1 
5 N-(β-phenylisopropyl)benzyl methyl ketimine  ketimine  C18H21N 251.37 2 
6 N-acetylamphetamine    C11H15NO 177.24 2 
7 Benzoylamphetamine    C16H17NO 239.31 2 
8 Benzylamphetamine    C16H19N 225.33 2 
9 phenyl-2-propanol    C9H12O 136.19 2 
10 1-oxo-1-phenyl-2-(β-
phenylisopropylimino)propane 
 1-oxo  C18H19NO 265.35 2 
11 2-oxo-1-phenyl-2-(β-
phenylisopropylamino)ethane 
 2-oxo  C17H19NO 253.34 2 
12 N,β-hydroxy-N,N-di(β-phenylisopropyl)amine  cathinol  C20H31NO 301.47 2 
13 N-(β-phenylisopropyl)cathinone  cathinone  C20H29NO 299.45 2 
14 4-methyl-5-phenylpyrimidine    C11H10N2 170.21 3 
15 1,3-diphenyl-2-propylamine  DPPA  C15H17N 211.30 3 
16 4-benzylpyrimidine    C11H10N2 170.21 3 
17 N-formylamphetamine    C10H13NO 163.21 4 
18 N,N-di-(β-phenylisopropyl)amine   DPIA  C18H23N 253.38 4 
19 N,N-di-(β-phenylisopropyl)methylamine   DPIMA  C19H25N 267.41 4 
20 N,N-di-(β-phenylisopropyl)formamide   DPIF  C19H23NO 281.39 4 
21 2,4-dimethyl-3,5-diphenyl pyridine    C19H18N 260.35 4 
 
 
Table 2 Instruments used by each Partner for obtaining the spectroscopic data. 
Partner Technique 
1 2 3 4 
GC-MS HP6890/5973 
(Agilent) 
HP6890/5973 (Agilent) HP6890/5973 
(Agilent) 
HP6890/5973 
(Agilent) 
FTIR ATI Mattson 
Genesis Series 
 
Spectrum 1600 
(Perkin-Elmer) 
Spectrum 2000 
(Perkin-Elmer) 
Mattson Cygnus 100 
 
1
H and 
13
C NMR Bruker DPX 40 Varian Inova 300 and 
Bruker Avance DRX 
500 
Bruker AF250 Bruker DPX 400 
UV Nicam UV2 
 
HP1090 DAD 
(Hewlett-Packard) 
HP 8453 
(Hewlett-Packard) 
Nicam UV2 
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The 21 synthesised compounds are briefly discussed below (IUPAC names are in brackets) : 
 
 
(1) Nitrostyrene [(2-Nitroprop-1-enyl)benzene] 
 
Nitrostyrene, also known as phenyl-2-nitropropene or trans-beta-methyl-beta-nitrostyrene is the intermediate 
compound in the so-called nitrostyrene route. It was therefore considered important to confirm identity by 
synthesising it and to use it as target compound. It is also commercially available from Sigma-Aldrich chemicals. 
 
(2) Benzyl methyl ketoxime [1-Phenylpropan-2-one oxime] 
 
Benzyl methly ketoxime, also abbreviated ketoxime through out this text, is thought to be the result of 
uncomplete reduction of nitrostyrene to amphetamine. It is therefore considered as an impurity specific to the 
nitrostyrene route. However, controlled syntheses showed that it could also be found in amphetamine 
synthesised by the reductive amination and Leuckart routes (although in lesser amounts). Thus, it is not a route-
specific impurity. In addition, this impurity occurs as two peaks in the chromatogramme because of the presence 
of the two isomers (E and Z). 
 
(3) N-(β-Phenylisopropyl)benzaldiimine [1-Phenyl-N-(phenylmethylidene)propan-2-amine] 
 
This impurity, abbreviated benzaldiimine or aldiimine, is an intermediate compound from the reductive 
amination of BMK to amphetamine. It is thought to be the result of a reaction between amphetamine and 
benzaldehyde, the latter being an impurity of commercial or synthesised BMK [Theuween and Verweij, 1980]. 
However, this impurity has been found in amphetamine synthesised via the three synthetic routes. Thus, it is not 
a route-specific impurity. 
 
(4) 2-Methyl-3-phenylaziridine  
 
This compound seems to be the result of reduction of the ketoxime. This impurity is therefore not theoretically 
route-specific. However, high amounts of this impurity was only found in nitrostyrene amphetamine whereas 
only traces were detected in reductive amination amphetamine. No traces of this impurity was found in Leuckart 
amphetamine. Synthesis of this impurity was carried out according to Kotera [Kotera et al., 1968]. 
 
(5) N-(β-Phenylisopropyl)benzyl methyl ketimine [N-(1-Methyl-2-phenylethylidene)-1-phenylpropan-2-
amine] 
 
This impurity, abbreviated ketiimine, is an intermediate compound from the reductive amination of BMK to 
amphetamine. It is thought to be the result of a reaction between amphetamine and BMK. However, this 
impurity has been found in amphetamine synthesised via the three synthetic routes [Sinnema and Verweij, 1981]. 
Thus, it is not a route-specific impurity. Isolation of this compound was difficult as it was found to be unstable. 
 
(6) N-Acetylamphetamine [N-Benzyl-1-phenylpropan-2-amine] 
 
This impurity has been found in amphetamine synthesised via the three synthetic routes [Theeuwen and Verweij, 
1981]. The origin of this impurity remains unclear. One hypothesis is the acetylation of amphetamine from the 
following sources : 
 
- Acetamide present as an impurity in commercial formamide (Leuckart). 
- Acetic acid present as an impurity in commercial formic acid (Leuckart). 
- Ammonium acetate in the reductive amination of BMK and the reduction of nitrostyrene. 
- Traces of formaldehyde / acetaldehyde in methanol 
 
(7) Benzoylamphetamine [N-(1-Methyl-2-phenylethyl)benzamide] 
 
This impurity has been found in amphetamine synthesised via the three synthetic routes. The origin of this 
impurity remains also unclear.  
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(8) Benzylamphetamine [N-Benzyl-1-phenylpropan-2-amine] 
 
This impurity has been found in amphetamine synthesised via the three synthetic routes. The origin of this 
impurity seems to be the same as for the aldiimine. In this case, the aldiimine is further reduced to produce 
benzylamphetamine. 
 
(9) 1-Phenyl-2-propanol [1-Phenylpropan-2-ol] 
 
When BMK is reduced to amphetamine, a competing reaction is the reduction to phenyl-2-propanol. Therefore, 
this impurity is often detected in high amounts in reductive amination amphetamine [Van den Ark et al., 1978b]. 
However, it is also observed in Leuckart and nitrostyrene amphetamine. Hence, it is not considered as a route-
specific impurity. 
 
(10) 1-Oxo-1-phenyl-2-(β-phenylisopropylimino)propane [2-[(1-Methyl-2-phenylethyl)imino]-1-
phenylpropane-1-one] 
 
This impurity has been found in reductive amination amphetamine [Theeuwen and Verweij, 1981]. The origin of 
this impurity is thought to be the result of the reaction between amphetamine and phenyl-1,2-propanedione, the 
latter being an impurity of commercial or synthesised BMK. Isolation of this compound was difficult as it was 
found to be unstable. 
 
(11) 2-Oxo-1-phenyl-(β-phenylisopropylamino)ethane [N-(1-Methyl-2-phenylethyl)-2-phenylacetamide] 
 
This impurity has been found in amphetamine synthesised via the three synthetic routes. The origin of this 
impurity remains unclear.  
 
(12) N-β-Hydroxy-N,N-di(β-phenylisopropyl)amine [2-[(1-methyl-2-phenylethyl)amino]-1-phenylpropan-
1-ol]  
 
This impurity has been found in reductive amination amphetamine. The origin of this impurity is thought to be 
the result of a further reduction of 1-oxo via cathinone (compound 13). 
It contained two diastereoisomers and recristallisation gave only one pure diastereoisomer. 
 
(13) N-(β-Phenylisopropyl)cathinone [2-[(1-Methyl-2-phenylethyl)amino]-1-phenylpropan-1-one] 
 
This impurity has been found in reductive amination amphetamine. The origin of this impurity is thought to be 
the result of a further reduction of 1-oxo. For these three impurities (1-oxo, cathinol and cathinone), it has not 
been determined if they are route-specific or not. However, they have not been observed in the nitrostyrene and 
Leuckart amphetamines. 
 
(14) 4-Methyl-5-phenylpyrimidine  
 
This impurity has always been considered as a route-specific impurity for Leuckart amphetamine. It is thought to 
be a specific product of a reaction between one molecule of BMK and two molecules of formamide [Van den 
Ark et al., 1977b, Van den Ark et al., 1978d]. However, trace amounts have been found in synthesised reductive 
amination amphetamine. Nevertheless, if a fair amount of this impurity is detected, it is reasonable to assume 
that the synthetic route used was Leuckart. 
Moreover, higher amounts of this impurity is produced when no formic acid is added during the Leuckart 
reaction [Huizer et al., 1985]. Synthesis of this impurity was carried out according to Koyama [Koyama et al., 
1975]. 
 
(15) 1,3-Diphenyl-2-propylamine 
 
This impurity is the product of the reaction between amphetamine and dibenzylketone [Noggle et al., 1985], the 
latter being an impurity of commercial or synthesised BMK [Kram, 1977]. Theoretically, it is therefore an 
impurity that could be found in Leuckart and reductive amination amphetamine. This was confirmed by 
controlled syntheses. Moreover, it was not detected in synthesised nitrostyrene amphetamine. 
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(16) 4-Benzylpyrimidine  
 
Same remarks as compound 14. Synthesis of this impurity was carried out according to Abbotto [Abbotto et al., 
1991]. 
 
(17) N-Formylamphetamine [1-Methyl-2-phenylethylformamide] 
 
This compound is the intermediate product which leads to amphetamine in the Leuckart reaction (see paragraph 
2.3). Its presence in the final product therefore results from incomplete hydrolysis. 
For these reasons, it was believed (and still is) to be specific to the Leuckart route. However, the controlled 
syntheses showed us that this compound is also present in reductive amination amphetamine as well as 
nitrostyrene amphetamine (although in lesser amount). 
 
(18) N,N-di-(β-Phenylisopropyl)amine [N-(1-Methyl-2-phenylethyl)-1-phenylpropan-2-amine] 
 
This impurity is the product of the reaction between amphetamine and BMK. The unstable ketiimine (compound 
5) is first produced which is further reduced to form this dimer also abbreviated DPIA. In the Leuckart reaction, 
it is the main impurity when formic acid is added in the first step of the reaction [Huizer et al., 1985]. 
However, as for the ketiimine, it is not route-specific and is detected in amphetamine synthesised via the three 
different routes. 
 
(19) N,N-di-(β-Phenylisopropyl)methylamine [N-Methyl-N-(1-methyl-2-phenylethyl)-1-phenylpropan-2-
amine] 
 
This impurity is thought to be the result of the reduction of impurity 20 [Huizer et al., 1985] and has been 
identified first as an impurity in methamphetamine [Bailey et al., 1974]. As impurity 20 is a result of the 
formylation of DPIA (compound 18), it is therefore assumed that this impurity, together with impurity 20, could 
be specific to the Leuckart reaction. Indeed, formylation could not, theoretically, occur in reductive amination or 
nitrostyrene amphetamine as no formamide or formic acid are present in these reactions. Further, this impurity 
was not found in amphetamine synthesised via reductive amination or via the nitrostyrene route. 
Synthesis of this impurity was carried out according to Schmitt [Schmitt et al., 1966]. 
 
(20) N,N-di-(β-Phenylisopropyl)formamide [bis-(1-methyl-2-phenylethyl)-formamide] 
 
As mentioned above, this impurity is thought to be the result of the formylation of DPIA (impurity 18).Synthesis 
was carried out by boiling DPIA with formamide [Huizer et al., 1985]. 
 
(21) 2,4-Dimethyl-3,5-diphenylpyridine  
 
This more complex impurity is thought to be the result of the reaction between two molecules of BMK with one 
molecule of formamide [Van der Ark et al., 1978]. Many pyridine impurities are detected in amphetamine 
synthesised via the Leuckart route. The differences reside in the various methyl and / or phenyl positions in the 
chemical structure. Unfortunately, partner 4 was only able to synthesises one of these pyridines. However, this is 
already quite an achievement as the synthesis of these pyridines has never been described in the forensic 
literature. Nevertheless, synthesis was possible by following the procedures described by Hauser [Hauser and 
Eby, 1956] and  Wajon [Wajon and Arens, 1957]. 
 
The pyridine impurities are considered to be specific to the Leuckart route. However, trace amounts were found 
in reductive amination amphetamine. Still, the amounts detected were at the ultra trace level. Therefore, these 
pyridines (as the pyrimidines 14 and 16) remain very strongly indicative of the Leuckart route. 
 
1.8 Preliminary conclusions from task 1 
 
All together 21 compounds found as impurities in street amphetamine have been successfully synthesised. Full 
spectroscopic data of these compounds was recorded. This data set is unique and offers a huge potential for 
future developments in chemical profiling of amphetamine.   
From these 21 impurities, few are considered to be route-specific. However, the data obtained in task 6 (see 
section 6.6.5) provide more clues as to the impurities which enable the distinction between the three synthetic 
routes studied in this project. 
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2. Task 2 – Stability of impurities in different solvents  
 
 
2.1 Introduction 
 
In gas chromatography it is essential that the analytes are stable in the solvent chosen for the introduction of the 
sample into the gas chromatograph. This is even more important when routine profiling analyses are performed. 
Indeed, 50 to 100 samples can be prepared on a given day and put on the sample tray of the gas chromatograph 
autosampler awaiting injection. Given the run time of a typical analysis (30 to 45 minutes), the time difference 
between the first injection and the last injection can be up to 100 hours. Therefore, it is of utmost importance that 
during this time delay no reaction occurs in the sample vial. Otherwise, the comparison between the first and last 
profile will be biased. 
 
For these reasons, the stability of the synthesised impurities in various solvents as a function of time and 
temperature was investigated in Task 2. Also, the experiments were repeated with synthesised amphetamine in 
order to determine the stability of the impurities after liquid-liquid extraction. 
The objective was to find the best solvent in terms of stability of the impurities.  
 
The subtasks within Task 2 were the following : 
 
- Evaluate the linearity of the detector response for each of the synthesised impurities. 
- Examine the stability of the impurities at two different temperatures (8°C and 25°C) over time 
(0 - 96 hours) as a total mixture in six different solvents. 
- Examine the stability of the impurities in extracts obtained from liquid-liquid extraction (LLE). 
 
 
2.2 Results and discussion 
 
 
2.2.1 Determination of linearity of FID and MSD response to target compounds 
 
Linearity was evaluated by least squares regression analysis in the concentration range of 0.1 – 500 µg/mL in 
isooctane using Method 1 (Annex 2). Briefly, this method consisted of a GC-FID-MSD method, with splitless 
injection into two similar columns to produce simultaneously both the MSD and the FID trace. This dual-column 
assembly was applied by Partners 1, 2 and 4, whereas Partner 3 used two separate GC units for FID and MSD. 
 
The linear regression equations have been described in Annex 4. 
 
The linearity of the FID was studied at each participating laboratory prior to the stability study to validate the GC 
method. Partner 2 and Partner 3 used the calibration range 0.1 - 20 µg/mL. Partner 1 and Partner 4 used the 
ranges 0.1 - 500 and 0.1 - 250 µg/mL, respectively. All labs used tetracosane as the internal standard. The 
concentration was however different. Partner 2 and 3 used 10 µg/mL, while Partner 4 and Partner 1 used 100 
µg/mL. This explains the difference in the calibration function.  
 
All data yielded r
2
 values greater than 0.994. Full results can be found in Annex 5. 
 
Thus, all compounds tested produced linear detector responses from the GC – FID over the concentration range 
in which the forthcoming experimentation was to be undertaken. Linearity of the MSD was not investigated at 
this stage since it was applied to qualitative use only.  
 
2.2.2 Determination of stability of impurities in synthetic mixtures and in synthesised amphetamine 
 
The stability of the synthesised impurities, each at 10 µg/mL, was examined as a mixture (synthetic mixture) in 
six different solvents namely iso-octane (2,2,4-trimethylpentane), toluene, dichloromethane, diethyl ether, ethyl 
acetate and ethanol. The stability was evaluated over 0, 4, 12, 24, 48 and 96 hours at 25 ºC. Some of the 
experiments were also carried out at 8 
o
C if decomposition was observed at 25°C. 
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An internal standard (tetracosane : C24H50; 10 µg/mL) was added to all mixtures of compounds and each 
injection was made in duplicate. 
Additionally, the stability of the impurities in extracts, prepared from the amphetamine synthesised as a part of 
this study, was investigated by the liquid-liquid extraction (LLE) method used routinely over the years in Partner 
2 and 3 laboratories [Kärkkäinen et al., 1994, Jonson and Strömberg, 1993]. This consists of dissolving 
amphetamine (300 mg) in 3.0 mL phosphate buffer (63.2 mM, pH 7.00 ± 0.03) and extracting the solution with 
1.2 mL of solvent. Synthesised impurities were added to the extract in cases they were otherwise absent in the 
extract. Ethanol was discarded from this experiment as it could not have been separated in the LLE process.  
 
A thermostatic bath equipped with a liquid circulation system was attached to the GC autosampler tray to 
provide precise temperature control of the sample vials stored in the tray.   
 
The results of the stability study can be found in Annex 6.  
 
An example of how the calculations have been made is shown below : 
 
 
 
 
Example for 2,4-dimethyl-3,5-diphenylpyridine in isooctane at 25°C 
 
 At T = 0 At T = + 4h At T = + 12h At T = + 24h At T = + 48h At T = + 96h RSD 
RRF 0.847 0.839 0.839 0.851 0.837 0.837 0.7 % 
Ratio 1.00 0.991 0.991 1.005 0.988 0.988 0.7 % 
 
 
As can be seen in the example above, no significant change was observed for this impurity in isooctane at 25°C 
(less than 1 % relative standard deviation). However, this was not the case with all impurities. The following 
paragraph describes the various problems encountered : 
 
2.2.3 Unstable impurities in synthetic mixtures and in synthesised amphetamine 
 
The stability of the cathinol in the Partner 2 synthetic mixture was poor as the compound was sometimes found 
in increasing concentration and sometimes the compound was completely lost. This phenomenon was most 
probably caused by the instability of the compound in the analytical system and thus its actual stability in 
different solvents could not be established. The stability of N-(β-phenyl-isopropyl)benzyl methyl ketiimine 
and 1-oxo-1-phenyl-2-(β-phenylisopropylimino)-propane in the Partner 2 samples was poor causing nearly 
complete loss of these analytes. This observation was further confirmed by preparing and analysing a separate 
solution of only these two compounds.  
DPPA in the synthetic mixture turned out to be unstable to some extent in dichloromethane, diethyl ether and in 
ethyl acetate. 
Benzaldiimine seem to start to decompose after a while in ethyl acetate, ethanol and dichloromethane. The same 
remark is valid for nitrostyrene in ethanol and to a lesser extent in dichloromethane whereas the ketoxime seem 
to decompose slightly in ethanol. 
 
Data at 8 ºC was collected only for the reductive amination impurities. No significant differences were found and 
thus full dataset was not collected. Moreover, it was also found rather difficult in practice to operate at low 
temperatures, i.e. the sample vials cannot be continuously maintained at 8 °C during the analysis without 
specially designed laboratory facilities. Thus the results obtained at 25 °C illustrate the stability that can be 
achieved in practice.  
 
As for impurities extracted from synthesised amphetamine, they mirrored the results obtained in synthetic 
mixtures. However, a few outlier results were observed (no real trend) in dichloromethane, diethyl ether and 
ethyl acetate. Ethanol was obviously not used for liquid-liquid extraction experiments but it was studied as it 
could later be considered for solid-phase extraction experiments (see section 4). 
standard internal of area Peak
impurity of area Peak
 =  (RRF) factor  response  Relative
0 time at factor  response  Relative
h) 96  or 48 24, 12, 4, (0,delay  time of factor  response  Relative
 =  Ratio
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Table 3 below summarises the results obtained by the four partners in terms of relative standard deviation (6 
injections at 6 different times) : 
 
Table 3 Relative standard deviations (in %) for six injections at time t = 0, 4, 12, 24, 48 and 96 hours 
Synthetic mixture isooctane toluene dichloromethane diethyl ether ethyl acetate ethanol 
Benzyl methyl ketone* 0.8 1.1 0.8 1.3 1.0 0.5 
2-methyl-3-phenyl aziridine 0.6 1.0 0.6 1.6 0.5 0.8 
Benzyl aziridine* 2.2 1.1 2.4 6.4 n/a n/a 
Benzyl methyl ketoxime (isomers 1+2) 1.5 1.9 2.4 4.0 1.2 4.0 
Nitrostyrene 0.7 0.7 9.3 1.6 0.7 5.9 
Benzaldiimine*** 0.9 2.1 9.5 1.4 19.5 6.1 
N-acetylamphetamine 2.3 4.6 3.8 1.8 2.4 0.9 
Benzylamphetamine 1.3 3.1 2.0 3.7 3.9 1.1 
Benzoylamphetamine 0.6 1.2 1.8 2.4 0.5 0.5 
2-oxo 0.9 1.0 2.2 2.4 0.5 0.9 
N-formylamphetamine 2.0 1.2 1.1 1.4 0.9 1.7 
4-methyl-5-phenylpyrimidine 0.9 1.1 1.9 2.6 2.3 2.8 
4-benzylpyrimidine** 1.2 1.0 1.8 1.8 1.5 2.4 
DPPA** 1.7 2.0 7.2 6.4 5.3 1.5 
DPIA** (isomers 1+2) 1.1 0.8 1.6 1.7 0.9 1.1 
DPIMA** (isomers 1+2) 2.3 3.2 2.1 1.7 4.3 2.8 
DPIF** (isomers 1+2) 1.0 1.1 1.8 7.8 0.6 0.6 
2,4-dimethyl-3,5-diphenylpyridine 0.7 1.4 1.6 2.7 0.5 0.6 
Mean 1.3 1.6 3.0 2.9 2.7 2.0 
       
Amph extract isooctane toluene dichloromethane diethyl ether ethyl acetate 
Benzaldiimine 10.0 8.5 n/a 11.7 10.7  
N-acetylamphetamine n/a 6.3 2.8 13.5 6.6  
Benzylamphetamine 1.9 4.0 8.0 8.7 1.6  
Benzoylamphetamine 7.1 5.4 n/a 1.6 1.5  
N-formylamphetamine n/a 1.1 1.4 6.5 1.6  
4-methyl-5-phenylpyrimidine 1.4 2.9 3.6 3.0 1.3  
4-benzylpyrimidine 1.3 2.1** 4.9 1.9 1.2  
DPIA** (isomers 1+2) 1.0 1.3 1.2 5.1 1.2  
DPIMA (isomers 1+2) 1.9 n/a 1.2 7.3 2.3  
DPIF** (isomers 1+2) 0.8 0.7 1.0 2.2 1.3  
2,4-dimethyl-3,5-diphenylpyridine 2.8 2.3 4.7 2.5 4.2  
Mean 3.1 3.5 3.2 5.8 3.0  
       
Total mean 2.2 2.6 3.1 4.4 2.9  
 
* BMK and benzyl aziridine were present as impurities and studied as well. Their identities were checked with 
available standards, benzyl aziridine being synthesised by partner 1 although not present in the task 1 list. 
 
** Mean values taken from partners 3 and 4 (some impurities were studied in both labs). 
 
*** Mean value taken from partner 1 and 2 (impurity studied in both labs). 
 
n/a : not available. Generally because of coelution problems. 
 
In table 3, cathinol, N-(β-phenyl-isopropyl)benzyl methyl ketiimine and 1-oxo-1-phenyl-2-(β-
phenylisopropylimino)-propane were not taken into account given their unstability in all solvents. 
Excluding these three unstable impurities, the results show that iso-octane, followed by toluene, are the best 
solvents in terms of stability of the analytes. However, good results were obtained for the other solvents as well 
but the relative standard deviations were somehow a little bit higher. Also, the use of diethyl ether highlighted 
some practical problems. Indeed, even with crimped sealed vials, it is not seldom that the solvent evaporates if 
the vial is kept for a long period of time on the sample tray. This is somehow not surprising given the very high 
volatility of this solvent. 
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2.3  Conclusion 
 
Whilst some impurities are more stable in amphetamine extracts and others more stable in a synthetic mixture, 
the overall results seem to indicate that iso-octane should be the solvent of choice for the subsequent Task 3 and 
method development. This did not preclude the use of toluene in other stages of the project (for example, 
optimisation of the extraction protocol) as it behaved similarly to iso-octane in terms of stability. At this stage, it 
may not as well preclude the use of any of the other solvents, except maybe for diethyl ether whose high 
volatility gives rise to practical problems. 
 
In general, the relative standard deviations (RSD) values obtained for iso-octane and toluene (which are 
somehow smaller compared to the other solvents) are in the order of magnitude typically met in valid GC 
applications. This fact strongly supports the hypothesis that the target compounds can be reliably analysed in 
these solvents with the exception of cathinol, N-(β-phenyl-isopropyl)benzyl methyl ketiimine and 1-oxo-1-
phenyl-2-(β-phenylisopropylimino)propane. These three compounds cannot be reliably quantified. 
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3. Task 3 - Optimisation of gas chromatographic system 
 
 
3.1 Introduction 
 
Optimisation of the GC system was carried out such that each operating parameter was individually investigated. 
The task was divided into three subtasks: 
 
 Subtask 3.1 Sample introduction technique and injector operating conditions. 
 Subtask 3.2 Column stationary phase and temperature programme. 
 Subtask 3.3 Detector type and operating conditions. 
 
 
3.2 Injection technique 
 
3.2.1 Experimental 
 
In this subtask, the injection port temperature was investigated using both split and splitless injection techniques. 
Extracts of Leuckart, nitrostyrene and reductive amination amphetamine were prepared according to the method 
described in Task 2. The solvent used was iso-octane. The extractions were performed in triplicate, the extracts 
combined and divided for subsequent method development to guarantee reproducible samples for all 
experiments. 
 
In the initial studies, reference values for relative response factors (RRF’s) for impurities found in the 
amphetamine synthesised by each laboratory were determined by Partner 2 using cool on-column (COC) 
injection. These results were required as they represent an “absolute” sample introduction technique, since the 
sample is not heated in the injection block and all of it enters the column directly. The analyses were performed 
using the oven track mode of the cool on-column inlet, which constantly maintains the temperature of the inlet 3 
°C higher than that of the column oven. Other parameters were the same as used in Task 2.   
 
In the second step the test samples were analysed using splitless and split injection techniques by all Partners. 
For the splitless mode a deactivated glass liner was installed (HP Part No. 18740-80220). Additionally, a 
retention gap pre-column was connected between the injection port and the analytical column. The reason for 
this is that splitless injection produces symmetric peaks for target compounds of various boiling points only if 
so-called solvent effect is fully utilised. Pre-columns are known to improve the solvent effect especially for the 
low-boiling point compounds. It was not necessary to study this phenomenon as it has been thoroughly described 
in the literature [Grob, 1993]. For the split mode the standard split method as applied in Task 2 was employed. 
However, in order to be able to detect the peaks when using the split injection, a lower split ratio of 1:20 and a 
higher injection volume of 2 µL were required. 
 
Both the split and splitless modes were evaluated in each laboratory using the same amphetamine extracts that 
had been used previously for the COC injection studies carried out by Partner 2. A number of different injector 
temperatures (220, 240, 260 and 280°C) were evaluated to determine the effects of temperature on responses 
from the compounds in the extracts when using split and splitless injections. Measurement of RRF values and 
examining both systematic and random errors were carried out to find the most suitable injection technique and 
optimum injection temperature.  
 
The percentage relative deviation between the COC and the split and splitless techniques were determined by 
measuring the RRF’s, i.e., peak area of a certain impurity per peak area of an internal standard, from the split and 
splitless injections and comparing them with those obtained with the COC technique. The relative deviation can 
be considered as a measure for systematic error and calculated as:  
 
100%×
column)on  RRF(cool
column)on  RRF(cooltechnique) RRF(inj.
=(%) deviation Relative
 
 -
 (1) 
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Each RRF value is the mean value calculated from three replicate injections. Values for the relative deviation 
can be positive or negative, depending on the type of discrimination the inlet causes to the analyte. Systematic 
error can be derived by summing the absolute values of the relative deviation: 
 
 
deviation Relative =value Absolute  (2) 
 
%100
n
 valueabsolute
(%)error  Systematic ×=
∑
n
i
, (3) 
  
where n is the number of target compounds. 
 
Random error of each injection technique and temperature was estimated by investigating the RSD’s of the 
RRF’s in three replicate analyses. Average of the relative standard deviations of the RRF’s illustrate the random 
error : 
 
%100
n
RSD
 (%)error  Random ×=
∑
n
i
, (4) 
 
where n is the number of target compounds. 
 
 
3.2.2 Results and discussion 
 
Random and systematic error : 
 
Random error cause replicate results to differ from one another and will affect the precision, or reproducibility, 
of an experiment. If the random error is small, then the result will be precise. 
 
Systematic error cause the results to be in error in the same sense (for example, all too high or all too low). 
However, in a given experiment, there may be several sources of systematic error, some positive and others 
negative. This is why, in equation 3, we are taking the absolute value of the relative deviation in order to get the 
total systematic error, also called the bias. 
 
The results illustrating the random and systematic errors are summarised in table 4 and table 5.  
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Table 4 Random error using different sample introduction techniques and conditions. Only 
compounds studied in Task 2 and found to be stable were used for this study.  
RANDOM ERROR  Splitless Split 
 On-column 220 oC 240 oC 260 oC 280 oC 220 oC 240 oC 260 oC 280 oC 
Ketoxime (1)  2.86 % 1.35 % 4.98 % 11.00 % 0.82 % 2.12 % 6.37 % 2.36 % 2.77 % 
Ketoxime (2) 2.97 % 2.47 % 2.89 % 8.57 % 0.51 % 10.20 % 1.10 % 1.57 % 3.05 % 
Formylamphetamine 2.38 % 2.15 % 7.29 % 7.66 % 3.38 % 3.48 % 3.20 % 0.43 % 21.78 % 
Acetylamphetamine 2.67 % 4.26 % 22.55 % 16.61 % 17.59 % 9.50 % 10.29 % 6.25 % 1.82 % 
Benzaldiimine 3.09 % 4.53 % 24.03 % 7.73 % 9.42 % 2.06 % 1.85 % 2.26 % 0.35 % 
Average (Partner 1) 2.79 % 2.95 % 12.35 % 10.31 % 6.34 % 5.47 % 4.56 % 2.57 % 5.95 % 
Benzaldiimine 2.59 % 2.83 % 0.99 % 4.99 % 4.58 % 3.56 % 1.48 % 1.02 % 0.96 % 
Benzylamphetamine  1.30 % 1.60 % 2.19 % 2.17 % 0.88 % 1.02 % 0.39 % 1.40 % 1.40 % 
DPIA (1) 1.05 % 1.89 % 1.33 % 1.80 % 0.40 % 0.94 % 0.47 % 1.55 % 1.54 % 
DPIA (2) 1.34 % 1.33 % 0.84 % 1.75 % 0.80 % 0.88 % 0.64 % 1.59 % 1.58 % 
Benzoylamphetamine  0.69 % 1.88 % 1.95 % 4.21 % 1.09 % 1.43 % 0.77 % 2.68 % 2.65 % 
Average (Partner 2) 1.39 % 1.91 % 1.46 % 2.98 % 1.55 % 1.57 % 0.75 % 1.65 % 1.63 % 
4-Methyl-5-phenylpyrimidine 0.16 % 5.25 % 1.72 % 6.09 % 6.10 % 1.47 % 0.86 % 1.45 % 0.55 % 
4-benzylpyrimidine  0.20 % 4.99 % 1.97 % 6.37 % 6.49 % 4.05 % 2.81 % 2.21 % 3.12 % 
Benzaldiimine 1.96 % 5.27 % 2.38 % 6.31 % 2.79 % 6.89 % 3.51 % 5.21 % 10.88 % 
Benzylamphetamine  0.12 % 3.42 % 1.45 % 3.90 % 3.76 % 1.45 % 0.17 % 2.67 % 1.31 % 
DPIA (1) 2.00 % 1.23 % 1.63 % 4.29 % 2.92 % 0.82 % 0.71 % 0.93 % 0.39 % 
DPIA (2) 3.96 % 7.62 % 2.40 % 5.61 % 3.59 % 0.44 % 0.51 % 1.12 % 0.54 % 
DPIMA 0.41 % 2.25 % 2.37 % 4.34 % 2.70 % 4.59 % 5.97 % 1.14 % 2.50 % 
DPIF (1) 0.05 % 0.46 % 0.97 % 1.80 % 1.38 % 1.56 % 3.85 % 3.38 % 0.94 % 
DPIF (2) 0.41 % 0.22 % 1.10 % 1.68 % 1.43 % 2.15 % 1.21 % 1.69 % 3.57 % 
Average (Partner 3) 1.03 % 3.41 % 1.78 % 4.49 % 3.46 % 2.60 % 2.18 % 2.20 % 2.64 % 
4-Methyl-5-phenylpyrimidine 0.35 % 2.04 % 0.93 % 1.27 % 1.11 % 0.45 % 0.29 % 0.91 % 1.24 % 
Formylamphetamine 0.69 % 2.11 % 0.96 % 1.22 % 0.61 % 0.90 % 0.18 % 0.26 % 1.95 % 
4-Benzylpyrimidine 0.27 % 1.86 % 1.03 % 1.34 % 0.93 % 0.69 % 0.24 % 0.49 % 1.40 % 
Benzaldiimine 1.15 % 4.89 % 1.45 % 0.92 % 3.37 % 0.10 % 0.23 % 1.14 % 4.81 % 
Benzylamphetamine  0.47 % 5.13 % 1.19 % 1.45 % 0.51 % 2.31 % 3.45 % 0.56 % 5.06 % 
DPIA (1) 1.52 % 1.64 % 2.02 % 1.06 % 0.73 % 0.38 % 0.20 % 0.78 % 0.42 % 
DPIA (2) 1.37 % 1.33 % 0.99 % 1.06 % 1.16 % 0.30 % 0.25 % 0.54 % 0.29 % 
DPIMA 0.33 % 1.30 % 1.05 % 0.64 % 0.36 % 0.37 % 0.31 % 0.64 % 0.39 % 
Benzoylamphetamine 2.92 % 1.67 % 1.06 % 0.72 % 1.64 % 0.49 % 0.31 % 0.78 % 1.14 % 
2,4-dimethyl-3,5-
diphenylpyridine 
4.14 % 3.63 % 26.86 % 24.79 % 32.66 % 0.31 % 0.60 % 0.89 % 1.44 % 
DPIF (1) 0.54 % 0.55 % 0.36 % 0.24 % 0.18 % 0.15 % 0.15 % 0.37 % 0.28 % 
DPIF (2) 0.64 % 0.00 % 0.36 % 0.20 % 0.21 % 0.12 % 0.07 % 0.33 % 0.29 % 
Average (Partner 4) 1.20 % 2.18 % 3.19 % 2.91 % 3.62 % 0.55 % 0.52 % 0.64 % 1.56 % 
Average (all Partners) 1.44 % 2.62 % 3.98 % 4.57 % 3.68 % 2.10 % 1.69 % 1.57 % 2.59 % 
 
 
With exception of the results from Partner 1 the random error (repeatability) is less than 5%. High deviation in 
Partner 1 results is most probably due to instrumental problems. The most repeatable injection technique is split 
at 260 °C.  
 
In general, the random error is smaller in split injection compared to splitless injection. 
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Table 5 Systematic error using different sample introduction techniques and conditions. Partner 1 
data was considered as outlier and not included in the average values. 
SYSTEMATIC ERROR Splitless Split 
 220 oC 240 oC 260 oC 280 oC 220 oC 240 oC 260 oC 280 oC 
Ketoxime (1)  20.72 % 9.64 % 0.25 % 1.04 % 62.04 % 65.48 % 65.65 % 66.31 % 
Ketoxime (2) 62.92 % 57.80 % 53.20 % 54.19 % 4.82 % 6.15 % 6.08 % 9.13 % 
Formylamphetamine 20.58 % 12.73 % 2.85 % 2.80 % 70.08 % 70.27 % 67.75 % 50.87 % 
Acetylamphetamine 81.29 % 78.56 % 136.12 % 146.32 % 17.62 % 4.09 % 11.23 % 11.02 % 
Benzaldiimine 43.12 % 48.33 % 39.13 % 17.56 % 251.52 % 235.80 % 236.76 % 231.04 % 
Average (Partner 1) 45.73 % 41.41 % 46.31 % 44.38 % 81.22 % 76.36 % 77.49 % 73.67 % 
Benzaldiimine 68.11 % 80.91 % 108.36 % 126.22 % 56.79 % 51.65 % 49.98 % 59.58 % 
Benzylamphetamine  1.75 % 4.32 % 3.07 % 2.63 % 15.25 % 6.92 % 3.71 % 3.60 % 
DPIA (1) 10.12 % 4.08 % 4.78 % 4.36 % 14.25 % 5.73 % 4.50 % 3.90 % 
DPIA (2) 8.37 % 2.01 % 3.12 % 3.27 % 19.04 % 9.94 % 0.04 % 0.17 % 
Benzoylamphetamine  15.62 % 10.23 % 7.03 % 0.57 % 12.86 % 8.45 % 2.51 % 3.87 % 
Average (Partner 2) 20.79 % 20.31 % 25.27 % 27.41 % 23.64 % 16.54 % 12.15 % 14.22 % 
4-methyl-5-phenylpyrimidine 22.76 % 21.02 % 25.03 % 21.36 % 12.47 % 11.42 % 9.29 % 13.23 % 
4-benzylpyrimidine  21.41 % 21.02 % 25.14 % 21.36 % 14.97 % 12.34 % 13.37 % 13.09 % 
Benzaldiimine 15.18 % 14.35 % 23.59 % 36.97 % 9.87 % 0.76 % 0.51 % 3.50 % 
benzylamphetamine  7.14 % 5.34 % 7.27 % 5.41 % 5.36 % 1.49 % 0.44 % 1.32 % 
DPIA (1) 0.58 % 1.38 % 3.62 % 2.97 % 34.82 % 36.41 % 37.30 % 36.95 % 
DPIA (2) 23.77 % 15.08 % 15.32 % 13.64 % 92.89 % 87.62 % 84.85 % 86.02 % 
DPIMA 3.17 % 4.21 % 3.00 % 1.03 % 3.15 % 1.58 % 5.27 % 3.27 % 
DPIF (1) 2.68 % 1.38 % 0.20 % 0.71 % 5.57 % 6.41 % 1.96 % 4.88 % 
DPIF (2) 3.64 % 1.86 % 0.20 % 0.28 % 5.43 % 8.96 % 1.67 % 3.44 % 
Average (Partner 3) 11.15 % 9.52 % 11.49 % 11.53 % 20.50 % 18.55 % 17.18 % 18.41 % 
4-Methyl-5-phenylpyrimidine 26.93 % 14.23 % 6.02 % 4.87 % 45.69 % 34.02 % 25.29 % 16.16 % 
Formylamphetamine 9.28 % 0.89 % 7.73 % 7.72 % 19.82 % 10.77 % 3.70 % 0.77 % 
4-Benzylpyrimidine 19.92 % 9.27 % 2.11 % 1.41 % 43.54 % 31.98 % 22.99 % 13.89 % 
Benzaldiimine 13.09 % 22.82 % 26.75 % 23.43 % 12.01 % 7.01 % 1.04 % 7.11 % 
Benzylamphetamine  6.19 % 17.66 % 25.83 % 26.21 % 4.99 % 0.58 % 6.85 % 12.18 % 
DPIA (1) 16.78 % 5.06 % 5.14 % 6.49 % 16.11 % 9.89 % 4.09 % 0.13 % 
DPIA (2) 13.83 % 1.05 % 8.05 % 10.43 % 20.06 % 13.60 % 7.51 % 3.48 % 
DPIMA 6.91 % 3.52 % 12.65 % 15.08 % 4.47 % 0.86 % 3.22 % 6.47 % 
Benzoylamphetamine 3.35 % 11.58 % 16.54 % 17.79 % 37.99 % 33.61 % 27.61 % 23.37 % 
2,4-dimethyl-3,5-
diphenylpyridine 
0.44 % 18.19 % 30.53 % 40.65 % 3.77 % 6.37 % 11.15 % 13.00 % 
DPIF (1) 0.44 % 2.85 % 7.77 % 9.94 % 10.97 % 13.00 % 15.89 % 18.26 % 
DPIF (2) 3.86 % 6.08 % 9.93 % 11.73 % 13.33 % 15.13 % 17.82 % 20.14 % 
Average (Partner 4) 10.09 % 9.43 % 13.25 % 14.65 % 19.40 % 14.74 % 12.26 % 11.25 % 
Average (Partners 2 - 4 only) 12.5% 11.6% 15.0% 16.0% 20.6% 16.4% 13.9% 14.3% 
 
 
 
The systematic errors which mainly arise from discrimination problems of the vaporising inlets are all fairly high 
compared with the random errors. Partner 1 results must be excluded because of their inexplicably high 
deviation. According to Partners 2, 3 and 4 results the best condition is splitless at 240°C. However, split 
injection is not significantly different from the splitless technique although the lowest temperatures with splitless 
injection give the smallest systematic errors.  
 
In order to take into account both errors, a total error U was calculated. This error can be estimated with the 
formula often used for calculating combined measurement uncertainty : 
 
 ( ) ( )22 ransys uuU +=  (5) 
 
where usys and uran are bias (systematic error) and precision (random error), respectively [Eurachem, 2000]. 
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Table 6 concludes total error. The smallest total error is achieved with splitless injection at 240 °C. Almost the 
same results can be obtained with split injection at 260 °C.  
 
Table 6 Summary of errors affecting vaporising sample introduction techniques. 
TOTAL ERROR Splitless Split 
 220 oC 240 oC 260 oC 280 oC 220 oC 240 oC 260 oC 280 oC 
Random error, all Partners 2.62 % 3.98 % 4.57 % 3.68 % 2.10 % 1.69 % 1.57 % 2.59 % 
Systematic error, Partners 2 - 4 12.51 % 11.55 % 14.95 % 16.02 % 20.60 % 16.40 % 13.94 % 14.30 % 
Total error 12.78 % 12.22 % 15.63 % 16.44 % 20.71 % 16.49 % 14.03 % 14.53 % 
 
 
 
3.2.3. Conclusions 
 
Optimisation of the injection technique was difficult. The best injection technique, the cool on-column sample 
introduction, was excluded as it was considered not to be robust enough for everyday work. Thus the choice had 
to be made between different vaporising techniques. The results show that the split and splitless technique work 
similarly at different temperatures. The technique causing the smallest total error, i.e. splitless at 240 °C, 
probably offers the best performance especially if low concentration samples are to be analysed. Practically, the 
same results can be obtained using split injection at a higher temperature (260 °C). 
 
Split injection at 260 °C was chosen for Subtask 3.2 as this technique provides better chromatographic 
performance under various conditions than splitless technique. This was considered necessary because the aim of 
Subtask 3.2 was the optimisation of chromatographic separation. Also, split injection at 260°C gave a much 
better random error than splitless at 240°C (1.6 % vs 4.0 %). However, this did not preclude the use of splitless 
injection at 240°C or even 250°C at a later stage in the project. 
 
Although splitless injection at 240 °C gave the best overall performance, 250 °C was used in all other tasks as 
this temperature is commonly used in many laboratories performing amphetamine profiling. It is expected that 
this 10 °C difference does not have a significant impact on the results. 
 
 
3.3 Choice of Column and Oven Temperature 
 
3.3.1 Experimental 
 
It was decided that in the framework of the current study only columns of standard dimensions would be used. 
Thus the length, the internal diameter and the film thickness were fixed to 25 – 30 m, 0.20 – 0.25 mm and 0.25 – 
0.33 µm, respectively. In addition, potential stationary phases were limited to those that can be operated up to 
300 °C. Taking these restrictions into consideration each Partner initially evaluated three phenyl methyl silicone 
stationary phase columns with different stationary phase ratios, namely Ultra 1, Ultra 2 and HP50+. All columns 
were 25 m x 0.20 mm, df 0.33 µm (HP50+ : 0.31 µm) from the Agilent company. An additional column, HP-
1701, also from the Agilent company was studied by Partner 2 although the maximum temperature of this 
column was only 280°C. This was because the HP-1701 column is widely used for the analysis of polar 
compounds.  
 
In addition to the choice of column, column temperature programme was also evaluated and optimised. 
Temperature program profiles were limited to only linear ramps to ensure the best possible reproducibility of 
retention times (tR) and retention factors (k). Six different column temperature programme rates, ranging from 2 
to 12 ºC/min, were employed, all starting at 60ºC and ending at 300°C. Injections were performed in split mode 
with an injection temperature of 260ºC according to the decision made in subtask 3.1. Simultaneous FID/MSD 
detections was applied such that chromatographic performance was calculated for the FID trace and peak 
purity/co-elution was monitored using the MSD trace. Samples of home-made amphetamine, prepared as in the 
previous subtask, were used as test samples.  
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3.3.2 Results and discussion 
 
3.3.2.1 Separation power, resolution and inertness  
 
The performance of each column was assessed by measuring separation power, resolution and inertness. Overall 
separation power was estimated on the basis of the number of peaks that could be integrated in the 
chromatogram. Sensitivity of the integrator was individually calibrated for each chromatogram relative to the 
size of the internal standard peak. Resolution of the target compounds was investigated through the concept of 
graphical resolution. 
 
Graphical resolution can determined by the following equation 
 
 
(6) 
 
Where ∆tR is the difference between retention times of two peaks and Wb is the width of the peak at its base. 
 
Example : 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 : example illustrating the concept of graphical resolution 
 
 
In this case, tR1 is 19.45 min and tR2 is 19.53 min. Wb1 and Wb2 are 0.07 min. Therefore the resolution is : 
 
R = 2 x (19.53 – 19.45) / (0.07 + 0.07) = 0.16 / 0.14 = 1.14 
 
In this subtask, the resolution between target compounds were calculated. In table 8, results are given as a 
percentage of target compounds which are separated with a resolution > 1. 
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Inertness was estimated on the basis of peak asymmetry, calculated as a ratio of second and first half-widths (at 
10% height) of each peak, respectively. 
 
Example : 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 : graphical representation for the calculation of inertness 
 
 
 
In this case, if B is 0.08 min and A is 0.16 min, the inertness will be calculated as 0.16 / 0.08 = 2. 
A value above 1 will mean that the peak is tailing while a value below 1 will correspond to peak fronting. Of 
course, the ideal value is one (perfect symmetry). 
 
Resolution and asymmetry were calculated using the peak performance functions of the macro tools in the 
Agilent GC Chemstation (Rev. A06.03) software. At this stage of the project, it was decided that the target 
compounds would be divided in Classes A and B on the basis of their stability (Task 2 results), presence in street 
samples and based on experience from previous profiling internal studies [Kronstrand, 1990, Johansson, 1991, 
Lindberg 1991, Alm et al., 1992]. Class A compounds are presumed to be more important and reliable. The list 
of the target compounds is given in Table 7. 
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Table 7 Identified amphetamine impurities synthesised by Leuckart, reductive amination and 
nitrostyrene methods.  Compounds printed with strike-out font have been excluded from all 
calculations due to their instability. 
No. Class Compound New compound and type of 
identification 
1 B Benzyl methyl ketone - 
2 B 4-methyl-5-phenylpyrimidine* - 
3 B N-formylamphetamine* - 
4 B 4-benzylpyrimidine* - 
5 A 1,3-diphenyl-2-propylamine* - 
6 B N,N-di(β-phenylisopropyl)amine (1)* - 
7 B N,N-di(β-phenylisopropyl)amine (2)* - 
8 A N,N-di(β-phenylisopropyl)methylamine (1)* - 
9 A N,N-di(β-phenylisopropyl)methylamine (2)* - 
10 A 1-benzyl-3-methylnaphthalene* Id. based on a RM from UN
1
 
11 A 1,3-dimethyl-2-phenylnaphthalene* Id. based on a RM from UN
1
 
12 A 2,6-dimethyl-3,5-diphenylpyridine* Id. based on literature data
2
 
13 A 2,4-dimethyl-3,5-diphenylpyridine* - 
14 A 2,6-diphenyl-3,4-dimethylpyridine* Id. based on a RM from NFI
3
 
15 A N,N-di(β-phenylisopropyl)formamide (1)* - 
16 A N,N-di(β-phenylisopropyl)formamide (2)* - 
17 A/B 2-benzyl-2-methyl-5-phenyl-2,3-dihydropyrid-4-one* Id. based on literature data
4
 
18 A Pyridine 14 Id. based on MSD data 
19 A Pyridine 7 Id. based on MSD data 
20 A/B Pyridine X Id. based on MSD data 
21 A Phenyl-2-propanol - 
22 A Acetylamphetamine - 
23 A N-(β-phenylisopropyl)benzaldimine* - 
24 A/B Benzylamphetamine* - 
25 - N-(β-phenyl-isopropyl)benzyl methyl ketimine - 
26 A 1-oxo-1-phenyl-2-(β-phenylisopropylimino)propane - 
27 A Benzoylamphetamine* - 
28 A 2-oxo-1-phenyl-(β-phenylisopropylamine)ethane - 
29 B 1-hydroxy-N,N-di(β-phenylisopropyl)amine (Cathinol) - 
30 B N-(β-phenylisopropyl)cathinone - 
31 A 2-methyl-3-phenylaziridine - 
32 A dimethyl-3-phenylaziridine Id. based on MSD data 
33 A 2-phenylmethylaziridine Id. based on MSD data 
34 A Benzyl methyl ketoxime (1) - 
35 A Benzyl methyl ketoxime (2) - 
36 B Phenyl-2-nitropropene  - 
 
 
1
 Reference material (RM) from the United Nations Office of Drugs and Crime (scientific section) 
2
 [Van den Ark et al., 1978a] 
3
 Reference material (RM) from the Netherlands Forensic Institute 
4
 [Van den Ark et al., 1977a] 
* Compounds studied by partner 4 in this subtask 
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The results obtained by Partner 4 are summarised in Table 8. The reader is advised to note that the results are 
based on only 19 target compounds (see asterisks in table 7). 
 
Table 8 Performance of each column at each temperature programme. The results are averages of  
19 compounds in one sample analysed in IPSC, n=3. “n.a.” stands for “not analysed”.  
Column T-program 
° C/min 
Separation 
power (no. of 
integrated peaks) 
Target peaks with 
resolution ≥ 1 
Target peak 
asymmetry 
(absolute value) 
Ultra 1 2 64 84 % 1.60 
 4 67 84 % 1.45 
 6 66 76 % 1.55 
 8 64 82 % 1.52 
 10 65 71 % 1.35 
 12 62 71 % 1.39 
Ultra 2 2 67 76 % 1.46 
 4 70 66 % 1.58 
 6 69 76 % 1.38 
 8 66 79 % 1.48 
 10 66 84 % 1.44 
 12 63 82 % 1.42 
HP 50+ 2 62 92 % 1.39 
 4 58 89 % 1.29 
 6 52 95 % 1.25 
 8 52 95 % 1.21 
 10 52 87 % 1.27 
 12 55 87 % 1.36 
 
From these results, it can be seen that slow temperature programmes give, in general, better separation power. 
The best results were obtained with the Ultra 1 and Ultra 2 columns with slow temperature programmes (2, 4 and 
6°C per min). In terms of resolution, the best result was obtained with the HP 50+ column at 6 and 8°C per min. 
Also, this same column and temperature programmes gave the best inertness. 
The following chromatogrammes illustrate the resolution results from table 8 (best resolution for each column). 
Only part of the chromatogramme where resolution problems were occuring are shown : 
 
Ultra 1, 2 deg / min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 : Chromatogramme illustrating separation of Leuckart impurities on a Ultra 1 column at 2 deg / 
min. Identification of peaks: 1: DPIMA 1, 2: DPIMA 2, 3: 1-benzyl-3-methylnaphthalene, 4: 
1,3-dimethyl-2-phenylnaphthalene, 5: Benzoylamphetamine, 6: 2,6-dimethyl-3,5-
diphenylpyridine, 7: 2,4-dimethyl-3,5-diphenylpyridine, 8: 2,6-diphenyl-3,4-dimethylpyridine, 
9: DPIF 1, 10: DPIF 2. 
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Ultra 2, 10 deg / min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 : Chromatogramme illustrating separation of Leuckart impurities on a Ultra 2 column at 10 deg / 
min. Identification of peaks: same as figure 11. 
 
 
HP 50+, 8 deg / min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 : Chromatogramme illustrating separation of Leuckart impurities on a HP 50+ column at 8 deg / 
min. Identification of peaks: same as figure 11. 
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The combined results for all partners are summarised in Table 9. The reader is advised to note that the results are 
based on all 35 target compounds (table 7). 
 
Table 9 Performance of each column at each temperature programme. The results are averages of  
35 compounds in four different samples analysed in four different laboratories, n=3. “n.a.” 
stands for “not analysed”.  
Column T-program 
° C/min 
Separation 
power (no. of 
integrated peaks) 
Target peaks with 
resolution ≥ 1 
Target peak 
asymmetry 
(absolute value) 
Ultra 1 2 125 81 % 2.37 
 4 128 79 % 2.18 
 6 125 74 % 2.23 
 8 113 74 % 2.23 
 10 112 73 % 1.95 
 12 107 64 % 1.96 
Ultra 2 2 141 81 % 2.51 
 4 140 74 % 2.26 
 6 129 79 % 2.18 
 8 126 75 % 2.24 
 10 126 77 % 1.97 
 12 114 78 % 1.92 
HP 50+ 2 130 91 % 1.99 
 4 117 85 % 1.93 
 6 100 91 % 1.75 
 8 102 88 % 1.75 
 10 103 89 % 1.60 
 12 99 84 % 1.65 
HP 1701 2 75 n.a. n.a. 
 4 75 n.a. n.a. 
 6 68 n.a. n.a. 
 8 64 n.a. n.a. 
 10 63 n.a. n.a. 
 12 62 n.a. n.a. 
 
 
HP 1701 column was not further investigated due to its inferior separation power. 
 
 
Again, the combined results confirm that slow temperature programmes give better results in terms of separation 
power. It also confirms that the HP 50+ column gives somehow better resolution and better inertness compared 
to the two other columns.  
 
At this stage of the project, it was decided to continue with a HP 50+ column due to its better performance in 
terms of inertness and resolution. Also, visual comparisons showed that it was probably the best column for 
satisfactory separation of all target compounds (as illustrated in figures 11, 12 and 13). 
Therefore, this column was used in Task 4, but at a later stage the noise level of the column caused by excessive 
bleeding was found to be unacceptable. The bleeding seemed to vary from column to column but overall it was 
much higher than could be accepted (see figure 14) : 
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Figure 14  Illustration of the bleeding of HP50+ column (top) compared to that of the Ultra 2 column 
(bottom). Temperature programme: 60 °C, 8 °C/min => 300 °C (10 min). FID detection. 
Chromatograms have been recorded by Partner 2. 
 
 
To overcome this problem other columns of similar or nearly similar stationary phase were investigated. HP-35, 
DB-35MS and DB-17MS were chosen for the study. The number 35 meaning that the stationary phase is made 
of 35 % poly(diphenylsiloxane) and 65 % poly(dimethylsiloxane) whereas the DB-17MS contains the same 
stationary phase as the HP50+ column, namely 50 % poly(diphenylsiloxane) and 50 % poly(dimethylsiloxane). 
Therefore, the DB-35MS and HP-35 are slightly less polar than the HP 50+ and DB-17MS. 
J&W columns (i.e., DB columns) were chosen on the basis that the Agilent company was merged with the J&W 
company and thus the columns were available from the same source. It was considered an advantage that only 
one manufacturer would represent the entire analytical system.  
 
The same experiments were carried out to evaluate the target compounds resolution and inertness of the J&W 
columns. The data was calculated for Class A compounds only as they were recognised as having the main 
priority. Moreover, the data was recorded only for temperature programme rates providing analysis time of 30 
min or less, i.e. 8, 10 and 12 °C/min. Table 10 summarises the performance of each column.  
 
Note : These further experiments were carried out by partners 2 and 3 only. 
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Table 10 Performance of each column at each temperature programme. The results are based on the 
Class A compounds only.  
Column T-program 
°C/min 
Target peaks (Class A) 
with resolution > 1.0 
Asymmetry  
Average (absolute value) 
Ultra 1 2 74 % 2.74 
 4 72 % 2.49 
 6 65 % 2.57 
 8 62 % 2.54 
 10 66 % 2.23 
 12 65 % 2.29 
Ultra 2 2 75 % 2.98 
 4 66 % 2.43 
 6 74 % 2.51 
 8 72 % 2.62 
 10 75 % 2.19 
 12 79 % 2.11 
HP 50+ 2 89 % 2.36 
 4 85 % 2.22 
 6 88 % 2.00 
 8 85 % 1.84 
 10 85 % 1.76 
 12 82 % 1.76 
HP-35 8 87 % 1.91 
 10 87 % 1.43 
 12 89 % 1.53 
DB-35MS 8 87 % 1.28 
 10 87 % 1.42 
 12 72 % 1.33 
DB-17MS 8 88 % 1.78 
 10 84 % 1.43 
 12 83 % 1.50 
 
 
The best overall resolution for the Class A compounds was obtained on HP-35 column at 12°C/min, although 
DB-35MS gave nearly the same performance at 8°C/min. Also DB-17MS performed well in terms of overall 
resolution.  
 
The DB-35MS was the most inert column and bleeding was negligible compared to the other columns. Thus, 
taking all aspects into consideration, DB-35MS was found to be the best compromise to meet all the 
requirements. The column was chosen for the following tasks (tasks 5 and 6). 
 
 
3.3.3 Conclusions 
 
The non-polar columns Ultra 1 and Ultra 2 had the highest overall separation power which is commonly known 
as these columns have the highest efficiency. For the current application however other features had to be 
emphasised. Resolution of the targeted analytes, i.e. the synthesis impurities, was the most important selection 
criterion. Inertness is nearly as important since it illustrates the ability of the column to separate compounds of 
varying chemical characteristics. HP 50+ offered great performance but column to column reproducibility was 
insufficient, as clearly demonstrated by the varying stationary phase bleed. Besides, the Agilent company has 
acknowledged the excessive bleeding of this column. Taking all these factors into consideration the DB-35MS 
column was the best compromise in terms of chromatographic performance. 
 
Temperature programme rate was shown to have a great impact on the performance of each column. Finally, 8 
°C/min was chosen as it provided an acceptable compromise between analysis time and chromatographic 
performance. 
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3.4 Selection of the detection technique 
 
3.4.1 Introduction 
 
Evaluation of different detection techniques was performed using FID and MSD in Scan and SIM (Single Ion 
Monitoring) modes. The reader is advised to note that some MSD results of this subtask have been obtained 
using ‘Ultra’ ion source parts in the HP5973 mass spectrometer. At some stage, the standard ion source caused 
excessive tailing, especially of the hydrocarbon peaks, caused by contaminated and thus activated metal surface 
in the ion source. This phenomenon occured almost at the same time in all four laboratories indicating a common 
problem directly related to the standard ion source. Illustrations will be shown in section 4.4.3. Meanwhile, the 
part numbers (Agilent Technologies) of the new ion source parts can be found below : 
 
1) G2589-20043 Ultra Ion Chamber 
2) G2589-20044 Ultra Repeller 
3) G2589-20045 Drawout Plate 
 
In this subtask, splitless injection was used. One of the reasons was to determine the lowest concentrations which 
can be detected with each detector. Also, as mentioned in section 4.2.3, the injection port was set at 250°C. 
Finally, the oven temperature programme started at 90°C. It was determined that this increased the speed of 
analysis without affecting the chromatographic performance. 
For MS data (Scan and SIM), ion response was measured instead of peak area using the Chemstation software. 
Additionally, Partner 3 evaluated performance of nitrogen-phosphorus selective detection (NPD). 
 
3.4.2 Experimental 
 
A modified Grob test mixture was used in this subtask. The following chromatogramme shows the various 
compounds used in this subtask by partner 4 (all compounds were commercially purchased): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 : FID chromatogramme containing the 18 compounds used for this subtask by partner 4. Run 
acquired on a DB-35MS column (see annex 2 for full method). . Identification of peaks: 1: 
dodecane, 2: 2,6-dimethyl phenol, 3: tridecane, 4: 2,6-dimethyl aniline, 5: Decanoic acid 
methyl ester, 6: pentadecane, 7: undecanoic acid methyl ester, 8: dicyclohexylamine, 9: 
hexadecane, 10: dodecanoic acid methyl ester, 11 : heptadecane, 12: octadecane, 13: 
nonadecane, 14: eicosane, 15: N-methyldiphenethylamine, 16: ketamine, 17: tetracosane, 18: 
trimipramine. 
 
A dilution series of the test mixture was prepared for the evaluation of sensitivity and linearity. Different 
performance tests were carried out as follows : 
 
Repeatability : The modified Grob mixture was injected repeatedly twenty times and the relative standard 
deviation (RSD) calculated for all relative peak areas (relative to the internal standard). This 
data was produced for FID and for MSD in Scan and SIM modes.  
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Reproducibility : The modified Grob mixture was injected once every day for twenty days. Calculations 
were performed as for repeatability. 
 
Sensitivity : Different concentrations of the Grob mixture were injected in three replicates. 
Concentrations producing a signal-to-noise ratio of 10:1 was then extrapolated. 
Detection limits as well as limits of determination were calculated. 
 
Linearity : The test mixture was run at five different concentrations covering a range of five 
orders of magnitude (but having the internal standard at constant concentration). The 
correlation coefficient was calculated and linearity checked.  
 
3.4.3 Results and discussion 
 
Tailing problem : 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 : MS chromatogramme showing the tailing problem in a Grob mixture. From left to right : 
nonadecane, eicosane, N-methyldiphenethylamine, ketamine, tetracosane, and trimipramine 
 
As can be seen in figure 16, tailing begins to occur as from nonadecane and particularly affects the highest 
boiling alkane, namely tetracosane. Also, a loss of sensitivity was observed for this compound. The tailing 
values were calculated with the Chemstation software (see section 4.3.2.1, figure 10). 
 
Figure 17 below shows the same Grob mixture after installation of the new ultra ion source MS parts : 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 : Same as figure 16 but after installation of the new MS parts. 
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As can be seen in figure 17, the peaks are now almost perfect and there is no loss of sensitivity for the high 
boiling alkane (tetracosane). 
 
As will be shown below, the direct effect of using the new MS parts was much better overall repeatability and 
reproducibility. However, as mentioned by the manufacturer (Agilent Technologies), the small drawback is a 
slight loss in sensitivity. Nevertheless, this was found to be not so obvious as the improvement in peak shape 
somehow compensated for the slight weaker response of the ultra ion source. 
 
Repeatability 
 
The modified Grob mixture was injected repeatedly twenty times and the relative standard deviation (RSD) 
calculated for all relative peak areas (relative to the internal standard). This data was produced for FID and for 
MSD in Scan and SIM modes. 
All compounds were prepared in toluene at a concentration of 0.001 mg / ml, except the internal standard 
(eicosane) which had a concentration of 0.01 mg / ml.  
Table 11 Repeatability of the Grob mixture with FID, MS in SCAN and SIM mode  
 
 IPSC 
 FID SCAN OLD MS SCAN NEW MS SIM OLD MS SIM NEW MS 
Dodecane (C12) 1.6 % 1.8 % 1.7 % 0.6 % 0.7 % 
2,6-dimethylphenol 1.8 % 2.0 % 1.4 % 0.9 % 0.7 % 
Tridecane (C13) 1.3 % 1.9 % 1.5 % 1.1 % 1.0 % 
2,6-dimethyl aniline 1.3 % 1.9 % 1.5 % 0.8 % 0.7 % 
Decanoic acid Me-ester 0.9 % 2.3 % 1.0 % 1.2 % 0.5 % 
Pentadecane * 1.0 % 4.0 % 2.7 % - - 
Undecanoic acid Me-ester  2.4 % 4.3 % 5.9 % 5.1 % 2.0 % 
Dicyclohexylamine 14.7 % 11.2 % 14.8 % 11.8 % 20.9 % 
Hexadecane* 0.9 % 3.9 % 2.5 % - - 
Dodecanoic acid Me-ester  1.0 % 5.7 %  1.6 % 8.2 % 2.7 % 
Heptadecane (C17) 0.6 % 4.1 % 1.5 % 1.3 % 0.5 % 
Octadecane (C18) 0.5 % 4.3 % 2.1 % 1.4 % 0.5 % 
Nonadecane (C19) 0.4 % 3.6 % 2.2 % 1.6 % 0.7 % 
N-methyl-diphenethylamine 3.1 % 3.2 % 2.0 % 3.3 % 2.1 % 
Ketamine 4.1 % 3.9 % 2.2 % 4.5 % 1.0 % 
Tetracosane (C24) 0.7 % 11.9 % 3.5 % 6.7 % 2.1 % 
Trimipramine 2.1 % 3.9 % 2.7 % 4.2 % 2.6 % 
Average 2.3 % 4.3 % 3.0 % 3.5 % 2.6 % 
 
*) 
 In SIM mode, pentadecane and undecanoic acid methyl ester could not be separated as they coelute and 
selected ions were only chosen for undecanoic acid methyl ester. The same for hexadecane and 
dodecanoic acid methyl ester where only the latter was measured. 
 
The results show that the repeatabilities of different detectors are rather similar and that the MSD performs better 
after installation of the new MS parts. 
 
 
Reproducibility 
 
The modified Grob mixture was injected once every day for twenty days. Preparation of samples and 
calculations were performed as for repeatability. 
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Table 12 Reproducibility of the Grob mixture with FID, MS in SCAN and SIM mode  
 
 IPSC 
 FID SCAN OLD MS SCAN NEW MS SIM OLD MS SIM NEW MS 
Dodecane (C12) 1.3 % 7.6 % 3.5 % 6.3 % 2.3 % 
2,6-dimethylphenol 1.5 % 3.9 % 2.4 % 2.2 % 1.5 % 
Tridecane (C13) 1.8 % 7.3 % 3.3 % 6.6 % 2.3 % 
2,6-dimethyl aniline 1.0 % 3.2 % 2.7 % 1.6 % 1.4 % 
Decanoic acid Me-ester 1.3 % 5.2 % 3.3 % 3.2 % 2.2 % 
Pentadecane * 2.5 % 9.0 % 10.6 % - - 
Undecanoic acid Me-ester  2.4 % 11.6 % 10.0 % 6.4 % 7.6 % 
Dicyclohexylamine 6.9 % 11.2 % 7.7 % 9.7 % 9.7 % 
Hexadecane* 1.3 % 8.9 % 9.0 % - - 
Dodecanoic acid Me-ester  1.0 % 11.4 %  8.4 % 6.1 % 4.7 % 
Heptadecane (C17) 1.1 % 5.4 % 3.1 % 3.4 % 2.2 % 
Octadecane (C18) 1.0 % 4.4 % 3.1 % 2.8 % 1.9 % 
Nonadecane (C19) 0.5 % 3.6 % 2.7 % 2.9 % 1.6 % 
N-methyl-diphenethylamine 2.5 % 13.3 % 2.6 % 13.7 % 2.5 % 
Ketamine 6.7 % 20.5 % 3.8 % 21.7 % 3.8 % 
Tetracosane (C24) 3.3 % 26.8 % 5.1 % 26.7 % 5.0 % 
Trimipramine 1.8 % 15.8 % 3.2 % 17.4 % 3.2 % 
Average 2.2 % 9.9 % 5.0 % 8.7 % 3.5 % 
 
 
The results show that the reproducibility of FID is slightly better. This was however expected as this detector is 
known to be very stable. However, the MSD performed quite well (in SCAN and SIM mode) and it is here 
evident that the “old” MSD showed reproducibility problems with the later eluting compounds. 
 
 
Sensitivity 
 
Limits of determination : 
 
Limits of determination are regarded as the lower limits for precise quantitative measurements, as opposed to 
qualititative detection [Miller and Miller, 2000]. For this matter, the RSD values for three replicates were taken 
into account and the limit of determination was defined as the lower limit where RSD values were still below 10 
%. 
Unfortunately, the limits of determination could only be calculated for FID and the MS modes (Scan and SIM) 
with the standard ion source. Replicates were not performed with the new ion source, thus limits of 
determination could not be calculated. However, partners 2 and 3 did perform these experiments and were able 
to calculate the limits of determination for the new ion source. 
Table 13 below shows the separate results regarding limits of determination : 
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Table 13 Results of the limits of determination study (n = 3). N.D. stands for not detected. RSD are in 
% and are average values calculated from all compounds in the modified Grob mixture. 
 
Partner 2 FID NPD MS SCAN 
(NEW) 
MS SIM 
(NEW) 
 
MS SCAN 
(OLD) 
MS SIM 
(OLD) 
1 µg / ml - - - - - - 
0.1 µg / ml 0.1 - 6 2 - - 
0.05 µg / ml 16 - 18 2 - - 
0.01 µg / ml 21 - 20 6 - - 
0.005 µg / ml 25 - N.D. 11 - - 
Partner 3 
 
 -     
0.5 µg / ml 2 2 3 3 - - 
0.1 µg / ml 7 6 3 5 - - 
0.05 µg / ml 8 9 9 11 - - 
0.01 µg / ml N.D. N.D. N.D. 34 - - 
0.005 µg / ml N.D. N.D. N.D. 50 - - 
Partner 4 
(IPSC) 
      
1 µg / ml 2 - - - 6 2 
0.1 µg / ml 4 - - - 10 9 
0.05 µg / ml 7 - - - 23 12 
0.01 µg / ml N.D. - - - N.D. 17 
0.005 µg / ml N.D. - - - N.D. 9 
 
 
The table shows the average RSD values of the target compounds at various concentrations. The lowest 
concentration with acceptable repeatability is considered as the limit of determination. This concentration is 
obviously difficult to define, but, in this context, between days reproducibility values have been used as a 
reference and thus RSD values less than 10% are considered acceptable. 
From this table, it can be seen that there are slight differences between labs. However, it shows that the limit of 
determination for FID is probably around 0.05 µg / ml (as for NPD) while it’s more like 0.1 µg / ml for MS in 
the SCAN mode. As for MS in the SIM mode, results from different labs seem to be a little contradictory and the 
true limit of determination is difficult to define. However, the absolute sensitivity of SIM is definitely ten times 
better compared to the other detection methods as it’s still possible to detect compounds at a concentration of 
0.005 µg / ml (or 5 ng / ml). 
 
 
Detection limits : 
 
The limit of detection can be described as the concentration which gives an instrument signal significantly 
different from the blank or background signal [Miller and Miller, 2000]. The general trend is to define the limit 
of detection as the analyte concentration giving a signal equal to the blank signal + three standard deviations of 
the blank. 
In this subtask, detection limits were calculated as follows : 
 
exp
exp
exp
=
N
S
C
N
S
C
ld
dl
dl
    (7) 
 
Where Sdl, Ndl and Cdl are, respectively, the signal, noise and concentration at the detection limit. Sexp, Nexp and 
Cexp are, respectively, the signal, noise and concentration for experimental values. 
The ratio Sdl / Ndl was defined as 3 (signal to noise ratio of 3) and Nexp was defined as the amplitude noise (see 
figure 18) : 
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Figure 18 : FID chromatogramme illustrating the amplitude noise. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From figure 18, the amplitude noise can be estimated by looking at the Y scale. In this case, Nexp would be : 
(144350-143850) = 500. 
 
From figure 19 below, the peak height (Sexp) can now be obtained visually or by using the Chemstation 
software : 
 
 
Figure 19 : FID chromatogramme showing tridecane at a concentration of 0.05 µg / ml 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this case, the peak height is 3400. Thus, the detection limit can be calculated as follows (from equation 7) : 
 
 
ml / g 0.022  =  3×
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The following table (table 14) summarises the results obtained (partner 4 only) : 
 
 
17.00 17.10 17.20 17.30 17.40 17.50 17.60 17.70 17.80
143750
143800
143850
143900
143950
144000
144050
144100
144150
144200
144250
144300
144350
Time-->
Abundance
005UG-ML.D\FID1A
7.20 7.30 7.40 7.50 7.60 7.70 7.80 7.90 8.00 8.10
143600
143800
144000
144200
144400
144600
144800
145000
145200
145400
145600
145800
146000
146200
146400
146600
146800
147000
147200
147400
147600
147800
148000
148200
Time-->
Abundance
005UG-ML.D\FID1A
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Table 14 Results of the detection limits. Concentrations are in ng / ml (partner 4 only). 
 
Partner 4 FID MS SCAN 
(NEW) 
MS SIM 
(NEW) 
 
MS SCAN 
(OLD) 
MS SIM 
(OLD) 
Dodecane 20.7 10.1 0.7 7.4 0.6 
2,6-dimethylphenol 30.1 15.9 0.7 11.7 0.7 
Tridecane 22.2 11.8 1.5 9.6 1.5 
2,6-dimethylaniline 31.2 16.7 0.3 10.8 0.3 
C10 ester 36.3 16.6 0.4 15.0 0.5 
Pentadecane 22.4 15.4 - 18.9 - 
C11 ester 31.4 16.8 0.5 14.1 0.6 
Dicyclohexylamine 62.9 31.8 0.3 48.0 1.2 
Hexadecane 22.8 17.0 - 20.3 - 
C12 ester 31.7 17.7 0.6 17.4 0.8 
Heptadecane 28.8 31.4 14.3 42.6 13.6 
Octadecane 28.9 31.1 10.5 43.4 7.3 
Nonadecane 28.6 32.5 11.1 45.5 9.7 
N-methyl-di-PEA 42.4 37.8 0.6 53.8 1.1 
Ketamine 63.7 91.8 1.1 123.1 2.0 
Tetracosane 30.8 37.7 4.3 83.0 3.4 
Trimipramine 42.0 49.5 1.1 95.7 3.0 
Mean 33.9 28.3 3.2 38.8 3.1 
 
 
This table shows that, in terms of qualitative detection limits, the MS is as sensitive as the FID detector. 
Moreover, it has to be noted that, although the new MS ion source was believed to be less sensitive compared to 
its standard counterpart, this is not the case. As mentioned earlier, this is probably due to the better 
chromatographic performance which is obtained with the new MS ion source. Finally, this table confirms that 
the SIM mode is approximately ten times more sensitive than the SCAN mode. 
 
 
Linearity 
 
The test mixture was run at five different concentrations covering a range of five orders of magnitude (but 
having the internal standard at constant concentration). The correlation coefficient was calculated and linearity 
checked.  
The linearity of different detectors has been calculated as explained in Annex 4. The concentration range studied 
by Partners 2, 3 and 4 was 1 – 100 µg/mL, 1 – 500 µg/mL and 1 – 500 µg/mL, respectively. A range of 1 – 10 
000 µg/mL was investigated for FID and NPD by Partner 3. The results have been summarised in Annex 7. 
As for partner 4, the experiments were carried out with the standard and new MS ion source parts. The range of 
concentrations were 10 to 500 µg/mL with the standard ion source and 1 to 500 µg/mL for the new ion source. 
The reader should note that linearity was not calculated for the SIM mode. However, the following figure shows 
the difference in linearity between the standard ion source and new ion source.  
 
Figure 20 : graphs showing linearity of tetracosane and dicyclohexylamine with different detectors 
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Figure 20 clearly shows that the standard ion source suffers from linearity problems already as from 100 µg / 
mL. The new ion source gave excellent linearity for tetracosane, even over five orders of magnitude. The same 
remark is valid for all other compounds in the Grob mixture. However, for an amine compound 
(dicyclohexylamine), 500 µg / mL seems to be the limit of linearity. 
As for FID, the linearity is excellent. This was expected as this detector is known to have excellent linearity, 
even up to seven orders of magnitude. NPD, studied by partner 3, also showed good linearity. 
 
3.4.4 Conclusions 
 
Overall, all detectors performed well in terms of repeatability, reproducibility, sensitivity and linearity. The only 
exception being the MSD with the standard ion source. Indeed, this short study clearly demonstrated that, if the 
tailing phenomenon occurs, as it was the case in the four laboratories, the detector will loose in sensitivity and 
produce poor results in terms of reproducibility and linearity, especially for high boiling compounds which elute 
later in the chromatogram. 
 
MSD in SCAN and SIM mode, with the ultra ion source, has almost equal performances compared to FID 
detection. The main advantage of MS detection is, of course, the ability to identify compounds as a full mass 
spectrum which is retrievable for all chromatographic peaks. Moreover, it is capable of quantifying coeluting 
peaks (by measuring the ion responses separately instead of the peak areas). This very important feature, also 
described as selectivity, is of course not available with FID detection. NPD is also selective as it will detect only 
compounds containing nitrogen and phosphorous atoms. However, although most of amphetamine impurities 
contain nitrogen, some do not and most of them only contain one atom of nitrogen. 
 
Finally, the good performance of the MSD with the new ultra ion source indicated that it might become the 
choice of detection for the final method. The reader is however noted that FID was used in parallel to MSD in 
scan mode for Tasks 4, 5 and 6 to evaluate the long-term stability of the MSD technique.  
 
3.5 Quality control 
 
During the course of the study, quality control criteria were investigated. A Grob mixture was used to control the 
performance of the system. The final Grob mixture was the same as the one used in subtask 3.3 with the 
following modifications : pentadecane and hexadecane were removed and n-octanol and 2-ethylhexanoic acid 
added. Peak asymmetry values for 2-ethyl hexanoic acid are typically low because the peak is strongly fronting 
due to the acidity of the compound. The presence of this compound is only visually evaluated as it gives an 
indication of the activity of the column. If this compound is not detected, it is a strong indication that the column 
is becoming active, i.e. the stationary phase is deteriorating. 
Concentrations of the individual compounds in the Grob mixture should be 1.0 µg/mL except for 2-ethyl 
hexanoic acid which should be at 10 µg/mL concentration (for splitless injection). 
 
The reader should note that control charts provide a good means to control the parameters in practice. Moreover, 
new acceptance range may need to be calculated for peak area each time a new Grob stock solution is prepared.  
Very narrow retention time range could be used because the final method applies the retention time locking 
system (Agilent ChemStation software), feature that locks the retention time of the internal standard. However 
the retention times of other compounds may fluctuate e.g. as a result of ageing of the column or after 
maintenance actions. Therefore, quality control procedures with clearly defined acceptance criteria are required. 
 
Rather high deviation can be accepted for absolute peak areas since relative peak areas are used in this study. 
 
The following graphs are examples which illustrate the criteria that should be checked : 
 
The red line represents the average value. 
The green lines represent two times the standard deviation and are considered as the warning limits. 
The blue lines represent three times the standard deviation and are considered as the action limits. 
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Figure 21 : examples of control charts for quality control 
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As can be seen in figure 21, two additional criteria are applied : efficiency and selectivity. Efficiency is a term 
indicating the ability of the column to elute in a narrow chromatographic peak. In our case, it has been 
approximately calculated by multiplying the absolute peak area by two and divide by the peak height : 
 
height peak
area peak×2
=Efficiency        (8) 
 
Therefore, if peaks get broader (loss of efficiency), the peak area will remain constant while the peak height will 
decrease. Thus, the overall value will increase. 
 
Selectivity is defined as the degree by which the stationary phase differentiates solutes. Separation in gas 
chromatography is based on different selectivities for components present in a sample. In our case, selectivity 
has been estimated by dividing the retention times of the compounds by the retention time of dodecane. 
 
The quality control criteria need to be precisely monitored in order to check the instrument performance. It is 
also essential that immediate corrective action is taken if any significant deviation from the acceptable range is 
observed. This is particularly important if exchange of data is to be carried out between laboratories.  
 
In figure 21, an example can be seen in the top chart (retention time). Runs 14 and 15 showed a faster retention 
time on the border of the action limit although the first 13 runs showed perfect stability. As a corrective action 
the method was relocked (Retention Time Locking) and the deviation corrected. 
 
 
3.6 Additional liner study 
 
During task 3, almost all injection and detection parameters were studied. However, the influence of the choice 
of liner was not studied. A preliminary study performed by partner 2 showed that tapered liners gave generally 
better results in terms of recovery and repeatability compared to straight liners. Although this study was done on 
a limited number of amphetamine impurities, partner 4 decided to further study three different tapered liners and 
compare their efficiency in terms of recovery and repeatability. Both a Grob mixture and a synthesised 
amphetamine extract were used in order to study the influence on Grob compounds and amphetamine impurities. 
 
 
Sample preparation 
 
A Grob sample was used at a concentration of 0.001 mg / ml in toluene. Three different volumes were injected : 
0.2, 1 and 2 microlitres. Three replicates were analysed for each volume. 
 
 
GC method 
 
The same GC method as in subtask 3.3 was used (see Annex 2). FID data was used for the calculations. 
 
 
Liners 
 
Three liners were studied (all purchased from Agilent Technologies) :  
 
a) 5183-4647 : tapered liner packed with glass wool (middle). Volume : 870 microlitres. 
b) 5181-3316 : tapered liner without glass wool. Volume : 900 microlitres. 
c) 5062-3587 : tapered liner packed with glass wool (bottom). Volume : 900 microlitres. 
 
 
Results for Grob compounds 
 
First, the absolute peak areas obtained with the three injection volumes were compared between each liner. 
Three replicates were injected for each volume and the mean peak area calculated. Table 15 below illustrate the 
results obtained : 
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Table 15 Ratios in % of peak response between the three chosen liners 
5062-3587 vs 5181-3316 Peak area vs peak area in %   
 0,2 µl 1 µl 2 µl 
2,6-dimethylphenol 119% 99% 113% 
Tridecane 99% 109% 115% 
2,6-dimethylaniline 104% 105% 114% 
Tetradecane 105% 109% 117% 
Undecanoic acid methyl ester 104% 110% 118% 
Dicyclohexylamine 89% 100% 111% 
Dodecanoic acid methyl ester 103% 109% 119% 
Heptadecane 105% 108% 120% 
Octadecane 105% 109% 120% 
Nonadecane 108% 109% 119% 
Tetracosane 109% 105% 112% 
Mean 105% 107% 116% 
 
5062-3587 vs 5183-4647 Peak area vs peak area in %   
 0,2 µl 1 µl 2 µl 
2,6-dimethylphenol 109% 120% 123% 
Tridecane 106% 116% 119% 
2,6-dimethylaniline 112% 120% 128% 
Tetradecane 105% 112% 119% 
Undecanoic acid methyl ester 109% 115% 121% 
Dicyclohexylamine 109% 111% 114% 
Dodecanoic acid methyl ester 111% 110% 118% 
Heptadecane 107% 107% 112% 
Octadecane 104% 105% 110% 
Nonadecane 109% 105% 107% 
Tetracosane 104% 100% 99% 
Mean 108% 111% 115% 
 
5181-3316 vs 5183-4647 Peak area vs peak area in %   
 0,2 µl 1 µl 2 µl 
2,6-dimethylphenol 92% 121% 108% 
Tridecane 107% 107% 103% 
2,6-dimethylaniline 107% 114% 112% 
Tetradecane 100% 103% 102% 
Undecanoic acid methyl ester 105% 104% 102% 
Dicyclohexylamine 122% 111% 103% 
Dodecanoic acid methyl ester 109% 101% 99% 
Heptadecane 103% 98% 93% 
Octadecane 99% 96% 91% 
Nonadecane 100% 96% 90% 
Tetracosane 96% 95% 89% 
Mean 104% 104% 99% 
 
 
Table 15 shows that there are significant differences between the 5062-3587 liner and the two others, particularly 
if 1 or 2 microlitres are injected. Thus, these results indicate that the 5062-3587 liner performs better in terms of 
recovery for Grob compounds. Secondly, the repeatability for each liner was calculated (three replicates for three 
injection volumes). The mean values for all Grob compounds were taken into account. Table 16 below illustrate 
the results obtained : 
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Table 16 Repeatability in % for each liner (N = 3) 
 5062-3587 5181-3316 5183-4647 
0,2 µl 3.7 % 3.1 % 4.5 % 
1 µl 1.7 % 8.3 % 1.4 % 
2 µl 1.3 % 9.2 % 0.9 % 
 
These results show that both liners, 5062-3587 and 5183-4647 gave similar repeatability whereas 5181-3316 
gives somehow high deviation, particularly when 1 or 2 microlitres are injected. 
 
Results for amphetamine extract 
 
200 mg of synthesised amphetamine were dissolved in 4 ml Tris buffer 1M (ph 8.10). 200 microlitres of toluene 
containing nonadecane at 0.01 mg /ml were added. 
An extract of 100 µl was taken with a pipette and diluted with the internal standard solution to 1 ml. 2 microlitres 
were injected in triplicate. The same GC method as above was used. The relative peak areas (to internal 
standard) were compared between each liner. Table 17 below illustrate the results obtained : 
Table 17 Ratios in % of relative peak response between the three chosen liners 
 5062-3587 5183-4647 5181-3316 
4-methyl-5-phenylpyrimidine 100 % 89 % 94 % 
4-benzylpyrimidine 100 % 91 % 94 % 
1,3-diphenyl-2-propylamine 100 % 98% 92 % 
N,N-di(β-phenylisopropyl)amine (1) 100 % 98 % 90 % 
N,N-di(β-phenylisopropyl)amine (2) 100 % 98 % 90 % 
N,N-di(β-phenylisopropyl)methylamine (1) 98 % 100 % 90 % 
N,N-di(β-phenylisopropyl)methylamine (2) 97 % 100 % 90 % 
1,3-dimethyl-2-phenylnaphthalene 100 % 90 % 87 % 
2,6-dimethyl-3,5-diphenylpyridine 100 % 98 % 91 % 
2,4-dimethyl-3,5-diphenylpyridine 100 % 98 % 91 % 
pyridine 7-14 100 % 100 % 92 % 
pyridine 272 100 % 100 % 93 % 
pyridine X 100 % 99 % 93 % 
2,6-diphenyl-3,4-dimethylpyridine 100 % 100 % 93 % 
N,N-di(β-phenylisopropyl)formamide (1) 99 % 100 % 94 % 
N,N-di(β-phenylisopropyl)formamide (2) 99 % 100 % 94 % 
2-benzyl-2-methyl-5-phenyl-2,3-dihydropyrid-4-one 98 % 87 % 100 % 
Mean 99.4 % 96.8 % 92.2 % 
 
These results confirm the previous ones obtained with the Grob mixture. Thus, the 5062-3587 liner is also the 
best choice in terms of recovery for amphetamine impurities. Finally, the repeatability for each liner was 
calculated (three replicates). The mean values for all impurities were taken into account. Table 18 below 
illustrate the results obtained : 
 
Table 18 Repeatability in % for each liner (N = 3) 
5062-3587 5181-3316 5183-4647 
1.2 % 1.8 % 0.8 % 
 
 
As for the Grob compounds, the 5183-4647 liner gave the best result for amphetamine impurities in terms of 
repeatability and the 5181-3316 the worst. 
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Conclusions 
 
On the basis of this short study, it is clear that the liner containing no glass wool (5181-3316) is not as good as 
the two others in terms of recovery and repeatability. The two other liners seem to be equivalent in terms of 
repeatability but the 5062-3587 liner which contains a thin plug of glass wool at the bottom of the liner seems to 
give better peak response, hence better recovery. This liner was only introduced into the final GC method in task 
6. However, as mentioned in the general conclusions below, this liner may cause some tailing when used in a 
single-column system (which was not the case in this short study as MS and FID detection was used 
simultaneously with a two-column system). However, this has only been confirmed by partner 2 and concerns 
only Grob compounds. Besides, later studies showed that this tailing only concerned the first eluting compounds 
in the Grob mixture and that it could be solved by using a shorter splitless time (30 seconds instead of 60). 
 
 
3.7 General conclusions of task 3 
 
Task 3 established that excellent performance could be obtained using the following conditions. 
 
 
Instrument: HP 6890 gas chromatograph, HP 5973 mass selective detector with HP MS 
Chemstation rev. B.01.00 
 
Column: 35% phenyl methyl silicone column 30 m (L) x 0.25 mm (i.d.), df 0.25 µm (DB-
35MS, HP part no. 122-3832) attached to: 
 Thin-film column 35% phenyl methyl silicone pre-column, 2 - 3 m (L) x 0.25 mm 
(i.d.), df 0.10 µm (DB-35MS). The thin-film column can be ordered as a custom-
made product from the Agilent/J&W company. Alternatively a deactivated 
retention gap can be used, but this type of pre-column has shorter lifetime. 
 
Column connector: Non-deactivated press-fit connector (HP part no. 5181-3395) was used to connect 
the retention gap pre-column onto the analytical column 
 
Carrier gas: Helium, ca. 41 cm/s at 90 °C at MSD, constant flow (see retention time locking). 
 
Sample introduction: 1 µL splitless, 60 mL/min total flow after 1 min (gas saver 20ml/min after 1.5 
min), single-tapered glass wool packed liner (HP part no. 5062-3587). Injection 
volume may be varied from 0.2 to 4.0 µL depending on the concentration of the 
sample. 
 
Temperatures: 
 Injector: 250°C 
 Oven T-programs: 90 °C (1 min), 8 °C/min, 300 °C (10 min) 
 GC-MS interface: 310 °C 
 FID: 310 °C 
 
Retention time locking: The retention time of internal standard (nonadecane) should be locked to 15.00 
min (MSD). 
 
MS information: 
 Solvent delay: 4 min  
 Mass range: 40 - 300 a.m.u. (0-30 min), then 30 to 500 amu.  
 Sample rate #: 3, A/D samples 8 
 MS quad temp: 150 °C 
 MS source: 230 °C 
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4 Task 4 – optimisation of extraction procedure 
 
 
4.1 Introduction 
 
Liquid-liquid extraction (LLE) and solid phase extraction (SPE) methods were evaluated to establish the best 
sample preparation method. Home-made amphetamines synthesised by the nitrostyrene (partner 1), reductive 
amination (partner 2) and Leuckart methods (partners 3 and 4) were used as the main test samples (TEST-1). 
Another set of these samples (TEST-2) containing lactose and caffeine was prepared to study matrix effects. 
Additionally, the efficiency of the extraction methods was assessed using standard impurities made by each 
Partner. The efficiency of the extraction was measured using relative peak areas for the target compounds and 
the overall selectivity.  
 
Before starting this Task, all Partners had to prepare a large homogenised sample of amphetamine (40-50 g) so 
that the amount was sufficient to complete all studies. Method development was carried out with the aim of 
obtaining a robust and straightforward method having excellent repeatability, reproducibility, accuracy and 
sensitivity. 
 
This Task was divided into Subtasks with the first four covering the LLE method development work and the fifth 
concentrating on the SPE: 
 
Subtask 4.1  Screening study for the optimisation of type, pH and concentration of buffer and type of 
solvent  
Subtask 4.2  Further optimisation of type, pH and concentration of buffer using the best solvent 
Subtask 4.3  Optimisation of extraction procedure  
Subtask 4.4  Study of matrix effects 
Subtask 4.5  Optimisation of SPE procedure. 
 
All data presented in this task have been obtained with MS detection in the SCAN mode (ion quantitation). 
 
4.1.1 Preparation of buffers and test samples 
 
TEST-1 sample : 
 
Six different batches were synthesised via the Leuckart route and synthesis conditions varied in order to produce 
a maximum of impurities. These were mixed together and homogenised with a pestle and a mortar. Then, the 
powder was transferred to a 1L round bottom flask. Petroleum ether was added until a slurry was obtained. This 
was mixed on a Rotavapor for 3 hours. The solvent was then let to evaporate at room temperature overnight. 
Once dried, the powder was recovered with a spatula and mixed again with a pestle and a mortar. A total of 57 
grams were available. 
 
TEST-2 sample : 
 
7 grams of TEST-1 sample were mixed together with 14 grams of anhydrous caffeine (Fluka) and 14 grams of D 
(+) lactose monohydrate (Fluka ). The mixture was thoroughly homogenised with a pestle and mortar. 
 
BUFFERS : 
 
The pH meter was calibrated before preparation of every new buffer and a magnetic stirrer used during pH 
adjustment.  
 
1. Preparation of 0.1 M citrate buffer, pH 6.20 
 
Solution A: 21.0 g of citric acid were dissolved in 1 litre of deionised water. 
Solution B: 29.4 g of sodium citrate (C6H5O7Na3⋅2H2O) were dissolved in 1 litre deionised water. 140 ml of 
solution A and 856 ml of solution B were mixed. pH was adjusted exactly to pH 6.20 by adding dropwise at first 
1.0 M and thereafter 0.1M NaOH or HCl.  
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2. Preparation of 0.1 M phosphate buffer, pH 7.00 
 
Solution A: 13.8 g of NaH2PO4⋅H2O were dissolved in 1 litre deionised water. Solution B: 26.8 g of 
Na2HPO4⋅7H2O were dissolved in 1 litre distilled water. 390 ml of solution A and 610 ml of solution B were 
mixed. pH was adjusted exactly to pH 7.00 by adding dropwise at first 1.0 M and thereafter 0.1M NaOH or HCl.  
 
3. Preparation of 0.1 M Tris buffer, pH 7.9 
 
Solution A: 12.11 g of Trizma base (Tris(hydroxymethyl)aminomethane, C4H11NO3) were dissolved in 1 litre 
distilled water. 
Solution B: 0.1 M hydrochloric acid solution was prepared. 50 ml of solution A and 32.0 ml of solution B were 
mixed. pH was adjusted exactly to pH 7.90 by adding dropwise at first 1.0 M and thereafter 0.1M NaOH or HCl.  
 
The corresponding 1.0 M solutions were prepared accordingly by using 10 times higher concentrations. 0.5 M 
solutions can be made by diluting the 1.0 M solutions. 
 
Extraction : 
 
200 mg of TEST-1 (respectively TEST-2) samples are weighed and transferred in a test tube. 2 ml of buffer are 
added and the test tube shaken vigorously for 30 min. The pH is then measured and adjusted to the pre-defined 
value (pH 6.20 or 7.00 or 7.90) using 0.1M NaOH or HCl. 
200 µl of solvent are added (isooctane, toluene and dichloromethane) or 400 µl (diethyl ether and ethyl acetate) 
and again the test tube is shaken vigourously for 30 min. The test tube is centrifuged at 3000 rpm for 5 min. 
50 – 80 µl of the organic phase is then collected, placed in an autosampler vial (with insert vial) and injected. 
The reader should note that 400 µl was the minimum possible volume in order to have phase separation with 
diethyl ether and ethyl acetate. 
 
4.1.2 Buffer Capacity and dissolution power 
 
It was considered of the utmost importance that the buffer of choice had (i) high dissolution power and (ii) high 
buffer capacity. The former is required in order to dissolve an amount of amphetamine which is large enough to 
allow sufficient sensitivity for trace level concentrations of synthesis impurities. This is extremely important 
since a partly dissolved sample may have a different profile compared to the same sample which is entirely 
dissolved [Jonson and Artizzu, 1998]. Recent trends in the characteristics of street amphetamine have shown that 
very pure amphetamine containing very few impurities occur more and more often and therefore a method with 
high sensitivity and selectivity is required. 
 
Street amphetamine can be very acidic or basic, depending on the batch of drug and also on the eventual 
adulterants which are used to cut the drug. For example, the use of aspirin (acetylsalicylic acid) as a cutting agent 
will render the powder slightly acidic. High buffer capacity is required to avoid the need for laborious 
adjustment of pH to the designated value. The ideal situation would be one in which no pH adjustment is 
required after dissolving the amphetamine in the buffer. 
 
The dissolution power and buffer capacity of different buffers were studied for the TEST-1 and TEST-2 
amphetamine samples of different concentrations. Solubilities of these "model" samples in each buffer were 
investigated using citrate, phosphate and TRIS buffer solutions at concentrations of 0.1 and 1.0 M. The former 
concentration represents buffers commonly used in the existing profiling methods (0.1 M) and the latter is a high 
concentration which represents the almost maximum concentration possible for these buffers. 
The results for dissolution power were as expected. TEST-2 samples were difficult to dissolve in all buffers. This 
is due to the high amount of caffeine (40 %) which is not very soluble in aqueous solutions. On the other hand, 
TEST-1 samples were dissolved in all buffers. However, the phosphate buffer 1 M was the one that required the 
most time to dissolve all the amphetamine. In general, no significant differences were observed between 0.1 and 
1 M buffers, indicating that the use of more concentrated buffers is possible without loss in dissolution power. 
Finally, from a subjective point of view (visual observations), it seems that TRIS buffers were the best in terms 
of dissolution power. 
 
As for buffer capacity, each buffer was studied by measuring the pH after the amphetamine had been added to 
the buffer and by the amount of 1M sodium hydroxide that had to be added to return to the nominal pH of the 
buffer. These results, which were obtained by partners 2 and 3 only, are presented in table 19 : 
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Table 19 : Buffer capacity. The nominal pH values of the citrate, phosphate and Tris buffers were 6.2, 7.0 and 
7.9, respectively. The reader should be noted that the TRIS-buffer is harmful to gel based KCL electrode. 
Therefore, the measurements in this buffer were made quickly and the measurements were less accurate. It was 
found out later on during the study that electrode manufacturers recommend special electrodes for organic 
buffers.  It was also found out that pH adjustment of different buffers at different concentrations was found to be 
very difficult, hence pH was adjusted to target pH±0.05. 
 
   Partner 2 Partner 3 Mean 
Samples Buffers Nominal 
pH 
pH after addition of amph. pH after addition of amph. delta pH 
TEST-1 0.1 M citrate  6.20 5.62 6.06 0.36 
 1.0 M citrate 6.20 6.17 6.25 0.04 
TEST-1 0.1 M phosphate  7.00 6.38 6.71 0.46 
 1.0 M phosphate 7.00 6.87 6.98 0.07 
TEST-1 0.1 M TRIS * 7.90 3.94 7.95 2.01 
 1.0 M TRIS 7.90 7.81 7.88 0.06 
      
TEST-2 0.1 M TRIS 7.90 7.99 7.67 0.16 
 1.0 M TRIS 7.90 8.02 7.82 0.10 
TEST-2 0.1 M citrate  6.20 6.01 6.17 0.11 
 1.0 M citrate 6.20 6.22 6.18 0.02 
TEST-2 0.1 M phosphate  7.00 6.78 6.88 0.17 
 1.0 M phosphate 7.00 6.99 7.02 0.01 
 
*
 It is unknown whether the unexpectedly high delta pH values is due to incompatibility of the electrode for Tris 
buffer.  
 
As expected, the results clearly show that 1.0 M buffers have much better buffer capacity in all cases compared 
to 0.1 M buffers. The applicability of buffers at various concentrations for extraction purposes was studied in 
more detail in the next Subtasks. 
 
 
4.2 Type, pH and concentration of buffer and type of solvent 
 
4.2.1 Experimental 
 
In the preliminary screening study buffers were prepared at 0.1 and 1.0 M concentrations, and at pH 6.2 (citrate), 
pH 7.0 (phosphate) and pH 7.9 (Tris). All these pH values deviate 0.2 pH units from the pKa value of their 
corresponding acids. Iso-octane, toluene, dichloromethane, diethyl ether and ethyl acetate were used as the 
solvents. Matrix interferences were studied by using pure home-synthesised amphetamine and the same 
amphetamine mixed with lactose and caffeine in 20:40:40 (%, w/w) proportions.  
The parameters such as type, pH and concentration of buffer, type of solvent and influence of matrix are very 
probably dependent on each other and they all have an influence on the partition coefficient of each target 
compound. Table 20 below summarises the parameters studied and the number of experiments performed :  
Table 20 Variables used and number of experiments 
Parameters  N° of 
experiments 
Buffer type  
pH 
citrate  
6.20 
phosphate 
7.00 
Tris 
7.90 
  3 
Concentration (mol/L) 0.1 1.0    2 
Buffer volume 2 mL     1 
Solvent type iso-octane  toluene dichloromethane diethyl 
ether 
ethyl 
acetate 
5 
Solvent volume  200 µL     1 
Matrix effect none lactose + 
caffeine 
   2 
Replicates 1     1 
 
Overall, the number of experiments is 3 x 2 x 1 x 5 x 1 x 2 x 1, which equals to 60.  
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4.2.2 Results and discussion 
 
In order to generate an overview of the results, relative response factors (RRF) were calculated in both TEST-1 
and TEST-2 samples (peak area of target compound / peak area of internal standard). Z-scores were then 
calculated, i.e. the RRF values were normalised by substracting the mean and dividing by the standard deviation 
according to equation 9 : 
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Where Zi is the z-score and i is the target compound and n = 30 (n = 30 for TEST-1 samples and 24 for TEST-2 
samples). Thus, the mean and standard deviation are calculated for one target compound in all conditions. 
Then, the average z-score was calculated for all target compounds in each condition according to equation 10 : 
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Where i is the target compound and N is the number of target compounds studied. In this subtask, N = 15 
because the following impurities were studied by partner 4 : 
 
1. Benzyl methyl ketoxime 1 
2. Benzyl methyl ketoxime 2 
3. Benzylamphetamine 
4. 1,3-diphenyl-2-propylamine (DPPA) 
5. DPIA 
6. DPIMA 1 
7. DPIMA 2 
8. 1-benzyl-3-methylnaphtalene 
9. 1,3-dimethyl-2-phenylnaphtalene 
10. Benzoylamphetamine 
11. 2,6-dimethyl-3,5-diphenylpyridine 
12. 2,4-dimethyl-3,5-diphenylpyridine 
13. 2,6-diphenyl-3,4-diphenylpyridine 
14. DPIF 1 
15. DPIF 2 
 
 
These impurities were detected in the amphetamine batch synthesised by partner 4. Twelve of them are 
considered Class A compounds (see table 7, section 4.3.2). Although DPIA (the two isomers put together) was 
considered as a class B compound in section 4.3.2, it was added to the list as it is now considered an important 
impurity especially in reductive amination amphetamine. The two phenyl-2-propanone oxime isomers were also 
added to the list as they were found to be important impurities, especially for nitrostyrene amphetamine. 
Nevertheless, it can also be detected in Leuckart amphetamine and, as it was detected in this amphetamine batch, 
it was decided to include it in the list of impurities. 
 
The results were separately calculated for TEST-1 (100 % amphetamine) and TEST-2 (20 % amphetamine, 40 % 
caffeine, 40 % lactose) samples. They are shown in table 21 and were sorted in downward order, the highest 
value indicating the best condition : 
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Table 21 : Z-scores for 15 amphetamine impurities with various buffers and solvents 
 
TEST-1    TEST-2    
Solvent pH Buffer Average Solvent pH Buffer Average 
Toluene 7 Phosphate 1M 1.333 Toluene 7 Phosphate 1M 1.540 
Toluene 7.9 TRIS 1M 1.197 Toluene 7.9 TRIS 0.1M 1.275 
Dichloromethane 7 Phosphate 1M 1.001 Toluene 7.9 TRIS 1M 1.145 
Dichloromethane 7.9 TRIS 0.1M 0.972 Toluene 7 Phosphate 0.1M 0.956 
Toluene 7.9 TRIS 0.1M 0.955 Toluene 6.2 Citrate 0.1M 0.913 
Toluene 6.2 Citrate 1M 0.914 Toluene 6.2 Citrate 1M 0.782 
Dichloromethane 7.9 TRIS 1M 0.902 Isooctane 7.9 TRIS 0.1M 0.765 
Dichloromethane 7 Phosphate 0.1M 0.839 Isooctane 7.9 TRIS 1M 0.592 
Dichloromethane 6.2 Citrate 0.1M 0.803 Isooctane 7 Phosphate 1M 0.416 
Toluene 7 Phosphate 0.1M 0.712 Isooctane 7 Phosphate 0.1M 0.267 
Dichloromethane 6.2 Citrate 1M 0.694 Isooctane 6.2 Citrate 0.1M 0.218 
Toluene 6.2 Citrate 0.1M 0.501 Isooctane 6.2 Citrate 1M 0.121 
Isooctane 7.9 TRIS 1M 0.236 Ethyl acetate 7.9 TRIS 1M -0.291 
Isooctane 7.9 TRIS 0.1M 0.108 Ethyl acetate 7.9 TRIS 0.1M -0.508 
Isooctane 6.2 Citrate 1M 0.033 Ethyl acetate 7 Phosphate 1M -0.513 
Isooctane 7 Phosphate 1M 0.032 Diethyl ether 7 Phosphate 1M -0.536 
Isooctane 6.2 Citrate 0.1M -0.126 Diethyl ether 7.9 TRIS 0.1M -0.640 
Isooctane 7 Phosphate 0.1M -0.131 Diethyl ether 7.9 TRIS 1M -0.713 
Ethyl acetate 7 Phosphate 1M -0.727 Ethyl acetate 6.2 Citrate 1M -0.775 
Ethyl acetate 7.9 TRIS 1M -0.742 Ethyl acetate 6.2 Citrate 0.1M -0.821 
Diethyl ether 7 Phosphate 1M -0.812 Diethyl ether 7 Phosphate 0.1M -0.826 
Ethyl acetate 6.2 Citrate 1M -0.854 Ethyl acetate 7 Phosphate 0.1M -0.834 
Ethyl acetate 7.9 TRIS 0.1M -0.887 Diethyl ether 6.2 Citrate 1M -0.922 
Ethyl acetate 7 Phosphate 0.1M -0.898 Diethyl ether 6.2 Citrate 0.1M -0.935 
Diethyl ether 7.9 TRIS 1M -0.930 
Diethyl ether 7.9 TRIS 0.1M -0.938 
Ethyl acetate 6.2 Citrate 0.1M -1.018 
Diethyl ether 6.2 Citrate 1M -1.085 
Diethyl ether 7 Phosphate 0.1M -1.109 
Diethyl ether 6.2 Citrate 0.1M -1.223 
 
First of all, it was not possible to perform extractions with the TEST-2 samples and dichloromethane. Indeed, the 
first problem is that dichloromethane lies beneath the aqueous phase, thus making the collection of the organic 
layer more difficult. Moreover, it was impossible to separate the two phases with this type of sample and with 
the chosen extraction method. This is unfortunate as dichloromethane showed to be a good extraction solvent. 
Even doubling the volume of dichloromethane (200 to 400 µl) did not help as the other partner laboratories were 
not able to separate the two phases with 400 µl. 
Also, this double volume of solvent probably explains why diethyl ether and ethyl acetate gave poor results 
compared to toluene and isooctane. Indeed, their extraction power could not compensate for the volume used. It 
is probable that the same remarks would be valid if dichloromethane could have been extracted when using a 
volume of 400 µl. 
 
4.2.3 Conclusions 
 
Table 21 clearly shows that toluene is the most suitable solvent, followed by isooctane. It also shows that the 
type of solvent was the most influential parameter in this subtask. Regarding concentration of buffer, it is 
difficult to tell if it has a significant influence on the extraction power. In terms of pH, it is also difficult to draw 
a definitive conclusion. However, the results indicate that phosphate at pH 7.0 and TRIS at pH 7.9 give better 
results than citrate at pH 6.2. This is probably due to the fact that some impurities are slightly basic and the 
remaining are rather neutral, hence the small overall difference of extraction power between pH 7.0 and 7.9. 
Results from other partners were in agreement with these findings. 
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4.3 Further optimisation, multiple extractions, buffer and solvent volumes 
 
4.3.1 Introduction 
 
The next stage was to compare one and multiple (3) step extractions and buffer and extraction volumes. Total 
recovery and relative standard deviation of results obtained with different methods were studied with the aim of 
finding conditions providing the highest sensitivity and the best repeatability. 
 
Based on subtask 4.1 results, TRIS and phosphate buffers were used in this Subtask. The pKa values of the 
buffers were chosen as their pH values to maximise buffer capacity. The variables were investigated according to 
table 22 : 
 
Table 22 Parameters for subtask 4.2 
Parameters TEST-2 sample (20 % amphetamine, 40 % caffeine, 40 % 
lactose) 
N° of 
experiments 
Buffer volume 2 mL 8 mL   2 
Buffer type 
Solvent type 
Tris, pH 8.1 
toluene 
Phosphate, pH 7.2 
iso-octane 
  2 
Solvent volume 200 µL 3 x 200 µL 600 µL 3 x 600 µL 4 
Replicates  3    3 
    Total 48 
 
 
4.3.2 Nitrostyrene amphetamine 
 
At this stage of the project, there was a lack of data and results for nitrostyrene amphetamine. Partner 1 who was 
responsible for studying nitrostyrene impurities encountered various problems which hampered their work. 
Therefore, it was decided that, at least for this subtask, partner 4 would synthesise a batch of nitrostyrene 
amphetamine and perform the required analyses. 
For this purpose, a batch of nitrostyrene amphetamine was synthesised according to the recipe described in 
ANNEX 1. Some new impurities were identified and included in the data analysis. These are described below : 
 
 
1,2-diphenethylamine      1,2-diphenyl ethanone               Dibenzylamine                α-methyl-diphenethylamine 
                                         (Benzylphenylketone) 
 
Figure 22 : chemical structures of new nitrostyrene impurities 
 
 
As 1,2-diphenyl ethanone and dibenzylamine are commercially available, these two compounds were purchased. 
The identity of these two nitrostyrene impurities were then confirmed after comparison of their retention times 
and mass spectra with those of the reference compounds. Regarding 1,2-diphenethylamine, it was simply 
synthesised by reductive amination of the purchased 1,2-diphenylethanone. Again, its identity was further 
confirmed in the same way. As for α-methyl-diphenethylamine, it is not absolutely certain that the impurity is 
indeed this compound as no reference material was available. The identification is only based on its mass 
spectrum which perfectly matches the mass spectrum of α-methyl-diphenethylamine found in the NIST library. 
However, further identification could be performed by synthesising this compound, synthesis that could be 
performed by reacting BMK and 2-phenethylamine. For time reasons, this synthesis was not carried out. 
 
 
 
NH
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N
H
N
H
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4.3.3 Results and discussion 
 
Relative response factors values (RRF) were calculated by dividing the peak areas of the impurities by the peak 
area of the internal standard (nonadecane in this subtask). The following impurities were studied : 
 
1. 2-methyl-3-phenylaziridine 
2. Benzyl methyl ketoxime 1 
3. Benzyl methyl ketoxime 2 
4. 1,2-diphenethylamine 
5. Dibenzylamine 
6. 1,2-diphenyl ethanone 
7. Benzylamphetamine 
8. α-methyl-diphenethylamine 
 
 
Sensitivity was calculated by dividing the RRF value of a certain impurity under a specified condition by the 
maximum value obtained for that compound. For each condition an average value was calculated for all 
compounds to illustrate the overall performance. The highest average value was used to indicate the best 
sensitivity.  
 
Recovery was calculated in the same way. However, the volume of solvent was taken into consideration, i.e. 
values of samples extracted three times with 200 µl were multiplied by three, values of samples extracted with 
600 µl were multiplied by three and values of samples extracted three times with 600 µl were multiplied by 9. 
The highest average value was used to identify the best recovery.  
 
The lowest relative standard deviation value indicated the best repeatability (three replicates). 
 
The results obtained for the sensitivity, repeatability and recovery for the nitrostyrene TEST-2 sample are shown 
in table 23 : 
 
Table 23 : Sensitivity, recovery and repeatability for nitrostyrene impurities 
 
 Sensitivity Recovery Repeatability (n=3) 
8mL Tris+200µL toluene 77% 58% 8% 
8mL Tris+600µL toluene 31% 68% 4% 
8mL Tris+3x200µL toluene 37% 80% 9% 
8mL tris+3x600µL toluene 13% 82% 4% 
8mL phosphate+200µL iso-octane 27% 21% 13% 
8mL phosphate+600µL iso-octane 16% 36% 5% 
8mL phosphate+3x200µL iso-octane 19% 44% 5% 
8mL phosphate+3x600µL iso-octane 8% 55% 2% 
2mL Tris+200µL toluene  100% 75% 8% 
2mL Tris+600µL toluene 36% 79% 8% 
2mL Tris+3x200µL toluene 44% 97% 6% 
2mL Tris+3x600µL toluene 14% 89% 10% 
2mL phosphate+200µL iso-octane  36% 28% 8% 
2mL phosphate+600µL iso-octane 18% 39% 7% 
2mL phosphate+3x200µL iso-octane 23% 50% 5% 
2mL phosphate+3x600µL iso-octane 9% 59% 4% 
    
Toluene all, average 44% 79% 7% 
Iso-octane all, average 20% 42% 6% 
    
One-step 200 all, average 60%  9% 
One-step 600 all, average 25% 56% 6% 
Three-steps 200 all, average 31% 68% 6% 
Three-steps 600 all, average 11%  5% 
    
2 mL all, average 35% 65% 7% 
8 mL all, average 29% 56% 6% 
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The results in table 23 can be summarised in the following way : 
 
In general, toluene gave better sensitivity than iso-octane. One-step extraction with 200 µL solvent was the most 
sensitive method whereas three-steps extraction 600 µL solvent was the worst method. This is somehow 
expected as sensitivity in this case is a matter of concentration. 
Regarding the volume of buffer, 2 mL was better than 8 mL.  
 
Toluene gave far better recovery than iso-octane. Three-steps extraction with 600 µL gave the best recovery and 
one-step extraction with 200 µL the worst. Finally, the use of 2 mL of buffer enabled a better recovery compared 
to 8 mL. 
 
Regarding repeatability, no significant differences were observed between the various conditions. Only the one-
step extraction with 200 µL seem to be a little worse. 
 
These results, which are only for nitrostyrene impurities, were combined with those from other partners. Partner 
2 studied the reductive amination impurities and partner 3 the Leuckart impurities. As can be seen in table 24, 
the overall results do not deviate much from the results obtained in table 23. 
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Table 24 : Sensitivity, recovery and repeatability for all impurities. Combined results from partners 2,3 and 4. 
 
 Sensitivity    Recovery    Repeatability (n=3)    
 Amination Leuckart Nitrostyr. All Amination Leuckart Nitrostyr. All Amination Leuckart Nitrostyr. All 
8mL Tris+200µL toluene 84% 97% 77% 86% 60% 77% 58% 65% 5% 7% 8% 7% 
8mL Tris+600µL toluene 25% 35% 31% 30% 49% 84% 68% 67% 23% 6% 4% 11% 
8mL Tris+3x200µL toluene 41% 38% 37% 39% 84% 90% 80% 85% 3% 9% 9% 7% 
8mL tris+3x600µL toluene 16% 13% 13% 14% 84% 90% 82% 85% 4% 13% 4% 7% 
8mL phosphate+200µL iso-octane 40% 75% 27% 47% 29% 60% 21% 37% 15% 7% 13% 12% 
8mL phosphate+600µL iso-octane 11% 24% 16% 17% 24% 58% 36% 39% 4% 9% 5% 6% 
8mL phosphate+3x200µL iso-octane 9% 31% 19% 20% 63% 73% 44% 60% 8% 13% 5% 9% 
8mL phosphate+3x600µL iso-octane 12% 10% 8% 10% 70% 69% 55% 65% 4% 10% 2% 5% 
2mL Tris+200µL toluene  100% 97% 100% 99% 68% 77% 75% 73% 5% 4% 8% 6% 
2mL Tris+600µL toluene 42% 36% 36% 38% 76% 84% 79% 80% 5% 5% 8% 6% 
2mL Tris+3x200µL toluene 48% 40% 44% 44% 87% 95% 97% 93% 2% 6% 6% 5% 
2mL Tris+3x600µL toluene 21% 13% 14% 16% 97% 90% 89% 92% 3% 10% 10% 8% 
2mL phosphate+200µL iso-octane  68% 71% 36% 58% 50% 56% 28% 45% 2% 18% 8% 9% 
2mL phosphate+600µL iso-octane 28% 27% 18% 24% 60% 64% 39% 54% 3% 7% 7% 6% 
2mL phosphate+3x200µL iso-octane 40% 30% 23% 31% 88% 73% 50% 70% 4% 6% 5% 5% 
2mL phosphate+3x600µL iso-octane 29% 10% 9% 16% 60% 69% 59% 63% 8% 9% 4% 7% 
             
Toluene all, average    46%    80%    7% 
Iso-octane all, average    28%    54%    7% 
             
One-step 200 all, average    73%    55%    8% 
One-step 600 all, average    27%    60%    7% 
Three-steps 200 all, average    33%    77%    6% 
Three-steps 600 all, average    14%    76%    7% 
             
2 mL all, average    41%    71%    6% 
8 mL all, average    33%    63%    8% 
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From the overall results illustrated in table 24, It is very clear that the most sensitive extraction method is 2 mL 
TRIS buffer with 200 µl of toluene. This is valid for all impurities regardless of the synthetic route. The 
repeatability is also quite good with this extraction method. 
 
Regarding recovery, it is evident that three-step extraction will recover a higher percentage of impurities. 
However, the dilution that results from this operation causes a significant loss in sensitivity. Nevertheless, the 
recovery results show again that toluene is a much better solvent than isooctane and that 2 mL of buffer is to be 
preferred to 8 mL. 
 
 
4.3.4 Conclusions 
 
The best performing liquid-liquid extraction method for all impurities was the Tris / toluene system, 2 mL buffer 
volume and one-step extraction with 200 µL of solvent. This method did not give the best recovery, but this 
could only have been improved by using more solvent, either in one step or in three steps. However, such an 
increase in solvent volume seriously decreases the sensitivity. Moreover, three-steps extractions were considered 
far too laborious and time-consuming for routine use in forensic laboratories. 
 
 
 
4.4 Study on influence of the matrix 
 
4.4.1 Introduction 
 
Matrix effects were studied using amphetamine at various concentrations. Synthesised amphetamine (via the 
Leuckart route) was cut with caffeine (the most common adulterant found in street amphetamine) in order to 
have concentrations of 15 and 50 % amphetamine. Two buffers and solvents were evaluated also in this subtask 
to verify their performance for different types of samples. Therefore, Tris and phosphate buffers were evaluated 
with both isooctane and toluene. This time 4 mL buffer was chosen as the lowest buffer volume as 2 mL was 
found to be insufficient in terms of dissolution power for heavily cut samples. Additionally, the phosphate buffer 
was chosen as 0.5 M by concentration as the phosphate salt tended to crystallise at higher concentrations. The 
parameters studied are summarised in table 25 : 
 
Table 25 Variables used for the study on the influence of the matrix 
Parameter LEVEL 
Type of buffer  
pH  
Concentration 
phosphate 
7.2 
0.5M 
TRIS 
8.1 
1.0M 
 
Solvent  iso-octane toluene  
Solvent volume 200 µL   
Buffer volume 4 mL 8 mL  
Sample:  amount of amphetamine  
               amount of caffeine  
30 mg 
170 mg 
100 mg 
100 mg 
200 mg 
0 mg 
Replicates 3   
 
 
4.4.2 Results and discussion 
 
The results of this subtask are summarised in table 27. The RRF values of all impurities were normalised against 
the amount of amphetamine (15%, 50% and 100%). RRF values were calculated by dividing the peak area of the 
impurity by the peak area of the internal standard. For the 15 % amphetamine, RRF values were therefore 
multiplied by 100 / 15 and for 50 % amphetamine, they were multiplied by 2. 
Averages were then calculated for the figures obtained for the three concentrations. Sensitivity was calculated by 
dividing the RRF value of a certain impuritiy under a specified condition by the maximum value for that 
compound. The sensitivity illustrates ability of the method to compare samples with low concentration 
impurities. 
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In order to illustrate the stability of the method against matrix effects, the deviations between RRF values at 
different concentrations of amphetamine were calculated. For example, if no matrix effects are present, the 
normalised RRF value of an impurity in 15 % amphetamine should be the same as the RRF value in 100 % 
amphetamine. Table 26 provides an example for one impurity. In this case, 2,4-dimethyl-3,5-diphenylpyridine : 
 
Table 26 : example of calculation for the deviation of RRF values 
 
Tris buffer and toluene RRF values of 2,4-dimethyl-3,5-diphenylpyridine 
4 ml and 15 % amphetamine 31.80 
4 ml and 50 % amphetamine 34.52 
4 ml and 100 % amphetamine 34.67 
Relative Standard Deviation (RSD) 4.8 % 
 
The same calculations were made for each conditions and all impurities. The final RSD’s shown in table 27 are 
the averages for all impurities in each condition. 
 
 
Table 27 : sensitivity and deviations for the study on the influence of matrix effects 
 
Extraction system Sensitivity RSD between different dilutions 
TRIS, 4 ml, toluene 98 % 4 % 
TRIS, 4 ml, isooctane 90 % 7 % 
TRIS, 8 ml, toluene 94 % 5 % 
TRIS, 8 ml, isooctane 84 % 9 % 
Phosphate, 4 ml, toluene 83 % 17 % 
Phosphate, 4 ml, isooctane 78 % 17 % 
Phosphate, 8 ml, toluene 86 % 9 % 
Phosphate, 8 ml, isooctane 78 % 8 % 
 
 
4.4.3 Conclusions 
 
Overall, it is clear that the best extraction system is 4 ml TRIS buffer with toluene. Indeed, this system not only 
gives the best sensitivity, but also is the most robust against matrix effects. 
Results obtained from partner 3 (also Leuckart amphetamine) confirmed these observations. As for reductive 
amination impurities (partner 2), the best sensitivity was given by 4 ml phosphate buffer and toluene. However, 
the deviations were quite high with this extraction system. 4 ml TRIS buffer with toluene was second best and 
gave almost the same sensitivity. Also, the deviations were very small with this system confirming that it is 
robust against matrix effects. 
Regarding nitrostyrene impurities, unfortunately no results are available for this subtask. 
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4.5 Optimisation of solid phase extraction (SPE)  
 
4.5.1 Introduction 
 
Solid-phase extraction (SPE) resembles liquid-liquid extraction (LLE) since both are based on partition 
mechanism, although the former is a dynamic process whereas LLE is based on static equilibrium. The partition 
mechanism, however, enables application of the best buffer found for the optimised LLE method also in SPE. 
This is also a prerequisite for obtaining interchangeable results between these two extraction techniques. On the 
other hand, the elution solvent used in SPE has a different function than the organic solvent used in LLE.  
 
In LLE the solvent acts as one of the phases participating in the partition process. The SPE stationary phase such 
as octadecyl silica has the same function. In SPE, the organic solvent is used to elute all target compounds out of 
the SPE column for subsequent GC analysis. In theory, the elution solvent should have as good elution power 
(see "eluotropic values" or "solvent strength values" in HPLC literature) as possible although solubility in water 
may also play an important role: residual water in an SPE column may hinder elution of the analytes if an apolar 
solvent is used. In conclusion, selection criteria for the organic solvent used in LLE and in SPE are rather 
different.  
 
In this study two SPE columns were evaluated. The best buffer found in Subtasks 4.1 - 4.3 (TRIS), two buffer 
volumes and two solvents with different eluotropic values were studied as well.  
 
4.5.2 Experimental 
 
Fourteen different SPE columns (100 mg/1mL) obtained from IST (International Sorbent Technology) were 
considered. These include the following various types : non-endcapped, endcapped and monofunctional 
octadecyl (C18), non-endcapped and endcapped octyl (C8), non-endcapped, and endcapped cyanopropyl (CN), 
non-endcapped, and endcapped phenyl (PH), aminopropyl (NH2), ethylenediamine-N-propyl (PSA) and 2,3-
dihydroxypropoxypropyl (DIOL). 
Additionally, mixed-mode extraction columns, namely Confirm HCX containing both non-polar (C8) and strong 
cation exchange (-SO3
-
) functional groups and Multimode containing non-polar (C18), strong cation exchange 
and strong anion exchange (-NR3
+
) functional groups were studied. Finally, a polymer-based Oasis HLB (Waters 
Inc.) column was evaluated. 
 
From some initial studies performed by partner 2 and based upon extraction efficiencies, the HCX and Oasis 
HLB columns were selected for further investigation. The parameters used for the comparison of these columns 
are presented in table 28 : 
 
Table 28 Variables used for the optimisation of solid phase extraction 
Parameter LEVEL 
SPE columns   HCX Oasis HLB 
Type of buffer  TRIS
 
 
Solvent  type ethyl acetate toluene
 
 volume 200 µL  
Buffer  volume 4 mL 8 mL 
 concentration 1.0 M  
Number of eluate fractions 3   
 
 
The SPE column was conditioned with 1mL of methanol and 1 mL of 1M Tris buffer. 200 mg of amphetamine 
(TEST-2 : 20% amphetamine, 40% caffeine, 40% lactose) were weighed into a test tube. The powder was 
dissolved in 4 mL of 1M Tris buffer (pH 8.1) by shaking for 30 min. The sample was loaded into the SPE 
column using a flow rate of 1 mL/min. The column was washed with 2 mL of water and dried with nitrogen gas 
using a flow rate of approx. 60 mL/min for 10min. The analytes were eluted using three times 200 µL of solvent 
containing nonadecane as an internal standard at a concentration of 10 µg / ml. Each fraction was collected 
separately in an appropriate test tube. The extracts were finally placed in GC vials. The samples were analysed 
using the GC method described in Annex 2.  
 
 
 59 
 
4.5.3 Results and discussion 
 
First, the HCX columns were evaluated as the OASIS HLB columns were not yet available. The target 
compounds were identified and relative response factors (RRF's) calculated for each target compound, i.e. ratio 
between the analyte and the internal standard peak areas. The values were normalised by calculating RRF / 
maximum RRF for each condition. The recovery was calculated for the sum of the RRF’s of the three different 
fractions at each condition. An average of the recoveries of different target compounds was calculated to 
estimate the overall performance of the extraction. The highest value indicates the best recovery. The recoveries 
as well as the repeatabilities (for three replicates) are summarised in table 29 : 
 
Table 29. Relative recoveries and repeatability of the target compounds obtained with the HCX columns. 
RECOVERY REPEATABILITY 
 HCX, 4mL 
Tris+et.ac. 
HCX, 8mL 
 Tris+et.ac. 
HCX, 4mL 
Tris+tolu 
HCX, 8mL  
Tris+tolu 
HCX,  4mL  
Tris+et.ac, 
HCX, 8mL 
 Tris+et.ac. 
HCX, 4mL 
Tris+tolu 
HCX, 8mL  
Tris+tolu 
DPPA 100 % 95 % 0 % 0 % 2 % 3 % - - 
DPIA 1 + 2 100 % 84 % 21 % 22 % 8 % 2 % 15 % 5 % 
DPIMA 1 100 % 84 % 40 % 41 % 10 % 3 % 11 % 11 % 
Naphtalene 1 85 % 100 % 47 % 56 % 4 % 4 % 9 % 15 % 
Benzoylamph. 100 % 93 % 48 % 50 % 8 % 4 % 3 % 4 % 
2,6-3,5 pyridine 93 % 100 % 53 % 69 % 7 % 8 % 10 % 11 % 
2,4-3,5 pyridine 91 % 100 % 25 % 40 % 1 % 5 % 10 % 6 % 
Pyridine 7 95 % 100 % 58 % 74 % 3 % 7 % 3 % 9 % 
Pyridine 14 100 % 93 % 43 % 45 % 13 % 6 % 7 % 14 % 
DPIF 1 98 % 100 % 42 % 47 % 6 % 5 % 4 % 6 % 
DPIF 2 97 % 100 % 42 % 47 % 7 % 4 % 5 % 6 % 
Average  97 % 94 % 35 % 41 % 6 % 5 % 8 % 9 % 
 
 
Table 29 clearly shows that ethyl acetate is by far superior in terms of recovery with this type of SPE column. 
Repeatability is also better with ethyl acetate. Regarding the buffer volume, there is no significant difference 
between the use of 4 and 8 mL. 
In the next phase, the OASIS HLB column should have been studied in the same way and the results compared 
to the HCX column. However, for time reasons, it was only possible to study one condition. As 4 mL Tris and 
ethyl acetate give the best recovery for the HCX column, this condition was chosen. The values were calculated 
in the same way as table 29 and are presented in table 30 below : 
 
Table 30. Relative recoveries and repeatability of the target compounds obtained with the OASIS and 
HCX columns (4 mL TRIS, ethyl acetate). 
RECOVERY REPEATABILITY 
 HCX, 4mL 
Tris+et.ac. 
OASIS, 4mL 
 Tris+et.ac. 
HCX, 4mL 
Tris+et.ac. 
OASIS, 4mL 
 Tris+et.ac. 
DPPA 83 % 100 % 2 % 3 % 
DPIA 1 + 2 100 % 92 % 8 % 3 % 
DPIMA 1 100 % 63 % 10 % 12 % 
Naphtalene 1 100 % 99 % 4 % 13 % 
Benzoylamph. 79 % 100 % 8 % 14 % 
2,6-3,5 pyridine 100 % 76 % 7 % 12 % 
2,4-3,5 pyridine 77 % 100 % 1 % 3 % 
Pyridine 7 100 % 87 % 3 % 8 % 
Pyridine 14 36 % 100 % 13 % 3 % 
DPIF 1 100 % 100 % 6 % 5 % 
DPIF 2 99 % 100 % 7 % 5 % 
Average  89 % 92 % 6 % 7 % 
 
 
Table 30 show that very similar results are found between the OASIS HLB column and the HCX column. 
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However, after observation of the reductive amination amphetamine, it was noticed that the OASIS HLB column 
extracted more of the polar compounds. This was confirmed by the results of partner 2 who studied reductive 
amination amphetamine. Their results show a far better recovery for their corresponding impurities which are 
more polar than Leuckart impurities. Table 31 below illustrate their results : 
 
Table 31. Relative recoveries of reductive amination target compounds obtained with the OASIS and 
HCX columns. 
RECOVERY HCX 4mL HCX 8 ml HCX 4mL HCX 8 ml Oasis 4mL Oasis 8 ml Oasis 4mL Oasis 8 ml 
 AcOEt AcOEt toluene toluene AcOEt AcOEt toluene toluene 
Acetylamphetamine 100% 16% 16% 6% 42% 32% 26% 23% 
Benzylamphetamine 77% 65% 99% 82% 82% 93% 98% 100% 
DPIA (1) 75% 63% 100% 83% 75% 83% 88% 89% 
DPIA (2) 73% 61% 100% 83% 71% 78% 85% 85% 
Cathinol (1) 81% 67% 83% 67% 96% 100% 99% 93% 
Cathinol (2) 67% 55% 76% 62% 87% 91% 100% 92% 
Benzoylamphetamine 15% 8% 11% 7% 85% 100% 81% 84% 
2-oxo 21% 13% 15% 8% 87% 100% 79% 82% 
Mean 64% 44% 63% 50% 78% 85% 82% 81% 
 
As can be seen in table 31, the Oasis column performs much better in terms of recovery for reductive amination 
impurities. It also shows that there doesn’t seem to be any significant difference between the use of ethyl acetate 
or toluene with the Oasis column. This has been confirmed for Leuckart impurities by partner 3. 
 
Finally, the HCX and OASIS columns were briefly compared to liquid-liquid extraction. Two extracts from two 
different Leuckart amphetamines (20 % amphetamine and 50 % amphetamine) were extracted with 4 ml TRIS 
1M and 200 microlitres of toluene (optimised LLE procedure). The results were compared to those obtained by 
SPE with 4 ml TRIS 1M and 200 microlitres ethyl acetate (HCX and OASIS columns). Table 32 illustrates the 
results obtained : 
 
Table 32. Comparison of recoveries between LLE (4ml TRIS, 200 µl toluene), SPE with HCX and OASIS 
(4ml TRIS, 200 µl ethyl acetate). 
 HCX vs LLE HCX vs LLE OASIS vs LLE OASIS vs LLE OASIS vs HCX OASIS vs HCX 
 20% amph. 50% amph. 20% amph. 50% amph. 20% amph. 50% amph. 
DPPA 127% 121% 226% 170% 178% 141% 
DPIA 1 142% 124% 146% 138% 103% 112% 
DPIMA 1 227% 132% 142% 143% 63% 109% 
Naphtalene 1 40% 78% 26% 65% 65% 84% 
Naphtalene 2 45% 71% 30% 56% 66% 79% 
Benzoylamphetamine 178% 165% 182% 169% 102% 102% 
2,6-3,5-pyridine 65% 84% 52% 80% 80% 96% 
2,4-3,5-pyridine 64% 83% 63% 81% 99% 97% 
pyridine 7 74% 80% 59% 77% 80% 97% 
pyridine 14 85% - 72% - 85% - 
DPIF 1 129% 120% 127% 126% 98% 105% 
DPIF 2 131% 121% 125% 124% 95% 103% 
Mean 109% 107% 104% 112% 93% 102% 
Mean 2 samples 108 % 108 % 98 % 
 
This table confirms the previous results where no significant difference was found between the HCX and Oasis 
columns in terms of recovery for Leuckart impurities. It also shows that SPE gives a slightly better recovery 
compared to the optimised LLE method. This also has been confirmed by other partner results. Indeed, SPE 
gives slightly better recovery not only for Leuckart but also for reductive amination impurities. 
 
Still, it was expected that recovery for SPE would be far better to the value shown in table 32 (i.e. 108 % 
compared to LLE). 
The probable explanation was found later as it was determined that the non-polar impurities were somehow not 
totally transferred to the SPE column from the test tube containing the dissolved amphetamine. 
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Indeed, it seemed that these « oily » compounds were sticking to the walls of the test tube and were therefore not 
entirely transferred to the SPE column. 
To improve the transfer, the Tris buffer was modified in such a way that it contained 10 % methanol. This indeed 
removed a fair amount of the non-polar impurities from the test tube and thus improved the transfer. 
 
However, adding methanol is a risk in the further elution of the SPE column as the impurities could be partially 
lost in the loading phase of the SPE column (i.e. elute with the buffer / methanol and not be retained in the 
column). 
Unfortunately, for time reasons it was not possible to carry out further investigations in order to determine the 
exact influence of these modifications. 
Moreover, it was also found out that this « sticking » effect is dependent upon the test tubes which are used for 
dissolving the amphetamine. Indeed, this phenomena was observed for polypropylene tubes (used by partner 4) 
and for used glass tubes (used by partner 2). However, for partner 3, who used brand new Kimax
®
 test tubes 
(made of borosilicate glass), this effect was not significant. 
 
4.5.4 Conclusions 
 
In conclusion, SPE gives good results. Recovery and repeatability are quite similar to liquid-liquid extraction. 
However, there are some concerns regarding the future inter-laboratory results if SPE is chosen as the extraction 
method. Indeed, standardization of the equipment would be of paramount importance as the same SPE 
equipment should be purchased as well as the same test tubes in order to guarantee comparable data. We also 
have no information regarding the reproducibility of SPE columns in time. 
For these reasons, it was finally decided to choose liquid-liquid extraction as the final extraction method. 
 
Outside of the studies shown above the dissolving and extraction times in the LLE method were separately 
optimised. As an outcome of this study it was found that dissolving and extraction times could be reduced to 10 
minutes without any loss in the performance. 
 
The final optimised LLE method is described in detail below. 
 
- Buffer: 1M Tris buffer, pH 8.10. 
 
- Organic solvent: Toluene (HPLC quality) containing nonadecane as internal standard at 10µg/mL 
concentration. 
 
- Balance: Analytical balance with minimum 0.1mg resolution. 
 
- Test tubes: New (or as good as new) glass test tubes (ca. 10mL) with Teflon lined screw caps. 
 
- Shaking system: Horizontal or rotating system. 
 
- LLE procedure: Dissolve 200 ± 5 mg amphetamine in 4 mL Tris buffer and shake vigorously for 10 
minutes. Add 200 µL toluene and shake again for another 10 min. Centrifuge the tubes 
for 2-3 min at ca. 2500 rpm to separate the phases. Take an aliquot of the toluene layer 
and place it in a GC vial containing 100 µL insert vial (Agilent part no. 5181-1270). 
Analyse the samples using the GC method described in Annex 3. 
 
- Calibration : Calibrated pipettes are used for all liquid measurements. Accuracy for 4 mL 
measurement (buffer) is ± 0.04 mL and ± 0.02 mL for 0.2 mL (organic solvent). Water 
is used for calibration of the large pipette (4 mL) and toluene for the small pipette (0.2 
mL) taking into account that the density of toluene (0.867 g/mL). 
 
 Example : put a GC vial on an analytical balance, set to zero, add 0.2 mL of toluene, the 
weight should be 173.4 mg (0.2 * 0.867 * 1000). Calibrate the pipette accordingly. 
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5 Task 5 – determination of the variability of the 
optimised method 
 
 
5.1 Introduction 
 
The aim of this task was to investigate the stability of the optimised method developed in the previous tasks. 
Variations within a day, between days and between laboratories were investigated. For this task, twelve batches 
of amphetamine were prepared and homogeneised. Each batch was split into four equal parts. 
One part stayed at the « manufacturing » laboratory, the three others were sent to Partner’s laboratories. Each 
laboratory had then 3 x 4 = 12 samples. In addition, a 13
th
 sample was prepared in each laboratory by cutting one 
of the samples by a factor ten in order to study the influence of dilution. 
At this stage of the project, the final choice of detector was not made. Therefore, FID and MS detection were 
recorded simultaneously and both were studied. Moreover, one laboratory also studied within day and between 
days variations with NPD detection. 
 
5.2 Experimental 
 
5.2.1 Preparation of samples 
 
For this task, twelve batches of amphetamine were prepared. Six of them were synthesised via the Leuckart 
route, three via the nitrostyrene route and three via the reductive amination route. 
For the Leuckart amphetamine, phenyl-2-propanone (Fluka
®
) was refluxed with formamide and formic acid, 
then hydrolysed with sulfuric or hydrochloric acid. Amphetamine base was then isolated and cristallised as the 
sulphate salt. 
For reductive amination amphetamine, phenyl-2-propanone was stirred at room temperature with ammonium 
acetate and sodium cyanoborohydride. Amphetamine base was then isolated and cristallised as the sulphate salt. 
For nitrostyrene amphetamine, phenyl-2-nitropropene (Sigma-Aldrich
®
) was stirred at room temperature with 
sodium dihydrobis(2-methoxyethoxy)aluminate (Fluka
®
) according to Butterick [Butterick and Unrau, 1974]. 
Amphetamine base was then isolated and cristallised as the sulphate salt. 
 
 
5.2.2 Composition of samples 
 
Red 1, 2 and 3 had to be spiked with target compounds previously synthesised because of their absence or too 
low concentrations in these batches.  
Most of the synthesised batches were cut with various adulterants and / or diluents in order to reflect 
amphetamine samples seized in the illicit market. Table 33 describes the composition of the studied 
amphetamines : 
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Table 33.  Composition of the sixteen amphetamine batches.  
Sample Amphetamine (%) Caffeine (%) Lactose (%) Mannitol (%) Koffisal® (%)* Sucrose (%) 
Leuckart 1 10 - 70 - 20 - 
Leuckart 2 10 25 65 - - - 
Leuckart 3 15 - - 41  44 
Leuckart 4 100 0 0 - - - 
Leuckart 5 50 25 25 - - - 
Leuckart 6 20 40 40 - - - 
Nitro 1 6 16 78 - - - 
Nitro 2 6 12 - 82 - - 
Nitro 3 6 - 47 47 - - 
Red 1 20 40 40 - - - 
Red 2 20 40 40 - - - 
Red 3 15 - 85 - - - 
Leu 1 diluted 1 - 97 - 2 - 
Leu 5 diluted 5 22,5 72,5 - - - 
Leu 6 diluted 2 4 94 - - - 
Red 1 diluted 2 4 94 - - - 
 
 
* Koffisal 
®
 is a Danish preparation used as adulterant in illicit amphetamine (in Denmark) containing 
phenazone salicylamide, phenazone salicylate and caffeine. 
 
 
5.2.3 Integration and target compounds 
 
Fixed integration parameters were used to enable data comparability. When small peaks were not automatically 
integrated using these parameters and / or when obvious deviations occurred for some compounds, manual re-
integration was performed. 
Relative Response Factors (RRF) values were calculated by normalising the peak areas of the target compounds 
to the peak area of the internal standard. 
For MS quantitation, ion responses were used. A target ion was chosen for each target compound as well as two 
qualifiers. The target compounds as well as their target ions chosen for MS quantitation are shown in table 34 : 
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Table 34. Target compounds and their target ions used in task 5. 
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Benzaldehyde oxime e)          X X X 121 
2-methyl-3-phenylaziridine a)          X X X 132 
Benzyl methyl ketoxime (isomer 1) a)          X X X 149 
Benzyl methyl ketoxime (isomer 2) a)          X X X 131 
N-acetylamphetamine a)       X X X    118 
1,2-diphenethylamine e)          X X X 106 
Benzenemethanamine, N-(phenylmethyl)- d) (commercial name : dibenzylamine)          X X X 106 
Benzylamphetamine a)   X X X X X X X X X X 134 
DPPA : 1,3-diphenyl-2-propylamine a) X X X          120 
Diphenethylamine, α-methyl- e)          X X X 148 
DPIA 1 : N, N-di-(β-phenylisopropyl)amine (isomer 1) a)       X X X    162 
DPIA 2 : N, N-di-(β-phenylisopropyl)amine (isomer 2) a)       X X X    162 
DPIMA 1 : N,N-di(β-phenylisopropyl)methylamine 1 (isomer 1) a) X  X X         176 
DPIMA 2 : N,N-di(β-phenylisopropyl)methylamine 1 (isomer 2) a) X  X X         176 
Cathinol 1 : 1-hydroxy-N,N-di(β-phenylisopropyl)amine (isomer 1) a)       X X X    162 
Cathinol 2 : 1-hydroxy-N,N-di(β-phenylisopropyl)amine (isomer 2) a)       X X X    162 
1,3-dimethyl-2-phenylnaphthalene b) X   X X X       232 
Benzoylamphetamine a)  X   X X X X X    105 
2-oxo-1-phenyl-(β-phenylisopropylamine)ethane a)       X X X    162 
2,6-dimethyl-3,5-diphenylpyridine c) X X X X X X       259 
2,4-dimethyl-3,5-diphenylpyridine a) X X X X X X       259 
Pyridines 7 and 14 f)  X X  X X X       258 
Pyridine 272 g) X    X        272 
Pyridine X h) X            258 
2,6-diphenyl-3,5-dimethylpyridine c) X X X X X        258 
DPIF 1 : N,N-di(β-phenylisopropyl)formamide (isomer 1) a) X X X X X X       190 
DPIF 2 : N,N-di(β-phenylisopropyl)formamide (isomer 2) a) X X X X X X       190 
 
a) Synthesised within the SMT project. 
b) Compounds of which standards were provided by the United Nations Office for Drugs and Crime (UNODC). 
c) Compounds of which standards were provided by the Netherlands Forensic Institute (NFI). 
d) Other compounds for which standards were available. 
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e) Other compounds for which standards were not available. Identification based only upon comparison with Wiley or NIST MS library. 
f) Two compounds not separated with the GC method. Their mass spectra indicate that they are pyridine derivatives. The names pyridine 7 
and pyridine 14 are those used by partner 3 in their laboratory (SKL, Sweden). 
g) Pyridine derivative tentatively identified as 2,4-dimethyl-3-phenyl-6-(phenylmethyl)-pyridine by van den Ark [van den Ark et al., 1978c]. 
h) Compound with the same mass spectrum as identified pyridines. The name “pyridine x” was given as the exact chemical structure could 
not be determined. 
 
5.2.4 Time frame of analyses 
 
Each test sample was analysed at day 0 (T0), after 7 days (T7) and after 14, 28, 42 and 56 days (T14, T28 , T42 and 
T56). For the determination of the within day variation, six extracts were prepared and analysed on a chosen day 
for each batch of amphetamine. 
The between days variation was calculated using the values for each day and the average value of the day where 
six replicates were analysed, thus n = 6. 
Additionally, each laboratory had to choose one batch of amphetamine and dilute it 10 times. Table 35 
summarises the analyses carried out : 
 
Table 35. Time frame of analyses 
Samples Number of analyses  
 
 Day 0 Day 7 Day 14 Day 28 Day 42 Day 56 Total 
Leuckart 1 
a
 6 1 1 1 1 1 11 
Leuckart 2 
a
 1 6 1 1 1 1 11 
Leuckart 3 
a
 1 1 6 1 1 1 11 
Red 1 
b
 1 1 1 6 1 1 11 
Red 2 
b
 1 1 1 1 6 1 11 
Red 3 
b
 1 1 1 1 1 6 11 
Leuckart 4 
c
 6 1 1 1 1 1 11 
Leuckart 5 
c
 1 6 1 1 1 1 11 
Leuckart 6 
c
 1 1 6 1 1 1 11 
Nitro 1 
d
 6 1 1 1 1 1 11 
Nitro 2 
d
 1 6 1 1 1 1 11 
Nitro 3 
d
 1 1 6 1 1 1 11 
dilute sample 
*
 1 1 1 6 1 1 11 
Total 28 28 28 23 18 18 143 
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a
 Samples synthesised via the Leuckart route in laboratory n° 4 (IPSC, Lausanne, Switzerland). 
b 
Samples synthesised via the reductive amination of benzylmethyl ketone in laboratory n° 2 
(NBI, Finland). 
c 
Samples synthesised via the Leuckart route in laboratory n° 3 (SKL, Sweden). 
d 
Samples synthesised via the nitrostyrene route in laboratory n° 4 (IPSC, Lausanne, 
Switzerland). 
*
   The last sample in this table corresponds to the diluted sample. Leuckart 1 was used by 
Laboratory n° 4, Red 1 was used by Laboratory n° 2, Leuckart 5 by Laboratory n° 3 and 
Leuckart 6 by Laboratory n° 1. 
 
Extractions of the amphetamine samples were performed with the method optimised in task 4 and described in 
section 4.5.4. GC methods are described in Annex 2. 
 
 
5.3 Results and discussion 
 
5.3.1 Within day variations 
 
In this section, the results of Laboratory n° 1 have been presented separately because this laboratory had some 
chromatographic problems and was not able to meet the requirements of the quality control sample before the 
beginning of this task. This is the reason why only FID data is available for this laboratory.  
The within day variations of different laboratories when analysing the synthesised batches using FID and MS are 
summarized in tables 36 and 37 respectively. 
 
Table 36. Within day variation of different laboratories given as the average RSD (%) of all target 
compounds for each sample. Samples were analysed with GC-FID. The relative standard 
deviations (RSD’s) have been calculated on the basis of relative response factor (RRF) 
values. 
Sample Lab 2 Lab 3 Lab 4 Mean of labs 2 - 4 lab 1 Mean of all labs 
Leuckart 1 10 % 4 % 7 % 7 % 7 % 7 % 
Leuckart 2 6 % 6 % 8 % 7 % 12 % 8 % 
Leuckart 3 5 % 4 % 9 % 6 % 10 % 7 % 
Leuckart 4 3 % 3 % 6 % 4 % 4 % 4 % 
Leuckart 5 6 % 6 % 8 % 7 % 12 % 8 % 
Leuckart 6 3 % 2 % 6 % 4 % 8 % 5 % 
Red 1 2 % 2 % 3 % 2 % 8 % 4 % 
Red 2 4 % 4 % 5 % 4 % 11 % 6 % 
Red 3 6 % 4 % 4 % 5 % 4 % 5 % 
Nitro 1 5 % 4 % 5 % 5 % 15 % 7 % 
Nitro 2 9 % 7 % 5 % 7 % 9 % 8 % 
Nitro 3 7 % 8 % 6 % 7 % 8 % 7 % 
Dilute sample 3 % 6 % 8 % - 6 % - 
Average 5 % 5 % 6 % 5 % 9 % 6 % 
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Table 37. Same as table 36 but for GC-MS 
Sample Lab 2 Lab 3 Lab 4 Mean of labs 2 - 4 
Leuckart 1 5 % 2 % 4 % 4 % 
 Leuckart 2 5 % 5 % 9 % 6 % 
Leuckart 3 5 % 4 % 7 % 5 % 
Leuckart 4 3 % 3 % 8 % 5 % 
Leuckart 5 8 % 5 % 9 % 7 % 
Leuckart 6 4 % 2 % 5 % 4 % 
Red 1 4 % 5 % 2 % 4 % 
Red 2 3 % 5 % 4 % 4 % 
Red 3 5 % 4 % 2 % 4 % 
NITRO 1 7 % 7 % 6 % 7 % 
NITRO 2 8 % 9 % 6 % 8 % 
NITRO 3 8 % 8 % 6 % 7 % 
Dilute sample 4 % 18 % 4 % - 
Average 5 % 6 % 6 % 5 % 
 
 
Finally, the within day variations for NPD detection are presented in table 38. Relative Response Factors (RRF) 
values were calculated by normalising the peak area of the target compound to the peak area of the internal 
standard which, in this case, was 2,6-dimethyl aniline. Only one laboratory (lab n° 3) performed the analyses 
with NPD detection. 
 
Table 38. Same as tables 36 and 37 but for GC-NPD 
NPD detection Within day variation 
Leuckart 1 3 % 
Leuckart 2 6 % 
Leuckart 3 5 % 
Leuckart 4 3 % 
Leuckart 5 7 % 
Leuckart 6 4 % 
Red 1 4 % 
Red 2 4 % 
Red 3 5 % 
Nitro 1 4 % 
Nitro 2 8 % 
Nitro 3 10 % 
Dilute sample 6 % 
Average 5 % 
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As can be seen from the results illustrated in tables 37, 38 and 39, the within day variations are in the order of 5 
to 6 % with three different detectors. It seems that the detection method does not have any significant influence 
on the results. 
 
5.3.2 Between days variations 
 
 
Again, the results of Laboratory n° 1 have been presented separately for the same reasons as mentioned 
previously. The between days variations of different laboratories when analysing the synthesised batches using 
GC-FID, GC-MS and GC-NPD are summarized in tables 39 to 41 respectively. 
 
 
Table 39. Between days variations of different laboratories given as the average RSD (%) of all 
target compounds for each sample. Samples were analysed with GC-FID. 
 
Sample Lab 2 Lab 3 Lab 4 Mean of labs 2 - 4 Lab 1 Mean of all labs 
Leuckart 1 9 % 8 % 6 % 8 % 8 % 8 % 
Leuckart 2 7 % 9 % 8 % 8 % 16 % 10 % 
Leuckart 3 13 % 6 % 11 % 10 % 21 % 13 % 
Leuckart 4 5 % 7 % 8 % 7 % 16 % 9 % 
Leuckart 5 10 % 6 % 11 % 9 % 16 % 11 % 
Leuckart 6 9 % 6 % 10 % 8 % 15 % 10 % 
Red 1 4 % 6 % 3 % 4 % 13 % 7 % 
Red 2 9 % 10 % 6 % 8 % 16 % 10 % 
Red 3 8 % 9 % 7 % 8 % 11 % 9 % 
Nitro 1 10 % 9 % 7 % 9 % 14 % 10 % 
Nitro 2 6 % 8 % 7 % 7 % 14 % 9 % 
Nitro 3 8 % 8 % 8 % 8 % 21 % 11 % 
Dilute sample 13 % 22 % * 7 % - 11 % - 
Average 9 % 9 % 8 % 8 % 15 % 10 % 
 
 
*
 Exceptionally high deviation due to inhomogeneity of the sample. 
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Table 40. Same as table 39 but for GC-MS. 
 
Sample Lab 2 Lab 3 Lab 4 Mean of labs 2 - 4 
Leuckart 1 4 % 7 % 6 % 6 % 
Leuckart 2 5 % 11 % 5 % 7 % 
Leuckart 3 10 % 10 % 8 % 9 % 
Leuckart 4 4 % 10 % 8 % 7 % 
Leuckart 5 8 % 4 % 7 % 6 % 
Leuckart 6 11 % 8 % 6 % 8 % 
Red 1 7 % 10 % 4 % 7 % 
Red 2 6 % 10 % 4 % 7 % 
Red 3 5 % 7 % 3 % 5 % 
Nitro 1 11 % 11 % 7 % 10 % 
Nitro 2 11 % 12 % 7 % 10 % 
Nitro 3 12 % 11 % 8 % 10 % 
Dilute sample  4 % 11 % 4 % - 
Average 8 % 9 % 6 % 8 % 
 
 
Table 41. Same as tables 39 and 40 but for GC-NPD. 
 
NPD detection Between days variation 
Leuckart 1 5 % 
Leuckart 2 9 % 
Leuckart 3 6 % 
Leuckart 4 8 % 
Leuckart 5 6 % 
Leuckart 6 7 % 
Red 1 6 % 
Red 2 10 % 
Red 3 8 % 
Nitro 1 12 % 
Nitro 2 8 % 
Nitro 3 10 % 
Dilute sample 18 % 
Average 9 % 
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As can be seen from the results illustrated in tables 39, 40 and 41, the between days variations (over a period of 
two months) are in the order of 8 % both with FID and MS and 9 % for NPD. Again, it seems that the detection 
method does not have any significant influence on the results. 
 
5.3.3 Effects of dilution 
 
Four samples were diluted 10 times with lactose. The aim was to determine the effect of dilution on the 
extraction and GC analyses in terms of variation. Each laboratory used one sample for dilution. 
The average of the relative response factors for each target compound was calculated. The values for the diluted 
samples were then multiplied by ten. The variation was then calculated for each target impurity according to 
equation 11 : 
 
( )
2÷  
)y+x(
y-x value absolute
=  % inimpurity  target Variation     (11) 
 
Where x  is the mean value for the sample and y  is the mean value for the diluted sample. 
For the total variation, the average of all target impurities was calculated and results are shown in table 42 : 
 
Table 42. Deviation in % between diluted and undiluted samples (factor 10) 
 Lab 2 Lab 3 Lab 4 Mean of labs 2 - 4 Lab 1 Mean of all labs 
FID detection 7 % 10 % 9 % 9 % 17 % 11 % 
MS detection 15 % 13 % 18 % 15 % - - 
 
 
5.3.4 Inter-laboratory variation 
 
As in sections 5.3.1 and 5.3.2, results from laboratory n°1 are presented separately. In order to calculate the 
variations between laboratories, both mean values for within day and between days were taken into account for 
each laboratory (n = 8). Table 43 below shows an example on how the relative standard deviations were 
calculated and overall results are presented in table 44. 
 
 
Table 43. Example of calculation for determination of the inter-laboratory variation 
 
sample Red 1 Lab 2 Lab 2 Lab 3 Lab 3 Lab 4 Lab 4 Lab 1 Lab 1   
  within day betw. day  Within day betw. day  within day betw. day  within day betw. day Mean RSD 
N-acetylamphetamine 3.45 3.72 3.80 3.94 4.12 4.14 3.07 3.46 3.71 10% 
benzylamphetamine 39.00 38.95 38.29 38.42 37.44 36.94 28.31 35.86 36.65 10% 
DPIA 1 2.53 2.51 2.48 2.52 2.51 2.51 1.81 2.38 2.41 10% 
DPIA 2 5.58 5.54 5.69 5.66 5.42 5.39 4.31 5.40 5.37 8% 
Cathinol 1 21.54 21.45 18.72 19.15 20.96 20.88 13.31 19.48 19.44 14% 
Cathinol 2 1.06 1.01 0.94 0.99 1.10 1.09 0.70 1.06 1.00 13% 
Benzoylamphetamine 7.38 7.26 6.70 6.82 6.66 6.70 5.53 6.89 6.74 8% 
2-oxo 15.81 15.51 14.65 14.58 14.14 14.19 11.52 14.59 14.37 9% 
           
         Mean 10% 
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Table 44. Inter-laboratory variations given as the average RSD’s (%) of all target compounds for 
each sample. 
 
 Inter-laboratory (FID) Inter-laboratory (FID) Inter-laboratory (MS) 
 Mean labs 2, 3 and 4 Mean all labs Mean labs 2, 3 and 4 
Leuckart 1 9 % 10 % 9 % 
Leuckart 2 10 % 14 % 9 % 
Leuckart 3 6 % 13 % 14 % 
Leuckart 4 7 % 9 % 10 % 
Leuckart 5 8 % 10 % 7 % 
Leuckart 6 11 % 11 % 9 % 
Red 1 4 % 10 % 13 % 
Red 2 12 % 14 % 9 % 
Red 3 7 % 10 % 6 % 
Nitro 1 10 % 15 % 15 % 
Nitro 2 8 % 12 % 11 % 
Nitro 3 9 % 14 % 12 % 
Mean 8 % 12 % 10 % 
    
 
 
As can be seen in table 44, inter-laboratory variation is in the same order of magnitude as the between days 
variation (8 %). If laboratory n° 1 is taken into account, this value raises to 12 %. Regarding MS detection, good 
results were obtained as the variation was determined to be 10 % in average. However, some chromatograms had 
to be re-evaluated in order to present the results shown in table 44. Indeed, some integration problems (especially 
for FID detection) were observed. The purpose of the next paragraph (5.3.5) is to illustrate some examples of 
these potential problems. 
Figure 23 is an illustration of a « Leuckart » sample analysed in four laboratories : 
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Figure 23 : FID chromatograms of sample Leuckart 3 analysed in four laboratories. Major impurities are annotated : I.S. : internal standard (nonadecane), 1. 1,3-
diphenyl-2-propylamine, 2. DPIA isomers, 3. DPIMA isomers, 4. DPIF isomers. 
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5.3.5 Factors affecting integration 
 
During the course of this study, it was observed that the combination of polypropylene test tubes (for liquid-
liquid extraction) with toluene caused some contamination of the extracts due to co-extracted oligomers. This is 
easily illustrated by chromatograms of blank extracts in figure 24 : 
 
 
 
 
 
 
 
Figure 24 : FID chromatogrammes of blank extracts. Top : blank extract of toluene with polypropylene tube. Middle : blank 
extract of isooctane with polypropylene tube. Bottom : blank extract of toluene with new glass tube (Pyrex). 
 
Therefore, some deviations occured between laboratories when polypropylene tubes were used with toluene, 
especially when integrating very small peaks. An example of integration errors due to this problem is shown in 
figure 25 : 
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Figure 25 : FID chromatogrammes illustrating integration 
problems. 
Integration of DPPA as a target impurity co-eluting 
with co-extracted unknown compounds. 
A. : Extraction was perfomed in lab 4 with a polypropylene 
tube. 
B. : same sample analysed in lab 2 extracted with a glass tube. 
C. : same sample analysed in lab 1 extracted with a glass tube. 
D. : same sample analysed in lab 3 extracted with a glass tube 
(Kimax). 
E. : same sample analysed in lab 4, this time with a new glass 
tube (Pyrex). 
 
Because of coelution with unknown compounds present in the sample extract (toluene + polypropylene, see 
figure 25, chromatogram A), the integration gave a higher relative response factor for this target impurity and 
this laboratory. After having prepared a new extract in a glass test tube, these interfering compounds disappeared 
and the chromatograms from the three labs became almost identical. 
Relative standard deviation between laboratories for this target impurity was reduced from 17 to 8 %. Similar 
phenomena were also encountered with other target impurities and appropriate corrections were made. 
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5.3.6 Comparison of toluene and isooctane for Leuckart amphetamine 
 
Three samples from the list shown in table 33 were chosen to be extracted with isooctane and analysed. As 
mentioned earlier, toluene is definitely a better solvent for nitrostyrene and reductive amination amphetamines as 
many of the target impurities in these amphetamines are more polar compounds. However, for Leuckart 
amphetamine, no significant differences were yet observed. Therefore, the variability (within day, between days, 
between laboratories) was studied for these three samples extracted with both isooctane and toluene. Results are 
summarised in table 45 below : 
 
Table 45. Summary of variations for three Leuckart samples extracted with both isooctane and 
toluene and both analysed with FID and MS (within day, between days, between 
laboratories). 
 
FID Toluene Isooctane Toluene Isooctane Toluene Isooctane Toluene Isooctane 
 Within day Within day Between days Between days Between 3 labs* Between 3 labs* Between 4 labs Between 4 labs 
IPSC 1 7% 4% 8% 5% 9% 8% 10% 16% 
SKL 1 4% 7% 9% 7% 7% 7% 9% 11% 
SKL 2 8% 5% 11% 10% 8% 9% 10% 16% 
Mean 6% 5% 9% 7% 8% 8% 10% 14% 
         
MS Toluene Isooctane Toluene Isooctane Toluene Isooctane   
 Within day Within day Between days Between days Between 3 labs* Between 3 labs*   
IPSC 1 4% 5% 6% 7% 9% ?   
SKL 1 5% 4% 7% 7% 10% ?   
SKL 2 7% 5% 6% 8% 7% 9%   
Mean 5% 5% 6% 7% 9% 9%   
 
* Only laboratories 2, 3 and 4. 
 
 
5.4 Conclusions 
 
From the results obtained in this task, the following conclusions could be drawn : 
 
In general, within day variation for a same sample was in the order of 5 to 6 %. Between days variation was in 
the order of 8 to 10 %. As for inter-laboratory variation, it was in the order of 8 to 12 % depending on the 
detection method (FID or MS) and the number of laboratories (three or four). The results emphasised the 
importance of quality control as the only laboratory who failed to meet the quality control requirements gave 
expected higher deviations.  
In addition, homogeneity of studied samples also have a big influence on the results. Therefore, it was of the 
utmost importance to thoroughly homogeneise samples before analysis in order to get as minimal variations as 
possible. 
 
Dilution of samples also had an influence on variations. The limited experiments showed that an increase in 
deviation is to be expected (in the order of 11 % according to table 43). However, concentration effects will be 
further studied in task 6.  
 
MS quantitation gave similar results to FID in terms of repeatability and reproducibility. However, higher 
deviations occured when diluted samples were compared to original samples. This may be due to a linearity 
problem as FID is by far a more linear detector compared to MS. Moreover, for some samples, variations 
between laboratories seemed to be slightly higher when using MS values instead of FID. As for NPD which was 
studied separately by laboratory n° 3, it gave similar results as MS and FID in terms of repeatability and 
reproducibility. 
Nevertheless, a more thorough comparison of the detection techniques can be found in a previous task (see 
chapter 3.4). 
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Also, MS quantitation will be further investigated in task 6 as new MS parts were used in this task. Indeed, the 
standard ion source was replaced by an Ultra ion source (Agilent part number G2589-20043), the standard 
repeller was replaced by an Ultra repeller (Agilent part number G2589-20044) and a new draw out plate was 
installed which has a hole with a larger diameter (Agilent part number G2589-20045). Preliminary results have 
shown that this change considerably improves the linear range and stability of the MS detector. 
Moreover, the selectivity of the MS detector has the advantage of eliminating co-elution problems. This 
important feature in integration might outweigh the disadvantage of a less linear detector compared to FID and 
NPD. 
 
Regarding impurities having deviations higher than 10 % the source of deviation was not always found. 
However, almost all of these high deviations concerned very small peaks or peaks coeluting with unidentified 
matrix compounds (especially in FID detection). 
 
It was observed that new glass tubes should be used in order to ensure a stable baseline and reduce the risks of 
extracting other interfering compounds with toluene. This improved significantly the results between 
laboratories. 
 
Regarding the choice of solvent it could be concluded that iso-octane gave very similar results compared to 
toluene for Leuckart amphetamine. However, inter-laboratory variation (FID, four laboratories) seems to be 
slightly better with toluene (10 vs. 14 % for isooctane). This confirms that toluene is a very stable solvent and is 
the solvent of choice for the optimised method. 
 
Although not mentioned previously in this task, peak height was tested for quantitation. However, studies on a 
few samples immediately showed that relative standard deviations were much higher compared to peak area. 
 
Relative response factors were used as a measure of the peak size in this study. It could, however, be expected 
that use of different peak size normalisation procedures would reduce the variation. This will be studied in more 
detail in the following task. 
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6 Task 6 – Evaluation of methods for the comparison 
and classification of amphetamine profiles 
 
 
6.1 Introduction 
 
There were many aims in Task 6. We wanted to evaluate different methods for comparison and classification of 
amphetamine profiles in order to : 
 
- Identify which synthetic route was used (Leuckart, reductive amination or nitrostyrene). 
- Discriminate between amphetamine samples synthesised with different recipes within the same 
synthetic route. 
- Identify amphetamine samples synthesised with the same or similar recipes. 
- Identify amphetamine samples from the same batch of synthesis. 
 
In order to evaluate the extent to which samples of different degrees of similarity could be discriminated from 
each other, we had to focus our attention on the intra-variability (samples from the same batch) and the inter-
variability (samples from different batches). A number of syntheses were carried out for this matter. 
 
The task was divided in three subtasks. In the first, amphetamine samples were synthesised and street samples 
collected. It was recognised that the quality and number of these samples would have a big influence on the final 
conclusions. That is, the data set may not be representative enough to validate the conclusions. However, the 
maximum input was applied in the time frame allowed for this part of the project. 
 
In the second subtask, the samples were analysed by the three partner laboratories using the optimised sample 
preparation procedure and GC method. A control sample (synthesised amphetamine) was used in order to ensure 
that the three partner laboratories continuously gave comparable data. 
 
Finally, in the third subtask, the generated data was used to evaluate the numerical classification and comparison 
methods.  
 
 
6.2 Synthesis of amphetamine and collection of street samples 
 
Amphetamine synthesised using different recipes 
 
Several batches of amphetamine were synthesised using the reductive amination route (NBI 1, NBI 2 and NBI 
3), the Leuckart route (SKL 1, SKL 2, SKL 3, IPSC 1, IPSC 2 and IPSC 3) and the nitrostyrene route (ST 1 and 
ST 2). In order to vary the profiles as much as possible the two laboratories responsible for the Leuckart 
synthesis co-operated in the choice of recipes. The conditions employed in the Leuckart synthesis are 
summarised in table 46. The recipes used in the synthesis of benzyl methyl ketone can be found in annex 8. 
Regarding reductive amination amphetamine, more or less the same recipe was used for all three batches, since it 
was found to be hard to vary the synthetic conditions. The conditions used were similar to those used in Task 1 
(see annex 1). Partner 1, who did not participate in Task 6, provided two batches of nitrostyrene amphetamine. 
Unfortunately, no detailed information on the synthetic conditions was available. 
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Table 46. Different conditions used in the synthesis of Leuckart amphetamine. The numbers given in 
the columns of BMK, formamide and formic acid represent the molar proportions used in 
the syntheses. 
Batch 
BMK Formamide 
Formic 
acid 
Boiling 
temp. (ºC) 
Boiling 
time (h) 
Hydrolysis 
temp. (ºC) 
Hydrolysis 
time (h) 
Precipitation 
(pH) 
SKL 1 1 4 4 150 5 110 2 6 
SKL 2 1 6 6 160-180 4 110 2 3 
SKL 3 1 2.5 2.5 140-150 6 110 2 5 
IPSC 1 1 7 3.5 175-180 6 150-170 2 neutral 
IPSC 2 1 17 0 175-180 4 150-170 4 neutral 
IPSC 3 1
*)
 10 2 175-180 3.5 150-170 5 neutral 
Repeated 
synthesis 
1 6.7 3.5 160 2.5 110 1.5 7 
Control 
sample 
1 2.4 2.7 150-160 4 110 2 7 
 
*) 
Synthesised BMK was used. 
 
 
Part of these amphetamine batches were further diluted using caffeine and lactose to provide samples with 
different concentrations. Therefore, in addition to 100 % Leuckart and reductive amination amphetamines, we 
also had 40 % and 5 % amphetamines. The original concentrations of the nitrostyrene batches were found to be 
only 16 % (ST 1) and 7 % (ST 2). Their impurity content, however, was very high, and thus these samples could 
be further diluted. The concentrations of these samples are, for simplicity, hereafter referred to as 20 and 100 %, 
although their concentrations in reality were 3.2 and 16 % (ST 1) and 1.4 and 7 %  (ST 2), respectively. 
 
Repeated synthesis 
 
Repeated syntheses using a Leuckart recipe were carried out by Partners 3 and 4 (six batches each). The recipe 
employed is summarised in table 46 and a detailed description of the synthesis is presented in annex 8. It has to 
be emphasised that this recipe was kindly provided by the Netherlands Forensic Institute and was representative 
of the current recipes used in illicit laboratories in the Netherlands. 
The aim was to produce batches of amphetamine and hence impurity profiles which represented the highest 
degree of similarity that could be achieved by applying the same recipe (within a laboratory by one operator and 
between two laboratories with two operators). To achieve this, the syntheses were carried out under tightly 
controlled conditions.  
 
Control sample 
 
Partner 3 synthesised a large batch of Leuckart amphetamine to be used as a control sample by all Partners. The 
recipe used (table 46) was chosen such that a rich impurity profile was obtained. A total amount of 246 g of 
amphetamine sulphate was produced and distributed to the participating Partners.  
 
Other synthesised samples 
 
Nine Leuckart amphetamine samples precipitated from the same batch of amphetamine base were taken from the 
reference collection of partner 3. Three samples were precipitated at each of pH 3, 5 and 7. Additionally, six 
Leuckart and three nitrostyrene batches synthesised in Task 5 were made available for Task 6. The reductive 
amination samples from Task 5 were not used, since they had been spiked with additional impurities.  
 
Street samples  
 
The aim was to collect a representative number of samples of all synthetic routes. However, it should be noted 
that the true synthetic route of these samples was unknown before analysis. In total, 361 street samples were 
collected by the three partners (100 by partner 2, 149 by partner 3 and 112 by partner 4). By street samples, we 
meant samples that were seized by law enforcement agencies (police, customs, etc.). In general, this represents 
small seizures (typically a few grams). However, big seizures (a few hundred grams to a few kilograms) could be 
included as well. 
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As for the samples obtained by the Swiss partner, they are summarized in Annex 9. The Zurich Canton Police 
and the City of Zurich Police (WD, Wissenschaftlicher Dienst) are greatly acknowledged for providing the 
majority of the Swiss amphetamine samples. A few samples were obtained from various Canton Police forces 
(Neuchâtel, Genève, Jura, Valais). Their contribution is acknowledged as well. 
 
As for the whole data set of samples used in task 6, it is summarized in table 47 : 
 
Table 47 Synthesised and collected samples analysed in Task 6.  
No. of analyses per concentration, 
batch and Partner Samples 
Synthetic 
route 
Amphetamine 
concentration 
Partner 2 Partner 3 Partner 4 
NBI 1 - 3 
Reductive 
amination 
5, 40 and 100 % 3 3 3 
SKL 1 - 3 Leuckart 5, 40 and 100 % 3 3 3 
IPSC 1 - 3 Leuckart 5, 40 and 100 % 3 3 3 
ST 1 - 2 Nitrostyrene 20 and 100 % 3 3 3 
Repeated recipe SKL 
 (6 batches) 
Leuckart 100 % 0 3 0 
Repeated recipe IPSC  
(6 batches) 
Leuckart 100 % 0 0 3 
Precipitated  from same oil 
(9 batches) 
Leuckart 100 % 0 1 0 
Control sample Leuckart 100 % 2/sequence 2/sequence 2/sequence 
Task 5 samples 
6 Leuckart, 
3 Nitrostyrene 
20-100 % 1 1 1 
100 street samples - Unknown 1 0 0 
149 street samples - Unknown 0 1 0 
112 street samples - Unknown 0 0 1 
15 street  samples * - Unknown 1 1 1 
 
* These were blind samples and were taken from the data set of 361 street samples. 
 
 
 
6.3 Selection of target compounds and their analysis 
 
Target compounds : 
 
The target compounds for task 6 were selected based on the experience and knowledge gained in previous tasks. 
The number of amphetamine impurities synthesised during the course of task 1 was limited, therefore a number 
of other compounds found in amphetamine extracts were added to the target compound list. In task 3, a group of 
class A compounds was established, which was used for evaluation in tasks 4 and 5. During the course of these 
tasks it was established that some of the class A compounds were commonly absent, whereas some other new 
compounds could often be identified. The name and structure of some of these substances are unknown, 
although recorded mass spectra can be used for tentative identification. After tasks 4 and 5, the target list of 
impurities contained altogether 51 compounds. The list of 51 ompounds and mass spectra of the new compounds 
are given in Annex 10. However, during the processing of GC data it became obvious that collecting data for all 
51 peaks was very time consuming. Moreover, a number of the 51 compounds were considered troublesome, i.e. 
some of them were seldom present or otherwise hard to identify, while others showed high standard deviation 
when samples were repeatedly analysed. Due to the above mentioned reasons the number of target compounds 
for task 6 was reduced to 33 (table 48) by removing the troublesome compounds, i.e. impurities 35 – 51 in 
Annex 10 (note that the two isomers of N,N-di(β-phenylisopropyl)amine (compounds 14 and 15) were 
combined and treated as one compound). 
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Table 48 List of the 33 amphetamine target compounds used in the profiling method. N,N-di(β-
phenylisopropyl)amine 1 and 2 were combined.  
# Compound 
1 2-methyl-3-phenylaziridine 
2 Benzylmethyl ketoxime 1 
3 Benzyl methyl ketoxime 2 
4 4-Methyl-5-Phenylpyrimidine  
5 Possibly N-propylbenzamide * 
6 4-Benzylpyrimidine  
7 N-Acetylamphetamine 
8 N-Formylamphetamine  
9 1,2-Diphenylethylamine 
10 N,N-Dibenzylamine  
11 1,2-Diphenylethanone  
12 Benzylamphetamine  
13 1,3-diphenyl-2-propylamine 
14 N,N-di(β-phenylisopropyl)amine 1 
15 N,N-di(β-phenylisopropyl)amine 2
 
16 α-methyldiphenethylamine 
17 N,N-di(β-phenylisopropyl)methylamine 1 
18 N,N-di(β-phenylisopropyl)methylamine 2 
19 Unknown A2 
20 1-benzyl-3-methylnaphthalene 
21 Unknown A3 
22 1-hydroxy-N,N-di(β-phenylisopropyl)amine 1 (cathinol 1) 
23 1,3-dimethyl-2-phenylnaphthalene 
24 Unknown A4 
25 Benzoylamphetamine 
26 Unknown B2 
27 2-oxo-1-phenyl-(β-phenylisopropylamino)ethane 
28 2,6-dimethyl-3,5-diphenylpyridine 
29 2,4-dimethyl-3,5-diphenylpyridine 
30 Pyridine 7 and 14 
31 Pyridine 272 
32 2,6-diphenyl-3,5-dimethylpyridine 
33 N,N-di(β-phenylisopropyl)formamide 1 
34 N,N-di(β-phenylisopropyl)formamide 2 
 
 
* Compound №  5 has a very similar mass spectrum compared to N-propylbenzamide (according the Wiley MS 
library). Purchase of this compound from Sigma – Aldrich (after the end of the project) confirmed the similarity 
of the mass spectrum but also showed that its retention time was slighly different (around 0.4 min) compared to 
the target compound found in our synthesised amphetamine. Although the identity of the purchased chemical 
was not guaranteed by Sigma – Aldrich, it is reasonable to assume that target compound №  5 is probably not N-
propylbenzamide. Still, for sake of simplicity, this name is used throughout the remaining text in this chapter. 
 
A few compounds in the above list were not evaluated in task 5. Therefore, their variability (within and between 
laboratories) were somehow unknown. However, partner 3 re-evaluated the data for four of them, namely the 
unknowns A2, A3, A4 and B2. No significant variations were found. Indeed, the within and between laboratories 
reproducibilities were found to be in the order of magnitude of the other studied compounds. 
 
Analysis : 
 
The amphetamine samples were prepared and analysed according to the optimised liquid-liquid extraction 
procedure and gas chromatographic method, respectively. In IPS, the divider dual column system was used (see 
annex 2). Partner 2 used the same system while partner 3 used separate instruments for MSD and FID analyses. 
The Agilent Retention Time Locking system (RTL) was used to lock the retention time of the internal standard 
(nonadecane; C19) to 16.30 min on the FID. 
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In the dual column system the retention time of nonadecane on the MSD column was shorter, i.e. approximately 
15.00 min, due to the lower pressure at the capillary outlet. One target ion and two qualifier ions were used for 
identification and quantification of the 33 target compounds on the MSD. For the FID the number of variables 
was 32 instead of 33 as a consequence of the coelution of unknown A4 and benzoylamphetamine, which 
accordingly were treated as one peak. 
As mentioned earlier, the two isomers of DPIA were combined both in FID and MS detection. The number of 
analysis per sample is summarised in table 47. However, following our findings from tasks 3 and 5 regarding the 
comparison between FID and MS detection, it was decided to only use the MS data in task 6.  
 
Quality control : 
 
The quality of the gas chromatographic analyses was controlled by use of a blank sample, a modified Grob 
mixture and an amphetamine control sample. The blank samples were prepared using the optimised LLE 
procedure except that no amphetamine was added (blank extracts). The amphetamine control sample was 
prepared and analysed in the same way as the other amphetamine samples. The analytical sequence always 
started with two blank samples to clean the system followed by a Grob sample and the amphetamine control 
sample. Then, the amphetamine samples were analysed with a blank sample inserted after every fifth 
amphetamine sample. At the end of each sequence there was a blank sample followed by a Grob sample and 
again an amphetamine control sample.  
Control charts, as described in section 3.5, were plotted for retention time, peak area and peak asymmetry. Peak 
widths were only inspected visually due to the limitations of the Chemstation software. A visual inspection of 
the profile of the amphetamine test sample was also useful, although a bit subjective. 
 
 
6.4 Pre-treatment methods 
 
The aim of this subtask was to find a suitable pre-treatment method for our data and also for our subsequent 
mathematical algorithms. Indeed, certain algorithms that will be presented later require certain normalisation 
procedures. Also, in amphetamine profiles and especially in Leuckart amphetamine, it is often the case that one 
target compound (namely DPIA) is 100 to 1'000 times bigger than the other target compounds. This poses 
problems in the further mathematical comparison as this big peak will have a huge influence in the numerical 
results (see closure effect below). 
 
There are many methods that can be employed for pre-treatment of data. These can be used alone or in 
combination with each other. It would be unrealistic to test all of them and all possible combinations. So we 
limited ourselves to the following which seemed to be well suited to our purpose : 
 
Normalisation : 
 
Each target peak in a chromatogram is divided by the area sum of all target peaks. This enables comparison of 
samples of different amphetamine concentration. A typical problem associated with this method is referred to as 
the closure effect. This effect appears when a huge peak makes up a significant part of the area sum and 
therefore reduces the influence of the other peaks. One way to avoid this problem is to exclude large peaks in the 
peak area sum that is used in the normalisation. Another way is to perform weighing before the normalisation or 
by applying the logarithm or fourth square root functions to the normalised data. 
 
Weighing : 
 
The area of each peak is divided by its standard deviation calculated from the whole data set. The procedure will 
give small peaks the same influence as large ones (if the relative variation is the same). When weighing the data 
there is, however, a risk that small peaks, where the risk of integration error is higher, will have too much an 
influence. This could mean that noise peaks will have an influence in the profile. 
 
Logarithm : 
 
This is a common method used to reduce the influence of large peaks while still allowing large peaks to have a 
greater influence than small peaks. With this method, noise is not a problem. However, problems do occur when 
there are zeroes in the data set because log10 (0) can not be calculated. This can result in important information 
being lost. However, replacing the zeroes with a low value (e.g. a value below the detection limit) can overcome 
this problem.  
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Fourth square root : 
 
This method is sometimes used instead of the logarithm when there are zeroes in the data. Large peaks get a 
somewhat higher influence when using the fourth square root (4root) as compared to the logarithm [Sjöström, 
2003]. An advantage with this method is that it can be applied to zeroes.  
 
Handling of zeroes : 
 
Handling of zeroes is an important issue in the mathematical calculations because it influences the calculated 
results. Two approaches were used for handling of zeroes. These are referred to as Alternatives 1 and 2.  
 
In Alternative 1, zeroes were left unchanged in the database and then omitted in the calculations. For example, if 
two profiles are compared, all peak areas corresponding to zeroes will be considered as non-existent. 
 
In Alternative 2, zeroes were replaced with a peak area corresponding to an estimate of half the detection limit of 
the method. These values were determined to be 200 for MS and 1000 for FID. 
 
Example : 
 
Alternative 1 Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 
Sample A 150000 269000 0 389000 0 
Sample B 143000 256000 0 401000 47000 
      
Alternative 2 Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 
Sample A 150000 269000 200 389000 200 
Sample B 143000 256000 200 401000 47000 
 
In this fictitious example, two samples with only five peaks are compared. With alternative 1, the zeroes are 
considered as blanks. Therefore, only peaks 1, 2 and 4 will be compared to each other. 
With alternative 2, the zeroes are replaced by the value 200 (for MS data), hence all five peaks are compared to 
each other. 
 
6.5 Distance methods 
 
Once the data is acquired and treated, mathematical calculations come into play in order to evaluate the distance 
between two or more samples. Various algorithms are available for this purpose. In this project, the distance 
methods evaluated were : Euclidean distance, Manhattan distance, Pearson correlation, Similarity index, 
Quotient method, Canberra index and the Squared sinus function. Although they are not technically all distance 
methods (Pearson calculates a correlation, squared sinus calculates an angle between two vectors, etc.), they 
were called as such for simplicity. The choice of these methods was made for the following reasons : three of 
them were already in use in the partner’s laboratories as part of their own profiling programs (partner 2 : 
Similarity index [Kärkkäinen et al., 1994], partner 3 : Quotient method [Jonson and Strömberg, 1993], partner 4 : 
squared cosinus which is the reverse of the squared sinus [Esseiva et al., 2003]). As for the Euclidean distance, it 
has been used in relation to methamphetamine profiling [Tanaka et al., 1994, Perkal et al., 1994] and to heroin 
profiling [Klemenc, 2001]. Pearson correlation is being used in Poland for amphetamine profiling [Krawczyk, 
2001]. Finally, Manhattan distance has been used in relation to heroin [Myors, 2001] whereas the Canberra 
distance was used in physical evidence comparisons [Thornton et al., 1975]. 
 
The minimal and maximal values given by these methods are not all the same. Therefore, some normalisation 
was applied in order to have a range between 0 and 100, 0 being the perfect match whereas 100 would be the 
complete mismatch. This approach allowed us to directly compare the performance of these methods. 
The distances were calculated using a home-made software programmed by Partner 3 or an Excel macro 
provided by Partner 4. After verification, both systems could be used as they gave the same results. The distance 
methods employed are briefly described below. 
 
Euclidean distance : 
 
The most commonly known distance method is probably the Euclidean distance. Graphically, it can be 
visualised as the distance between two points (samples) in space. The Euclidean distance is calculated according 
to equation 12,  
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where xi denotes the area of the i:th peak in profile X and yi the peak area of the i:th peak in profile Y. The total 
number of peaks is n. In order to get values between 0 and 100, each distance had to be divided by the largest 
distance in the data set and then multiplied by 100. 
 
Pearson correlation : 
 
In this method the correlation coefficient (r) between peak areas in two profiles is calculated. Two very similar 
samples will have a high correlation with a r value close to 1 and two very dissimilar (negatively correlated) 
samples will have a value close to –1. Uncorrelated samples will have a r value close to 0. The correlation 
coefficient is calculated according to equation 13 , 
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where xkj and xlj are the j:th peaks of profiles K and L, respectively, and kx and lx  are the means of the peaks of 
profiles K and L, respectively. Conversion of distances to the range 0 - 100 was obtained using equation 14. 
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Similarity index : 
 
Similarity index (SI) is a metric where a high number corresponds to a high similarity. The formula is given in 
equation 15, 
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where k , k2 , m and w are constants. The xi is chosen as the bigger of xi and yi, which gives xi/yi≥ 1. 
According to Eerola and Lehtonen [Eerola and Lehtonen, 1988], the constants k, k2, m and w are given the 
values 6, 0.25, 50 and 1, respectively, which results in equation 16, 
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The highest value that can be obtained from this formula is 101.67. Conversion of distances to the range 0 - 100 
was obtained using equation 17, 
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Quotient method : 
 
In the quotient method the quotients of peak areas of corresponding impurities in the two profiles to be compared 
are calculated. This means that there will be as many quotients as there are target impurities. The quotient 
calculation is illustrated mathematically by equation 18, 
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where qi is the i:th quotient of xi and yi, which are the i:th impurity in profiles X and Y, respectively. If the two 
profiles are similar the calculated quotients will be similar. The next step is to calculate the distances between 
each quotient and the other quotients. These calculations are made according to equation 19,  
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where qi and qk are quotients of peaks i and k, respectively. Since there is always a random variation present a 
value, rmax, has been introduced. By experience it is known that a rmax value of 20 % is useful in amphetamine 
profiling [ref]. This value gives the spread within which the quotients are considered to be similar. For each 
quotient the number of quotients where rik < rmax is calculated. The maximum of these numbers (i.e. the number 
of peaks within rmax) is then transformed to a distance. This is made by dividing the number of quotients where 
rik > rmax with the total number of peaks and multiplying this value with 100, which will provide distances in the 
range 0-100. 
 
Example : 
 
If 33 target compounds are used and the number of quotients where rik < rmax is 32, the number of quotients 
where rik  > rmax is 1. Therefore, the distance will be equal to (1 / 33) * 100 = 3.03. 
One characteristic of this method is that it is discontinuous. Indeed, if the number of quotients where rik < rmax is 
31, we jump to a distance of 6.06. This feature had to be taken into account in the interpretation of the results. 
One important other characteristic is that a  rmax value has to be chosen before proceeding to the calculations. 
 
It should be noted that alternative 1 (see section 6.4) was used a bit differently with the quotient method. Indeed, 
zeroes were left in the database as such and when two corresponding target compounds in two profiles had the 
value zero it was considered as a match. In other words, the quotient of these two target compounds (although 
absent) was considered as 1. 
On the other hand, if one of the two corresponding target compounds had a value (and the other a zero) it was 
considered as a non-match. Both the home-made software (partner 3) and the Excel macro (partner 4) were set in 
order to take care of these considerations. 
Moreover, in some cases, partner 3 have included some missing values. This was the case when a peak area 
could not be determined although the target compound was thought to be present. Therefore, the peak area was 
given a missing value defined as « m ». For all distance methods, these « m » values were treated as zeroes with 
one exception : when a zero was compared with a « m », it was considered as non-match with the quotient 
method. 
It should be noted that partners 2 and 4 avoided the use of this supplementary variable by giving either a value or 
a zero when confronted to such a problem. 
 
Canberra index : 
 
Canberra index is a kind of block distance where the difference in each variable is weighed by the sum of the 
two values of the variable. This means that the contribution from each variable / target compound can not be 
larger than 1/n. The equation of the Canberra index is given in equation 20, 
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where xi and yi are the area of the i:th peak in profiles X and Y, respectively. The total number of peaks is n. In 
order to get distances in the range 0-100 the Canberra index is multiplied by 100. 
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Manhattan : 
 
Manhattan is related to the Canberra index. The difference is that Manhattan does not take the size of peaks into 
consideration in the comparison. The Manhattan distance is calculated according to equation 21,  
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where xkj and xlj are the areas of the j:th peak in profiles K and L, respectively.  
 
In order to get values between 0 and 100, each distance had to be divided by the largest distance in the data set 
and then multiplied by 100. 
 
Squared sinus [Keto, 1989, Esseiva et al., 2003] : 
 
The sinus of the angle between two profiles in space is calculated and the obtained value is squared. When the 
angle is 0º the distance is 0 (sinus 0º =0), which means that the profiles are identical. When the angle is 90º the 
distance is 1 (sinus 90º =1) and means that the profiles are completely different. 
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where xkj and xlj are the j:th peaks of profiles K and L, respectively and n is the number of target compounds. 
Conversion of distances to the range 0 - 100 was obtained by multiplying the value by 100. 
 
 
6.6 Evaluation of pre-treatment methods 
 
6.6.1 The data set 
 
The correct choice of pre-treatment method is an extremely important decision since it will affect the quality of 
the extracted information. For this purpose, it was decided to study a relatively small data set and its composition 
is shown in table 49. This data set also had to be representative and contain various amphetamine profiles. This 
is why amphetamines from different synthetic routes were included as well as related samples (from controlled 
syntheses) and unrelated samples (street samples from police seizures). The different pre-treatment methods (one 
at a time or in combination) were applied to this data set of 44 samples. Only MSD data were evaluated for this 
purpose with 33 target compounds (see table 48). 
 
Table 49 Samples included in the data set used for distance calculations and evaluation of pre-
treatment methods. In total, 44 samples were used. 
Type of sample Leuckart Reductive amination Nitrostyrene All methods 
Different recipe 12 6 4 22 
Repeated synthesis 2 0 0 2 
Precipitated from same oil 
but at different pH 
2 0 0 2 
Task 5 samples 6 0 3 9 
Street samples 3 6 0 9 
Sum 25 12 7 44 
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6.6.2 The pre-treatment and distance combinations 
 
The various algorithms described in section 6.5 were applied to this data set after various pre-treatment data 
combinations. An exception was made for the quotient method. Indeed, this method, used by partner 3 for many 
years in their laboratory, was mainly designed to be used with raw data. Therefore, other comparisons with the 
quotient method were carried out at a later stage. The various combinations are summarized in table 50 : 
 
Table 50. Combinations of pre-treatment and distance methods 
 
Pre-treatment 
method * 
Manhattan Canberra Euclidean Pearson 
Similarity 
index 
Squared 
Sinus 
 Alternative 1 
N x x x x x x 
N + W x x x x x x 
W + N x x x x x x 
N + log x x x x x x 
N + 4root x x x x x x 
W + N + log x x x x x x 
W + N + 4root x x x x x x 
 Alternative 2 
N x x x x x x 
N + W x x x x x x 
W + N x x x x x x 
N + log x x x x x x 
N + 4root x x x x x x 
W + N + log x x x x x x 
W + N + 4root x x x x x x 
 
* N = Normalisation. N+W = Normalisation + Weighing. W+N = Weighing + Normalisation. N+log = 
Normalisation + logarithm. N+4root = Normalisation + 4
th
 square root. W+N+L = Weighing + Normalisation + 
Logarithm. W+N+4root = Weighing + Normalisation + 4
th
 square root.  
 
 
6.6.3 Principal Component Analysis (PCA) 
 
Principal Component Analysis (PCA) is a bilinear modeling method that is used to simplify interpretation of 
large data matrices. A bilinear modeling method is designed for situations where collinearity exists among the 
original variables. The information carried by the original variables is projected onto a smaller number of 
underlying variables called principal components (PC’s). The latter are linear functions of the original variables. 
PCA is thus a data reduction or compression method. 
The first principal component covers as much of the variation in the data as possible. The second principal 
component is orthogonal to the first and covers as much of the remaining variation as possible, and so on. 
By plotting the principal components, one can view interrelationships between different variables, and detect and 
interpret sample patterns, groupings, similarities or differences. 
In this section, two types of plots will be illustrated : score plots and loading plots. Score plots show the 
locations of the samples according to the model, and can be used to detect sample patterns, groupings, 
similarities or differences. Loading plots show how well a variable is taken into account by the model. They can 
be used to understand how much each variable contributes to the meaningful variation in the data, and to 
interpret variable relationships.  
Finally, it should be remembered that PCA is an exploratory (or unsupervised) method. 
 
6.6.4 Evaluation of false positives in the data set 
 
The first aim was to investigate how well various pre-treatment methods performed in combination with distance 
methods. As a measure of the performance, the idea was to determine the ability of each combination to 
discriminate between linked and unlinked samples. 
In this data set of 44 samples, 18 links were present. 11 of them were between original samples and diluted 
samples. 6 were between samples synthesised with the same recipe by the same operator and the last one was 
between two samples that came from the same batch of amphetamine. These 18 links, translated into distance 
values, consisted our linked population.For the unlinked population, distances were calculated between unrelated 
samples. This gave us a number of 617 distances. 
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The first measure of the performance of these 84 combinations was to determine the percentage of false 
positives. For this, the maximum distance in the linked population was calculated (for each combination) and 
considered as the threshold value. Then, all distances between unlinked samples that were inferior to this 
threshold value were considered as false positives. In other words, the distance between two unrelated samples 
which is smaller that the maximum distance between two linked samples is a false positive. 
As for false negatives, it was not considered useful to calculate them in this subtask as the percentage would be 
based only on 18 distances (from 18 links). The results are shown in table 51 : 
 
Table 51. Percentage of false positives in the data set of 44 samples (out of 617 distances) 
 
Pre-treatment 
method * 
Manhattan Canberra Euclidean Pearson 
Similarity 
index 
Squared 
Sinus 
 Alternative 1 
N 5.3 0.8 4.4 11.0 1.9 7.5 
N + W 9.2 0.8 7.1 2.4 1.9 1.3 
W + N 4.1 1.5 8.9 4.5 1.3 2.1 
N + log 6.3 0.2 2.9 0.8 1.0 0.6 
N + 4root 1.9 1.0 1.5 1.0 1.9 1.1 
W + N + log 20.1 1.0 4.7 2.1 1.1 1.0 
W + N + 4root 6.5 1.3 2.9 1.5 1.9 1.0 
 Alternative 2 
N 3.9 14.3 2.8 7.0 9.1 6.5 
N + W 4.4 14.3 4.1 1.1 9.1 1.1 
W + N 4.2 19.6 47.2 10.2 10.7 13.6 
N + log 6.3 2.1 3.4 6.5 1.1 3.4 
N + 4root 1.8 7.0 0.6 0.6 11.2 0.8 
W + N + log 12.6 2.3 6.6 7.9 2.6 6.2 
W + N + 4root 1.8 14.1 3.2 6.5 22.4 4.5 
 
From the results in table 51, it was not possible to draw any conclusion as to the best combination. Even the 
choice between alternatives 1 and 2 seemed not possible. Therefore, it was decided to keep each distance method 
and both alternatives. However, it was judged possible to choose the best pre-treatment method for each distance 
method from the results above. Thus, normalisation followed by the fourth square root was the best compromise 
with Manhattan, Euclidean, Pearson and the squared sinus whereas normalisation followed by the logarithm was 
the best compromise for the Similarity and Canberra indexes. 
Thus, a further investigation will be carried out with a larger data set in a next section. Meanwhile, the same data 
set was evaluated with principal component analysis in order to study the influence of the pre-treatment methods 
in the classification of the samples into the three synthetic routes present in this data set. 
 
6.6.5 Evaluation with PCA 
 
The data concerned 33 variables and 44 samples. Both alternatives 1 and 2 were considered together with the 
seven pre-treatment methods, hence 14 models. This data was introduced into the Unscrambler
®
. This is a 
commercial software for multivariate analysis which was kindly made available for the last 8 months of the 
project by Camo Process AS, Oslo, Norway. The results are illustrated and explained below : 
 
Figure 26 : Normalisation to the sum with alternative 1. Left : scores plot. Right : loadings plot. 
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The plot on the left hand side shows the scores plot. It can be seen that the three synthetic routes are not well 
separated. The explanation is found in the loadings plot on the right hand side and is directly related to the 
closure effect described in section 6.4. Indeed, three huge peaks (DPIA, phenyl-2-propanone oxime and 
unknown B2) are making up a significant part of the area sum in the samples of our data set and are responsible 
for this poor model. All other target compounds have almost no influence (they are all in the center of the 
loadings plot). 
As mentioned before, one way of avoiding this problem is to exclude large peaks in the peak area sum that is 
used in the normalisation. However, this was considered unwise as DPIA has a major influence in the 
discrimination between Leuckart and reductive amination samples and phenyl-2-propanone oxime has the same 
role in the discrimination between the nitrostyrene route and the two others. 
Another solution is to apply the other pre-treatment combinations. The best results was obtained with 
normalisation followed by the 4
th
 square root (with both alternatives) and are shown below. The plots from the 
other combinations can be found in annex 11. 
 
Figure 27 : Normalisation + 4
th
 square root. Alternative 2 only. Left : scores plot. Right : loadings plot. 
 
 
 
With this pre-treatment method, the three synthetic routes are well separated. The Leuckart samples are on the 
right hand side whereas the reductive amination samples are on the top left and the nitrostyrene in the bottom 
left. In addition, The nitrostyrene samples from task 5 and task 6 could be differentiated. This was to be expected 
as the task 5 samples were synthesised by partner 4 and the task 6 samples by partner 1 and through a totally 
different recipe. Also, the seized reductive amination samples (top left) could be discriminated from the 
synthesised ones (middle left). 
These results are quite in accordance with those obtained in section 6.6.4 where normalisation followed by the 
4
th
 square root gave the lowest percentage of false positives together with normalisation and logarithm. 
As for PCA, normalisation and logarithm also gave satisfactory results (second best) although not as good as the 
4
th
 square root. 
 
In conclusion, based on the results obtained from this small data set, normalisation followed by the 4
th
 square 
root is the best pre-treatment method and will be used in the subsequent task. 
However, normalisation followed by the logarithm will still be considered with the Similarity index and the 
Canberra index as it gave the better results with these distance methods. 
As for alternatives 1 or 2, there are still both under consideration as they seem to give both similar results. 
 
 
 
 
 
 
 
 
 
 
 
 
Nit T5 
Nit T6 
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6.7 Further reduction of target compounds 
 
6.7.1 Introduction 
 
At this stage of the project, it was thought necessary to decrease the number of target compounds. Indeed, the 
idea was to test whether the same results could be obtained with fewer variables. 
At first, 27 target compounds were used instead of 33 : The two isomers of the phenyl-2-propanone oxime were 
combined whereas cathinol 1, pyridine 272, unknown A4, 4-methyl-5-pyrimidine and 4-benzylpyrimidine were 
removed. 
The two isomers of phenyl-2-propanone oxime were combined as it was difficult to integrate them separately 
when this compound is present in high amounts. Cathinol 1 was removed as it was found in very few samples 
and in very small proportions. Pyridine 272 is generally a small peak and as a number of pyridine derivatives are 
already present in the list, it was thought that its removal would not be harmful. The same applies to unknown 
A4. Unknown A2 and A3, which are isomers of unknown A4, are still present in the list. 
As for the two pyrimidines, although they are considered specific to the Leuckart route, especially if they are 
present in relatively high proportions, they were removed because of their well known volatility. Indeed, they are 
known to evaporate relatively quickly depending on the storage conditions of the amphetamine powder. 
Therefore, it was considered preferable to seek a profiling method without these two compounds. 
Further, depending on the results, the number of target compounds was even further reduced or increased. 
 
 
6.7.2 Evaluation of false positives in the data set 
 
According to the conclusions of section 6.6, normalisation followed by the fourth square root seemed to be the 
best compromise. In order to reduce the amount of work, it was therefore decided to use this pre-treatment 
method in this subtask and to use only one distance method. Based on the results displayed in table 52 (section 
6.6.4), the choice was made for the Pearson correlation. Still, both alternatives (1 and 2) were tested. 
 
In table 52, it could be seen that only 1.0 % false positives was found with alternative 1 and 0.8 % with 
alternative 2. This corresponds to 6 and 5 false positives respectively (N = 617). By reducing the number of 
target compounds to 27, these numbers were further reduced. Indeed, only two false positives were found with 
alternative 1 and one false positive with alternative 2. Thus, even better results were obtained with less target 
compounds in terms of false positives. 
 
Therefore, three additional target compounds were removed : phenyl-2-propanone oxime (isomers 1 + 2), N-
propylbenzamide and the aziridine leaving us with 24 target compounds. These three compounds were 
tentatively removed as they were eluting first in the chromatogram and were therefore presumed to be the most 
volatile. 
The same results were obtained compared to 27 compounds. That is : two false positives with alternative 1 and 
one with alternative 2. However, these three compounds are mainly found in nitrostyrene amphetamine and the 
following PCA analysis will show that they can not be all removed. Indeed, they were found important in the 
discrimination between nitrostyrene and the two other synthetic routes. 
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6.7.3 Evaluation with PCA 
 
PCA models with 33, 27 and 24 compounds were made with both alternatives. Normalisation followed by the 
fourth square root was used. Results are shown below : 
 
 
Figure 28 : Normalisation + 4
th
 square root. 33 compounds. Left : alternative 2. Right : alternative 1. 
 
Figure 29 : Normalisation + 4
th
 square root. 27 compounds. Left : alternative 2. Right : alternative 1. 
 
 
Figure 30 : Normalisation + 4
th
 square root. 24 compounds. Left : alternative 2. Right : alternative 1. 
 
 
As can be seen in figure 30, some nitrostyrene samples could not be differentiated from reductive amination 
samples when only 24 compounds are used. This confirms that the three removed compounds are important for 
discriminating the nitrostyrene route. However, the use of 27 target compounds give similar PCA models 
compared to 33 compounds.  
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Still, an attempt was made to reduce the number of target compounds from 27 to 25 or 26 by removing one or 
two of these nitrostyrene compounds, i.e. phenyl-2-propanone oxime, 2-methyl-3-phenylaziridine and N-
propylbenzamide. According to the loadings plot of the PCA models, phenyl-2-propanone oxime is a very 
important variable in order to discriminate the nitrostyrene route. It was therefore kept. After some fine tuning, it 
was determined that 2-methyl-3-phenylaziridine could be removed leaving us with 26 compounds. With these 26 
compounds, the number of false positives was the same as with 27 (two with alternative 1 and one with 
alternative 2). The PCA model with 26 compounds is shown below : 
 
 
 
Figure 31 : Normalisation + 4
th
 square root. 26 compounds. Left : alternative 2. Right : alternative 1. 
 
 
Although a bit subjective, observations of these PCA models tend to indicate that alternative 2 provides a better 
separation of the three synthetic routes compared to alternative 1 (especially between nitrostyrene and reductive 
amination). The following chapter will actually show that alternative 2 is indeed probably better suited than 
alternative 1. 
 
 
6.8 Final evaluation and choice of the distance method 
 
6.8.1 The new data set 
 
The outcome of the previously performed experiments was not sufficient to decide which distance method to use 
in the final method. Consequently, a new and bigger data set was designed to further compare the different 
distance methods. For this purpose, two populations were created : the first consisted of distances calculated 
between samples known to be from the same batch of amphetamine and the second consisted of distances 
between samples known not to be from the same batch. The two sets of data were compared and the number of 
distances being in the overlapping zone were determined and used as a measure of the performance of each 
distance method in discriminating between linked and unlinked samples. The number of false positives and false 
negatives were calculated from this overlapping region. The following figures illustrates graphically the idea : 
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Figure 32a : schematic illustration of the overlapping region in the evaluation of the performance of the 
distance methods. The coloured zone indicates the region of false positives. 
 
 
 
 
Figure 32b : schematic illustration of the overlapping region in the evaluation of the performance of the 
distance methods. The coloured zone indicates the region of false negatives. 
 
 
In figures 32a and 32b, the overlapping region is situated between x and y, x being the minimum distance 
between unlinked samples and y being the maximum distance between linked samples (same batch). If x and y 
are chosen as the thresholds, the coloured region in figure 32a corresponds to the number of false positives and 
the coloured region in figure 32b to the number of false negatives. 
Of course, in the ideal situation, there would be no overlap. Moreover, in the data set used in this section, there 
should be no overlap as we are comparing synthesised samples (within batch population) with street samples 
(samples seized on the illicit market). Thus, the aim was to determine the distance method which would give the 
smallest overlap, i.e. the smallest number of false positives and negatives. 
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Within batch population : 
 
The samples used for calculation of distances between samples of the same batch were made up of those 
synthesised within the project. Where applicable, different concentrations (5, 40 and 100 %), were included in 
the calculations. Moreover, all replicates and analyses in different laboratories were included. In total this 
generated 3901 within batch distances. The detailed composition is as follows : 
 
- Reductive amination sample n°1 synthesised by partner 2 : 27 analyses  number of pairs : 351 
- Reductive amination sample n°2 synthesised by partner 2 : 27 analyses    351 
- Reductive amination sample n°3 synthesised by partner 2 : 27 analyses    351 
- Leuckart sample n°1 synthesised by partner 3 :  24 analyses    276 
- Leuckart sample n°2 synthesised by partner 3 :  24 analyses    276 
- Leuckart sample n°3 synthesised by partner 3 :  27 analyses    351 
- Leuckart sample n°1 synthesised by partner 4 :  27 analyses    351 
- Leuckart sample n°2 synthesised by partner 4 :  27 analyses    351 
- Leuckart sample n°3 synthesised by partner 4 :  27 analyses    351 
- Nitrostyrene sample n°1 synthesised by partner 1 :  18 analyses    153 
- Nitrostyrene sample n°2 synthesised by partner 1 :  18 analyses    153 
- Control sample synthesised by partner 3 :   34 analyses    561 
- Leuckart sample n°1 (partner 3, task 5)  :  3 analyses        3 
- Leuckart sample n°2 (partner 3, task 5):   3 analyses        3 
- Leuckart sample n°3 (partner 3, task 5):   3 analyses        3 
- Leuckart sample n°1 (partner 4, task 5):   3 analyses        3 
- Leuckart sample n°2 (partner 4, task 5):   3 analyses        3 
- Leuckart sample n°3 (partner 4, task 5):   3 analyses        3 
- Nitrostyrene sample n°1 (partner 2, task 5) :   3 analyses        3 
- Nitrostyrene sample n°2 (partner 2, task 5) :   3 analyses        3 
- Nitrostyrene sample n°3 (partner 2, task 5) :   2 analyses        1 
 
Total : 3901 
 
Not linked population : 
 
In order to create the unlinked population described in figures 32a and 32b, 20 synthesised samples (from 20 
different batches, 13 Leuckart, 3 reductive amination and 4 nitrostyrene) were compared to street samples 
(samples seized on the illicit market). Including a few replicates, this represented 390 samples (about 40 % from 
Sweden, 30 % from Finland and 30 % from Switzerland). Thus, 20 x 390 = 7'800 distances were generated. 
 
6.8.2 Evaluation of false positives and false negatives 
 
As mentioned in section 6.6.4, only the following combinations were studied with this new data set : 
 
- Pearson (normalised + 4
th
 square root). Alternatives 1 and 2. 
 
- Squared sinus (normalised + 4
th
 square root). Alternatives 1 and 2. 
 
- Similarity index (normalised + logarithm). Alternatives 1 and 2. 
 
- Canberra index (normalised + logarithm). Alternatives 1 and 2. 
 
- Euclidean distance (normalised + 4
th
 square root). Alternatives 1 and 2. 
 
- Manhattan distance (normalised + 4
th
 square root). Alternatives 1 and 2. 
 
- Quotient (raw data). Zeroes as such. With rmax at 5, 10, 15 and 20 %. 
 
Once the distances calculated, the data was plotted as histograms in order to get graphics similar to those shown 
in figures 32a and 32b. All histograms can be found in annex 12. 
Only the two best results are illustrated here in figures 33a and 33b : 
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Figure 33a : schematic illustration of the overlapping region with Pearson correlation after normalisation 
+ 4
th
 square root and alternative 2. 
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Figure 33b : schematic illustration of the overlapping region with squared sinus after normalisation + 4
th
 
square root and alternative 2. 
 
 
In terms of numbers, table 52 summarizes the percentages of false positives and false negatives for each distance 
method : 
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Table 52 Percentages of false positives and false negatives for each distance method. N = 7800 for 
the calculation of false positives and N = 3901 for the calculation of false negatives.  
 
Distance method Alternative 
False 
positives in % 
False 
negatives in % 
Pearson 1 9.0 93.4 
Pearson  2 0.1 1.2 
Squared sinus 1 0.3 4.3 
Squared sinus 2 0.1 0.9 
Euclidean  1 1.2 19.0 
Euclidean  2 0.9 3.4 
Manhattan 1 2.2 42.5 
Manhattan 2 1.5 2.5 
Similarity Index  1 1.6 7.4 
Similarity Index 2 0.3 4.3 
Canberra 1 0.6 3.5 
Canberra 2 1.3 8.2 
Quotient 20 % - 1.1 4.6 
Quotient 15 % - 1.7 8.3 
Quotient 10 % - 5.8 19.4 
Quotient 5 % - 16.0 42.6 
 
Note: The percentage values given for the Quotient method corresponds to the rmax value used. 
 
 
6.8.3 Discussion and conclusions 
 
First of all, table 52 shows an interesting result which illustrates quite well the main disadvantage of alternative 1 
with some distance methods. Indeed, the most outstanding value is 93.4 % of false negatives with Pearson and 
alternative 1. This is explained by the fact that two unrelated samples (a reductive amination synthesised sample 
and a reductive amination street sample) had only two target compounds in common. Some other target 
compounds were present in one sample and absent in the other and vice-versa. With alternative 1 only the peak 
areas of the two compounds are taken into consideration for the comparison. This is of course not sufficient for 
discriminating the two samples. Thus, a very low correlation value was obtained (close to 0) and was used as the 
threshold value for the calculation of false negatives. As this value was very low, the majority of the within batch 
distances were over this threshold, hence a high percentage of false negatives.  
However, in this kind of situation, not all distance methods will give a very low value. For example, the squared 
sinus will accentuate the difference between two samples if target compounds are present in a sample and absent 
in the other. This is directly related to the mathematical algorithm (see equation 22, section 6.5).  
 
Nevertheless, these results clearly indicate that alternative 2 with Pearson or squared sinus are the most powerful 
methods in discriminating between two populations of linked (same batch) and unlinked samples, thus 
minimizing the risks of false positives and false negatives. Of course, these results are valid only for the data set 
tested. However, they confirm the results obtained in section 6.6.4 and it is therefore a strong indication of the 
advantages of these comparison methods over the others. Moreover, these results are in total accordance with 
those obtained by Esseiva [Esseiva et al., 2003] who found that Pearson and the cosine function (the inverse of 
the sinus) were the best methods in relation to the profiling of heroin. Therefore, it is an additional indication that 
these methods are indeed the most suited for the purpose. 
 
Finally, it should be mentioned that the replacement of zeroes by the value 200 (alternative 2) is not that critical 
with these two methods. Indeed, zeroes could be left as such as this does not interfere with the fourth square root 
(the 4
th
 square root of 0 is 0) and has little influence in the algorithms of Pearson or the squared sinus. Therefore, 
this alternative that we could call alternative 3 would give almost the same results as alternative 2. A few 
subsequent calculations made by partner 3 confirmed this assumption. However, it was decided to stick to the 
decision of replacing zeroes by 200 as the conclusions are based on this alternative. Moreover, it was considered 
too much time consuming and useless to perform again all calculations with this third alternative which would 
not bring any improvement. 
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6.9 Estimation of useful thresholds 
 
6.9.1 Thresholds for determination of samples from the same batch 
 
At this time, Pearson correlation and the squared sinus function were both considered as the best distance 
methods for comparing pairwise amphetamine samples in a database. Before that, the GC-MS raw data (with 
zeroes replaced by the value 200) should be normalised to the sum and each normalised peak submitted to the 
fourth square root. After comparison of two or more samples, numerical values between 0 and 100 will be 
obtained where 0 is the perfect match. 
 
If the profiling method is to be applied in routine work, it is important to determine an estimate of one or more 
thresholds which would help the analyst in the interpretation. For this purpose, calculations were made between 
samples coming from the same batch which were at the same or different concentrations and which were 
analysed in the same laboratory or in different laboratories. The synthesised batches from task 6 were used in 
this case as their origin are known. The results are shown in tables 53a and 53b and in figures 34a and 34b : 
 
Table 53a Mean, min, max and standard deviation values for distances between samples coming 
from the same batch. Pearson correlation (N+4root, alternative 2). 
 
 N° of distances Mean Std deviation Min Max 
Within batch, 
within lab and 
same concentration 
 
174 
 
0.013 
 
0.027 
 
0.0001 
 
0.200 
Within batch, 
between lab and 
same concentration 
 
792 
 
0.257 
 
0.274 
 
0.010 
 
1.876 
Within batch, 
within lab and 
diff. concentration 
 
243 
 
0.278 
 
0.206 
 
0.011 
 
0.733 
Within batch, 
between lab and 
diff. concentration 
 
747 
 
0.370 
 
0.279 
 
0.009 
 
1.894 
 
Table 53b Mean, min, max and standard deviation values for distances between samples coming 
from the same batch. Squared sinus (N+4root, alternative 2). 
 
 N° of distances Mean Std deviation Min Max 
Within batch, 
within lab and 
same concentration 
 
174 
 
0.022 
 
0.045 
 
0.00005 
 
0.297 
Within batch, 
between lab and 
same concentration 
 
792 
 
0.480 
 
0.491 
 
0.022 
 
2.759 
Within batch, 
within lab and 
diff. concentration 
 
243 
 
0.638 
 
0.441 
 
0.067 
 
1.768 
Within batch, 
between lab and 
diff. concentration 
 
747 
 
0.766 
 
0.487 
 
0.020 
 
3.002 
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Figure 34a : schematic illustration of the distances of samples from the same batch. Pearson after 
normalisation + 4
th
 square root and alternative 2. 
 
 
 
Figure 34b : schematic illustration of the distances of samples from the same batch. Squared sinus after 
normalisation + 4
th
 square root and alternative 2. 
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From table 53a and especially from figure 34a, it can be seen that the majority of distances for samples from the 
same batch are in the region 0 to 0.5 for Pearson. As for the squared sinus, table 53b and figure 34b show us that 
the majority of distances are in the region from 0 to 1. 
Of course, the distances are smaller if the samples are analysed in the same laboratory. Also, the distances are 
smaller if the compared amphetamine samples are of the same concentration. 
Full detailed mean, standard deviation, min and max values describing all combinations can be found in annex 
13. 
 
6.9.2 Thresholds for samples synthesised with the same recipe 
 
As mentioned in section 6.2, both partners 3 and 4 synthesised six batches of amphetamine using the same 
recipe. The syntheses were thoroughly controlled in order to get as reproducible profiles as possible. The idea 
was to determine the degree of variation of the profiles when one person in one laboratory synthesised multiple 
batches. In addition, it was also considered interesting to investigate the degree of variation between batches 
synthesised by two different people in two different laboratories but following exactly the same recipe. 
For each batch, three replicates (three extracts) were prepared and analysed. Results are illustrated in figure 35a 
for Pearson and in figure 35b for the squared sinus : 
 
Figure 35a : schematic illustration of the Pearson distances between samples from multiple batches 
synthesised in one lab and one operator (in red). In blue, distances between samples from batches synthesised in 
two laboratories by two operators following exactly the same recipe. 
 
 
As expected, the distances increase when different batches are compared although they were synthesised with 
the same recipe in one laboratory. Figure 35a shows us that the majority of distances are situated between 0 and 
1.5 for Pearson whereas they were between 0 and 0.5 for samples coming from the same batch.  
Regarding the distances between samples of batches synthesised in two different laboratories using the same 
recipe, they increase expectedly as well although some batches are very close. Indeed, the majority of distances 
are between 3.0 and 8.0 although a few distances are between 0.8 and 2.2. 
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Figure 35b : schematic illustration of the squared sinus distances between samples from multiple batches 
synthesised in one lab and one operator (in red). In blue, distances between samples from batches synthesised in 
two laboratories by two operators following exactly the same recipe. 
 
 
The same remarks are valid for the distances calculated with the squared sinus. The only difference is that the 
values are slightly shifted to the right with the squared sinus (if zero is considered to be the further left). Indeed, 
figure 35b shows us that the majority of distances are situated between 0 and 3.0 whereas they were between 0 
and 1.0 for samples coming from the same batch.  
Regarding the distances between samples of batches synthesised in two different laboratories using the same 
recipe, the majority of distances are between 4.0 and 13.5 although a few distances are between 1.2 and 3.8. 
 
Overall results are summarized in table 54 : 
 
Table 54 Mean, min, max and standard deviation values for distances between samples coming 
from different batches. Pearson and Squared sinus (N+4root, alternative 2). 
 
 N° of distances Mean Std deviation Min Max 
Same recipe, same 
lab. Pearson. 
135 0.92 1.03 0.02 4.09 
Same recipe, two 
labs, Pearson. 
324 3.12 1.72 0.70 7.74 
Same recipe, same 
lab. Squared sinus. 
135 1.65 1.87 0.03 7.33 
Same recipe, two 
labs, Squared sinus. 
324 4.98 2.92 1.12 13.15 
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Finally, in order to visualise the distribution of distances, figures 36a and 36b were drawn from table 55 values 
as well as from the values shown in tables 54a and 54b. The within batch values used here are those from the 
analyses made in different laboratories for batches of the same concentration. This represents the closest 
situation to the batches made from the same recipe as the latter were analysed in two different laboratories and 
were of the same concentration (approx. 100 % amphetamine). 
 
 
Figure 36a : graph of the Pearson distances summarizing the results from tables 54a and 55. The black 
areas represent the mean ± standard deviation. The extremities of the black lines represent the minimum and 
maximum values. 
 
 
Figure 36b : graph of the squared sinus distances summarizing the results from tables 54b and 55. The 
black areas represent the mean ± standard deviation. The extremities of the black lines represent the minimum 
and maximum values. 
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6.9.3 Conclusions 
 
From section 6.9.1, it could be estimated that Pearson distances between 0 and 0.5 are representative of samples 
coming from the same batch. For the squared sinus, the estimate is between 0 and 1.0. 
Figures 36a and 36b, which is the summary of this small experiment of repeated syntheses, indicate to us that 
several batches synthesised successively in one laboratory gave Pearson distances between 0 and 2.0. For the 
squared sinus, the estimate is between 0 and 3.5. 
Finally, when the batches synthesised with the same recipe by partners 3 and 4 were compared, the Pearson 
distances varied between 1.4 and 4.8. For the squared sinus, the values varied between 2.0 and 8.0. 
Although these estimates don’t take into account the minimum and maximum values (only mean ± standard 
deviation), they still give an idea of the thresholds to use in further interpretation. 
For example, if two unknown samples are compared and a Pearson distance value of 0.1 is found, it is a strong 
indication that they probably come from the same batch. If a value of 1.0 is found, it is rather an indication that 
they were synthesised by the same laboratory with the same recipe but belong to a different batch. However, if a 
value of 1.5 is found, no conclusion could be drawn as they could originate from two different sources. Still, in 
this situation, it is very probable that the exact same recipe was used. 
 
Nevertheless, these values are based only on a small data set and on a limited number of controlled syntheses. 
Only extensive future work will enable us to determine if these values are correct and could be used in further 
interpretation. A much larger number of samples from known sources will have to analysed for this purpose. 
Also, the distances between batches synthesised with the same recipe in two laboratories are probably too 
pessimistic (or optimistic depending on how you look at them). Indeed, the synthetic conditions were really too 
carefully controlled and are probably not at all representative of the synthetic conditions used in clandestine 
laboratories. Therefore, it is expected that the distances values would be much higher for illicit samples coming 
from multiple batches of one laboratory as well as from batches originating from different laboratories using the 
same recipe. 
 
Finally, it should be remembered that the results in section 6.9.2 are valid for Leuckart amphetamine only as it 
was not possible to repeat these experiments for reductive amination and nitrostyrene amphetamine. 
 
 
6.10 Analysis of blind samples 
 
6.10.1 Introduction 
 
In order to determine if the final method was performing correctly, it was decided to check the ability of the 
method to find correct links in the database. Therefore, each partner sent a few of their samples to the others 
without any labels or indications about their identities. However, these samples were already analysed previously 
and the corresponding data stored in a common database. Thus, the analyses and the subsequent calculations 
should enable us to correctly identify these so-called blind samples. 
For this matter, partner 4 sent five samples (I1 to I5) to partners 2 and 3. Unfortunately, sample I3 could not be 
analysed by partner 2 as the glass recipient broke during transportation. Alternatively, partner 4 received five 
blind samples from partner 2 (N1 to N5) and also five blind samples from partner 3 (S1 to S5). 
To avoid partners from sending by accident the same samples to each other, it was decided that partners should 
only send five of their « street samples ». In this way, each partner would analyse a blind sample which was not 
analysed previously in their laboratory. Nevertheless, all partners would be using the same database which 
consists of 768 samples (synthesised + street samples) and try to find the identity of the blind samples by 
comparing them to the whole common database. 
 
6.10.2 Results 
 
The results are summarized in table 55. Pearson and squared sinus gave the same results. However, for sake of 
simplicity, only Pearson distances are given here : 
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Table 55 Results from the blind test study. In brackets, Pearson distances obtained. Each 
laboratory put their best match as the possible candidate. 
 
  Results 
Sample 
number 
Expected results Partner 2 Partner 3 Partner 4 
I1 B1643  (0.24)  (0.09) - 
I2 GEJU  (2.22)  (1.08) - 
I3 18A Not analysed  (0.87) - 
I4 5012B  (0.32)  (0.02) - 
I5 7922  (0.39)  (0.08) - 
S1 S015  (0.19) -  (0.09) 
S2 S047 
S035 (0.31) 
 (0.32) 
- 
S035 (0.25) 
 (0.26) 
S3 S081  (0.47) -  (0.37) 
S4 Not in database S087 (0.41) - S087 (0.44) 
S5 S003  (0.31) -  (0.19) 
N1 NC3545 -  (0.07)  (0.32) 
N2 NC12662 -  (1.06)  (0.14) 
N3 NC19078A -  (0.04)  (0.07) 
N4 NC3911 -  (0.17)  (0.08) 
N5 NC15906A - 
NC15906B (0.16) 
 (0.35) 
NC15906B (0.11) 
 (0.56) 
 
 
 
6.10.3 Discussion and conclusions 
 
As can be seen in table 55 above, they were three false positives (for samples S2, S4 and N5) but they could all 
be explained quite simply. 
First, subsample S2 was taken from sample S047. However, comparison between samples S035 and S047 
showed a Pearson correlation of 0.001, which means that it is almost impossible to discriminate between these 
two samples, at least with our 26 target compounds, and very strongly indicates that these two « street » samples 
are coming from the same batch of amphetamine. Therefore, when analysing this sample as blind, it is almost 
impossible to determine if it belongs to sample S035S or S047S. Indeed, the Pearson distances are almost exactly 
the same between the blind samples and samples S035S and S047S, independently of which laboratory is 
analysing the samples. 
Secondly, sample S4, which was sent by partner 3, was actually a sample which was not in our database. 
Therefore, no correspondence was supposed to be found. Still, a good match was found with sample S087S (with 
a Pearson value of less than 0.5). In this case, we can not exclude that this sample belongs in fact to the same 
batch of amphetamine as the real sample S4.  
Finally, subsample N5 came from sample NC15906A sent by partner 2. But a better match was found with the B 
sample. Again, it is probable that the subsamples A and B from sample NC15906 are from the same batch of 
amphetamine and that the reason for a better match with sample B is just a result of small random variation. 
 
Otherwise, all other blind samples were correctly identified and were always found to be the best match in the 
database. Also, the distances were generally quite small and below the 0.5 threshold which was determined in 
section 6.9.1 (within batch distances). 
One rather big exception is sample I2. Partners 2 and 3 correctly identified the blind sample but with rather big 
Pearson values. This could be explained by the probable inhomogeneity of this sample. Indeed, sample GEJU 
consisted of about a thousand capsules filled with amphetamine powder (two or three of these capsules have to 
be emptied in order to have enough powder for analyses). Thus, partners 2 and 3 received powdered samples 
from different capsules. So the relatively large Pearson values could be explained by the inhomogeneity of the 
amphetamine in these capsules. In a ideal situation, all capsules should have been emptied beforehand, the 
powder homogeneised and then the samples sent to other partners. 
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In general, table 55 shows very good results. However, this outcome was not quite straightforward. Indeed, a 
number of corrections had to be made in the integration of the 26 target compounds. This topic, which is a very 
important one, will be further discussed in the final conclusions. Still, the main drawback of analysing samples 
in different laboratories was found to be the integration and not the analysis itself. That is, when especially 
confronted to very small peaks, different operators will make different decisions. Some will discard the peak if 
its shape is not adequate and a qualifier ion is missing, others will still integrate the peak as they believe that the 
compound is still there although the peak is not perfect. The MS Chemstation software could take the decision to 
avoid the human factor but, unfortunately, its possibilities are quite limited and also often lead to integration 
errors. 
Therefore, a number of rules have to be set and applied, particularly if new inexperienced operators have to 
perform the integration of MS chromatograms. For the three partners in this task, it was absolutely necessary in 
order to obtain the results in table 55. Thus, if in the future such a method would be used in routine in different 
laboratories and the data exchanged, a solution to this problem has to be found. 
 
 
6.11 General conclusions for task 6 
 
In task 6, the optimised method developed in the project was used to analyse a number of new amphetamine 
samples. Although the instrument was still set with a dual column system (one column to the FID detector and 
the other to the MS), only the MS data was used for the evaluation as GC-MS was found to be the method of 
choice. In a first stage, amphetamine batches were synthesised through different recipes and different synthetic 
routes and 361 “street samples” were collected by the three partners. The synthetised samples were further 
diluted 2.5 and 20 times (generally with caffeine and lactose) and all samples synthesised in task 6 were analysed 
in triplicate (three extracts). In total, this represented a database with 768 entries. 
As for the data analysis, 33 target compounds were selected. Application of Principal Component Analysis 
(PCA) to a smaller data set helped us to reduce the number of target compounds to 26 without affecting the 
discrimination power of the method. Indeed, it was still possible to discriminate samples synthesised via the 
three different synthetic routes (Leuckart, reductive amination and nitrostyrene). Moreover, the number of false 
positives was minimised. 
Pre-treatment of the data before application of a numerical comparison method was found to be a crucial step. 
Normalisation has to be applied in order to be able to compare amphetamine samples of different concentrations 
without changing the sample preparation. Weighing (or standardization) is necessary to reduce the influence of 
one (or more) huge peaks. These can be one hundred to a thousand times bigger than the remaining target 
compounds and can bias the comparison. Dealing with zeroes was also an important issue with some numerical 
methods. 
Finally, the best pre-treatment method was found to be the following : 
 
- All zeroes are replaced by 200 (value correspoonding to the half detection limit of the MS system). 
- Each peak response is divided by the sum of all peak responses (normalisation). 
- Each normalised value is square rooted twice (fourth square root). 
 
Once the data is pre-treated, it can be used to calculate distances between amphetamine samples. Seven different 
methods were evaluated : Euclidean distance, Manhattan distance, Pearson correlation, Similarity index, 
Quotient method, Canberra index and the Squared sinus function.  
Pearson correlation and the squared sinus were found to be the best suited numerical methods for comparison of 
amphetamine profiles. After discussion with all partners, it was finally decided to carry out future work with the 
Pearson correlation as it is an integrated function in Microsoft Excel and might be more convenient to use, 
especially if special computer programs are not available. 
 
When varying the recipe within a synthetic route, it was found very easy to discriminate the resulting 
amphetamine profiles. However, if exactly the same recipe is used, the discrimination is more difficult, 
especially if the same operator has performed the syntheses. To help in the interpretation, some thresholds values 
are proposed which have to be confirmed and updated in the future. These values give an idea of the intra-
variability and inter-variability in amphetamine production but a much larger number of amphetamine samples 
from known sources (such as samples from clandestine laboratories) need to be analysed in order to confirm or 
negate these values. 
For the time being, the proposed thresholds are the following (Pearson values normalised from 0 to 100) : 
 
 
 104
 
0 to 0.5 : Samples probably originate from the same batch or, at least, originate from the same laboratory 
(using one recipe). 
0.5 to 1.0 : Samples probably originate from the same laboratory. They could be from the same batch but 
are more likely to be from different batches (always using the same recipe). 
1.0 to 2.0 : Samples possibly originate from the same laboratory. However, they could be from another 
laboratory which is using exactly the same recipe. 
2.0 to … : Samples were synthesised with a different recipe or even a different synthetic route. 
 
These values are, of course, only rough guidelines. In practice, they are used to sort samples in a database. All 
potential links are then carefully checked visually. Indeed, Total Ion Chromatograms (TIC) and even Extracted 
Ion Chromatograms (EIC)* are compared and special attention is paid to the similarities and dissimilarities of 
the profiles. This is where the experience of the forensic chemist comes into play and also some subjectivity. 
This is why only “certain” links are generally reported to the law enforcement agencies where the correlation 
value is almost a perfect match and the chromatograms are almost mirror images. In these cases, there is a very 
little place for error and it is almost certain that the link is true, meaning that the two (or more) samples come 
from the same batch or, at least, from the same clandestine laboratory. 
The grey area is when the match is not perfect, for example, when Pearson values are between 1.0 and 2.0 as 
described above. In these cases, it is almost impossible to draw a conclusion unless some special similarities or 
dissimilarities can be found in the chromatograms. Then, the forensic chemist might have some more indications 
that would confirm or negate the link or he might be unable to draw any further conclusions. 
 
As mentioned in section 6.10.3, the main problem in the final optimised method is the integration of peaks. It 
also has to be harmonised although the MS chemstation software does the integration automatically with fixed 
parameters. Indeed, the operator still has to check the integration manually in order to verify that the software 
has correctly integrated each target compound. Although, this verification can be very quick (30 seconds per 
chromatogram for an experienced operator), many corrections are often necessary. 
The most common dilemma is to integrate a very small peak or not. This occurs when the software has 
integrated a very small peak and the operator thinks it should not be or vice versa. Depending on the operator 
and its experience, the decision will be different. This can lead to inconsistencies when comparing data between 
laboratories. In a ideal world, all data could be centralised in one laboratory and only one operator would 
perform the integration of all chromatograms. However, this is, of course, inconceivable. Therefore, a number of 
rules have to be set and applied or another solution has to be found. 
In the last few years, Agilent Technologies
®
 in collaboration with the National Institute of Standards and 
Technology (NIST) have commercialised an automated mass spectrometry deconvolution and identification 
system (AMDIS) which works with the Agilent Chemstation [ref. application note]. This system is more 
powerful than the usual MS Chemstation in identifying compounds in complex MS chromatograms and could be 
a future solution to our problem. 
The MS Chemstation identifies target compounds by integrating the target ion as well as two or up to three 
qualifier ions. It also compares the ion ratios to known ratios. However, complex matrices affect ion ratios and 
background noise can do the same with ion ratios of very small peaks. This can cause numerous false positives 
(the software integrates a peak when it shouldn’t) and false negatives (the software does not integrate the peak 
when it should). Therefore, to be certain of the results, manual verification is performed and, as mentioned 
above, leads to inconsistencies if many operators are integrating the same samples. 
AMDIS fully deconvolutes the MS data file by using mathematical algorithms [Colby, 1992] and « cleans » the 
contaminated mass spectra. For all targeted compounds, the full mass spectrum is cleaned from matrix 
interferences and background noise. It is then compared to the mass spectra of an user-constructed library (for 
special applications such as ours) or to a NIST library. This comparison uses full mass spectra and not just two 
or three ion ratios and is retention time independent. However, after spectral identification, it can use the 
Retention Time Locking (RTL) system in order to accept or reject peaks based on a time-window. 
If successful, this system could totally eliminate the human factor in integration as it will decide consistently if 
the target compound is present or not. 
Still, this will hopefully be tested in a future project called CHEDDAR. This project will be discussed in the final 
conclusions (section 8). 
 
* An extracted ion chromatogram is a chromatogram of a particular mass or mass range from data acquired in scan mode. Multiple ions can 
be chosen and extracted. In this project, a macro was developed by Kaisa Jalava (partner 2) which extracts 14 ions representative of the 
Leuckart target compounds (5 for reductive amination and 5 for nitrostyrene). This allows us to obtain « clean » chromatograms where all 
matrix and interfering compounds are removed. Thus, the visual comparison becomes much easier, especially with complex samples or 
samples of different concentration. 
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7 Application of the profiling method to real samples 
 
 
7.1 Analysis of powdered samples 
 
At this stage of the project a number of powdered samples had been analysed with the new optimised profiling 
method. As mentioned in task 6, 112 samples coming from various police seizures were analysed in IPS. These 
were compared with the help of the new numerical comparison method and the potential links were recorded. 
Chromatograms of these potential links were visually compared in order to evaluate the correctness of the 
numerical result. These comparisons were solely used for research purposes and for somehow validating the 
analytical method. There was no aim to report links to the concerned police forces for operational or strategic 
purposes. Still, in order to illustrate the methodology of the comparison, an example is presented below : 
 
A new sample consisting of a white capsule containing amphetamine powder was taken from the IPS collection. 
This sample (internal number 1071) was not used during the project and was therefore not in the project 
database. It was analysed with the new profiling method and compared to the whole database (N = 768 entries). 
Only one possible match came out of the comparison with a good Pearson correlation of 0.39. It concerned the 
sample 3343 / 00 from the WD Zürich (Scientific Section, city of Zürich police). At first, the total ion 
chromatograms (TIC) were compared and are shown below in figure 37 : 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37 : Top : total ion chromatogram of sample 1071. 
  Bottom : total ion chromatogram of sample 3343 / 00 from project database. 
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As can be seen in figure 37, TIC chromatograms are not always ideal for direct comparison as many matrix 
peaks can be present as well as peaks from volatile compounds which can be present in one sample and absent 
(or present in much lower amounts) in the other sample. Still, TIC chromatograms can be useful as most cutting 
agents or other compounds can be identified (for example, caffeine, lidocaine, 1-phenethylamine, etc.). 
Therefore, extracted ion chromatograms (EIC) are considered much more practical for direct comparison as they 
provide « cleaner » chromatograms and the peaks present are generally those of the target compounds. Figure 38 
below shows the corresponding EIC chromatograms of the samples described above : 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38 : Top : extracted ion chromatogram of sample 1071. 
  Bottom : extracted ion chromatogram of sample 3343 / 00 from project database. 
Ions extracted (in this case for Leuckart amphetamine) : 105, 106, 118, 120, 134, 143, 148, 
160, 162, 176, 190, 232, 258, 259. 
 
The big advantage of EIC is also that the chemstation macro will automatically normalise the chromatogram to 
the highest target compound peak. Therefore, amphetamines of different concentrations can be directly 
compared without any manual adjustment of the y axis. 
Figure 38 above show that these two samples are indeed very close and confirm the Pearson correlation result. It 
is therefore very probable that these two samples belong to the same batch of amphetamine. 
 
Another way of comparing two samples is to draw a graph of the normalised and standardised data where the 
numerical values are represented on the y axis and the 26 target compounds are on the x axis. This kind of 
illustration is especially useful for determining which target compound is responsible for small (or maybe big) 
differences. Figure 39 is the graph regarding the two samples 1071 and 3343/00 : 
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Figure 39 : graphical representation of the 26 target compounds values for samples 1071 and 3343 / 00. 
 
 
Figure 39 confirm the very strong similarities between samples 1071 and 3343 / 00. Finally, the link was 
confirmed indirectly. Indeed, 1071 is just an internal number and further investigation into the sample collection 
of IPS indicated that this sample originated from the WD Zürich and that the corresponding police number was 
3343 / 00 ! 
Therefore, the two samples came in fact from the same case but they were obtained through two different 
channels at two different times : sample 1071 was received in 2000 from the WD Zürich whereas sample 3343 / 
00 was sampled in 2002 in the WD Zürich and taken back to IPS for the purpose of the project. 
 
 
7.2 Analysis of tabletted samples 
 
IPS has a collection of illicit tablets which started in 1995. The majority of the tablets contain MDMA 
(MethyleneDioxyMethylAmphetamine) and are sold as « Ecstasy » on the illicit market. However, a number of 
these contain amphetamine as the active ingredient. At the time, around 10 % of seized tablets received by IPS 
contained amphetamine as the active ingredient [Anglada et al., 2002]. It was possible to analyse 87 of such 
tablets in order to test the new profiling method on tablets. 
 
However, there are three problems when analysing tablets : i) the amount of amphetamine present in a tablet is 
generally low, ii) in the sample preparation, an emulsion can form between the aqueous and organic layer 
making the pipetting of the organic solvent very difficult, iii) palmitates and stearates present in tablets can 
interfere with the chromatographic analysis. 
Indeed, the tablets analysed contained an average of 25 mg amphetamine with a standard deviation of ± 20 mg.  
Therefore, in order to obtain a suitable profile a whole tablet has to be crushed and analysed. 
Regarding emulsions, they are probably due to certain additives which are used in the tablet manufacture. Still, 
no tablets in this study showed intense emulsions. As a result, it was possible to sufficiently separate the aqueous 
and organic layer in all cases. 
But the main problem is the presence of fatty acids which can cause major interferences in the chromatogram 
depending on the amount present. In most cases, their concentrations were low and target compounds could still 
be integrated thanks to the selectivity of the mass spectrometer. However, in some cases, their concentrations 
were extremely high and the amphetamine target compounds were consequently quite difficult to identify and 
integrate. Figure 40 illustrates an example of a sample where high concentrations of fatty acids were detected : 
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Figure 40 : Total ion chromatogram of the profile of an amphetamine tablet sample. Peak 1 : 
amphetamine, peak 2 : myristic acid, peak 3 : palmitic acid, peak 4 : stearic acid. 
 
 
In the example shown in figure 40, target compounds situated in the time interval from 17 to 20 minutes were 
quite difficult to identify and integrate. In some cases, the concentration of fatty acids was even greater 
increasing the peak width of these compounds and causing major, if not fatal, interferences in the chromatogram. 
However, there is a way of removing these fatty acids prior to analysis. Indeed, after dissolution in the aqueous 
buffer, the test tube can be centrifuged and the supernatant transfered to a syringe fitted with a PTFE disk filter 
(Schleicher & Schuell, diameter 30 mm, pore size 0.45 µm ). After filtration, The organic solvent is added to the 
recovered aqueous solution. Experience has shown that this is an efficient method of removing almost 100 % of 
the fatty acids with very little loss of target compounds. It also reduces the emulsion formation if present without 
filtering. Unfortunately, for time and availability reasons, the amphetamine tablets analysed in this study could 
not be prepared and analysed again with this method. 
However, the majority of tablets contained very low amounts of fatty acids and despite the fact that a few tablets 
contained very high concentrations of fatty acids, all 87 samples could be profiled using the method developed in 
the previous tasks. A number of interesting results have been found and are presented below : 
 
7.2.1 Similar / different external characteristics and similar organic profiles 
 
 
 
 
Figure 41 : front pictures of three different tablets coming from the same case 
 
Figure 41 shows three different tablets. The first tablet (left in figure 41) has a different logo and a different 
colour compared to the two other tablets. There were also differences between the other physical characteristics 
but these were very small and probably not significant (see further details in Annex 14). 
However, they all displayed very similar organic profiles (see Annex 14A) which indicated a possible common 
origin (same batch of amphetamine). In addition, the probable link was somehow confirmed by the fact that the 
first two tablets (left and middle in figure 41) were part of the same police seizure. Regarding the third tablet 
(right in figure 41), although it was seized in a different part of Switzerland and a year earlier, it displayed 
almost identical visual and physical characteristics compared to the second tablet. 
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Thus, the hypothesis is that the two « smiling sun » tablets have a common source of manufacture. The similarity 
of the organic profile pushes the hypothesis further and indicates a common source of the amphetamine itself. 
In conclusion, the organic profiling of tablets can be useful in two ways : i) it can reveal links between tablets 
bearing different visual and physical characteristics, ii) it can confirm links which are based only on visual and 
physical characteristics. In the latter case, differences in the organic profiles would not automatically negate the 
link but would rather indicate that different batches of amphetamine were used by the same tablet manufacturer 
(see section 7.2.2). 
In Annex 14, three other cases are illustrated where very similar organic profiles were found between tablets 
bearing various visual and physical characteristics. All corresponding chromatograms can be found in Annex 
14A. 
 
7.2.2 Similar external characteristics and different organic profiles 
 
 
  
 
Figure 42 : front pictures of two similar tablets coming from two different cases 
 
This is an example of a case where two tablets with almost identical visual, physical and also chemical 
characteristics (same cutting agents and same concentration of amphetamine, see Annex 15) displayed quite 
different organic profiles (see Annex 15A). As the two seizures are more than a year apart, the first hypothesis 
would be that different batches of amphetamine were used in the manufacture of these tablets and even that two 
distinct illicit amphetamine laboratories are the source of these two batches of amphetamine. However, the fact 
that the two amphetamine batches came from the same illicit amphetamine laboratory can not be excluded. 
Indeed, the difference in the organic profile may be the result of a high variation in the production of one illicit 
laboratory. Still, this remains a hypothesis as very little knowledge of the variations within illicit laboratories is 
available at this time. 
In conclusion, when identical visual, physical and even chemical characteristics are observed between tablets, it 
does not guarantee that the amphetamine contained in these tablets come from the same batch or even have the 
same origin, especially if there is a large time difference between the seizures. 
 
In Annex 16, another similar case concerning three seizures is presented. In that case, two out of three tablets 
showed almost identical visual, physical and chemical characteristics including their organic profiles. However, 
the third tablet, which was visually and physically indistinguishable from the two others, contained lactose as an 
extra cutting agent. It should be noted that it was seized two, respectively three years later. 
Observation of its organic profile showed small differences but also strong similarities (see Annex 16A). In that 
case, the more likely hypothesis is that the amphetamine contained in the third tablet comes from a different 
batch but from the same illicit amphetamine laboratory. But again, this remains a hypothesis. Indeed, the 
variations observed in Annex 16A could be the result of batch inhomogeneity. Thus, the amphetamine contained 
in these three tablets could still come from the same batch despite the fact that the seizures were made in three 
different years (1998, 1999 and 2001). 
Annex 17 shows five tablets with similar visual and physical characteristics. However, slight differences are 
found in the chemical composition. Indeed, the first tablet contains 28 mg of amphetamine and is cut with 
lactose. The fifth tablet contains 44 mg of amphetamine and is cut with caffeine. Regarding the three other 
tablets, they contain similar amounts of amphetamine (13, 15 and 19 mg) and are cut with both caffeine and 
lactose. 
Observation of the organic profiles show strong similarities between the three tablets with similar chemical 
composition whereas the two other tablets show very different organic profiles. This case is an example where 
tablets with similar visual and physical characteristics can have a different chemical composition and also 
different organic profiles. However, in this case, time may have an influence as these tablets were seized over a 
period of four years (1995, 1997, 1997, 1998 and 1999). Therefore, a possible hypothesis is that the same tablet 
manufacturer has varied his tablet composition over time (amount of amphetamine and cutting agents) and used 
different batches of amphetamine. 
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7.2.3 Similar external characteristics and similar profiles 
 
In general, tablets with almost identical visual, physical and primary chemical characteristics have also very 
similar organic profiles. This was the most common observation in this study as all contemporary tablets (from 
different cases) which beared the same visual, physical and primary chemical characteristics showed as well very 
similar organic profiles (with the exception of non-contemporary cases discussed in section 7.2.2). Therefore, 
only one example among others is illustrated in Annexes 18 and 18A. 
This raises the question whether organic profiling is really useful in cases of amphetamine tablets for 
determining common sources of the amphetamine itself. Indeed, if the organic profiling always confirms the 
links already established by the visual and physical characteristics as well as the primary chemical information 
(amount of amphetamine and cutting agents), then these latter characteristics may be sufficient for linking tablets 
also at the amphetamine level. Thus, the investment into organic profiling analyses may be unnecessary, at least 
on a routine basis. 
Nevertheless, as shown in section 7.2.1, organic profiling has the potential of linking tablets which are different 
from a visual and physical point of view. This could be especially useful in the two following situations : i) 
linking tablets where one tablet manufacturer has used one large batch of amphetamine but different punches (to 
produce different logos) or different dyes (to produce different colours) or different tabletting machines (to 
produce different tablets) or any combination of the above ; ii) determining common sources of amphetamine in 
tablets produced by different tablet manufacturers. 
But the great majority of tablets found on the illicit market and sold as « ecstasy » contain MDMA 
(MethyleneDioxyMethylAmphetamine) as the active ingredient. Therefore, the above remarks are more relevant 
in relation to MDMA profiling and the reader is referred to the work of Zingg [Zingg, 2004] for further 
discussions in relation to MDMA tablets. 
 
 
8 Final conclusion and future activities 
 
This work dealt with the development of a gas chromatographic method for the profiling of amphetamine 
powder. Existing methods were already in use in some countries, especially in Sweden and Finland where 
amphetamine is still the number one illicit drug. However, the existing methods were never thoroughly 
optimised and did not take into account synthetic routes other than the Leuckart route. Although this synthesis 
method remains by far the most popular way of synthesising illicit amphetamine in Europe, this may change in 
the future. For example, in Finland almost half of the seized amphetamine is now produced via the reductive 
amination method. This figure was by far much lower at the beginning of this project. Also, in the case of 
Finland, there are strong indications that the amphetamine is smuggled from Estonia and even produced there. 
With the expansion of the EU to 25 member states including the baltic countries and Poland which are known to 
be amphetamine producers, who knows what the future helds for us in terms of amphetamine production 
methods. 
In addition, the existing methods were not harmonised and thus not adapted for data exchange. Therefore, if 
comparisons of samples were required, these had to be sent to one and only forensic laboratory which would 
carry out the analyses. This system of course implies many administrative barriers as it is not easy to send 
samples through borders even if efforts are being made to simplify the paperwork and transmission of samples. 
Further, the main drawback of sending drug samples is time. Indeed, as profiling results are forwarded to law 
enforcement agencies, these may not be interested in obtaining results months after the beginning of the 
corresponding investigation. The sooner the results can reach the concerned law enforcement agency, the more 
chances the information will be helpful and useful. 
This is why the ultimate aim of this work was to develop a harmonised method that could be used in many 
different forensic laboratories and where the data generated would be reliable enough for comparison purposes. 
Thus, samples analysed in different laboratories could be directly compared and the sending of samples to a 
central laboratory would no longer be required. This would result in a significant gain in response time and 
efficiency and enhance collaboration between different forensic laboratories in Europe. 
A previous attempt was made in using a common profiling method in different laboratories but it concerned a 
non-synthetic drug, namely heroin [Strömberg et al., 2000]. It was somehow unsuccessful as the reproducibility 
between the three participating different laboratories was not considered good enough. According to their 
conclusions, the undesired variations originated from difficulties in harmonizing integration of FID 
chromatograms (the method was GC-FID) and poor chromatography of some impurities which could not be 
ignored as they were considered essential for discrimination between samples. However, their relative lack of 
success may be explained by the fact that very little optimisation studies were performed prior to the use of the 
chosen method. 
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So, the challenge began in February 1999 and was divided in a number of subtasks. The first was to synthetise a 
number of known impurities in order to confirm their presence in illicit samples and use them as references in 
further tasks. Unfortunately, as mentioned in section 1.7, an amphetamine profile can contain more than 200 
peaks and it is impossible to identify and synthetise all compounds. Therefore, a selection was made based on 
prior knowledge, the literature available and the allocated time frame. 21 target compounds were successfully 
synthesised and full spectroscopic data is now available which makes this data set quite unique (mass spectra, 
infrared spectra, ultraviolet spectra, 
1
H-NMR and 
13
C-NMR spectra). 
 
In the second task, the stability of these target compounds were studied in various solvents. This enabled us to 
detect three unstable target compounds which could not be reliably quantified. It also demonstrated the difficulty 
of use of diethyl ether due to its very high volatility. Finally, it showed that isooctane and toluene were very inert 
solvents and therefore were probably the most suitable solvents for our application. 
 
The third task dealt with the optimisation of the sample introduction technique, the choice of column and 
temperature programme as well as the choice of detector and operating conditions. The results showed that split 
and splitless injection techniques work similarly at different temperatures. In order to make a final choice, 
random and systematic errors were calculated and splitless injection was found to be giving the smallest total 
error. Also, splitless injection is more suited if low concentration samples have to be analysed. 
Regarding the choice of column, separation power, resolution and inertness were the key factors in selecting an 
appropriate column. Finally, the choice was made for a DB-35 MS column with a temperature programme of 8 
degrees per minute. 
In terms of detection, this study enabled us to find out some limitations of the standard ion source of the Agilent 
5973 mass spectrometer. Replacement of the standard ion source with a so-called Ultra ion source gave much 
better results in relation to linear range, repeatability and reproducibility. The only drawback being a slight loss 
in sensitivity. This weakness in performance has been later acknowledged by the Agilent company and 
nowadays the new Agilent GC-MS systems are equipped with the Ultra ion source with a small modification in 
order to preserve maximum sensitivity (also known as Inert MS). 
MS (with the Ultra ion source) was finally chosen as the most appropriate detector for our application. It gave 
very similar results compared to FID and NPD in terms of repeatability, reproducibility and sensitivity. As for 
linearity, the linear range of the mass spectrometer will probably never be as large as the FID. Still, it was 
considered sufficient for our application. But the main advantage of the MS compared to other detectors is its 
selectivity. That is : its ability to quantitate two different compounds even if they are coeluting. This is 
performed by recording the response of ions specific to each compound. This also allowed the overall integration 
of target compounds to be much more reliable, easy and fast. 
 
The fourth task was dedicated to the optimisation of the sample preparation. In the case of liquid-liquid 
extraction, many different variables were studied such as the type of buffer, pH, concentration and volume of 
buffer, type and volume of organic solvent and even the influence of cutting agents such as lactose and caffeine. 
For solid phase extraction, 14 different types of cartridges were first of all tested by partner 2 and two of them 
were retained for further comparison. 
Buffer capacity, dissolution power of the buffer, repeatability, recovery and sensitivity were all important factors 
that were taken into account during this task. Practical aspects also partly influenced our final decision. Finally, a 
liquid-liquid extraction with a TRIS buffer at pH 8.1 and toluene was determined to be the best compromise. 
 
In the fifth task, the optimised method was tested on synthetised samples and the variations within and between 
laboratories were determined. Within laboratory and within day, the average relative standard deviation of the 
method was determined to be in the order of 5 to 6 %. Within laboratory and within a period of two months, this 
value was determined to be in the order of 8 to 10 %. Finally, as the same samples were sent to the various 
laboratories, it was possible to determine an inter-laboratory value. In this case, it was determined to be in the 
order of 8 to 12 %. It should be emphasised here that one of the main outcomes of this task was the realisation of 
the importance of quality control. Indeed, the only laboratory which failed to meet the quality control 
requirements gave the most deviating results. Therefore, the inter-laboratory value is rather closer to 8 % if all 
quality control requirements are met. These results were quite encouraging before tackling the sixth task which 
dealt with the study of numerical methods for the comparison of amphetamine profiles. 
 
For the purpose of this final task of the project, 768 samples were available. Almost half were street samples 
collected by partners 2, 3 and 4 and the rest were synthesised samples (analysed in triplicate) which were used as 
such or further diluted (usually with caffeine and / or lactose). At first, 33 target compounds were selected. 
However, it was finally possible to reduce the number of target compounds to 26 without affecting the 
discrimination power of the method. 
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Pre-treatment of the data before application of a numerical comparison method was found to be critical. It was 
finally determined that replacement of zeroes by a value of 200 (which corresponded at the time to half the 
detection limit of the MS detector) and normalisation to the sum of peaks was the most adapted to our 
application. Moreover, the obtained values had to be weighed in order to reduce the influence of dominating 
peaks. The most appropriate method was determined to be the application of the fourth square root to the 
normalised values. 
Various distance methods were evaluated : Euclidean distance, Manhattan distance, Pearson correlation, 
Similarity index, Quotient method, Canberra index and the Squared sinus function.  
Pearson correlation and the squared sinus were found to be the best suited numerical methods for comparison of 
amphetamine profiles. After discussion with all partners, it was finally decided to carry out future work with the 
Pearson correlation as it is an integrated function in Microsoft Excel and might be more convenient to use, 
especially if special computer programs are not available. 
 
Unfortunately, no time was available to further study other interesting numerical methods such as neural 
networks [Kingston, 1992, Casale and Watterson, 1993, Welsh et al., 1996] or even to evaluate continuous 
likelihood ratios based on the Bayes theorem as described by Dujourdy for heroin samples [Dujourdy, 2003]. 
However, a little time was found to test the method on amphetamine tablets. As described in section 7, 
preliminary results were encouraging and indicate that the method could easily be applied to tablets considering 
that filtering would be highly recommended in the sample preparation process. The information provided by the 
organic profile can then be combined with the visual, physical and other chemical characteristics of the tablet for 
interpretation purposes. However, it is at present not quite clear if results from amphetamine powders can be 
directly compared to results from tabletted amphetamine. 
 
At this stage, corresponding to October 2002, the project ended and discussions started in order to give a future 
to this new optimised method for profiling amphetamine. At the time, another project named CASE was already 
underway and concerned only EU member states and Norway. It was, and still is, financed by the Swedish 
government and consists of sending amphetamine samples (from large seizures only) to a central laboratory for 
profiling, namely the Swedish National Forensic Science Laboratory (SKL). For this purpose, SKL were, and 
still are, using the same profiling method they have been using for decades. Therefore, any further work would 
have to run parallel to this project, at least until the end of 2005, date of the ending of the CASE project. 
 
In this matter, Finland were the first to act as they developed a database for storing data acquired with the new 
optimised method and enable comparisons of profiles as part of their national profiling program. It was 
developed in the Crime Laboratory of the National Bureau of Investigation in Vantaa, Finland (partner 2) and 
runs under Microsoft Access. Excel macros were subsequently developed in order to automatically transfer data 
from the Chemstation to the database. The database can then display the fifty best matches when a new sample is 
compared to the rest of the database and also displays graphical representations of the chromatograms which are 
quite helpful for direct visual comparisons. It should be noted here that the program is extremely fast as 
thousands of calculations are made within a matter of seconds. 
This database is now also in use in the Netherlands Forensic Institute where this new method is now applied on a 
routine basis as part of a new European research project which was given the acronym CHEDDAR 
(Collaborative and Harmonised European Database for the Determination of Amphetamine Relations). Indeed, 
funding was obtained for a two year project through the AGIS program (Directorate General of Justice and 
Home Affairs) of the EU commission and the project started officially in December 2003 under the coordination 
of SKL. 
This project is somehow the continuation of the SMT project and many aspects that were not addressed 
previously will be, if possible, studied in this new project. First of all, the aim is to develop a database, similar to 
the Microsoft Access database, on a Microsoft SQL server. This server would be physically located in one 
laboratory and other partners would be able to upload their data directly through the internet. They could also 
consult the database from their local computer. 
A second aim is to improve our knowledge on the correlations between recipes used in the clandestine 
manufacture of amphetamine and the corresponding profiles. It is believed that this further knowledge will be of 
valuable help in the interpretation of eventual links between samples. For this matter, a number of syntheses 
according to illicit recipes are planned as well as the study of critical steps in the synthesis such as hydrolysis, 
cristallisation and the influence of the starting material. 
The third aim is to fully document the method in order to simplify the learning process for eventual new 
laboratories who would wish to apply the method. This also includes the development of macros for quality 
control purposes, the determination of quality control criteria for potential new partners, the problems of 
archiving and audit trail, the sending of control samples again for quality control purposes, the harmonisation of 
integration as discussed in section 6.11, etc. 
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Two other important issues which were unfortunately not addressed in the SMT project will be further studied : 
i) the influence of drying and ii) the influence of storage. 
Indeed, it is possible to encounter wet samples as clandestine manufacturers do not always wash and / or dry 
their product. Thus, depending on the manufacturing process, the packaging and the time interval between the 
production and the seizure, the sample will be more or less « wet » when arriving at the forensic laboratory for 
analysis. Some laboratories choose to not dry the sample, some others will apply different methods to dry the 
sample. Thus, the aim is to evaluate the influence of these processes on the organic profile. 
Regarding storage, little information is presently available in relation to the « ageing » of amphetamine powder. 
Therefore, stability and storage studies are planned to investigate this matter. 
Finally, there is an aim to study the variability in clandestine production as well as the variation in large seizures. 
As mentioned in the introduction (section A.2), this is directly related to the concept of inter-batch and intra-
batch variation. If sufficient samples can be obtained from such sources, this would provide invaluable 
information and be of great help in further interpretation of links between samples. 
 
Despite these remaining tasks, the development of a harmonised method for the profiling of amphetamine was a 
complete and successful project. The best illustration of this success could be the fact that already three 
laboratories are now applying this method to their amphetamine samples : the National Bureau of Investigation, 
Finland, the Netherlands Forensic Institute and the Forensic Science Service, England and Wales. Moreover, 
Sweden (SKL) have decided to switch to this method as from 2006 (after the end of the CASE project) in spite 
of their existing method that has been in routine use for the last 25 – 30 years. 
 
Still, one issue that has yet to be addressed is the relationship and cooperation with law enforcement agencies 
whether these are local, national or international. Indeed, there is very little use in keeping profiling results 
within one or more forensic laboratories. The information is ultimately destined for the law enforcement 
agencies in order to help them in their respective investigations (intelligence purpose). For this matter, a close 
and structured collaboration is necessary between the various protagonists in order to ensure the usefulness of 
profiling and also to guarantee a mutual understanding of the purpose. This is probably the biggest challenge to 
date. 
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ANNEX 1 SYNTHESIS OF AMPHETAMINE AND SPECIFIC IMPURITIES 
 
1 SYNTHESIS OF AMPHETAMINE 
1.1 Synthesis of amphetamine from nitrostyrene with reduction by LiAlH4 
 
CHO
CH3CH2NO2
NO2 NH2
LiAlH4
Et2ONH4OAc
CH3COOH  
 
Ammonium acetate (14.46 g, 0.188 mol), benzaldehyde (17.93 g, 0.169 mol), nitroethane (35 mL, 0.443 mol) and 
glacial acetic acid (140 mL) were mixed and refluxed at 110
o
C for 2 hours. The reaction mixture was subsequently 
poured onto crushed ice. The resultant nitrostyrene was removed by filtration and re-dissolved in warm ethanol and 
recrystallised. Nitrostyrene was obtained in 46% yield (12.8 g, 0.079 mol).  
 
LiAlH4 (0.24 g, 0.006 mol) was suspended in sodium dry diethyl ether and cooled to –78
o
C in a dry ice / acetone bath. 
Nitrostyrene (0.377g, 0.002 mol) in 10 mL of dry diethyl ether was added to the LiAlH4 and the temperature of the 
reaction mixture slowly allowed to rise to ambient. After the reaction appeared complete (30 minutes) 35 mL 20% 
aqueous sodium tartrate was added whilst the mixture was stirred, to quench the reaction. A biphasic system formed. 
The ether layer containing the amphetamine free base was removed and the free base analysed by GC – MSD. The final 
yield was 0.078 g amphetamine (0.0006 mol, 29%). 
 
1.2 Synthesis of amphetamine by reductive amination using sodium 
cyanoborohydride  
 
O NH2NaCNBH3
NH4OAc
 
 
Benzyl methyl ketone (5.0 g, 0.037 mol) and ammonium acetate (28.2 g, 0.37 mol) were stirred in MeOH at room 
temperature for 3 hours. NaCNBH3 (2.4 g, 0.037 mol) was added and stirring was continued another 4 hours. The 
reaction was quenched by evaporation of the solvent. The residue was dissolved in water/acetone and acidified with 
concentrated HCl. The mixture was washed with dichloromethane. The water phase was alkalised with NaOH and 
extracted with dichloromethane. The organic solvent was evaporated and amphetamine (2.5 g, 0.019 mol, 50%) was 
obtained as an oil. The oil was crystallised to amphetamine sulphate by addition of 37% sulphuric acid and MeOH.  
 
1.3 Synthesis of amphetamine by reductive amination using sodium borohydride 
 
O NH2NaBH4
NH4OAc
 
 
The mixture of benzyl methyl ketone (2.02 g, 0.015 mol) and ammonium acetate (12.51 g, 0.162 mol) in 100 mL of 2-
propanol was stirred at room temperature for 3 hours. NaBH4 (0.07 g, 0.0018 mol) was added and stirred for another 3 
hours. The reaction was quenched by addition of water and concentrated HCl. The reaction mixture was stirred 
overnight. The organic solvent was evaporated, and the residue acidic water layer was washed with dichloromethane. 
The water phase was basified with NaOH pellets and extracted with dichloromethane. The solvent was evaporated 
under reduced pressure yielding amphetamine oil (0.64 g, 0.0047 mol, 32%). The oily product was crystallised to 
amphetamine sulphate by addition of 37% sulphuric acid and MeOH.  
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1.4 Synthesis of amphetamine by the Leuckart route 
 
O HN CHO
NH2CHO
HCOOH
H
+
NH2
 
 
Benzyl methyl ketone (360 g, 2,6829 mol), formamide (309 g, 6,7130 mol) and formic acid (304 g, 6,749 mol) were 
refluxed for 4 hours. The mixture was allowed to cool to room temperature, and washed once with distilled water (800 
mL). NaCl was added to facilitate the phase separation.  
 
32% HCl (520 mL) was added to the organic layer and the mixture was refluxed for 1,5 hours. The mixture was allowed 
to cool and washed once with hexane (800 mL). The solution was basified with NaOH, and steam distilled under 
continuous addition of distilled water until all amphetamine oil had been removed from the reaction vessel. The distilled 
amphetamine oil was dissolved in 99.5% ethanol (1:4; w/v). 33% Sulphuric acid (diluted with 99.5% ethanol) was 
added to the solution of amphetamine under continuous stirring. At pH ~ 6.5, the addition was stopped and the 
precipitated crystals were filtered off and dried at room temperature. The yield of amphetamine sulphate was 82 g 
(0.494 mol, 18%). 
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2 SYNTHESIS OF IMPURITIES FOUND IN AMPHETAMINE 
 
A number of impurities commonly found in amphetamine manufactured in clandestine laboratories have been 
synthesised. Exemplar syntheses are described below. 
 
2.1 Synthesis of nitrostyrene 
 
NO2
CH3CH2NO2
CHO
 
 
Nitrostyrene was synthesised as described above (1.1). 
 
 
2.2 Synthesis of N-(β-phenylisopropyl)benzaldimine 
 
NH2
+
N
CHO
Dean and 
Stark trap
benzene
 
 
Amphetamine base (2.0 g, 0.015 mol), benzaldehyde (1.0 g, 0.008 mol) and 200 mL of benzene were placed in a flask. 
The mixture was refluxed at 82°C overnight. A Dean and Stark trap was used to remove the resulting water. The 
reaction was finished and benzene evaporated. N-(β-phenylisopropyl)benzaldimine was purified by vacuum distillation. 
The product contained 95% of aldimine and 5% amphetamine.  
 
2.3 Synthesis of benzyl methyl ketoxime 
 
 
 
Hydroxylamine hydrochloride (11.98 g, 0.176 mol), benzyl methyl ketone (12.0g, 0.090 mol) and sodium acetate (1.0 g, 
0.012 mol) were suspended in distilled water (80 mL) and ethanol (50 mL) added to dissolve all the reagents. The 
reaction mixture was refluxed at 79
o
C for 3 hours, at which point the reaction appeared to be complete as monitored by 
GC – MSD. The reaction mixture was cooled, and the solvent reduced to 1/3 volume in vacuo. The sodium acetate was 
removed by filtration. The mixture was transferred to a separating funnel and diethyl ether (100 mL) added. The ether 
fraction was collected and the ether removed by drying under nitrogen, yielding finally a pink oil.  
 
 
 
 
 
 
 
 
 
 
O NOH
NH2OH x HCl
NaOAc
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2.4 Synthesis of 2-methyl-3-phenyl aziridine 
 
 
 
Benzyl methyl ketoxime (0.74 g, 0.005 mol) was dissolved in distilled THF (20 mL), the vessel evacuated and the 
solution stored under argon. LiAlH4 (0.5 g, 0.013 mol) was placed in a Schlenk tube which had previously been 
evacuated and filled with argon. LiAlH4 was suspended in THF and cooled to -78°C. The ketoxime solution was slowly 
added to the suspension slowly via a syringe while argon was bubbled through the suspension. The reaction mixture 
was allowed to warm to room temperature with stirring. The reaction mixture was subsequently refluxed for 4 hours 
with stirring, cooled to room temperature and quenched using 5% NaOH until no more gas evolved and a white 
precipitate formed. 
The organic phase was extracted with sodium dried diethyl ether (3 × 20 mL). The ether was removed in vacuo leaving 
an oil, which was removed and dissolved in ethanol for GC-MSD analysis. The aziridine isomers were separated by 
column chromatography using a 20 cm x 1 cm i.d. column packed with silica gel (230 – 400 mesh), eluting with hexane 
: ethyl acetate (3:2 v:v). The column fractions were analysed by GC-MSD and those containing aziridine combined and 
the solvent removed, yielding finally 2-methyl-3-phenyl aziridine (0.40 g, 0.003 mol, 60%).  
 
2.5 Synthesis of N-(β-phenyl-isopropyl)benzyl methyl ketiimine 
 
O NNH2
+
Dean and 
Stark trap
benzene
 
 
Amphetamine (10 g, 0.075 mol), benzyl methyl ketone (5 g, 0.037 mol) and 200 mL of benzene were placed into a flask 
and the mixture was refluxed overnight. A Dean and Stark trap was used to remove the resulting water. The organic 
solvent was distilled under reduced pressure and the obtaining product was analysed by GC-MS. The purity of ketimine 
was 75%, and no other purification steps were taken since ketimine/amphetamine mixture was too unstable to be 
purified.  
 
2.6 Synthesis of N-acetylamphetamine 
 
NH2
CH3COCl
THF NH
O
 
 
Acetylchloride (3.0 g, 0.037 mol) was dissolved in THF (300 mL) and amphetamine base (5.0 g, 0.037 mol) added. The 
reaction mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure. The 
resulting oily residue was dissolved in water and acidified with HCl. The water phase was extracted with 
dichloromethane and the organic solvent was evaporated. The yield of N-acetylamphetamine, which was 95% pure, was 
3.0 g (0.017 mol, 46%). The product was recrystallised from petroleum benzene and ethanol. The yield of pure product 
was 1.5 g (23%). 
 
 
 
 
N
H
NOH
LiAlH4
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2.7 Synthesis of benzoylamphetamine 
 
O
OH SOCl2
toluene
O
Cl
NH2
THF HN
O
 
 
Benzoic acid (5.1 g, 0.042 mol) and thionyl chloride (9.2 mL, 0.126 mol) were refluxed in toluene for 3.5 h. The 
toluene was evaporated and the residue washed with benzene. The resulting benzoyl chloride (5.4 g, 0.039 mol, 92%) 
was dissolved in THF, amphetamine (5.8 g, 0.043 mol) added and the mixture stirred at room temperature overnight. 
The solvent was removed under reduced pressure and the solid residue dissolved in water and HCl added. The mixture 
was extracted with dichloromethane and organic phase washed with NaHCO3 solution. The solvent was evaporated, 
yielding a solid product (6.1 g, 0.025 mol, 66%). The product was recrystallised from petroleum benzene and ethanol, 
which gave benzoyl amphetamine in 40% yield (3.7 g, 0.015 mol). 
 
 
2.8 Synthesis of benzylamphetamine 
 
NH2
CHO
+
HN
NaCNBH3
 
 
Amphetamine (1 g, 0.0075 mol), benzaldehyde (0.8 g, 0.0075 mol), sodium cyanoborohydride (0.54 g, 0.0087 mol) and 
MeOH (50 mL) were placed in a flask. The mixture was stirred at room temperature overnight. The pH of the reaction 
mixture was adjusted to pH 7.0 by adding HCl as necessary. The reaction was quenched by evaporation of the solvent. 
The residue was dissolved in water and acidified with concentrated HCl and stirred overnight. The mixture was washed 
with CH2Cl2. The water phase was basified with NaOH pellets, extracted with CH2Cl2, the organic solvent evaporated 
and the residue (0.2 g, 0.0008 mol, 12%) analysed by GC - MS. The resulting reaction mixture contained 92.4% 
benzylamphetamine and 7.4% N-(β-phenylisopropyl)-benzaldimine. 
 
 
2.9 Synthesis of phenyl-2-propanol 
 
NaBH4
O OH
 
 
A mixture of benzyl methyl ketone (1.01 g, 0.0075 mol) and sodium borohydride (0.33 g, 0.0087 mol) in 30 mL of 
propan-2-ol was stirred at room temperature overnight. The reaction was quenched by adding water and concentrated 
HCl followed by stirring overnight. The solvent was evaporated and the mixture extracted with CH2Cl2. The residue 
was analysed by GC - MS. The resulting reaction mixture contained 99.4% phenyl-2-propanol and 0.6% benzyl alcohol. 
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2.10 Synthesis of 1-oxo-1-phenyl-2-(β-phenylisopropylimino)propane 
 
N
OO
O NH2
+ MeOH
 
 
Phenyl-1,2-propanedione (1.2 g, 0.0082 mol) and amphetamine (1.2 g, 0.0088 mol) were stirred in methanol (200 mL) 
at room temperature overnight. The solvent was evaporated, yielding 1-oxo-1-phenyl-2-(β-
phenylisopropylimino)propane (1.4 g, 0.0052 mol, 64%). The purity of the product was only 86%, since any subsequent 
attempt to purify the product was unsuccessful. 
 
2.11 Synthesis of 2-oxo-1-phenyl-(β-phenylisopropylamine)ethane 
 
OH
O
NH2
HN
O
SOCl2
Cl
O THFtoluene
 
 
Phenylacetic acid (4.4 g, 0.032 mol) was dissolved in toluene and thionylchloride (7 mL, 0.097 mol) added. The 
mixture was refluxed for 6 hours. The solvent was evaporated under reduced pressure. Benzene was added and 
evaporated twice to remove the resulting water from the reaction mixture. The reaction mixture was dissolved in THF 
and amphetamine (4.4 g, 0.033 mol) added. The mixture was stirred overnight at room temperature, and the THF 
removed in vacuo. The oily product was dissolved in water and acidified with HCl. The water phase was extracted with 
dichloromethane and the regenerated organic phase washed with NaHCO3 to remove phenylacetic acid and other acidic 
compounds. The dichloromethane phase was removed and solvent evaporated. The yield of solid product was 4.8 g 
(0.019 mol, 65%).  
 
To purify the product, the 2-oxo-1-phenyl-(β-phenylisopropylamine)propane was recristallised from petroleum benzene 
and ethanol. The yield of pure product was 2.0 g (0.008 mol, 27%).  
 
2.12 Synthesis of N,β-hydroxy-N,N-di(β-phenylisopropyl)amine 
 
MeOH+
NH2
O
O N
O
NaBH4
O
N
NaCNBH3
HN
OH
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Amphetamine (1.2g) and phenyl-1,2-propanedione (1.1g) in MeOH (200 mL) were stirred at room temperature 
overnight. An intermediate product, 1-oxo-1-phenyl-2-(β-phenylisopropylimino)-propane, was reduced with sodium 
cyanoborohydride (0.7g) to N-(β-phenylisopropyl)cathinone. The carbonyl group of cathinone was reduced to the 
corresponding alcohol by adding sodium borohydride (0.5 g) and stirring for 2 days. The MeOH was evaporated and the 
reaction quenched by addition of H2O and triethylamine (2mL). The reaction mixture was extracted with 
dichloromethane, the solvent evaporated and the oily product (1.0g) was purified by washing with saturated NaHCO3 
solution.  
 
The product which contained two diastereoisomers of N,β-hydroxy-N,N-di(β-phenylisopropyl)-amine was dissolved in 
ether and white crystals formed. The insoluble crystals were filtered and dried. Recristallisation gave one pure 
diastereoisomer (0.15g).  
 
2.13 Synthesis of N-(β-phenylisopropyl)cathinone 
 
NaCNBH 3
O
HN
MeOH+
NH2
O
O N
O
 
 
Phenyl-1,2-propandione (0.56 g, 0.0038 mol) and amphetamine (0.52 g, 0.0038 mol) was stirred at room temperature 
for 12 hours. The intermediate product, 1-oxo-1-phenyl-2-(β-phenylisopropyl-imino)propane was reduced to N-(β-
phenylisopropyl)cathinone by addition of sodium cyanoborohydride (0.5 g, 0.008 mol). The reaction mixture was 
stirred for an hour. MeOH was evaporated and the reaction quenched by adding water and HCl. The reaction mixture 
was stirred for 2 days. The acidic mixture was washed with dichloromethane. The water phase was basified with NaOH 
and extracted with dichloromethane. Acidic dichloromethane was evaporated and the cathinone product was anlalysed 
by GC-MS (78% pure). 
 
The product was recrystallised from diethyl ether and dichloromethane, which gave pure cathinone 0.3 g (0.0011 mol, 
29%).  
 
2.14 Synthesis of 4-methyl-5-phenylpyrimidine 
 
+
O
CH(NHCHO)3
H
+
HCONH2 N
N
H3C
 
 
A mixture of benzyl methyl ketone (8.9 g, 0.066 mol), trisformylaminomethane (20 g, 0.138 mol), formamide (14.7 g, 
0.326 mol) and p-toluenesulfonic acid (0.7 g, 0.004 mol) was refluxed for 8 hours. The reaction mixture was basified 
with 2 M NaOH and extracted once with 100 mL toluene:ether (1:1), followed by washing four times with 100 mL 
distilled water. The organic solvent was dried with MgSO4, filtered and evaporated to dryness to yield a crystalline 
mass, which was recrystallised from hexane/diethyl ether (2:1 v/v). The crystals (1.5 g) were 90% pure with respect to 
the target product. These were recrystallised with a subsequent syntheses from hexane / diethylether (1:1) to yield 6.0 g 
(0.035 mol, 53%) pure product. 
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2.15 Synthesis of 1,3-diphenyl-2-propylamine 
 
O
NH4OAc
NaCNBH3
NH2
 
 
Diphenylacetone (10 g, 0.048 mol), ammonium acetate (30 g, 0.390 mol) and sodium cyanoborohydride (3 g, 0.048 
mol) were added to methanol (200 mL) in a 500 mL round bottomed flask. The solution was stirred at ambient 
temperature for 48 hours. The mixture was basified with sodium hydroxide and refluxed for 2 hrs. The methanol was 
removed under reduced pressure, distilled water (100 mL) added to the residue and the water phase extract three times 
with 100 mL chloroform. The chloroform extract was dried over anhydrous magnesium sulphate, filtered and removed 
under reduced pressure yielding a yellow oil from which the product was crystallised after dissolving in diethylether 
and bubbling HCl gas through the solution, yielding finally 6.0 g (0.028 mol, 58%) of product. 
 
2.16 Synthesis of 4-benzylpyrimidine 
 
Cl
isopropanol
P[(CH2)3CH3]
P[(CH2)3CH3] Cl
n-BuLi P[(CH2)3CH3]
N
N
Cl
Cl sat. Na2CO3
N
N
Cl
CH2 N
N
CH2
10% Pd-C 
H2
 
 
Benzylchloride (18.4 g, 0.145 mol) and tri-butylphosphine (20 g, 0.227 mol) were added to 2-butanone (200 mL) in a 
three-necked 500-mL round bottomed flask. The reaction mixture was refluxed for five hours under a nitrogen 
atmosphere. The mixture was cooled overnight and the resulting product removed by vacuum filtration. 
Recristallisation was performed from toluene and the product was dried for 10 days in a dessicator at 60 °C, yielding 
finally 15.0 g of tri-n-butylbenzylphosphonium chloride (0.070 mol, 48%).  
 
Tri-n-butylbenzylphosphonium chloride (15 g, 0.070 mol) was added to dry dimethoxyethane (40 mL) in a three-necked 
250-mL round bottomed flask. The system was kept inert, under nitrogen. Butyllithium in hexane (29 mL, 1.6 M) was 
added dropwise to the mixture at an initial reaction temperature that was below –35 ºC. Thereafter, the temperature was 
allowed to rise slowly for two hours. Dichloropyrimidine (3 g, 0.020 mol) and dry dimethoxyethane (20 mL) was added 
to the reaction mixture and the temperature was kept below -35 
o
C. The reaction was allowed to proceed for 17 hours 
under nitrogen atmosphere. The temperature of the reaction vessel was gradually increased to ambient temperature. 
 
Saturated aqueous Na2CO3 (50 mL) was added into the reaction mixture and refluxed for five hours. It was extracted 
four times with 100 mL diethylether and the extract was dried, filtered and the solvent removed under reduced pressure. 
The residue was dissolved in dichloromethane : ethyl acetate (8:1 v/v) and was purified twice on a silica gel (230-400 
mesh) using dichloromethane: ethyl acetate (8:1 v/v) as the mobile phase. The solvent fractions containing 4-benzyl-6-
chloropyrimidine were combined and the solvent was removed under reduced pressure. The mass of the desired product 
was 1.64 g (0.008 mol, 40%).  
 
The 4-benzyl-6-chloropyrimidine (1.64 g, 0.008 mol) and magnesium oxide (0.95 g) were added to 95% ethanol (20 
mL). This suspension was added to a mixture of distilled water (20 mL), ethanol (20 mL) and 10% Pd-C (0.5 g). The 
mixture was hydrogenated for 1.5 hrs. The Pd-C was removed by filtration and washed with dichloromethane (30 mL), 
which was then added to the ethanol/water solution. The organic solvents were removed under reduced pressure and the 
aqueous residue was extracted with 50 mL dichloromethane. The dichloromethane was dried with MgSO4, filtered and 
removed under reduced pressure yielding 0.65 g pure 4-benzylpyrimidine (0.0038 mol, 48%). 
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2.17 Synthesis of N-formylamphetamine 
 
HCOOH
NH2CHO
HN CHOO
 
 
Benzyl methyl ketone (50 g, 0.373 mol) was refluxed with formamide (100 mL) and formic acid (50 mL) for 6 hours at 
175-180°C. The reaction was monitored by GC-MSD at regular intervals to determine the end of the reaction. After 
cooling, the reaction mixture was diluted with 400 mL deionized water and extracted with dichloromethane (3 x 100 
mL). The organic phase was dried over sodium sulphate and the organic solvent removed under vacuum. 
 
The product was purified by column chromatography using silica gel 60 (70-230 Mesh). The oily product was first 
eluted with petroleum ether / ethyl acetate (6 : 4) to remove impurities and then with ethyl acetate to obtain the N-
formylamphetamine. The extracts containing the N-formylamphetamine were combined, dried over sodium sulphate 
and evaporated under nitrogen yielding 32.5 g of N-formylamphetamine (0.199 mol, 53%) as an orange oil.  
 
2.18 Synthesis of N,N-di(β-phenylisopropyl)amine 
 
NH
NaBH4
NH2 O
+
 
 
Amphetamine oil (2.8 g, 0.021 mol) was added to a solution of benzyl methyl ketone (1.4 g, 0.010 mol) in methanol (10 
mL). The reaction mixture was left at room temperature for 3 hours. Sodium borohydride (0.20 g, 0.005 mol) were 
added and the solution stirred at room temperature for 30 minutes. Deionized water (200 mL) was added and the 
aqueous solution extracted with dichloromethane (3 x 50 mL). The combined extracts were evaporated under vacuo and 
8 mL of deionized water were added to the remaining oil. 
 
Concentrated hydrochloric acid (0.8 mL) was added dropwise and the resulting precipitate filtered and washed with 
diethyl ether. The precipitate was recrystallised in isopropanol yielding 1 g of N,N-di(β-phenylisopropyl)amine 
hydrochloride (0.0034 mol, 34%) as white crystals. 
 
 
2.19 Synthesis of N,N-di(β-phenylisopropyl)methylamine 
 
HCHO
HCOOH
NH NCH3
 
Formic acid (5 mL) and formaldehyde (8 mL) were added to N,N-di(β-phenylisopropyl)amine base (2 g, 0.0079 mol). 
The reaction mixture was kept overnight at 80°C on an oil bath. After cooling, the mixture was diluted with 150 mL of 
deionized water and extracted with dichloromethane (3 x 50 mL). The organic solution was dried over sodium sulphate 
and evaporated in vacuo. N,N-di(β-phenylisopropyl)methylamine (2.0 g, 0.0075 mol, 95%) as a transparent yellow-
green oil was obtained. 
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2.20 Synthesis of N,N-di(β-phenylisopropyl)formamide 
 
NH
NH2CHO
NCHO
 
 
N,N-di(β-phenylisopropyl)amine base (2 g, 0.0079 mol) was refluxed 30 minutes with formamide (50 mL) at 210°C. 
The reaction mixture was diluted with 250 mL of deionized water and extracted with dichloromethane (3 x 100 mL). 
The dichloromethane was dried over sodium sulphate and evaporated in vacuo yielding an orange-brown oil.The oil 
was purified by column chromatography using Silica Gel 60 (70-230 Mesh). The oil was eluted with dichloromethane / 
methanol (9 : 1). The extracts containing the N,N-di(β-phenylisopropyl)formamide were combined, dried over sodium 
sulphate and evaporated under nitrogen yielding 1.3 g of product (0.0046 mol, 59%) as a yellow-orange oil. 
 
 
2.21 2,4-dimethyl-3,5-diphenylpyridine 
NNCl
NO
H
H2SO4
O
+
O
CN
POCl3
PdOH/C
H2
 
 
α-Acetylbenzylcyanide (6.36 g, 0.040 mol) was mixed with benzyl methyl ketone (10.72 g, 0.080 mol) and 4 mL of 
concentrated sulphuric acid. The mixture was slowly heated to 80°C with stirring. After two hours the temperature was 
raised to 100°C and after another two hours to 120°C. This temperature was maintained for one hour. The reaction 
mixture was poured into water and neutralized with saturated aqueous sodium carbonate solution. After leaving the 
solution stand overnight, the solid was filtered off, washed with water and dried. 
 
The obtained 3,5-diphenyl-4,6-dimethyl-2-pyridone (5.5 g, 0.020 mol, 50%) and 20 mL of phosphorous oxychloride 
(POCl3) were stirred under reflux for 72 hours. After cooling, the mixture was poured into sodium carbonate solution. 
The mixture was then extracted with 3 x 50 mL of dichloromethane. The combined organic extracts were evaporated 
yielding brownish crystals. Because the chlorination process was not complete, these were purified by column 
chromatography using Silica Gel 60 (70-230 Mesh). Elution was performed with petroleum ether / ethyl acetate (80 : 
20). The obtained extract was evaporated yielding 1.4 g of light orange crystals of 2,4-dimethyl-3,5-diphenyl-6-
chloropyridine (1.4 g, 0.0048 mol, 28%). 
 
2,4-dimethyl-3,5-diphenyl-6-chloropyridine (1.4 g, 0.0048 mol) was dissolved in 180 mL of ethanol – ethyl acetate 
(1 :1). 1 g of palladium hydroxide on charcoal was added to the solution. This was hydrogenated for two days at 
atmospheric pressure and room temperature. The catalyst was removed by filtration and the solvent evaporated leaving 
yellowish-white crystals of 2,4-dimethyl-3,5-diphenylpyridine (0.560 g, 0.0022 mol, 45%) 
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ANNEX 2 GC METHODS USED IN DIFFERENT TASKS 
 TASK 1 TASK 2 TASK 3: Subtask 3.1 TASK 3: Subtask 3.2 
Instrument: HP 6890 gas chromatograph, HP 5973 mass selective detector with HP MS Chemstation rev. B.01.00 
Column: Methyl silicone column  
(HP Ultra-1) 
*)
 
5% Phenyl methyl silicone column 25 m (L) x 0.20 mm (i.d.),  
df 0.33 µm (HP Ultra-2) 
*)
 
HP Ultra-2, HP Ultra-1, HP-50+, HP-1701, HP-25, 
DB-35MS and DB-17MS 
*)
 
Pre-column: Deactivated retention gap 2 m (L) x 0.32 mm (i.d.) (HP part no. 19091-60600) 
Column connector Deactivated press-fit 
connector (HP part no. 
5181-3396) 
Deactivated press-fit connector (HP part no. 5181-3396) was used to connect the retention gap pre-column onto the analytical 
column 
Y-shaped press-fit connector (HP part no. 5181-3398) was used to split the sample between two columns, one for each detector 
Carrier gas: Helium, 25 cm/s at 60 °C at FID, constant flow 
Sample 
introduction: 
Volume: 
Total flow: 
Liner: 
 
 
or/and 
 
Volume: 
Total flow: 
 
Liner: 
 
 
Split, 1:148 
1 µl 
60 mL/min  
Glass wool packed liner 
with a volume of 990 µl 
(19251-60540) 
or 
Splitless  
1 µl 
30 mL/min, 1 min 
splitless time 
Splitless liner with a 
volume of 250 µl (HP 
part no. 18740-80220) 
 
Splitless 
1 µl  
30 mL/min, 1 min splitless 
time 
Splitless liner with a volume of 
250 µl. (HP part no. 18740-
80220) 
 
Split, 1:20 
1 µl 
60 mL/min  
Glass wool packed liner with a 
volume of 990 µl (19251-60540) 
 
and 
Splitless  
1 µl 
60 mL/min, 1 min splitless time 
 
Silanised splitless liner with a volume 
of 250 µL (HP part no. 18740-80220) 
and 
Cool on-column (oven track mode) 
 
Split, 1:20 
1 µl 
60 mL/min  
Glass wool packed liner with a volume of 990 µl  
(19251-60540) 
Gas saver: 20ml/min after 1.5 min 
Temperatures: 
Injector: 
GC-MS interface: 
FID: 
 
260°C 
305°C 
305°C 
 
220, 240, 260 and 280°C 
305°C 
305°C 
 
260°C 
305°C 
305°C 
Oven T-program: 60°C (1 min), 10°C/min, 300°C (10 min) 2, 4, 6, 8, 10 and 12°C/min **) 
MS information: 
Solvent delay: 
Mass range: 
Sample rate #: 
MS quad temp: 
MS source: 
 
3.5 min – 6 min depending upon the solvent 
30 - 550 a.m.u. 
2, A/D samples 4 
150 °C 
230 °C 
 126
FID sample rate:  20 Hz 
 
 TASK 3: Subtask 3.3 TASK 4 TASK 5 TASK 6 
Instrument: HP 6890 gas chromatograph, HP 5973 mass selective detector with HP MS Chemstation rev. B.01.00 
Column: 35% phenyl methyl silicone column 30 m 
(L) x 0.25 mm (i.d.), df 0.25 µm (DB-
35MS, HP part no. 122-3832)  
50% diphenyl dimethyl silicone column 25 
m (L) x 0.20 mm (i.d.), df 0.31 µm (HP-
50+, HP part no. 19091L-105) 
35% phenyl methyl silicone column 30 m (L) x 0.25 mm (i.d.), df 0.25 
µm (DB-35MS, HP part no. 122-3832)  
 
Pre-column: Deactivated retention gap 2 m (L) x 0.25 
mm (i.d.) (HP part no. 160-2255-5) 
Deactivated retention gap 2 m (L) x 0.25 
mm (i.d.) (HP part no. 19091-60610) 
Deactivated retention gap 2 m (L) x 0.25 mm (i.d.) (HP part no. 160-
2255-5) 
Column connector: Non-deactivated press-fit connector (HP part no. 5181-3395) 
A) Y-shaped press-fit connector (HP part no. 5181-3398) or B) divider (HP part no. 5021-7148) or C) two-hole ferrule (HP part no. 5062-3580) 
***)
 
Carrier gas: Helium, 25 cm/s at 90 °C at FID, constant flow 
Sample 
introduction: 
Volume: 
Total flow: 
 
Liner: 
 
Splitless 
1 µl 
60 mL/min, 1 min splitless time 
 
Single-tapered (glass-wool packed, 
deactivated) splitless liner (HP part no. 
5062-3587) 
 
Split, 1:20       or  Splitless  
2 µl 1 µL 
30 mL/min  60 mL/min 
 
Glass wool packed  Splitless liner  
liner with a volume  with a volume 
of 990 µl  of  250 µl 
 
Splitless 
1 µl,  
60 mL/min, 1 min splitless 
time 
Single-tapered (deactivated) 
splitless liner (HP part no. 
5181-3316). 
 
Splitless 
1 µl,  
60 mL/min, 1 min splitless time 
 
Single-tapered glass wool packed liner 
(HP part no. 5062-3587). 
Gas saver: 20ml/min after 1.5 min 
Detector cond’s: 
Injector: 
GC-MS interface: 
FID: 
NPD: 
 
250°C 
310°C 
310°C, Hydrogen flow : 40 mL/min, Air flow : 450 mL/min, Helium was used as make-up gas at 30 mL/min. 
Hydrogen flow: 4 mL/min, Oxygen: 55 mL/min, Nitrogen as make-up gas: 10 mL/min 
NPD bead: TID-4 from Detector Engineering & Technology 
NPD jet: Agilent part no. G1534-80580 (Subtask 3.3), Agilent part no. 18789-80070 (Task 5) 
Bead voltage: 2.8 volts 
Adjust offset: Not used 
Oven T-program: 90°C (1 min), 8°C/min, 300°C (10 min) 
MS information: 
Solvent delay: 
Mass range: 
Sample rate #: 
MS quad temp: 
MS source: 
 
4 min 
4 –300 a.m.u. (0-30 min), 30 to 500 amu. 
3, A/D samples 8 
150 °C 
230 °C 
****) 
 
3.5 min – 6 min depending upon the solvent 
30 - 550 a.m.u. 
2, A/D samples 4 
150 °C 
230 °C 
 
4 min 
4 -300 a.m.u. (0-30 min), 30 to 500 amu. 
3, A/D samples 8 
150 °C 
230 °C 
FID sample rate: 20 Hz 
RTLocking: The retention time of nonadecane was set to 16.30 minutes (FID) 
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*)
  5% Phenyl methyl silicone column   25 m (L) x 0.20 mm (i.d.), df 0.33 µm  
(HP Ultra-2, HP part no. 19091B-105) 
 
Methyl silicone column   25 m (L) x 0.20 mm (i.d.), df 0.33 µm  
(HP Ultra-1, HP part no. 19091A-105) 
 
50% diphenyl dimethyl silicone column 25 m (L) x 0.20 mm (i.d.), df 0.31 µm  
(HP-50+, HP part no. 19091L-105) 
 
17% cyanopropyl phenyl methyl silicone column  25 m (L) x 0.20 mm (i.d.), df 0.20 µm  
(HP-1701, HP part no. 19091U-102) 
 
50% phenyl methyl silicone column  30 m (L) x 0.25 mm (i.d.), df 0.25 µm  
(DB-17MS, HP part no. 122-4732) 
 
35% diphenyl dimethyl silicone column  25 m (L) x 0.20 mm (i.d.), df 0.33 µm  
(HP-35, HP part no. 19091G-105) 
 
35% phenyl methyl silicone column  30 m (L) x 0.25 mm (i.d.), df 0.25 µm 
(DB-35MS, HP part no. 122-3832) 
 
**)
 60°C (1 min), 2°C/min, 300°C (10 min) 60°C (1 min), 4°C/min, 300°C (10 min) 
60°C (1 min), 6°C/min, 300°C (10 min) 60°C (1 min), 8°C/min, 300°C (10 min) 
60°C (1 min), 10°C/min, 300°C (10 min) 60°C (1 min), 12°C/min, 300°C (10 min) 
 
***)
 
                     
 
****)
 SIM ions used for the modified Grob mixture. Tgt, Q1 and Q2 are the target ion and the first and the 
second qualifier ions, respectively.  
 
Group # Compound Time (min) Tgt Q1 Q2 
1 Octanol 4.00 69 84 97 
2 Hexanoic acid 4.30 88 101 116 
3 Dodecane 4.60 57 170 85 
4 2,6-dimethylphenol 5.00 122 107 121 
5 Tridecane 5.70 57 184 85 
6 2,6-dimethylaniline 6.50 121 106 120 
7 Decanoic ester 7.20 74 186 87 
8 Undecanoic ester 9.00 74 200 87 
9 Dicyclohexylamine 9.40 138 181 152 
10 Dodecanoic  ester 10.00 74 214 87 
11 Heptadecane 11.50 57 240 85 
12 Octadecane 13.00 57 254 85 
13 Nonadecane 14.00 57 268 85 
14 Eicosane 15.30 282 127 113 
15 Ketamine 18.00 57 71 85 
16 Tetracosane 20.00 57 294 85 
17 Trimipramine 21.50 282 127 113 
 
                       A                                                           B                                          C 
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ANNEX 3 SPECTROMETRIC DATA OF SYNTHESISED 
COMPOUNDS 
The chemical structures and analytical data obtained for the synthesised 
compounds are given in full detail below.  
 
 
(1) Nitrostyrene [(2-Nitroprop-1-enyl)benzene] 
 
 
NO2
 
 
MS m/z = 115 100%, 91, 105, 163, 146, 77, 130. 
 
IR γmax  (cm
-1
) : 766, 943, 1504, 869, 709, 1216, 505, 1650, 592. 
 
1
H NMR  δ = 2.46 (3H, s, CH3), 7.46-8.10 (5H, m, aromatic), 8.10 (1H, s, CH). 
 
13
C NMR δ = 136.5 (CH-C), 157 (C-CH3), 13.1 (CH3), 126 – 129 (aromatic). 
 
UV   λmax (nm) [MeOH] 220; [0.1M NaOH] 212, 220; [0.1M H2SO4] 196, 216, 224 (sh). 
 
Purity  98 – 100% 
 
 
(2) Benzyl methyl ketoxime [1-Phenylpropan-2-one oxime] 
 
 
N
OH
 
 
MS z-isomer: m/z = 91, 149, 116, 131, 117, 130, 132, 77. 
 e-isomer: m/z = 91, 116, 131, 130, 117, 132, 149, 77. 
 
IR γmax  (cm
-1
) : 1454, 701, 1494, 1371, 1670, 744, 1031, 1078. 
 
1
H NMR  z-isomer δ = 1.85 (3H, s, CH3), 3.77 (2H, s, CH2), 7.29 (5H, m, aromatic). 
 e-isomer δ = 1.83 (3H, s, CH3), 3.53 (2H, s, CH2), 7.29 (5H, m, aromatic). 
 
13
C NMR  z-isomer δ = 13.2 (CH3), 42.0 (CH2), 126.7 – 136.7 (aromatic), 157.6 (C=NOH). 
 e-isomer δ = 19.0 (CH3), 35.0 (CH2), 126.7 – 1136.7 (aromatic), 157.0 (C=NOH). 
 
UV λmax (nm) [MeOH] 212, 220, 260, 284(sh); [0.1M NaOH] 208, 224, 260; [0.1M H2SO4] 196, 
216, 224 (sh).  
 
Purity  98 – 100% 
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(3) N-(β-Phenylisopropyl)benzaldimine [1-Phenyl-N-(phenylmethylidene)propan-2-amine] 
 
  
N
 
 
 
MS m/z = 132 100%, 133, 105, 91, 117, 222. 
 
IR γmax  (cm
-1
) : 3027, 1645, 1122, 1581, 2928, 1381, 2845, 1308, 699, 745. 
 
1
H NMR δ = 1.30 (3H, d, CH3, J=6.6Hz), 2.90 (2H, m, CH2), 3.54 (1H, m, CH), 7.16-7.67 (10H, m, 
aromatic), 8.01 (1H, s, N=CH).  
 
13
C NMR δ = 22.24 (CH3), 44.59 (CH2), 68.20 (CH), 125.97-139.35 (aromatic), 159.30 (N=CH). 
 
UV λmax (nm) [MeOH] 247, [0.1 M NaOH] 275 and [0.1 M H2SO4] 247. 
 
Purity  98 – 100% 
 
 
(4) 2-Methyl-3-phenylaziridine  
 
  
N
H
 
 
 
MS m/z = 132 100%, 118. 91, 117, 104, 77.  
 
IR γmax  (cm
-1
) : 808, 1103, 1031, 1263, 2966, 702, 736, 1496, 1452, 3322. 
 
1
H NMR  δ = 0.87 (3H, CH3), 2.31 and 3.14 (1H, CH), 7.2 – 7.3 (5H, phenyl) 
 
13
C NMR  δ = 13.86 (CH3), 31.96 (CH-CH3), 36.93 (CH-Ph), 126.40-137.39 (aromatic). 
 
UV λmax (nm) [MeOH] 212, 260 (sh); [0.1M NaOH] 216, 224, 264 (sh); [0.1M H2SO4] 212, 220, 
256 (sh).  
 
Purity  98 – 100% 
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(5) N-(β-Phenylisopropyl)benzyl methyl ketimine [N-(1-Methyl-2-phenylethylidene)-1-phenylpropan-2-
amine] 
 
  
N
 
 
 
MS m/z = 160 100%, 91, 119. 
 
IR γmax  (cm
-1
) : 699, 1495, 743, 1452, 1658, 3026, 2965, 2926, 1600, 1713. 
 
1
H NMR Compound is unstable and too impure for NMR data.  
 
13
C NMR  Compound is unstable and too impure for NMR data.  
 
UV λmax (nm) [MeOH] <220; [0.1M NaOH] 247; [0.1M H2SO4] 250. 
 
Purity  86 – 100% 
 
 
(6) N-Acetylamphetamine [N-Benzyl-1-phenylpropan-2-amine] 
 
  
HN
O
 
 
 
MS m/z = 44 100%, 86, 118, 91, 117, 134,  
 
IR γmax  (cm
-1
) : 1653, 155, 701, 747, 1372, 507, 3250, 2968, 608, 1298. 
 
1
H NMR  δ = 1.10 (3H, d, Me, J=6.6Hz), 1.91 (3H, s, CO-Me), 2.70-2.83 (2H, dq, CH2, J=7.2 Hz), 4.20 
(1H, m, CH), 5.66 (1H, NH, d, J=6Hz), 7.16-7.29 (5H, m, aromatic). 
 
13
C NMR  δ = 19.93 (CH3), 23.93 (CH3-CO), 42.43 (CH2), 46.13 (CH), 126.4-138.05 (aromatic), 169.38 
(CO). 
 
UV λmax (nm) [MeOH] 259; [0.1M NaOH] 259; [0.1M H2SO4] 259. 
 
Purity  98 – 100% 
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(7) Benzoylamphetamine [N-(1-Methyl-2-phenylethyl)benzamide] 
 
 
  
HN
O
 
 
 
MS m/z = 105 100%, 148, 77, 118, 91, 233. 
 
IR γmax (cm
-1
) : 1630, 1539, 694, 3320, 1489, 678, 1447, 1351, 1579, 747. 
 
1
H NMR  δ = 1.22 (3H, d, Me, J=6.9Hz), 2.81-2.98 (2H, dq, CH2, J=6.9 Hz), 4.47 (1H, m, CH), 6.02 
(1H, NH, d, J=7.2 Hz), 7.21-7.71 (10H, m, aromatic). 
 
13
C NMR  δ = 19.99 (CH3), 42.39 (CH2), 46.49 (CH), 126.53-137.86 (aromatic). 
 
UV λmax (nm) [MeOH] < 220; [0.1M NaOH] <220; [0.1M H2SO4] <220. 
 
Purity 98 – 100% 
 
 
(8) Benzylamphetamine [N-Benzyl-1-phenylpropan-2-amine] 
 
 
  
HN
 
 
 
MS m/z = 91 100%, 134, 77, 224.  
 
IR γmax  (cm
-1
) : 698, 1452, 3026, 1495, 2963, 1374, 1140, 1028, 1602, 615. 
 
1
H NMR  δ= 1.09 (3H, d, CH3, J=6.0Hz), 2.65-2.67 (2H, dq, CH2, J=6.6Hz), 2.73-2.76 (2H, dq, NH-
CH2, J=6.6Hz), 2.93-2.95 (1H, m, CH), 3.70-3.87 (1H, q, NH), 7.14-7.30 (10H, m, aromatic). 
 
13
C NMR  δ= 20.21 (CH3), 43.60 (CH2), 51.29 (CH), 53.70 (NH-CH2), 126.15-140.54 (aromatic). 
 
UV λmax (nm) [MeOH] 259; [0.1M NaOH] 259, [0.1M H2SO4] 257. 
 
Purity 98 – 100% 
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(9) 1-Phenyl-2-propanol [1-Phenylpropan-2-ol] 
 
  
OH
 
 
 
MS m/z = 92 100%, 91, 136, 71. 
 
IR γmax  (cm
-1
) : 3413, 700, 1455, 742, 2968, 3027, 1078, 1495, 939, 505. 
 
1
H NMR δ= 1.21 (3H, d, CH3, J=6.6Hz), 1.80 (1H, s, OH), 2.60-2.80 (2H, m, CH2), 4.0 (1H, m, CH), 
7.20-7.40 (5H, m, aromatic). 
 
13
C NMR δ= 22.68 (CH3), 45.17 (CH2), 68.77 (CH), 126.36-138.49 (aromatic). 
 
UV λmax (nm) [MeOH] 259; [0.1M NaOH] 259; [0.1M H2SO4] 259. 
 
Purity 98 – 100% 
 
 
(10) 1-Oxo-1-phenyl-2-(β-phenylisopropylimino)propane [2-[(1-Methyl-2-phenylethyl)imino]-1-
phenylpropane-1-one] 
 
 
  
N
O
 
 
 
MS M/z = 91 100%, 119, 160, 105, 77, 174, 265. 
 
IR γmax (cm
-1
) : 700, 1670, 1448, 747, 1166, 2968, 1597, 1495, 3027, 1371. 
 
1
H NMR  δ = 1.25 (3H, d, CH3, J=6.3.Hz), 1.94 (3H, s, N=CCH3), 2.92 (2H, m, CH2), 4.15 (1H, m, CH), 
7.18-7.36 (10H, m, aromatic). 
 
13
C NMR  δ = 14.30 (CH3), 21.02 (N=C-CH3), 44.13 (CH2), 58.63 (CH), 126.09-139.59 (aromatic), 
164.40 (C=N), 194.19 (CO). 
 
UV λmax (nm) [MeOH] 249; [0.1M NaOH] 249; [0.1M H2SO4] 249. 
 
Purity 86 – 100% 
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(11) 2-Oxo-1-phenyl-(β-phenylisopropylamino)ethane [N-(1-Methyl-2-phenylethyl)-2-phenylacetamide] 
 
 
  
HN
O
 
 
 
MS m/z = 162 100%, 91, 119, 44, 252. 
 
IR γmax (cm
-1
) : 1638, 1539, 696, 3308, 743, 1496, 1453, 2970,  1359, 1204. 
 
1
H NMR  δ = 1.04 (3H, d, CH3, J=6.6Hz), 2.66 (2H, d, CH2, J=6.6Hz), 3.49 (2H, s, CO-CH2), 4.25 (1H, 
m, CH), 5.20 (1H, d, NH, J=6.6Hz), 7.01-7.33 (10H, m, aromatic). 
 
13
C NMR δ = 19.98 (CH3), 42.17 (CH2), 46.04 (CH), 126.39-137.61 (aromatic) 
 
UV λmax (nm) [MeOH] 259; [0.1M NaOH] 259; [0.1M H2SO4] 259. 
 
Purity 98 – 100% 
 
 
(12) N-β-Hydroxy-N,N-di(β-phenylisopropyl)amine [2-[(1-methyl-2-phenylethyl)amino]-1-phenylpropan-
1-ol]  
 
 
  
HN
OH
 
 
 
MS m/z = 162 100%, 91, 119, 178, 44, 105, 268.   
 
FTIR γmax (cm
-1
): 745, 997, 1377, 1437, 1453, 1491, 1602, 1583, 3288. 
 
1
H NMR  δ = 0.67 (3H, d, CH3, J=6.5Hz), 1.10 (3H, d, CH3, J=6.5Hz), 2.71 (2H, dd, CH2, J=6.6Hz), 
3.04 (1H, qd, NH-CH-COH, J=6.6Hz), 3.06 (1H, m, NH-CH, J=6.3Hz), 3.90 (1H, s, NH), 4.68 
(1H, d, CH-OH, J=4.0Hz), 7.15-7.31 (10H, m, aromatic). 
 
13
C NMR  δ = 14.9 (CH3), 21.3 (OHC-CH3), 43.90 (CH2), 51.30 (NH-CH), 55.4 (OHC-CH), 73.60 (OH-
C), 126.14-141.30 (aromatic). 
 
UV λmax (nm): [MeOH] 256, [0.1 M NaOH] 260 and [0.1 M H2SO4] 260. 
 
Purity 98 – 100% 
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(13) N-(β-Phenylisopropyl)cathinone [2-[(1-Methyl-2-phenylethyl)amino]-1-phenylpropan-1-one] 
 
 
  
HN
O
 
 
 
MS m/z = 162 100%, 91, 176, 119, 105, 132, 77, 44, 266.  
 
IR, NMR  Compound is too unstable to be analysed by other spectrometric 
and UV techniques. 
 
Purity 98 – 100% 
 
 
(14) 4-Methyl-5-phenylpyrimidine  
 
 
N
N
H3C
 
 
 
MS m/z = 170 100%, 169, 102, 115, 116. 
 
IR γmax  (cm
-1
) : 700, 768, 570, 559, 1430, 728, 1400, 520, 1544, 1576. 
 
1
H NMR  δ = 2.52 (3H, s, CH3), 7.28-7.53 (5H, m, aromatic), 8.54 (1H, s, CH), 9.08 (1H, s, N=CH-N). 
 
13
C NMR δ = 22.85 (CH3), 128.33-128.99-134.86 (aromatic), 135.80 (C-5), 156.33 (C-2) 157.18 (C-6), 
164.41 (C-4). 
 
UV λmax (nm) [MeOH] 202, 210(sh), 226(sh), 232, 259; [0.1M NaOH] 219, 233, 263(sh), 281(sh), 
283, 297(sh); [0.1M H2SO4] 203, 209(sh), 246(sh), 253, 266(sh). 
 
Purity  98 – 100% 
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(15) 1,3-Diphenyl-2-propylamine 
 
 
  
NH2
 
 
 
MS m/z = 120 100%, 91, 103, 77. 
 
IR γmax  (cm
-1
) : 698.8, 737.6 750.3, 1495, 1453, 2360, 507, 820, 3026, 1081, 2342. 
 
1
H NMR  δ = 1.42 (2H, broad s, NH2), 2.51-2.60 (2H, dd, J=13.5Hz; J=8.8Hz, CH2), 2.81-2.88 (2H, dd, 
J=13.5Hz; J=4.5Hz, CH2), 3.22-3.32 (1H, m, CH), 7.19-7.32 (10H, m, aromatic).  
 
13
C NMR  δ = 44.14 (CH2); 54.14 (CH), 126.30 (C-4), 128.48-139.39 (aromatic). 
 
UV λmax (nm) [MeOH] 201 (sh), 210, 222 (sh), 253; [0.1M NaOH] 218 (sh), 223, 225 (sh), 252 
(sh), 259, 270 (sh); [0.1M H2SO4] 200 (sh), 210, 219 (sh), 258. 
 
Purity 98 – 100% 
 
 
(16) 4-Benzylpyrimidine  
 
 
  
CH2 N
N
 
 
 
MS m/z = 169 100%, 170, 115, 91, 142. 
 
IR γmax  (cm
-1
) : 1578, 697, 616, 1385, 1548, 743, 562, 483, 1472, 1495. 
 
1
H NMR δ = 4.12 (2H, s, CH2), 7.09 (1H, d, J=5.5Hz, H-5), 7.11-7.37 (5H, m, aromatic), 8.57-8.59 (1H, 
d, J=5.5 Hz, H-6), 9.14 (1H, s, H-2). 
 
13
C NMR  δ = 44.17 (CH2), 120.57 (C-5), 127.00 -137.30 (aromatic), 157.00 and 158.71 (C-2 and C-6), 
169.38 (C-4). 
 
UV λmax (nm) [MeOH] 203, 214 (sh), 239 (sh), 247, 250 (sh); [0.1M NaOH] 216 (sh), 218, 221 
(sh), 239 (sh), 247, 250 (sh); [0.1M H2SO4] 203, 212 (sh), 236 (sh), 245, 254 (sh). 
 
Purity 98 – 100% 
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(17) N-Formylamphetamine [1-Methyl-2-phenylethylformamide] 
 
 
  
HN
CHO
 
 
 
MS m/z = 118 100%, 72, 91, 44, 117, 119. 
 
IR γmax (cm
-1
) : 1661, 2379, 3029, 1533, 2971, 1382, 1452, 2854, 736, 701. 
 
1
H NMR δ = 1.15 (3H, d, J = 6.4Hz, CH3), 2.71 (2H, m, CH2), 3.7 and 4.3 (1H, m, CH), 5.5 and 5.7 (1H, 
N-H), 7.1 – 7.3 (5H, m, aromatic) and 8.08 (1H, s, CHO). 
 
13
C NMR δ = 20.0 (CH3), 42.3 (CH2), 44.6 (C-N), 126 – 129 (aromatic), 137.6, (CH), 160.4 (CHO). 
 
UV λmax (nm) [MeOH] 204, 212, 224 (sh), 252, 260; [0.1M NaOH] 216, 228 (sh), 264 (sh); [0.1M 
H2SO4] 204, 216 (sh), 252, 260. 
 
Purity 98 – 100% 
 
 
(18) N,N-di-(β-Phenylisopropyl)amine [N-(1-Methyl-2-phenylethyl)-1-phenylpropan-2-amine] 
 
 
  
NH
 
 
 
MS m/z = 162 100%, 91, 119, 44. 
 
IR γmax (cm
-1
) : 2962, 744, 2924, 1451, 3025, 1493, 703, 1373, 1141, 1342.  
 
1
H NMR δ = 0.95 – 1.05, (3H, d, J=6.1Hz, CH3), 2.51-2.68 (2H, dd, J=6.7Hz, 6.9Hz, CH2), 2.83 (1H, 
dd, J=6.1Hz, J=6.1Hz, CH), 3.04 (1H, q, CH), 7.2 (10H, m, aromatic). 
 
13
C NMR δ = 20.2 and 21.3 (CH3), 43.4 and 44.2 (CH2), 51.4 and 51.6 (C-NH), 126 – 139.6 (aromatic). 
 
Note!  Resolution of some of the signals due to the isomers was possible using high field NMR. The 
data presented below is subject to confirmation. 
 
UV λmax (nm) [MeOH] 204, 252, 260; [0.1M NaOH] 204, 252, 260; [0.1M H2SO4] 208, 256. 
 
Purity 98 – 100% 
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(19) N,N-di-(β-Phenylisopropyl)methylamine [N-Methyl-N-(1-methyl-2-phenylethyl)-1-phenylpropan-2-
amine] 
 
  
NCH3
 
 
 
MS m/z = 176 100%, 91, 58, 119, 177. 
 
IR γmax (cm
-1
) : 2934, 3025, 2788, 1452, 698, 740, 1496, 1601, 1368, 1233. 
 
1
H NMR δ = 0.95 and 0.98 (3H, d, J=3.7Hz, CH3), 2.37 (N-CH3), 2.43 and 2.48 (2H, d, J=4.5Hz, CH2), 
3.03 (1H, m, CH), 7.12-7.29 (aromatic). 
 
13
C NMR δ = 13.8 and 14.1 (CH3), 31.9 and 32.3 (CH2), 38.1 and 38.4 (C-NH), 60.4 (N-CH3), 127 –
136.6 (aromatic). 
 
Note!  Resolution of some of the signals due to the isomers was possible using high field NMR. The 
data presented below is subject to confirmation. 
 
UV λmax (nm) [MeOH] 204, 216 (sh) 252, 260; [0.1M NaOH] 216, 228 (sh), 264 (sh); [0.1M 
H2SO4] 204, 216 (sh), 252, 260. 
 
Purity 98 – 100% 
 
 
(20) N,N-di-(β-Phenylisopropyl)formamide [bis-(1-methyl-2-phenylethyl)-formamide] 
 
 
  
NCHO
 
 
 
MS m/z = 190 100%, 91, 119, 162. 
 
IR γmax (cm
-1
) : 1659, 2973, 3056, 2936, 1451, 1494, 745, 1156, 1271, 1316.  
 
1
H NMR δ = 0.9 – 1.25 (3H, d, J=6.1Hz, CH3), 2.5 – 3.1 (2H, dd, J=8.0Hz, J=8.6Hz, CH2), 3.5 and 4.0 
(1H, m, CH), 7.0 – 7.2 (aromatic), 8.1 and 8.2 (CHO). 
 
13
C NMR δ = 17.7 – 20.8 (CH3), 43.0 – 43.5 (CH2), 51.7 – 54.9 (C-N), 126.4 – 139.3 (aromatic), 162.5 
(CHO). 
 
Note!  Resolution of some of the signals due to the isomers was possible using high field NMR. The 
data presented below is subject to confirmation. 
 
UV λmax (nm) [MeOH] 204, 252, 260; [0.1M NaOH] 212, 252, 260; [0.1mH2SO4] 208, 220.  
 
Purity 98 – 100% 
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(21) 2,4-Dimethyl-3,5-diphenylpyridine  
 
 
  
N CH3
CH3
 
 
 
MS 259 100%, 258, 244, 134, 115. 
 
IR γmax (cm
-1
) : 703, 768, 1441, 1390, 1575, 3056, 3027, 1602, 1504, 1010.  
 
1
H NMR  δ = 1.97 (3H, s, CH3), 2.36 (3H, s, CH3), 7.20 (2H, d, J ≅ 7 Hz, 2CHar), 7.34 (2H, d, J ≅ 7 Hz, 
2CHar), 7.38-7.44 (2x1H, m, 2xCHar), 7.46 (2H, t, J ≅ 7 Hz, 1x2CHar), 7.49 (2H, t, J ≅ 7 Hz, 
1x2CHar), 8.37 (1H, s, CH ar-pyr). 
 
13
C NMR  δ = 18.4 and 23.0 (q, CH3), 127.6 and 127.7 (t, 2xCHar), 128.5-129.5 (t, 2CHar), 136.1 (s, Car), 
137.6 (s, Car), 137.9 (s, Car), 138.5 (s, Car), 144.6 (s, Car), 146.5 (t, CH ar-pyr), 154.2 (s, Car).  
 
UV λmax (nm) [MeOH] 210; [0.1M NaOH] 215; [0.1M H2SO4] 215.  
 
Purity 98 – 100% 
 
 
Conclusions 
All together 21 compounds found as impurities in street amphetamines could be successfully synthesised. Full 
spectroscopic data of these compounds was recorded. This data set is unique and it did not only enable the 
present research project but also offers a huge potential for future developments in chemical profiling of 
amphetamine.   
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ANNEX 4 ANALYSIS OF LINEARITY 
The linearity of calibration curves is studied by measuring the Pearson product-moment coefficient of 
correlation, r, and the coefficient of determination, R
2
 [Miller, J.M. and Miller, J.N., Statistic for Analytical 
Chemistry, 1993]. The individual calibration points have values y1, y2, …, yn, and average value y . The Pearson 
product-moment coefficient of correlation, r, is calculated using equation 23. The value of r varied -1 ≤ r ≤ 1. 
Values of r obtained in instrumental analysis are normally very close to 1. 
 
( ) ( )
( ) ( )22yyxx
xy
SS SS
SS
r
yyxx
yyxx
ii
ii
−×−
−−
=
×
=
∑ ×
 (23) 
 
The deviation of an observation y from the regression line is ( yy ˆ- ). As the line goes through the point x  and 
y , the regression equation can be written as follows:  
 
   xbya          xbay -=→+=  
 
Therefore :  
)xb(xyyˆ       
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where the term ( iyˆ - y ) is known as the deviation, estimated y from average of y, and the sum of squares is 
defined ∑( yy i -ˆ )
2
. The sum of squares ∑( ii yy ˆ- )
2
 is the error of observed y from estimated y. The term ∑(yi - 
y )2  is known as the ‘sum of squares about y ’ (SSyy) and it can be defined by the sum of two terms referred to 
above. This can be proved as follows: 
 
yy=yˆy+yyˆ=)yˆ(y+)yyˆ( iiiiiii ----  
 
The term of sum of square y-residuals (SSE) ∑( ii yy ˆ- )
2
 should be as small as possible if the curve is a good fit 
to the data points. The coefficient of determination (R
2
) is defined using equation 30 and the value of R
2
 varied 0 
≤ R2 ≤ 1. 
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In the straight-line graph, R
2
 = r
2
, where r is the product-moment correlation coefficient.  
 
 
 
 140 
ANNEX 5 : SUMMARY OF THE LINEARITY STUDY 
 
 Summary of the linearity study. "Equation" describes the calibration curve through the 
slope and intercept. r
2
 is the correlation coefficient. Linearity has been calculated for 
concentrations of 0.1, 1.0, 5.0, 10.0 and 20.0 µg/mL for Partners 2 and 3. Concentrations used 
by Partners 1 and 4 were 0.1, 1.0, 10, 100 and 500, and 0.1, 1.0, 10, 100 and 250, respectively. 
All solutions were prepared in iso-octane. Only three significant figures are available for 
Partner 2 data. 
 
Partner Compound Equation r
2
 Range (µg/mL) 
1 Benzaldehyde Y=0.0082x + 0.0073 0.9999 0.1 - 500 
1 Ketoxime (1) and (2) Y=0.0074x - 0.0016 0.9998 0.1 - 500 
1 Nitrostyrene Y=0.0088x + 0.0043 0.9999 0.1 - 500 
1 Benzaldimine Y=0.0104x + 0.0126 0.9999 0.1 - 500 
2 Phenyl-2-propanol  Y=0.0680x - 0.0255 0.9994 0.1 - 20 
2 N-acetylamphetamine  Y=0.0639x - 0.0374
 
0.998 0.1 - 20 
2 Aldimine Y=0.07290x - 0.0144 1.00 0.1 - 20 
2 Benzylamphetamine  Y=0.0719x - 0.0301 0.998 0.1 - 20 
2 1-oxo Y=0.0442x - 0.001876 0.998 0.1 - 20 
2 Benzoylamphetamine  Y=0.0729x - 0.0270 0.998 0.1 - 20 
2 2-oxo Y=0.0722x - 0.0338 0.998 0.1 - 20 
2 Cathinol Y=0.0382x - 0.148 1.00 0.1 - 20 
3 4-benzylpyrimidine Y=0.0938x - 0.0139 0.9991 0.1 - 20 
3 4-methyl-5-phenylpyrimidine Y=0.0732x - 0.0141 0.9987 0.1 - 20 
3 DPPA Y=0.0777x - 0.0111 0.9980 0.1 - 20 
3 DPIA  Y=0.0965x - 0.0244 0.9987 0.1 - 20 
3 DPIMA Y=0.0481x - 0.0168 0.9949 0.1 - 20 
3 DPIF Y=0.0621x - 0.0062 0.9998 0.1 - 20 
4 N-formylamphetamine Y=0.0055154x + 0.025 0.9994 0.1 - 250 
4 DPIA  Y=0.0079664 + 0.0415 0.9991 0.1 - 250 
4 DPIMA Y=0.0049421x + 0.0124 0.9996 0.1 - 250 
4 DPIF Y=0.0075347x + 0.0359 0.9995 0.1 - 250 
4 2,4-dimethyl-3,5-diphenylpyridine Y=0.0089333x + 0.0427 0.9994 0.1 - 250 
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ANNEX 6 RESULTS OF THE STABILITY STUDY 
 
 Table A Partner 1 synthetic mixture at 25 ºC in different solvents. 
Iso-octane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
Benzyl methyl ketone 100 101 102 102 100 100 0.8 
2-methyl-3-phenyl aziridine 100 101 102 101 101 101 0.6 
Benzyl aziridine 100 101 98 100 103 104 2.2 
Benzyl methyl ketoxime (1+2) 100 102 103 102 102 105 1.5 
Nitrostyrene 100 101 102 101 101 102 0.7 
N-(β-phenylisopropyl)benzaldimine 100 101 102 101 101 101 0.7 
Average 1.1 
Toluene T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
Benzyl methyl ketone 100 100 102 101 102 103 1.1 
2-methyl-3-phenyl aziridine 100 100 102 101 102 103 1.0 
Benzyl aziridine 100 100 102 102 102 103 1.1 
Benzyl methyl ketoxime (1+2) 100 100 98 98 97 95 1.9 
Nitrostyrene 100 100 101 101 101 100 0.7 
N-(β-phenylisopropyl)benzaldimine 100 100 101 101 101 102 0.7 
Average 1.1 
Dichloromethane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
Benzyl methyl ketone 100 99 100 99 99 101 0.8 
2-methyl-3-phenyl aziridine 100 99 99 99 100 100 0.6 
Benzyl aziridine 100 95 96 96 94 94 2.4 
Benzyl methyl ketoxime (1+2) 100 96 98 98 98 93 2.4 
Nitrostyrene 100 97 99 98 98 77 9.3 
N-(β-phenylisopropyl)benzaldimine 100 96 93 87 79 59 17.6 
Average 5.5 
Diethyl ether  T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
Benzyl methyl ketone 100 102 99 99 100 98 1.3 
2-methyl-3-phenyl aziridine 100 102 98 99 101 97 1.6 
Benzyl aziridine 100 102 91 100 100 87 6.4 
Benzyl methyl ketoxime (1+2) 100 107 104 108 113 106 4.0 
Nitrostyrene 100 104 102 103 104 101 1.6 
N-(β-phenylisopropyl)benzaldimine 100 101 100 100 101 99 0.8 
Average 2.6 
Ethyl acetate T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
Benzyl methyl ketone 100 99 100 101 101 102 1.0 
2-methyl-3-phenyl aziridine 100 99 100 101 100 100 0.5 
Benzyl methyl ketoxime (1+2) 100 102 103 103 102 102 1.2 
Nitrostyrene 100 99 100 101 100 99 0.7 
N-(β-phenylisopropyl)benzaldimine 100 99 100 101 100 102 0.8 
Average 0.8 
Ethanol T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
Benzyl methyl ketone 100 99 100 100 100 99 0.5 
2-methyl-3-phenyl aziridine 100 101 101 102 101 100 0.8 
Benzyl methyl ketoxime (1+2) 100 95 93 94 95 88 4.0 
Nitrostyrene 100 99 99 97 93 85 5.9 
N-(β-phenylisopropyl)benzaldimine 100 98 98 97 93 89 4.1 
Average 3.1 
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Table B Partner 2 synthetic mixture at 25ºC in different solvents.  
Iso-octane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-acetylamphetamine 100 101 101 101 99 95 2.3 
Aldimine 100 99 97 98 99 99 1.0 
Benzylamphetamine 100 100 103 102 101 102 1.3 
Benzoylamphetamine 100 100 102 101 101 100 0.6 
2-oxo 100 101 102 102 101 100 0.9 
Cathinol 100 122 145 135 132 146 13.3 
 Average 3.2 
Toluene T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-acetylamphetamine             100 95 90 93 99 89 4.6 
Aldimine 100 94 91 93 97 93 3.5 
Benzylamphetamine 100 97 93 95 98 92 3.1 
Benzoylamphetamine 100 99 98 99 100 97 1.2 
2-oxo 100 100 99 99 101 98 1.0 
Cathinol 100 115 112 111 113 107 5.0 
 Average 3.1 
Dichloromethane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-acetylamphetamine 100 99 102 106 104 110 3.8 
Aldimine 100 100 102 102 104 101 1.4 
Benzylamphetamine 100 101 100 101 99 105 2.0 
Benzoylamphetamine 100 100 100 101 101 105 1.8 
2-oxo 100 100 100 102 101 106 2.2 
Cathinol 100 114 111 131 126 49 28.3 
 Average 6.6 
Diethyl ether T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-acetylamphetamine 100 98 101 100 102 103 1.8 
Aldimine 100 99 100 96 98 96 1.9 
Benzylamphetamine 100 101 104 102 97 109 3.7 
Benzoylamphetamine 100 97 99 100 102 104 2.4 
2-oxo 100 98 99 101 102 105 2.4 
Cathinol 100 123 136 149 0 0 79.8 
 Average 15.3 
Ethyl acetate T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-acetylamphetamine 100 98 99 95 95 95 2.4 
Aldimine 100 53 52 49 47 40 38.1 
Benzylamphetamine 100 97 103 99 103 93 3.9 
Benzoylamphetamine 100 100 101 100 101 101 0.5 
2-oxo 100 100 101 100 101 101 0.5 
Cathinol 100 0 0 0 0 0 40.8 
 Average 14.4 
Ethanol T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-acetylamphetamine 100 99 98 99 98 100 0.9 
Aldimine 100 89 91 90 86 78 8.1 
Benzylamphetamine 100 103 102 102 102 103 1.1 
Benzoylamphetamine 100 101 100 101 100 101 0.5 
2-oxo 100 103 101 101 101 101 0.9 
Cathinol 100 141 141 128 148 148 13.7 
 Average 4.2 
 
 143 
Table C Partner 3 synthetic mixture at 25 ºC in different solvents. 
Iso-octane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine 100 98 98 98 99 99 0.9 
4-benzylpyrimidine 100 99 99 99 99 100 0.6 
DPPA 100 99 101 101 99 97 1.5 
DPIA 100 97 99 100 100 100 1.3 
DPIMA 100 103 107 107 106 107 2.7 
DPIF (1) 100 101 100 100 101 100 0.5 
DPIF (2) 100 100 99 99 101 99 1.0 
 Average 1.2 
Toluene T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine 100 101 100 100 98 100 1.1 
4-benzylpyrimidine 100 101 100 100 98 99 1.3 
DPPA 100 101 100 100 99 94 2.6 
DPIA 100 102 101 101 100 99 0.9 
DPIMA 100 101 99 101 91 92 4.6 
DPIF (1) 100 99 98 100 98 99 0.9 
DPIF (2) 100 99 98 100 98 99 0.8 
 Average 1.7 
Dichloromethane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine     100 102 98 99 97 97 1.9 
4-benzylpyrimidine 100 102 99 99 97 98 1.7 
DPPA 100 103 100 94 79 86 10.3 
DPIA 100 101 101 100 100 104 1.5 
DPIMA 100 102 97 102 98 101 2.0 
DPIF (1) 100 101 101 100 101 102 0.8 
DPIF (2) 100 101 100 100 100 101 0.7 
 Average 2.7 
Diethyl ether T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine 100 96 98 97 93 95 2.6 
4-benzylpyrimidine 100 97 98 97 94 95 2.3 
DPPA 100 95 87 95 84 82 7.9 
DPIA 100 98 100 101 98 101 1.4 
DPIMA 100 100 95 97 97 103 2.7 
DPIF (1) 100 99 100 100 100 101 0.8 
DPIF (2) 100 100 100 100 100 100 0.2 
 Average 2.6 
Ethyl acetate T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine 100 99 96 97 99 94 2.3 
4-benzylpyrimidine 100 99 96 98 98 95 1.8 
DPPA 100 95 88 88 89 83 6.7 
DPIA 100 99 98 98 98 97 1.0 
DPIMA 100 105 98 103 95 109 5.0 
DPIF (1) 100 100 100 101 101 99 0.6 
DPIF (2) 100 100 100 101 100 99 0.7 
 Average 2.6 
Ethanol T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine 100 95 93 93 97 97 2.8 
4-benzylpyrimidine 100 95 93 94 96 97 2.7 
DPPA 100 101 101 100 98 97 1.5 
DPIA 100 97 96 98 98 100 1.4 
DPIMA 100 96 98 100 95 106 4.0 
DPIF (1) 100 100 100 101 100 100 0.5 
DPIF (2) 100 100 100 101 100 100 0.5 
 Average 1.9 
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Table D Partner 4 synthetic mixture at 25 ºC in different solvents. 
Iso-octane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-formylamphetamine 100 98 98 103 97 99 2.0 
4-benzylpyrimidine 100 99 99 103 98 100 1.8 
DPPA 100 100 100 104 99 100 1.8 
DPIA 100 98 99 101 99 100 0.9 
DPIMA 100 99 98 102 100 103 1.9 
2,4-dimethyl-3,5-diphenylpyridine 100 99 99 100 99 99 0.7 
DPIF 100 99 100 101 97 101 1.3 
 Average 1.5 
Toluene T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-formylamphetamine 100 102 102 102 102 104 1.2 
4-benzylpyrimidine 100 101 101 101 101 102 0.6 
DPPA 100 101 100 100 98 97 1.3 
DPIA 100 100 100 101 101 102 0.7 
DPIMA 100 103 104 105 103 105 1.8 
2,4-dimethyl-3,5-diphenylpyridine 100 101 101 99 101 103 1.4 
DPIF 100 101 101 100 102 104 1.4 
 Average 1.2 
Dichloromethane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-formylamphetamine 100 99 99 100 99 97 1.1 
4-benzylpyrimidine 100 99 99 99 98 95 1.8 
DPPA 100 101 104 101 111 106 4.1 
DPIA 100 99 100 99 102 97 1.7 
DPIMA 100 97 97 96 96 94 2.1 
2,4-dimethyl-3,5-diphenylpyridine       100 99 100 100 103 99 1.6 
DPIF 100 99 100 101 101 107 2.8 
 Average 3.2 
Diethyl ether T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-formylamphetamine 100 102 100 103 103 102 1.4 
4-benzylpyrimidine 100 103 100 102 102 102 1.2 
DPPA 100 101 103 103 109 113 4.9 
DPIA 100 102 101 105 105 101 1.9 
DPIMA 100 101 100 99 99 99 0.7 
2,4-dimethyl-3,5-diphenylpyridine 100 101 103 107 106 104 2.7 
DPIF 100 92 103 102 106 111 6.4 
 Average 2.7 
Ethyl acetate T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-formylamphetamine 100 100 100 100 99 102 0.9 
4-benzylpyrimidine 100 99 100 99 98 101 1.2 
DPPA 100 96 96 94 91 90 3.8 
DPIA 100 100 101 100 99 101 0.8 
DPIMA 100 98 97 95 93 91 3.5 
2,4-dimethyl-3,5-diphenylpyridine 100 100 100 100 100 101 0.5 
DPIF 100 100 100 99 101 99 0.5 
 Average 1.6 
Ethanol T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-formylamphetamine 100 102 99 100 100 97 1.7 
4-benzylpyrimidine 100 102 97 99 99 97 2.0 
DPPA 100 103 100 101 100 98 1.5 
DPIA 100 101 100 101 101 100 0.8 
DPIMA 100 101 99 99 98 96 1.6 
2,4-dimethyl-3,5-diphenylpyridine 100 101 99 100 100 100 0.6 
DPIF 100 101 100 99 100 101 0.6 
 Average 1.3 
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Table E  Partner 2 amphetamine extracts at 25 ºC in different solvents. 
Iso-octane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
Aldimine 100 90 94 97 79 107 10.0 
Benzylamphetamine              100 101 101 102 106 102 1.9 
Benzoylamphetamine 100 115 99 99 94 99 7.1 
 Average 6.3 
Toluene T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-acetylamphetamine 100 96 92 92 87 103 6.3 
Aldimine 100 91 84 88 88 105 8.5 
Benzylamphetamine 100 98 92 95 90 99 4.0 
Benzoylamphetamine 100 113 106 113 116 106 5.4 
 Average 6.1 
Dichloromethane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-acetylamphetamine 100 102 97 101 100 95 2.8 
Benzylamphetamine 100 99 93 94 90 80 8.0 
 Average 5.4 
Diethyl ether T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-acetylamphetamine 100 99 101 105 114 137 13.5 
Aldimine 100 107 101 94 76 89 11.7 
Benzylamphetamine 100 100 101 102 103 123 8.7 
Benzoylamphetamine 100 99 99 103 99 - 1.6 
 Average 8.9 
Ethyl acetate T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
N-acetylamphetamine 100 100 99 102 108 117 6.6 
Aldimine 100 104 103 104 120 85 10.7 
Benzylamphetamine 100 99 99 97 100 96 1.6 
Benzoylamphetamine 100 101 101 104 101 100 1.5 
 Average 5.1 
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Table F Partner 3 amphetamine extracts at 25 ºC in different solvents. 
Iso-octane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine        100 96 99 97 98 97 1.4 
4-benzylpyrimidine 100 98 100 98 101 100 1.3 
benzylamphetamine 100 100 101 99 102 101 1.2 
DPIA 100 99 101 99 100 99 0.8 
DPIMA - - - - - - - 
DPIF (1) 100 99 99 99 98 98 0.9 
DPIF (2) 100 99 99 98 96 97 1.3 
 Average 1.2 
Toluene T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine        100 97 100 99 93 97 2.9 
4-benzylpyrimidine 100 98 101 100 94 98 2.6 
benzylamphetamine 100 100 103 103 99 100 1.6 
DPIA 100 99 102 102 98 101 1.7 
DPIMA - - - - - - - 
DPIF (1) 100 99 99 99 98 99 0.7 
DPIF (2) 100 99 99 99 97 98 1.3 
 Average 1.8 
Dichloromethane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine        100 101 100 99 98 91 3.6 
4-benzylpyrimidine 100 98 100 99 98 87 4.9 
benzylamphetamine 100 102 101 101 98 91 4.0 
DPIA 100 102 101 101 98 99 1.3 
DPIMA - - - - - - - 
DPIF (1) 100 101 101 102 99 101 1.2 
DPIF (2) 100 101 101 102 99 99 1.4 
 Average 2.7 
Diethyl ether T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine        100 102 99 94 99 - 3.0 
4-benzylpyrimidine 100 102 98 97 99 - 1.9 
benzylamphetamine 100 102 98 102 97 - 2.3 
DPIA 100 86 100 102 102 - 6.9 
DPIMA - - - - - - - 
DPIF (1) 100 102 101 105 102 - 1.8 
DPIF (2) 100 102 100 105 102 - 1.9 
 Average 3.0 
Ethyl acetate T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine        100 101 99 98 100 101 1.3 
4-benzylpyrimidine 100 101 99 98 99 100 1.2 
benzylamphetamine 100 99 98 98 100 102 1.5 
DPIA 100 99 99 99 101 103 1.3 
DPIMA - - - - - - - 
DPIF (1) 100 98 101 104 101 99 1.9 
DPIF (2) 100 99 101 101 102 99 1.4 
 Average 1.4 
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Table G Partner 4 amphetamine extracts at 25 ºC in different solvents. 
Iso-octane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine 100 102 103 103 107 103 2.1 
DPIA 100 99 100 100 103 100 1.2 
DPIMA 100 99 100 98 97 96 1.9 
2,4-dimethyl-3,5-diphenylpyridine 100 100 99 103 107 100 2.8 
DPIF 100 100 101 100 100 100 0.4 
 Average 1.7 
Toluene T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine 100 98 101 99 99 99 1.2 
4-benzylpyrimidine 100 99 103 101 100 101 1.6 
N-formylamphetamine 100 98 101 99 99 99 1.1 
DPIA 100 98 100 99 98 98 0.9 
2,4-dimethyl-3,5-diphenylpyridine 100 99 103 97 102 102 2.3 
DPIF 100 100 100 100 100 100 0.3 
 Average 1.2 
Dichloromethane T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine 100 99 100 103 100 100 1.3 
N-formylamphetamine 100 101 103 100 101 104 1.4 
DPIA 100 102 101 100 102 103 1.1 
DPIMA 100 102 102 100 102 103 1.2 
2,4-dimethyl-3,5-diphenylpyridine           100 103 99 111 99 106 4.7 
DPIF 100 100 101 100 100 100 0.6 
 Average 1.7 
Diethyl ether T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine 100 101 94 105 125 125 12.4 
N-formylamphetamine 100 99 95 98 110 111 6.5 
DPIA 100 96 97 98 104 103 3.2 
DPIMA 100 102 98 99 105 118 7.3 
2,4-dimethyl-3,5-diphenylpyridine 100 103 101 102 107 104 2.5 
DPIF 100 100 97 100 104 104 2.5 
 Average 5.7 
Ethyl acetate T=0 T=4 T=12 T=24 T=48 T=96 RSD (%) 
4-methyl-5-phenylpyrimidine 100 101 103 100 104 107 2.8 
N-formylamphetamine 100 100 101 98 103 101 1.6 
DPIA 100 100 99 97 99 98 1.1 
DPIMA 100 99 98 95 97 94 2.3 
2,4-dimethyl-3,5-diphenylpyridine 100 92 97 99 104 101 4.2 
DPIF 100 100 101 99 101 100 0.8 
 Average 2.1 
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ANNEX 7 : RESULTS OF LINEARITY STUDY IN SUBTASK 3.4 
 
 
 Partner 2 Partner 3 Partner 4 
 FID SCAN SIM FID SCAN SIM FID SCAN SIM 
Octanol 
r2 0.99779 0.99999 0.99887 - - - - - - 
R2 0.99779 0.99999 0.99887 - - - - - - 
variable b -0.1068 0.00355 0.38256 - - - - - - 
variable a 0.12596 0.60451 0.90707 - - - - - - 
Dodecane (C12) 
r2 0.93109 0.98943 0.98376 - - - - - - 
R2 0.93109 0.98943 0.98376 - - - 0.9999 0.9984 - 
variable b -1.03007 0.48362 1.5712 - - - - - - 
variable a 0.25511 1.77077 2.73289 - - - - - - 
2,6-dimethylphenol 
r2 0.99803 0.99997 0.99897 1.0000 0.9938 0.9959 - - - 
R2 0.99803 0.99997 0.99897 1.0000 0.9953 0.9720 0.9999 0.9989  
variable b -0.12189 0.41087 1.95698 0.1025 0.6663 0.7344 - - - 
variable a 0.1514 3.09719 4.66908 0.0713 4.0956 3.2534 - - - 
Tridecane (C13) 
r2 0.99825 0.99952 0.99774 1.0000 0.9909 0.9987 - - - 
R2 0.99825 0.99952 0.99774 1.0000 0.9951 0.9952 0.9999 0.9988 - 
variable b -0.10626 0.88007 2.12257 0.1025 0.5438 0.7997 - - - 
variable a 0.14952 1.59394 2.45592 0.0713 4.2307 0.3428 - - - 
2,6-dimethyl aniline 
r2 0.99807 0.99997 0.99895 0.9999 0.9912 0.9928 - - - 
R2 0.99807 0.99997 0.99895 1.0000 0.9925 0.9899 0.9999 0.9983 - 
variable b -0.10379 0.48357 2.38515 0.0896 0.7896 0.8677 - - - 
variable a 0.13334 3.37029 5.05218 0.4747 6.6523 5.5648 - - - 
Decanoic acid methyl ester 
r2 0.99815 0.99976 0.99802 0.9999 0.9897 0.9894 - - - 
R2 0.99815 0.99976 0.99802 0.9999 0.9909 0.9852 0.9999 0.9977 - 
variable b -0.06729 0.89822 2.78145 outlier 0.6927 0.7777 - - - 
variable a 0.10476 2.54436 3.8578 outlier 6.2908 5.8583 - - - 
Undecanoic acid methyl ester 
r2 0.99826 0.99953 0.99761 - - - - - - 
R2 0.99826 0.99953 0.99761 - - - - - - 
variable b -0.17031 1.22746 3.27682 - - - - - - 
variable a 0.24325 2.42514 3.67272 - - - - - - 
Dicyclohexylamine 
r2 0.99785 0.99998 0.99869 1.0000 0.9872 0.9789 - - - 
R2 0.99785 0.99998 0.99869 1.0000 0.8753 0.9773 0.9999 0.9937 - 
variable b -0.13723 2.71827 -0.35236 0.0949 0.1120 0.1001 - - - 
variable a 0.13505 10.3525 0.12945 0.4241 1.1522 1.2155 - - - 
Dodecanoic acid methyl ester 
r2 0.99668 0.99882 0.99556 - - - - - - 
R2 0.99668 0.99882 0.99556 - - - - - - 
variable b -0.42095 1.60993 3.9259 - - - - - - 
variable a 0.24382 2.30159 3.48151 - - - - - - 
 Partner 2 Partner 3 Partner 4 
 FID SCAN SIM FID SCAN SIM FID SCAN SIM 
Heptadecane (C17) 
r2 0.99825 0.99931 0.99651 0.9999 0.9912 0.9924 - - - 
R2 0.99825 0.99931 0.99651 1.0000 0.9945 0.9945 0.9999 0.9986 - 
variable b -0.11131 0.97261 2.70882 0.1013 0.5559 0.5937 - - - 
variable a 0.15332 1.72628 2.63626 -0.2443 3.8793 3.7978 - - - 
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Octadecane (C18) 
r2 0.99814 0.99814 0.99676 0.9999 0.9885 0.9875 - - - 
R2 0.99814 0.99814 0.99676 0.9999 0.9947 0.9945 0.9999 0.9988 - 
variable b -0.09716 -0.09716 2.11271 0.0961 0.5524 0.5966 - - - 
variable a 0.12928 0.12928 2.26256 0.1316 3.8193 3.5914 - - - 
Nonadecane (C19) 
r2 0.99798 0.99954 0.99727 0.9999 0.9747 0.9869 - - - 
R2 0.99798 0.99954 0.99727 0.9999 0.9887 0.9942 0.9999 0.9988 - 
variable b -0.09154 0.55792 1.72402 0.0960 0.5217 0.5974 - - - 
variable a 0.11744 1.35732 2.08564 0.1337 4.5324 3.6546 - - - 
Tetracosane (C24) 
r2 0.99742 0.99955 0.99702 - - - - - - 
R2 0.99742 0.99955 0.99702 - - - 1.0000 0.9991 - 
variable b -0.12068 0.45172 1.86171 - - - - - - 
variable a 0.12589 1.46322 2.23888 - - - - - - 
Partner 3 only 
 
FID NPD SCAN SIM 
 Ketamine  
r2 0.9996 0.9917 0.9989 0.9975 
R2 0.9998 0.9918 0.9915 0.9994 
variable b 0.0704 0.1310 0.0754 0.0700 
variable a -0.1225 -1.2460 -0.0550 -0.0397 
 Diphenethylamine  
r2 0.9998 0.9999 0.9598 0.9687 
R2 0.9999 0.9999 0.9434 0.9773 
variable b 0.1005 0.0968 0.0784 0.1520 
variable a -0.0599 -0.0029 3.2599 2.1374 
 4-Methyl-5phenylpyrimidine  
r2 1.0000 0.9976 0.9951 0.9990 
R2 1.0000 0.9982 0.9469 0.9955 
variable b 0.0837 0.1505 0.0890 0.1100 
variable a 0.3279 5.6250 0.4975 0.0400 
 Dicyclohexylamine  
r2 1.0000 0.9991 0.9872 0.9789 
R2 1.0000 0.9994 0.8753 0.9773 
variable b 0.0949 0.0947 0.1120 0.1001 
variable a 0.4241 2.5085 1.1522 1.2155 
 Trimipramine  
r2 0.9995 0.9997 0.9910 0.9876 
R2 0.9999 0.9998 outlier 0.9912 
variable b 0.0710 0.0979 0.0444 0.0350 
variable a -0.0592 -0.0304 0.2603 0.3329 
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ANNEX 8  SYNTHESIS OF AMPHETAMINE IN TASK 6 
Synthesis of the benzyl methyl ketone  
First synthesis of benzyl methyl ketone 
A first synthesis of benzy methyl ketone was made according to Bobranski [Bobranski and Drabik, 1941]. α-
acetylbenzyl cyanide (32 g) was added to 60 mL of concentrated sulfuric acid (cooled in freezer and standing in 
ice). Water (20 mL) was also added. The solution was stirred during this process. The mixture was then heated 
under reflux for 21 hours (melting point of acetylbenzylcyanide: 92-94 °C). 50 % of benzyl methyl ketone was 
obtained (the other 50 % being unreacted acetylbenzylcyanide). This is probably due to the fact that a layer is 
formed above the acid hampering the reaction (not homogeneous mixture). 
 
The mixture was allowed to cool down and 200 mL water added. The aqueous solution was extracted with 3 x 50 
mL of dichloromethane. The combined extracts were left to evaporate at room temperature. Upon evaporation, 
crystals of acetylbenzylcyanide were formed. The remaining oil was then recovered and placed in the fridge. 
After a few days in the fridge, more crystals of acetylbenzylcyanide formed. The remaining oil was again 
recovered. A total amount of 8 g of benzyl methyl ketone was obtained (purity 95 %). The yield was 25 %.  
 
Second synthesis of benzyl methyl ketone 
The second synthesis of benzyl methyl ketone was made according to Shulgin and Shulgin [Shulgin and Shulgin, 
1991]. Phenyl-2-nitropropene (25 g, Sigma-Aldrich
®
) was dissolved in190 mL acetic acid and slowly dripped 
into a 2 L Erlenmeyer containing 61 g of iron in 270 mL acetic acid. The mixture was shaken manually and then 
slowly heated to 60 °C. The mixture was left on low heat for 2h while manual shaking took place every 10 min. 
Then, 1.5 L of water was added and the solution was filtered to remove the iron particles. 
 
The aqueous solution was extracted thrice with 300 mL dichloromethane. The combined extracts were then 
washed with 500 mL water and dried over magnesium sulphate. Finally, the solvent was evaporated under 
vacuum yielding a pale yellow oil. The weight of the obtained benzyl methyl ketone was 15 g (yield 60 %). The 
two batches of benzyl methyl ketone oils obtained during these syntheses were combined and used in the 
synthesis of batch 3 (IPSC 3). 
 
Leuckart recipe used in the repeated synthesis  
Benzyl methyl ketone (15 mL), formamide (30 mL) and formic acid (15 mL) were mixed and refluxed for 2.5 
hours at approximately 160 ºC (molar ratio: 1:6.7:3.5). The reaction was stopped and the mixture was allowed to 
cool at room temperature for 1 hour (<100 ºC). Water (60 mL) and the mixture from the first step was added to a 
250 mL separation funnel and the mixture were shaken for 1 minute. The two-phase system was allowed to 
equilibrate for 20 minutes after which approximately 15 mL formylamphetamine was recovered. HCl 32 % 
(same volume as formylamphetamine) was added and the mixture was refluxed at approximately 110 ºC for 1.5 
hours. The mixture was then allowed to cool over night. NaOH (60 mL 5M) was added dropwise to the mixture. 
The mixture was allowed to cool for 1 hour after which about 12-14 g of amphetamine oil were obtained. 
Methanol (60 mL) was added followed by sulphuric acid (32 % in water) until pH 7. The obtained amphetamine 
sulphate crystals were filtered off (filter paper without vacuum). The crystals were then washed thrice with 
acetone (100 mL + 50 mL + 50 mL). The amphetamine sulphate was then allowed to dry at room temperature.  
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ANNEX 9 
SWISS SEIZED AMPHETAMINE SAMPLES USED IN TASK 6 
Database name IPS name Police number Provenance Year 
I00G19I 00ge19 20916.1 Genève 2000 
I00N68AI 00ne68 12221.5 Neuchâtel 2000 
I00N68BI 00ne68 12221.7 Neuchâtel 2000 
I00N68CI 00ne68 12221.9 Neuchâtel 2000 
I00N68DI 00ne68 12221.11 Neuchâtel 2000 
I01G250I 01ge250-07.01 414973.5 Genève 2001 
I1104BI - 1104-00 B WD Zurich 2000 
I136I - 136-99 WD Zurich 1999 
I176I - 176-99 WD Zurich 1999 
I18AI - 18A -01 WD Zurich 2001 
I18BI - 18B -01 WD Zurich 2001 
I195I - 195-99 WD Zurich 1999 
I2006AI - 2006-02 A WD Zurich 2002 
I2006BI - 2006-02 B WD Zurich 2002 
I2009I - 2009-99 WD Zurich 1999 
I2058I - 2058-99 WD Zurich 1999 
I2061I - 2061-02 WD Zurich 2002 
I2062I - 2062-02 WD Zurich 2002 
I2097I - 2097-00 WD Zurich 2000 
I2317I - 2317-01 WD Zurich 2001 
I2349I - 2349-00 WD Zurich 2000 
I2418I - 2418-00 WD Zurich 2000 
I2436I - 2436-02 WD Zurich 2002 
I2514AI - 2514A-01 WD Zurich 2001 
I2516I - 2516-02 WD Zurich 2002 
I2866I - 2866-99 WD Zurich 1999 
I2937I - 2937-99 WD Zurich 1999 
I3027I - 3027-99 WD Zurich 1999 
I3069I - 3069-99 WD Zurich 1999 
I3126I - 3126-00 WD Zurich 2000 
I3261I - 3261-00 WD Zurich 2000 
I3264I - 3264-00 WD Zurich 2000 
I3343I - 3343-00 WD Zurich 2000 
I3346I - 3346-00 WD Zurich 2000 
I3348I - 3348-00 WD Zurich 2000 
I3497AI - 3497-00 A WD Zurich 2000 
I3499I - 3499-00 WD Zurich 2000 
I3500I - 3500-00 WD Zurich 2000 
I3631I - 3631-01 WD Zurich 2001 
I3740I - 3740-99 WD Zurich 1999 
I4331I - 4331-01 WD Zurich 2001 
I4469AI - 4469-00 A WD Zurich 2000 
I4469BI - 4469-00 B WD Zurich 2000 
I446I - 446-01 WD Zurich 2001 
I4576I - 4576-99 WD Zurich 1999 
I4578I - 4578-99 WD Zurich 1999 
I4695I - 4695-99 WD Zurich 1999 
I4705I - 4705-01 WD Zurich 2001 
I4723I - 4723-99 WD Zurich 1999 
I4837I - 4837-01 WD Zurich 2001 
I4960I - 4960-00 WD Zurich 2000 
I5010I - 5010-01 WD Zurich 2001 
I5012AI - 5012A-01 WD Zurich 2001 
I5012BI - 5012B-01 WD Zurich 2001 
I5150I - 5150-00 WD Zurich 2000 
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Database name IPS name Police number Provenance Year 
I5220I - 5220-00 WD Zurich 2000 
I5269AI - 5269A-01 WD Zurich 2001 
I5269BI - 5269B-01 WD Zurich 2001 
I5269CI - 5269C-01 WD Zurich 2001 
I5269DI - 5269D-01 WD Zurich 2001 
I5269FI - 5269F-01 WD Zurich 2001 
I5774I - 5774-01 WD Zurich 2001 
I5832 - 5832-99 WD Zurich 1999 
I5921I - 5921-99 WD Zurich 1999 
I6116I - 6116-01 WD Zurich 2001 
I61I - 61-99 WD Zurich 1999 
I6373I - 6373-01 WD Zurich 2001 
I6430I - 6430-99 WD Zurich 1999 
I6501I - 6501-00 WD Zurich 2000 
I6686BI - 6686-00 B WD Zurich 2000 
I6978I - 6978-00 WD Zurich 2000 
I7001AI - 7001A-01 WD Zurich 2001 
I7001BI - 7001B-01 WD Zurich 2001 
I7044I - 7044-01 WD Zurich 2001 
I7051I - 7051-00 WD Zurich 2000 
I7091I - 7091-00 WD Zurich 2000 
I7449I - 7449-01 WD Zurich 2001 
I7532BI - 7532B-01 WD Zurich 2001 
I7536I - 7536-01 WD Zurich 2001 
I7557I - 7557-01 WD Zurich 2001 
I7723I - 7723-01 WD Zurich 2001 
I7889I - 7889-01 WD Zurich 2001 
I7922I - 7922-01 WD Zurich 2001 
I98N166I 98ne166 9391.4 Neuchâtel 1998 
I98N196I 98ne196 9470.3 Neuchâtel 1998 
I98N19I 98ne19 8162.1 Neuchâtel 1998 
I98N22I 98ne22 8195.2 Neuchâtel 1998 
I98N51I 98ne51 8514 Neuchâtel 1998 
I98N74AI 98ne74 8732.1 Neuchâtel 1998 
I98N74BI 98ne74 8732.2 Neuchâtel 1998 
I99G46AI 99ge46 135705.1 Genève 1999 
I99G46BI 99ge46 135705.3 Genève 1999 
I99N10I 99ne10 10029 Neuchâtel 1999 
I99N141I 99ne141 10686.4 Neuchâtel 1999 
IB0106I - B-0106-99 Kanton ZH 1999 
IB1104I - B-1104-99 Kanton ZH 1999 
IB1221BI - B-1221b-99 Kanton ZH 1999 
IB1221CI - B-1221c-99 Kanton ZH 1999 
IB1433I - B-1433-00 Kanton ZH 2000 
IB1612AI - B-1612a-01 Kanton ZH 2001 
IB1612BI - B-1612b-01 Kanton ZH 2001 
IB1613I - B-1613-01 Kanton ZH 2001 
IB1643I - B-1643-01 Kanton ZH 2001 
IB1967I - B-1967-01 Kanton ZH 2001 
IB2338AI - B-2338a-01 Kanton ZH 2001 
IB2338BI - B-2338b-01 Kanton ZH 2001 
IB2353I - B-2353-01 Kanton ZH 2001 
IB2483I - B-2483-99 Kanton ZH 1999 
IB3001I - B-3001-01 Kanton ZH 2001 
IGEJUI - Jura Jura  
IGEVSI - Valais Valais  
IT532I 532 6631-97 WD Zurich 1997 
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ANNEX 10 LIST OF TASK 6 COMPOUNDS 
# Compound 
1 2-methyl-3-phenylaziridine   
a)
 
2 Benzylmethylketoxime 1 
a)
 
3 Benzylmethylketoxime 2 
a)
 
4 4-methyl-5-phenylpyrimidine 
a)
 
5 Possibly N-propylbenzamide 
e)
 
6 4-Benzylpyrimidine 
a)
 
7 N-Acetylamphetamine 
a)
 
8 N-Formylamphetamine 
a)
 
9 1,2-Diphenylethylamine 
e)
 
10 N,N-Dibenzylamine 
d)
 
11 1,2-Diphenylethanone 
d)
 
12 Benzylamphetamine 
a)
 
13 1,3-diphenyl-2-propylamine 
a)
 
14 N,N-di(β-phenylisopropyl)amine 1 
a)
 
15 N,N-di(β-phenylisopropyl)amine 2 
a) 
16 α-methyldiphenethylamine 
e)
 
17 N,N-di(β-phenylisopropyl)methylamine 1 
a)
 
18 N,N-di(β-phenylisopropyl)methylamine 2 
a)
 
19 Unknown A2 
e)
 
20 1-benzyl-3-methylnaphthalene 
b)
 
21 Unknown A3 
e)
 
22 1-hydroxy-N,N-di(β-phenylisopropyl)amine 1 
a) 
(Cathinol 1) 
23 1,3-dimethyl-2-phenylnaphthalene 
b)
 
24 Unknown A4 
e)
  
25 Benzoylamphetamine 
a)
 
26 Unknown B2 
e)
 
27 2-oxo-1-phenyl-(β-phenylisopropylamino)ethane 
a)
 
28 2,6-dimethyl-3,5-diphenylpyridine 
c)
 
29 2,4-dimethyl-3,5-diphenylpyridine 
a)
 
30 Pyridines 7 and 14 
f)
 
31 Pyridine 272 
g)
 
32 2,6-diphenyl-3,5-dimethylpyridine 
c)
 
33 N,N-di(β-phenylisopropyl)formamide 1 
a)
 
34 N,N-di(β-phenylisopropyl)formamide 2 
a)
 
35 Benzaldehyde oxime 
e) 
36 1-phenyl-1,2-propanedione 
d)
 
37 Phenylacetonitrile 
e)
 
38 Ethylamphetamine 
d)
 
39 Isopropylamphetamine 
e)
 
40 Phenyl-2-nitropropane 
e)
 
41 Phenyl-2-nitropropene 
a)
 
42 1,3-diphenyl-2-propanone 
e)
 
43 α-dimethyldiphenethylamine 
e)
 
44 1,5-diphenyl-4-methyl-4-penten-2-one 
i)
 
45 1-benzyl-2,3-dimethylaziridine 
e)
 
46 2-benzyl-2-methyl-5-phenyl-2,3-dihydropyrid-4-one 
c)
 
47 Pyridine X 
h)
 
48 Unknown C 
e)
 
49 Unknown A1 
e)
 
50 Unknown B1 
e)
 
51 1-hydroxy-N,N-di(β-phenylisopropyl)amine 2 
a)
 (Cathinol 2) 
 
a) Target compounds synthesised 
within the SMT project. 
 
b) Target compounds of which 
standards were provided by the 
United Nations Office for Drugs 
and Crime (UNODC). 
 
c) Target compounds of which 
standards were provided by the 
Netherlands Forensic Institute 
(NFI). 
 
d) Other target compounds for which 
standards were available. 
 
e) Other target compounds for which 
standards were not available. 
Identification based only upon 
comparison with Wiley and / or 
NIST MS library. 
 
f) Two compounds not separated 
with the GC method. Their mass 
spectra indicate that they are 
pyridine derivatives. The names 
pyridine 7 and pyridine 14 are 
those used by partner 3 in their 
laboratory (SKL, Sweden). 
 
g) Pyridine derivative tentatively 
identified as 2,4-dimethyl-3-
phenyl-6-(phenylmethyl)-pyridine 
by van den Ark [van den Ark et 
al., 1978c]. 
 
h) Compound with the same mass 
spectrum as identified pyridines. 
The name “pyridine x” was given 
as the exact chemical structure 
could not be determined. 
 
i)
 Target compound for which a 
standard was not available. 
Identification based only upon 
comparison with Wiley and / or NIST 
MS library and with compound 
tentatively identified by Huizer [Huizer 
et al., 1981] 
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MASS SPECTRA OF THE 51 TARGET COMPOUNDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. 2-methyl-3-phenylaziridine   2. Benzylmethylketoxime (isomer 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Benzylmethylketoxime (isomer 2)   4. 4-methyl-5-phenylpyrimidine 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Compound which could be N-propylbenzamide   6. 4-benzylpyrimidine 
40 50 60 70 80 90 100 110 120 130 140
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
5500
6000
6500
7000
7500
8000
8500
9000
9500
m/z-->
Abundance
#25: 2-methyl-3-phenylaziridine
132
91 105
117
77
51 63
42 8656
30 40 50 60 70 80 90 100 110 120 130 140 150
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/z-->
Abundance
#9492: 2-Propanone, 1-phenyl-, oxime
91
149
116
65 131
58
39
51
77 105
30 40 50 60 70 80 90 100 110 120 130 140 150 160
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
120000
130000
140000
150000
160000
170000
m/z-->
Abundance
Scan 926 (13.767 min): NITTK43B.D (-)
91
131
116
65
58
149
39
51
77
105
16031
85 98 141
30 40 50 60 70 80 90 100 110 120 130 140 150 160 170
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/z-->
Abundance
#15288: 4-Methyl-5-phenylpyrimidine
170
102
115
51
76
63
39 14289
155128
30 40 50 60 70 80 90 100 110 120 130 140 150 160 170
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
m/z-->
Abundance
#15289: 4-Benzylpyrimidine
169
115
91
65
14239 52
77
128 155
N
H
N
OH
N
OH
N
N
N
N
40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
500000
550000
600000
650000
m/z-->
Abundance
Scan 616 (12.239 min): 1001006.D (-)
105
77
51
163
118
42
14563 89 134 153 196 20797
 155 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. N-acetylamphetamine     8. N-formylamphetamine 
 
 
 
 
 
 
 
 
 
 
 
 
 
9. 1,2-Diphenylethylamine    10. N, N-dibenzylamine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11. 1,2-Diphenyl ethanone    12. Benzylamphetamine 
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#22129: 1,2-Diphenylethylamine
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  13. 1,3-diphenyl-2-propylamine (DPPA) 14. N,N-di(β-phenylisopropyl)amine (isomer 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
15. N,N-di(β-phenylisopropyl)amine (isomer 2)  16. α-methyldiphenethylamine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17. N,N-di(β-phenylisopropyl)methylamine (isomer 1)     18. N,N-di(β-phenylisopropyl)methylamine (isomer 2) 
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#3: 1,3-diphenyl-2-propylamine
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#31798: Diphenethylamine, .alpha.-methyl-
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Scan 2531 (18.916 min): I11REPI.D (-)
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   19. Unknown A2    20. 1-benzyl-3-methylnaphthalene 
 
 
 
 
 
 
 
 
 
 
 
 
   21. Unknown A3     22. Cathinol (isomer 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23. 1,3-dimethyl-2-phenylnaphthalene   24. Unknown A4 
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#19: 1-benzyl-3-methylnaphtalene
232
217
202
108
18994 152
165 17863 12851 77 13939
40 60 80 100 120 140 160 180 200 220 240
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
500000
550000
600000
m/z-->
Abundance
Scan 1704 (20.539 min): 128143.D (-)
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#20: 1,3-dimethyl-2-phenylnaphtalene
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  25. Benzoylamphetamine     26. Unknown B2 
 
 
 
 
 
 
 
 
 
 
 
 
27. 2-oxo-1-phenyl-(β-phenylisopropylamino)ethane  28. 2,6-dimethyl-3,5-diphenylpyridine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29. 2,4-dimethyl-3,5-diphenylpyridine  30. Pyridines 7 and 14 (one peak) 
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#17: Benzoylamphetamine
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Scan 2893 (21.081 min): I21100I.D (-)
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#16: 2-oxo-1-phenyl-2-(beta-phenylisopropylamine)propane
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#21: 2,6-dimethyl-3,5-diphenylpyridine
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31. Pyridine 272     32. 2,6-diphenyl-3,5-dimethylpyridine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33. N,N-di(β-phenylisopropyl)formamide (isomer 1)          34. N,N-di(β-phenylisopropyl)formamide (isomer 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  35. Benzaldehyde oxime    36. 1-phenyl-1,2-propanedione 
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#22: 2,6-diphenyl-3,5-dimethylpyridine
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#7: N,N-di(beta-phenylisopropyl)formamide (first stereo
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#8: N,N-di(beta-phenylisopropyl)formamide (second stero
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  37. Phenylacetonitrile     38. Ethylamphetamine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  39. Isopropylamphetamine   40. Phenyl-2-nitropropane 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  41. Phenyl-2-nitropropene    42. 1,3-diphenyl-2-propanone 
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#64397: Benzeneacetonitrile
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Scan 366 (8.337 min): ETHYLAMP.D (-)
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#16953: Isopropylamphetamine
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115
91
105
163
146
51 7763
135
40 85 98 121
40 50 60 70 80 90 100110120130140150160170180190200210
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
120000
130000
140000
m/z-->
Abundance
Scan 2160 (16.697 min): DBKNITRO.D (-)
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43. α-Dimethyldiphenethylamine                44. 1,5-Diphenyl-4-methyl-4-penten-2-one 
 
 
 
 
 
 
 
 
 
 
 
 
 
45. 1-Benzyl-2,3-dimethyl-aziridine       46. 2-Benzyl-2-methyl-5-phenyl-2,3-dihydropyrid-4-one 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   47. Pyridine X     48. Unknown C 
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Scan 2186 (16.853 min): NITRO1.D (-)
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#12723: Aziridine, 2,3-dimethyl-1-(phenylmethyl)-, trans-
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   49. Unknown A1     50. Unknown B1 
 
 
 
 
 
 
 
 
 
 
 
 
 
   51. Cathinol 2 
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ANNEX 11 
PCA SCORES AND LOADINGS PLOTS OF THE DATA SET OF 44 
SAMPLES AND 33 VARIABLES. SECTION 6.6.5 
 
Normalisation to the sum. Alternative 2. Left : scores plot. Right : loadings plot. 
 
 
 
Normalisation to the sum + Weighing. Alternative 1. Left : scores plot. Right : loadings plot. 
 
 
 
Normalisation to the sum + Weighing. Alternative 2. Left : scores plot. Right : loadings plot. 
 
 
 
 
 164 
 
 
 
 
Weighing + Normalisation to the sum. Alternative 1. Left : scores plot. Right : loadings plot. 
 
 
Weighing + Normalisation to the sum. Alternative 2. Left : scores plot. Right : loadings plot. 
 
 
Weighing + Normalisation + Logarithm. Alternative 1. Left : scores plot. Right : loadings plot. 
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Weighing + Normalisation + Logarithm. Alternative 2. Left : scores plot. Right : loadings plot. 
 
 
 
 
Weighing + Normalisation + 4
th
 square root. Alternative 1. Left : scores plot. Right : loadings plot. 
 
 
 
Weighing + Normalisation + 4
th
 square root. Alternative 2. Left : scores plot. Right : loadings plot. 
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Normalisation + Logarithm. Alternative 1. Left : scores plot. Right : loadings plot. 
 
 
 
 
Normalisation + Logarithm. Alternative 2. Left : scores plot. Right : loadings plot. 
 
 
Normalisation + 4
th
 square root. Alternative 1. Left : scores plot. Right : loadings plot. 
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ANNEX 12 
HISTOGRAM PLOTS : OVERLAPPING BETWEEN SYNTHESISED 
SAMPLES AND STREET SAMPLES WITH DIFFERENT DISTANCE 
METHODS. SECTION 6.8.2 
 
SMT, MS, Pearson (alternative 1)
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SMT, MS, Pearson (alternative 2)
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SMT, MS, Squared sinus (alternative 1)
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SMT, MS, Squared sinus (alternative 2)
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SMT, MS, Euclidian (alternative 1)
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SMT, MS, Euclidian (alternative 2)
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SMT, MS, Manhattan (alternative 1)
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SMT, MS, Manhattan (alternative 2)
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SMT, MS, Quotient 20 %
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SMT, MS, Canberra (alternative 1)
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SMT, MS, Canberra (alternative 2)
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SMT, MS, Similarity index (alternative 1)
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SMT, MS, Similarity index (alternative 2)
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ANNEX 13 DISTANCES BETWEEN AMPHETAMINE SAMPLES OF 
DIFFERENT DEGREES OF SIMILARITY.  
 
1 MSD DATA 
1.1 Pearson (alternative 2) 
MS data, 0=200 Pearson, N+4root 
samples Type of estimate analysing lab n mean SD max min 
Control samples Within day/sequence Partner 2 5 0.011 0.010 0.025 0.004 
Control samples Within day/sequence Partner 3 6 0.005 0.004 0.012 0.002 
Control samples Within day/sequence Partner 4 6 0.008 0.006 0.015 0.001 
Control samples Within day/sequence All 17 0.007 0.007 0.025 0.001 
Control samples Between day/sequence Partner 2 10 0.010 0.005 0.017 0.002 
Control samples Between day/sequence Partner 3 15 0.006 0.004 0.014 0.001 
Control samples Between day/sequence Partner 4 15 0.004 0.003 0.009 0.001 
Control samples Between day/sequence All 40 0.006 0.005 0.017 0.001 
Control samples Between lab Partners 2 vs 3 30 0.053 0.012 0.070 0.031 
Control samples Between lab Partners 2 vs 4 30 0.13 0.011 0.16 0.11 
Control samples Between lab Partner 3 vs 4 36 0.073 0.013 0.10 0.049 
Control samples Between lab All 96 0.086 0.036 0.16 0.031 
100 % samples Within lab, same conc Partner 2 33 0.024 0.055 0.27 0.001 
100 % samples Within lab, same conc Partner 3 33 0.010 0.020 0.077 0.001 
100 % samples Within lab, same conc Partner 4 33 0.005 0.008 0.043 0.0001 
100 % samples Within lab, same conc All 99 0.013 0.035 0.27 0.0001 
40 % samples Within lab, same conc Partner 2 27 0.024 0.064 0.25 0.001 
40 % samples Within lab, same conc Partner 3 24 0.008 0.011 0.038 0.001 
40 % samples Within lab, same conc Partner 4 24 0.031 0.059 0.20 0.0004 
40 % samples Within lab, same conc All 75 0.021 0.051 0.25 0.0004 
5 % samples Within lab, same conc Partner 2 33 0.18 0.42 1.7 0.001 
5 % samples Within lab, same conc Partner 3 33 0.033 0.037 0.13 0.001 
5 % samples Within lab, same conc IPSC 33 0.021 0.031 0.12 0.001 
5 % samples Within lab, same conc All 99 0.077 0.25 1.7 0.001 
5, 40 and 100% samples Within lab, same conc All 273 0.038 0.16 1.7 0.0001 
100 % samples Between lab, same conc All 33 0.26 0.20 0.84 0.016 
40 % samples Between lab, same conc All 23 0.25 0.25 0.82 0.015 
5 % samples Between lab, same conc All 33 0.34 0.37 1.6 0.027 
5, 40 and 100% samples Between lab, same conc All 89 0.28 0.28 1.6 0.015 
100% vs 40% Within lab, different conc. Partner 2 9 0.13 0.11 0.36 0.018 
100% vs 40% Within lab, different conc. Partner 3 8 0.093 0.11 0.33 0.034 
100% vs 40% Within lab, different conc. Partner 4 8 0.12 0.12 0.33 0.013 
100% vs 40% Within lab, different conc. All 25 0.12 0.11 0.36 0.013 
100% vs 5% Within lab, different conc. Partner 2 11 0.54 0.38 1.3 0.072 
100% vs 5% Within lab, different conc. Partner 3 11 0.41 0.26 0.97 0.063 
100% vs 5% Within lab, different conc. Partner 4 11 0.38 0.22 0.63 0.048 
100% vs 5% Within lab, different conc. All 33 0.45 0.29 1.3 0.048 
40% vs 5% Within lab, different conc. Partner 2 9 0.42 0.29 0.86 0.041 
40% vs 5% Within lab, different conc. Partner 3 8 0.25 0.13 0.45 0.033 
40% vs 5% Within lab, different conc. Partner 4 8 0.35 0.22 0.60 0.038 
40% vs 5% Within lab, different conc. All 25 0.34 0.23 0.86 0.033 
100% vs 40% Between lab, different conc. All 50 0.27 0.24 1.1 0.009 
100% vs 5% Between lab, different conc. All 66 0.58 0.40 2.1 0.051 
40% vs 5% Between lab, different conc. All 50 0.45 0.42 2.1 0.034 
Repeated synthesis, replicates Within lab Partner 3 and 4 36 0.041 0.14 0.61 0.001 
Repeated synthesis Within lab Partner 3 15 1.3 1.1 3.5 0.22 
Repeated synthesis Within lab Partner 4 15 0.94 1.1 4.0 0.032 
Repeated synthesis Within lab Partner 3 and 4 30 1.1 1.1 4.0 0.032 
Repeated synthesis Between lab Partner 3 and 4 36 3.1 1.7 7.5 0.70 
Same oil precipitated at diff pH Within lab/operator Partner 3 36 1.2 1.4 3.8 0.004 
100 % samples Diff. recipe within synth route Partner 3 19 15.4 9.1 37.6 3.5 
100 % samples Between synthetic route Partner 3 36 47.5 13.5 69.4 14.0 
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1.2 Squared sinus (alternative 2) 
 
MS data, 0=200 Squared sinus, N+4root 
samples Type of  estimate analysing lab n mean SD max min 
Control samples Within day/sequence Partner 2 5 0.023 0.020 0.055 0.009 
Control samples Within day/sequence Partner 3 6 0.011 0.013 0.036 0.002 
Control samples Within day/sequence Partner 4 6 0.011 0.008 0.021 0.003 
Control samples Within day/sequence All 17 0.015 0.014 0.055 0.002 
Control samples Between day/sequence Partner 2 10 0.017 0.009 0.030 0.002 
Control samples Between day/sequence Partner 3 15 0.012 0.010 0.028 0.001 
Control samples Between day/sequence Partner 4 15 0.005 0.004 0.013 0.001 
Control samples Between day/sequence All 40 0.011 0.009 0.030 0.001 
Control samples Between lab Partner 2 vs 
Partner 3 
30 0.12 0.032 0.18 0.070 
Control samples Between lab Partner 2 vs 
Partner 4 
30 0.39 0.031 0.44 0.32 
Control samples Between lab Partner 3 vs 
Partner 4 
36 0.16 0.036 0.22 0.096 
Control samples Between lab All 96 0.22 0.12 0.44 0.070 
100 % samples Within lab, same conc Partner 2 33 0.041 0.090 0.44 0.001 
100 % samples Within lab, same conc Partner 3 33 0.022 0.045 0.18 0.001 
100 % samples Within lab, same conc Partner 4 33 0.009 0.015 0.079 0.00005 
100 % samples Within lab, same conc All 99 0.024 0.060 0.44 0.00005 
40 % samples Within lab, same conc Partner 2 27 0.031 0.070 0.28 0.001 
40 % samples Within lab, same conc Partner 3 24 0.016 0.020 0.063 0.001 
40 % samples Within lab, same conc Partner 4 24 0.049 0.089 0.30 0.001 
40 % samples Within lab, same conc All 75 0.032 0.067 0.30 0.001 
5 % samples Within lab, same conc Partner 2 33 0.26 0.55 2.2 0.002 
5 % samples Within lab, same conc Partner 3 33 0.065 0.088 0.36 0.001 
5 % samples Within lab, same conc IPSC 33 0.041 0.060 0.21 0.001 
5 % samples Within lab, same conc All 99 0.12 0.34 2.2 0.001 
5, 40 and 100% samples Within lab, same conc All 273 0.062 0.21 2.2 0.00005 
100 % samples Between lab, same conc All 33 0.49 0.39 1.6 0.040 
40 % samples Between lab, same conc All 23 0.39 0.36 1.3 0.041 
5 % samples Between lab, same conc All 33 0.63 0.63 2.1 0.056 
5, 40 and 100% samples Between lab, same conc All 89 0.52 0.49 2.1 0.040 
100% vs 40% Within lab, different conc. Partner 2 9 0.24 0.18 0.56 0.055 
100% vs 40% Within lab, different conc. Partner 3 8 0.20 0.20 0.59 0.054 
100% vs 40% Within lab, different conc. Partner 4 8 0.24 0.23 0.73 0.079 
100% vs 40% Within lab, different conc. All 25 0.22 0.20 0.73 0.054 
100% vs 5% Within lab, different conc. Partner 2 11 1.1 0.67 2.4 0.084 
100% vs 5% Within lab, different conc. Partner 3 11 0.97 0.57 1.9 0.16 
100% vs 5% Within lab, different conc. Partner 4 11 0.88 0.51 1.7 0.086 
100% vs 5% Within lab, different conc. All 33 0.99 0.58 2.4 0.084 
40% vs 5% Within lab, different conc. Partner 2 9 0.90 0.44 1.6 0.18 
40% vs 5% Within lab, different conc. Partner 3 8 0.66 0.32 1.2 0.25 
40% vs 5% Within lab, different conc. Partner 4 8 0.76 0.29 1.1 0.18 
40% vs 5% Within lab, different conc. All 25 0.78 0.36 1.6 0.18 
100% vs 40% Between lab, different conc. All 50 0.47 0.35 1.7 0.035 
100% vs 5% Between lab, different conc. All 66 1.3 0.75 4.0 0.33 
40% vs 5% Between lab, different conc. All 50 0.95 0.67 3.7 0.20 
Repeated synthesis, replicates Within lab Partner 3 and 4 36 0.056 0.18 0.81 0.002 
Repeated synthesis Within lab Partner 3 15 2.1 1.8 5.7 0.32 
Repeated synthesis Within lab Partner 4 15 1.7 1.9 7.2 0.051 
Repeated synthesis Within lab Partner 3 and 4 30 1.9 1.8 7.2 0.051 
Repeated synthesis Between lab Partner 3 and 4 36 4.9 2.9 12.8 1.1 
Same oil precipitated at diff pH Within lab/operator Partner 3 36 2.4 2.6 7.3 0.008 
100 % samples Diff. recipe within synth route Partner 3 19 25.6 12.3 52.2 7.8 
100 % samples Between synthetic route Partner 3 36 71.3 15.1 93.4 31.7 
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ANNEX 14 
 
LINKS DETERMINED BY ORGANIC PROFILING BETWEEN AMPHETAMINE 
TABLETS WITH DIFFERENT EXTERNAL CHARACTERISTICS 
 
CASE 1 
 
 
Colour :    light yellow  white    white 
Diameter :   9 mm   9.1 mm    9.1 mm 
Width :    3.4 mm   3.3 mm    3.2 mm 
Weight :    275 mg   250 mg    252 mg 
Amount of amphetamine :  16 mg   12 mg    n.a. 
Adulterant(s) :   caffeine   caffeine    caffeine 
Diluent(s) :   -   -    - 
Shape code :   RBB   RBB    RBB 
Breakline :   YES   YES    YES 
Location and year of seizure: ZH, 1999  ZH, 1999   VD, 1998 
Internal number .   990a   990b    744 
 
CASE 2 
 
 
 
 
Colour :    beige   beige    beige 
Diameter :   11.3 mm  11.3 mm   11.2 mm 
Width :    3.6 mm   3.5 mm    3.7 mm 
Weight :    455 mg   452 mg    456 mg 
Amount of amphetamine :  51 mg   44 mg    51 mg 
Adulterant(s) :   -   -    - 
Diluent(s) :   glucose, sucrose  glucose, sucrose  glucose, sucrose 
Shape code :   RCC   RCC    RCC 
Breakline :   NO   NO    NO 
Location and year of seizure: ZH, 1999  ZH, 1999   ZH, 1999 
Internal number .   894i   894g    910a 
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CASE 3 
 
 
 
Colour :    light green  light violet   light violet 
Diameter :   8.6 mm   8.6 mm    8.7 mm 
Width :    5.3 mm   5.4 mm    5.3 mm 
Weight :    398 mg   398 mg    392 mg 
Amount of amphetamine :  15 mg   18 mg    13 mg 
Adulterant(s) :   caffeine   caffeine    caffeine 
Diluent(s) :   lactose   lactose    lactose 
Shape code :   RCC   RCC    RCC 
Breakline :   YES   YES    YES 
Location and year of seizure: ZH, 1997  ZH, 1997   ZH, 1997 
Internal number .   540   543    561 
 
CASE 4 
 
 
 
Colour :    white   yellow 
Diameter :   9.1 mm   8.6 mm 
Width :    3.5 mm   5.4 mm 
Weight :    224 mg   203 mg 
Amount of amphetamine :  22 mg   18 mg 
Adulterant(s) :   caffeine, 1-PEA*  caffeine, 1-PEA* 
Diluent(s) :   -   - 
Shape code :   R ? ?   R ? ? 
Breakline :   NO   YES 
Location and year of seizure: ZH, 1995  ZH, 1995 
Internal number .   084   093 
 
 
 
Note : see Annex 19 for explanation of the shape code. 
 
 
* 1-PEA is the short name for 1-phenethylamine. This compound is sometimes found in illicit amphetamine [Blachut et al., 2001, King, 
1996] 
 
 177 
ANNEX 14A 
 
EXTRACTED ION CHROMATOGRAMS OF AMPHETAMINE TABLETS : CASE 1 from annex 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note :  these three profiles are considered to be a match (Pearson correlations of 0.10, 0.18 and 0.49). 
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EXTRACTED ION CHROMATOGRAMS OF AMPHETAMINE TABLETS : CASE 2 from annex 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note :  these three profiles are considered to be a match (Pearson correlations of 0.05, 0.09 and 0.10). 
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EXTRACTED ION CHROMATOGRAMS OF AMPHETAMINE TABLETS : CASE 3 from annex 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note :  these three profiles are considered to be a match (Pearson correlations of 0.18, 0.84 and 0.84). 
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EXTRACTED ION CHROMATOGRAMS OF AMPHETAMINE TABLETS : CASE 4 from annex 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note :  these two profiles are considered to be a match (Pearson correlation of 0.21). 
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ANNEX 15 
 
AMPHETAMINE TABLETS SHOWING THE SAME VISUAL, PHYSICAL AND CHEMICAL 
CHARACTERISTICS BUT WHERE ORGANIC PROFILES DIFFER SIGNIFICANTLY 
 
 
CASE 5 
 
  
 
Colour :    light blue   light blue 
Diameter :   9.1 mm    9.1 mm 
Width :    3.9 mm    3.9 mm 
Weight :    292 mg    288 mg 
Amount of amphetamine :  21 mg    22 mg 
Adulterant(s) :   -    - 
Diluent(s) :   lactose, glucose (traces)  lactose, glucose (traces) 
Shape code :   RAA    RAA 
Breakline :   YES    YES 
Location and year of seizure: NE, Oct. 1998   NE, Jan. 2000 
Internal number .   823    974f 
 
 
 
Note : see Annex 19 for explanation of the shape code. 
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ANNEX 15A 
 
EXTRACTED ION CHROMATOGRAMS OF AMPHETAMINE TABLETS : CASE 5 from annex 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note : these two profiles show strong dissimilarities (Pearson correlation 5.85). 
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ANNEX 16 
 
AMPHETAMINE TABLETS WITH SIMILAR VISUAL AND PHYSICAL CHARACTERISTICS BUT 
WITH SLIGHT DIFFERENCES IN CHEMICAL COMPOSITION INCLUDING THE ORGANIC 
PROFILES 
 
 
CASE 6 
 
 
 
Colour :    light green  light green   light green 
Diameter :   9.1 mm   9.1 mm    9.2 mm 
Width :    3.4 mm   3.3 mm    3.5 mm 
Weight :    323 mg   315 mg    320 mg 
Amount of amphetamine :  18 mg   18 mg    26 mg 
Adulterant(s) :   caffeine   caffeine    caffeine 
Diluent(s) :   -   -    lactose 
Shape code :   RAA   RAA    RAA 
Breakline :   YES   YES    YES 
Location and year of seizure: ZH, 1998  ZH, 1999   ZH, 2001 
Internal number .   Z2B   885a    1461 
 
 
In this case, the first two tablets have almost identical visual, physical and chemical characteristics. Their 
respective organic profiles are also almost identical. However, the third tablet, which was seized two, 
respectively three years later, contains also lactose. Its organic profile (see Annex 16A) is very similar compared 
to the two other tablets although there are some very small differences. 
 
 
 
 
Note 1 : as can be seen above, the pictures are unfortunately not all on the same scale although they should be. 
 
 
Note 2 : see Annex 19 for explanation of the shape code. 
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ANNEX 16A 
EXTRACTED ION CHROMATOGRAMS OF AMPHETAMINE TABLETS : CASE 6 from annex 16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note : top and middle profiles are considered to be a match (Pearson correlation : 0.19). Bottom chromatogram 
shows very slight differences (Pearson correlations : 0.84 and 0.85). 
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ANNEX 17 
AMPHETAMINE TABLETS WITH SIMILAR VISUAL AND PHYSICAL CHARACTERISTICS BUT 
WITH SLIGHT DIFFERENCES IN CHEMICAL COMPOSITION INCLUDING THE ORGANIC 
PROFILES 
 
CASE 7 
 
 
 
 
Colour :  white  white  white  white   white 
Diameter : 9 mm  9.1 mm  9 mm  9.1 mm   9 mm 
Width :  3.4 mm  3.6 mm  3.6 mm  3.5 mm   3.6 mm 
Weight :  290 mg  286 mg  291 mg  286 mg   280 mg 
Amount of 
amphetamine : 28 mg  15 mg  13 mg  19 mg   44 mg 
Adulterant(s) : -  caffeine  caffeine  caffeine   caffeine 
Diluent(s) : lactose  lactose  lactose  lactose   - 
Shape code : RBB  RBB  RBB  RBB   RBB 
Breakline : YES  YES  YES  YES   YES 
Location and 
year of seizure: ZH, 1995 ZH, 1997 ZH, 1997 ZH, 1998  GE, 1999 
Internal number . 127  557a  560a  Z9   857 
 
 
 
 
Note 1 : again, the pictures are unfortunately not all on the same scale although they should be. Also, the 
differences in colour are due to non-standardization (at the time) of the digital recording of the images. 
 
 
Note 2 : see Annex 19 for explanation of the shape code. 
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ANNEX 17A 
EXTRACTED ION CHROMATOGRAMS OF AMPHETAMINE TABLETS : CASE 7 from annex 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note :  these three samples (Z9, 557a and 560a) are considered as a match (Pearson correlations : 0.32, 
0.36 and 0.39 respectively). 
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Note :  these two samples (127 and 857) are considered different from each other and also different 
from the three other samples. 
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ANNEX 18 
AMPHETAMINE TABLETS WHERE LINKS WERE ESTABLISHED BY MEANS OF VISUAL, 
PHYSICAL AND CHEMICAL CHARACTERISTICS AND CONFIRMED BY THE ORGANIC 
PROFILES 
CASE 8 
 
 
 
Colour :  beige   beige   beige   beige 
Diameter : 9 mm   9 mm   9 mm   9 mm 
Width :  4.4 mm   4.4 mm   4.4 mm   4.4 mm 
Weight :  321 mg   320 mg   320 mg   320 mg 
Amount of 
amphetamine : 63 mg   59 mg   64 mg   64 mg 
Adulterant(s) : -   -   -   - 
Diluent(s) : lactose   lactose   lactose   lactose 
Shape code : RAA   RAA   RAA   RAA 
Breakline : NO   NO   NO   NO 
Location and 
year of seizure: ZH, 1995  ZH, 1995  ZH, 1995  ZH, 1995 
Internal number . 089   102   106   129 
 
 
 
 
 
Note 1 : the differences in colour are due to non-standardization (at the time) of the digital recording of the 
images. 
 
 
Note 2 : see Annex 19 for explanation of the shape code. 
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ANNEX 18A EXTRACTED ION CHROMATOGRAMS OF AMPHETAMINE TABLETS : CASE 8 FROM ANNEX 18 
 
 
 
 
          
 
 
 
 
 
 
 
 
 
          
 
 
 
 
 
 
 
Note : all samples are considered as matching, Pearson correlations from 0.08 to 0.23. 
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ANNEX 19 CODE SHAPE FOR TABLETS * 
 
This is the three letter code shape used in the IPS tablet database (Institut de Police Scientifique, University of 
Lausanne, Switzerland). 
 
The first letter represents the shape of the tablet from a top view. If it is round (as in most cases), then the first 
letter will be R, if it is a capsule, then it will be G, etc. 
 
The second and third letters represents the shape of the tablet from the side views. The second letter is given to 
the side view which bears an imprint whereas the third letter is given for the side view which generally bears the 
break line. If no imprint or break lines are present, then the alphabetical rule is followed. 
 
 
 
 
 
 
 
 
 
 
* [Zingg C., 2004] 
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